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Samenvatting/summary 
Nederlandstalige  SAMENVATTING 
 
Genderdysforie wordt omgeschreven als het lijden dat een persoon ervaart ten gevolge van de 
incongruentie tussen enerzijds zijn/haar genderidentiteit -het gevoel man, vrouw of 
ongedetermineerd te zijn- en zijn/haar geboortegeslacht anderzijds. Om dit lijden te verminderen 
wordt vaak een medische behandeling ondergaan die bestaat uit een hormonale behandeling en 
chirurgische ingrepen.  
Deze hormonale behandeling heeft als voornaamste doel om de secundaire geslachtskenmerken 
van het gewenste geslacht te bekomen en deze van het geboortegeslacht te onderdrukken. De 
hormonale behandeling van de transvrouw, of man-naar-vrouw transseksuele persoon, bestaat 
meestal uit een combinatie van anti-androgenen, welke de effecten van het mannelijk 
geslachtshormoon testosteron onderdrukken, en vrouwelijke hormonen of oestrogenen, die de 
feminisatie induceren. Bij de transman of vrouw-naar-man transseksuele persoon wordt 
testosterontherapie gegeven om masculinisatie te bekomen en de menstruatie te onderdrukken.  
Naast de effecten op de ontwikkeling van de geslachtsorganen en secundaire 
geslachtskenmerken, spelen geslachtshormonen ook een rol in tal van fysiologische processen in 
spier-, vet- en botweefsel alsook in de huid, het immuunsysteem en het cardiovasculair stelsel. 
Hierdoor wordt de veiligheid van de hormonale behandeling bij transpersonen soms in vraag 
gesteld. Tot op heden zijn de effecten van de hormonale behandeling op korte en lange termijn 
echter niet goed gekend mede door de zeldzaamheid van deze diagnose, een gebrek aan studies 
en grote variaties in behandelingsschema’s tussen verschillende centra.  
In de afgelopen jaren werd het belang van kwaliteit van leven van patiënten en de invloed van de 
behandeling op de kwaliteit van leven van patiënten steeds meer belangrijk in de research agenda. 
Deze informatie ontbrak echter nog in deze specifieke populatie. 
De doelstellingen van deze thesis waren daarom tweeledig. Ten eerste was het de bedoeling om 
meer informatie te verwerven over de klinische effecten en bijwerkingen van cross-sex 
hormonale behandeling op korte en lange termijn, zowel bij transmannen als transvrouwen. Ten 
tweede wilden we de kwaliteit van leven van transpersonen nagaan na de hormonale behandeling 
en associaties onderzoeken tussen kwaliteit van leven en verschillende aspecten van de 
behandeling.  
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In hoofdstuk 1 wordt de synthese en het werkingsmechanisme van geslachtshormonen en hun 
klinische effecten beschreven. Daarnaast worden ook de reeds gekende effecten en bijwerkingen 
van cross-sex hormonale behandeling bij transpersonen besproken. Tot slot werden in dit 
hoofdstuk de doelstellingen van dit werk geformuleerd, de bestudeerde populaties en gebruikte 
materialen en methodes toegelicht.  
Het doel van hoofdstuk 2.1 was om de klinische effecten en bijwerkingen van de hormonale 
therapie tijdens de eerste 12 behandelingsmaanden na te gaan aan de hand van een prospectieve 
multicentrische studie in 53 transvrouwen en 53 transmannen. De resultaten van deze studie 
toonden dat de gebruikte behandelingsschema’s in transvrouwen met cyproteroneacetaat 50 mg 
in combinatie met oestrogenen (<45 jaar: oestradiol valeraat 4 mg per dag, ≥45 jaar: transdermale 
17β oestradiol pleister 100 µg/24u) en in transmannen (3 maandelijkse injecties met testosteron 
undecanoaat 1000 mg) veilig en effectief waren. Tijdens deze studieperiode werden geen ernstige 
bijwerkingen zoals cardiovasculaire aandoeningen of sterfte waargenomen. Bij 5.6% van de 
transvrouwen werd een transiënte stijging van de leverenzymes opgemerkt en bij 15.7% een 
stijging van de prolactinespiegels (tweemaal hoger dan de  bovenlimiet van de referentiewaarden). 
Tijdens de behandeling met anti-androgenen en oestrogenen werd een significante stijging van 
symptomen van borstgevoeligheid, warmteopwellingen, emotionaliteit en verlaagd seksueel 
verlangen gevonden. Transmannen hadden een klein risico voor het ontstaan van erythrocytose 
(3.8%) en transiënte stijging van de leverenzymes (1.9%) en rapporteerden beduidend meer 
symptomen van hoog seksueel verlangen, steminstabiliteit en clitorale pijn tijdens de 
testosterontherapie. 
In hoofdstuk 2.1 maar vooral in hoofdstuk 2.2 beschreven we de veranderingen in 
cardiovasculaire risicofactoren tijdens de cross-sex hormonale behandeling. We toonden aan dat 
deze behandeling bij transvrouwen enerzijds gunstige veranderingen in cardiovasculaire 
risicofactoren induceerde zoals een verbetering van het lipidenprofiel en het ontstaan van een 
gynecoïde lichaamsbouw (of ‘peervorm’ waarbij de vetmassa zich voornamelijk opstapelt ter 
hoogte van de dijen); maar anderzijds ook ongunstige veranderingen teweegbracht door een 
daling in de spiermassa en insulinegevoeligheid en een stijging van de vetmassa thv het abdomen. 
Net zoals bij transvrouwen, induceerde de hormonale behandeling bij transmannen behalve 
gunstige ook ongunstige veranderingen. Enerzijds werd er een daling in vetmassa en een stijging 
in spiermassa en insulinegevoeligheid geobserveerd maar anderzijds induceerde de 
testosterontherapie, geheel in tegenstelling tot de behandeling bij de transvrouw, een minder 
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gunstig lipidenprofiel en de zogenaamde androïde lichaamsbouw (of ‘appelvorm’ waarbij 
vetmassa zich voornamelijk ter hoogte van de buik opstapelt).  
Dat een teveel aan androgenen of mannelijke hormonen bij vrouwen zorgt voor dermatologische 
bijwerkingen zoals hirsutisme, acne en androgene alopecie (ook gekend als 'klassieke mannelijke 
kaalheid') is gekend. Een van onze onderzoeksdoelen was dan ook de dermatologische effecten 
van de testosterontherapie na te gaan aangezien de gegevens hierover schaars waren (hoofdstuk 
2.3). Zoals verwacht (en beoogd) observeerden we tijdens het eerste jaar van de 
testostosteronbehandeling een stijging in gezicht- en lichaamsbeharing zodat 80% van de 
transmannen hirsutisme hadden op basis van de Ferriman and Gallwey score, een frequent 
gebruikte evaluatiemethode. We vonden een relatief laag risico voor het ontwikkelen van 
androgene alopecie tijdens de eerste 12 behandelingsmaanden maar een hoog risico voor het 
ontstaan van acne. Deze acneletsels namen toe zowel op het gezicht als op de rug en borstkas 
zodat ongeveer de helft van de transmannen een lokale of orale acnebehandeling startte. Toch 
moet gezegd worden dat de meeste mannen slechts milde of matige acneletsels hadden en bij 
geen enkele man ernstige of zeer ernstige acneletsels werden vastgesteld.  
Niet alleen de effecten van de testosteronbehandeling op de huid bij transmannen op korte 
termijn maar ook deze op lange termijn werden beschreven in hoofdstuk 2.3 aan de hand van 
een studie bij 50 transmannen die een gemiddelde behandelingsduur van 10 jaar hadden. Deze 
studie toonde dat de gezicht- en lichaamsbeharing nog flink toeneemt tijdens de 
testosterontherapie en dat de tevredenheid van transmannen ook sterk geassocieerd was met deze 
toename in beharing. In tegenstelling tot de gezicht- en lichaamsbeharing nam de 
schedelbeharing verder af zodat bij ongeveer 64% van de transmannen androgene alopecie werd 
vastgesteld. De acne scores waren daarentegen veel lager dan deze tijdens het eerste jaar van de 
testosterontherapie. 
In hoofdstuk 2.4 en hoofdstuk 2.5 werd aan de hand van drie verschillende studies de 
langetermijneffecten op de algemene gezondheid van transpersonen beschreven. De eerste twee 
studies werden uitgevoerd bij respectievelijk 50 transvrouwen en 50 transmannen, die gemiddeld 
10 jaar met hormonale therapie werden behandeld. We observeerden dat 11,5% van de 
transvrouwen en 26,7% van de transmannen suprafysiologische hormonale waarden hadden tov 
de normale referentiewaarden van het gewenste geslacht, wat het risico op cardiovasculare 
aandoeningen kan vergroten. Anderzijds hadden 63% van de transvrouwen en 8.9% van de 
transmannen subfysiologische waarden tov de normale referentiewaarden, wat dan weer het risico 
verhoogt op bijwerkingen zoals gekend bij hypogonadale personen. Inderdaad, een belangrijke 
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bevinding van deze studie was dat ongeveer een vierde van de transvrouwen osteoporose had ter 
hoogte van de lumbale wervelzuil, heup of arm. Daarentegen werd bij transmannen geen 
osteoporose vastgesteld. Er werden geen hormoongerelateerde kankers genoteerd noch bij 
transvrouwen noch bij transmannen. 
In hoofdstuk 2.1 en 2.2 beschreven we veranderingen in cardiovasculaire risicofactoren tijdens de 
eerste 12 maanden van de hormonale behandeling. De langetermijneffecten van de hormonale 
behandeling op het cardiovasculair risicoprofiel werden gerapporteerd in hoofdstuk 2.4. We 
observeerden dat transvrouwen en transmannen een gelijkaardige prevalentie van cardiovasculaire 
risicofactoren zoals obesitas, roken, hoge bloeddruk en verhoogde cholesterolspiegel hadden na 
een gemiddelde behandelingsduur van 10 jaar. Tevens hadden transpersonen een vergelijkbaar 
cardiovasculair risicoprofiel als beschreven in de algemene populatie, afgezien van een hoger 
aantal rokers in de transpopulatie. Desondanks vonden we in deze studie dat transvrouwen, maar 
niet transmannen, een opmerkelijk hogere prevalentie hadden van cardiovasculaire aandoeningen 
(12% versus 0%). Ook in deze studies werden geen verhoogd risico voor hormoongerelateerde 
kankers vastgesteld. 
Omdat deze onderzoekspopulaties eerder klein waren, initieerden we de TransBel studie, een 
cross-sectionele multicentrische vragenlijststudie met als doel om de morbiditeit van de 
hormonale behandeling bij transpersonen beter in kaart te brengen. De recrutering in andere 
centra is momenteel nog lopende en daarom werden in dit proefschrift enkel de gegevens van 
ons eigen centrum besproken. Een totale populatie van 352 transpersonen werd geïncludeerd, 
gemiddeld 7,4 jaar behandeld met hormonale therapie. We bevestigden de resultaten van de 
klinische studies die geen verhoogd risico op hormoongerelateerde kankers aantoonden maar wel 
een verhoogd risico op cardiovasculaire ziekten bij transvrouwen doen vermoeden. Zo hadden 
respectievelijk 5,1% en 3,7% van de transvrouwen een veneuze trombose of cardiovasculaire 
aandoening doorgemaakt tijdens de hormonale behandeling. De voornaamste risicofactoren voor 
cardiovasculaire ziekte in deze studie waren oudere leeftijd en aanwezigheid van gekende 
cardiovasculaire risicofactoren met als voornaamste roken.  
Afgezien van deze fysieke veranderingen toonden we in hoofdstuk 3 en hoofstuk 4 dat cross-
sex hormonale behandeling ook een belangrijke invloed heeft op het seksueel functioneren en de 
kwaliteit van leven van transpersonen. We hebben reeds vermeld dat transvrouwen een lager 
seksueel verlangen en transmannen een hoger seksueel verlangen rapporteerden in onze 
prospectieve studie. Dit werd bevestigd in de TransBel studie aangezien 62,4% van de 
transvrouwen retrospectief een daling- en 71,0% van de transmannen een stijging in seksueel 
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verlangen rapporteerden (hoofdstuk 3.1). Bovendien vermeldde 73% van de transvrouwen dat ze 
zelden of nooit spontaan en responsief seksueel verlangen ervaren. Een derde van deze vrouwen 
(en dus 22% van de gehele groep van transvrouwen) gaf aan hierdoor persoonlijk of relationeel 
lijden te ervaren, een aantal dat hoger ligt dan beschreven in de algemene populatie. In 
tegenstelling tot transvrouwen, werd bij transmannen een gelijkaardige prevalentie gevonden van 
deze stoornis van hypoactief seksueel verlangen als in de algemene populatie. Bovendien gaf een 
kleine groep transmannen (3,6%) aan dat zij persoonlijk of relationeel lijden hebben ervaren door 
een teveel aan seksueel verlangen. 
In een vorige studie van onze onderzoeksgroep werd geen verband aangetoond tussen 
concentraties in het bloed circulerende geslachtshormonen en seksueel verlangen bij 
transvrouwen. In hoofdstuk 3.2 rapporteerden we deze potentiële associaties bij transmannen. 
In overeenstemming met de resultaten bij transvrouwen, werden geen directe associaties 
gevonden tussen (vrij) testosteron concentraties en solitair of dyadisch seksueel verlangen 
(respectievelijk het verlangen van een individu naar seksueel contact met zichzelf en het 
verlangen naar seksuele activiteiten met een partner). Maar we vonden wel een associatie tussen 
LH spiegels en solitair seksueel verlangen. Transmannen die hogere LH waarden hadden, wat een 
suboptimale testosterontherapie suggereert, hadden minder seksueel verlangen in vergelijking met 
transmannen met lagere LH waarden. Transmannen met lagere LH waarden rapporteerden ook 
een hogere nood te hebben aan seksuele activiteiten en meer last te hebben van een teveel aan 
seksueel verlangen. 
In hoofdstuk 4 werd de kwaliteit van leven van transpersonen geëvalueerd en vergeleken met 
een voor leeftijd en geslacht gepaarde controlepopulatie, die gerecruteerd was uit een groot 
Vlaams populatieonderzoek over seksuele gezondheid (de Sexpert-studie). Deze resultaten 
toonden dat transpersonen een lagere kwaliteit van leven hadden in vergelijking met deze 
controlepopulatie, ook na correctie voor belangrijke determinanten zoals leeftijd en socio-
economische status. Zowel fysiek functioneren als mentaal functioneren scoorden significant 
lager bij transpersonen, maar het absoluut verschil was veel groter voor mentaal welzijn in 
vergelijking met fysiek welzijn. Ten tweede, werden de voornaamste determinanten van kwaliteit 
van leven bij transpersonen onderzocht. Wij vonden dat hormonale tevredenheid en werkstatus 
onafhankelijke predictoren waren van kwaliteit van leven zowel bij transvrouwen als bij 
transmannen. Het hebben van kinderen en het ondergaan hebben van de vaginoplastie waren 
additionele onafhankelijke negatieve predictoren van fysiek functioneren bij de transvrouw. Deze 
laatste associatie verdween echter wanneer we transvrouwen die recent geopereerd waren 
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excudeerden. Daarentegen was het ondergaan hebben van een gezichtsveranderende operatie een 
positieve determinant van mentaal welzijn bij de transvrouw. Bij transmannen was het hebben 
van kinderen een positieve determinant van mentaal welzijn.  
Tot slot worden in hoofdstuk 5 de belangrijkste bevindingen van deze verschillende studies 
samengevat en besproken, gevolgd door een vermelding van aantal mogelijke toekomstige 
onderzoeksvragen.  
Samenvattend hebben we in dit proefschrift aangetoond dat onze huidige hormonale behandeling 
bij transpersonen effectief en relatief veilig is op korte termijn. Anderzijds toonden we aan dat 
langdurige hormonale behandeling mogelijk het risico kan verhogen op cardiovasculaire ziekte, 
vooral bij transvrouwen. Naast deze effecten op de fysieke gezondheid van transpersonen, 
observeerden we ook belangrijke effecten van de hormonale behandeling op het seksueel 
verlangen en kwaliteit van leven van transpersonen.  
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SUMMARY  
 
Gender dysphoria is described as a condition in which a person experiences a discrepancy 
between the sex assigned at birth and the gender they identify with, leading to extensive personal 
distress. To conform to the other sex, trans persons often undergo treatment which may include 
hormonal therapy and surgery. 
The main goals of cross-sex hormone therapy are to acquire the secondary sex characteristics of 
the desired sex and to reduce those of the natal sex. Trans women or male-to-female transsexual 
persons usually receive a combination of anti-androgen and estrogen therapy to induce 
feminization whereas trans men or female-to-male transsexual persons receive testosterone 
treatment to induce virilisation and suppress menstruation. 
Besides its effects on secondary sex characteristics and reproductive tissue development, sex 
steroids are also involved in many other physiological processes in muscle, fat, bone, skin, larynx, 
immune system, hematopoietic cells and cardiovascular system. The latter raise concerns about 
the safety of cross-sex hormone treatment. Although this treatment has been used for several 
decades, our knowledge regarding short- and long-term effects and adverse effects of cross-sex 
hormone therapy is scarce, mainly due to the low prevalence of this diagnosis, lack of prospective 
studies and wide variations in treatment modalities between centers.  
In the past years, the importance of patients’quality of life (QoL) and the changes in QoL 
induced by medical treatment has become increasingly important, but these data were scarce in 
trans persons. 
The objectives of this thesis were therefore twofold: first, to investigate the short-and long-term 
physical changes, side effects and adverse events of cross-sex hormonal therapy in trans persons 
and second to study QoL of trans persons and its association with cross-sex hormone therapy. 
In Chapter 1, a general background with a review of the available literature on effects and side 
effects of cross-sex hormone therapy was presented and discussed. In addition, we stated our 
research objectives and described our studies conducted for this purpose. We continued with 
material and methods used in our research.  
The aim of Chapter 2 was to investigate the effects, side effects and adverse events during the 
first year of cross-sex hormone therapy using a multicenter prospective study in 53 trans women 
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and 53 trans men. We observed that our current treatments with cyproterone acetate 50 mg daily 
and estrogens (< 45 years: estradiol valerate 4 mg daily and ≥ 45 years 17β estradiol patch 100 
µg/24h) in trans women and 3-monthly injections with testosterone undecanoate in trans men, 
were all effective and safe therapies. None of our trans patients experienced severe adverse 
events such as cardiovascular events or death. About 5.7% of trans women experienced transient 
elevation of the liver enzymes whereas 15.7% had prolactin above double the upper limit of the 
normal range. During anti-androgen and estrogen treatment, a significant increase in breast 
tenderness, hot flashes, emotionality and low sexual desire was found. In trans men a small risk 
for erythrocytosis and transient elevation of the liver enzymes was observed. Trans men reported 
an increase in sexual desire, voice instability and clitoral pain (chapter 2.1).  
In chapter 2.2 we focused on the changes in cardiovascular risk factors during the first year of 
cross-sex hormonal therapy. Hormone therapy in trans women caused favourable changes in 
lipid profile and induced a gynoid pattern of fat distribution but less favourable changes in 
glucose metabolism and body composition, with an increase in insulin resistance and fat mass 
and decrease in lean mass. Similar to trans women, testosterone therapy induced both favourable 
and unfavourable changes in cardiovascular risk factors. A decrease in appendicular and trunk fat 
mass and an increase in lean mass and insulin sensitivity was seen. In contrast, testosterone 
therapy induced a poor lipid profile and an android pattern of fat distribution.  
As it is well-known that androgen excess in women is associated with important dermatological 
effects, such as acne vulgaris, hirsutism and androgenetic alopecia with potentially important 
psychological disturbing effects, we also aimed to investigate dermatological changes during 
treatment with testosterone undecanoate (chapter 2.3). As expected, testosterone therapy 
increased facial and body hair and about 4 out of 5 trans men developed Ferriman and Gallwey 
scores indicative of hirsutism. In addition, we observed a rather low risk for development of 
androgenetic alopecia but a high risk for acne during the first 12 months of testosterone therapy. 
Both facial acne scores and acne scores at back or chest increased, causing the need for topical or 
oral acne treatment in half of partcipants. However, most men developed only mild acne and 
none suffered from severe or very severe acne. 
In chapter 2.3 we also described long-term effects of testosterone therapy on the skin of trans 
men using a study of 50 trans men, who were on average 10 years on hormonal therapy. We 
showed that long-term testosterone therapy further increased facial and body hair and that this 
further increase contributes to increased patient satisfaction because this was strongly associated 
with the obtained male hair pattern. In contrast, scalp hair further decreased during treatment so 
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that about 64% of trans men had androgenetic alopecia. Our long-term observations also show 
markedly lower acne scores compared to scores during the first year of treatment.  
How long-term cross-sex hormone therapy affects physical health of trans persons was addressed 
in chapter 2.3, 2.4 and 2.5 using three different studies. The first two studies were performed in 
respectively 50 trans men and 50 trans women who were on average 10 years on cross-sex 
hormone therapy. We observed that 11.5% of trans women and 26.7% of trans men had 
supraphysiological levels, which may increase the risk for cardiovascular events. In contrast, 63% 
of trans women and 8.9% of trans men exhibited subphysiological sex steroid levels which put 
trans persons at risk for side effects known from hypogonadal states. Indeed, an important 
finding of these studies was that a high number of trans women (about 25%)  present with 
osteoporosis at the lumbar spine, hip or radius, whereas in trans men no osteoporosis was 
diagnosed. No hormone-related cancers were observed in either trans women or men but 12% of 
trans women in this study experienced a cardiovascular adverse event during hormonal therapy, 
compared to not a single trans man.  
Because the sample sizes were rather small in our clinical studies, the TransBel was initiated, a 
cross-sectional multicenter questionnaire study with the aim to investigate morbidity of trans 
persons in Belgium. As recruitment in other centers is still ongoing, we present in this thesis data 
from our center including 352 trans persons with an average hormone treatment duration of 7.4 
years (chapter 3.5). We confirmed the results from our clinical studies showing a low risk for 
cardiovascular events and cancer in trans men, whereas our results in trans women suggested no 
higher risk for cancer but again an increased risk for cardiovascular disease. About five percent 
(5.1%) of trans women experienced venous thrombosis and 3.7% cardiovascular event during 
hormonal therapy. Risk factors for cardiovascular disease were older age and prevalent 
cardiovascular risk factors, especially smoking. 
Besides physical health changes, cross-sex hormone therapy also affects sexual functioning and 
QoL. We already showed in our prospective study (chapter 2.1) that trans women experience 
lower levels- and trans men higher levels of sexual desire after initiation of cross-sex hormone 
therapy. These results were also confirmed in our TransBel study as trans women reported a 
decrease of sexual desire since the start of cross-sex hormone therapy whereas trans men 
mentioned an increase (chapter 3.1). Moreover, in the TransBel study, 73% of trans women 
never or rarely experienced spontaneous and responsive sexual desire. A third of these women 
also reported associated personal or relational distress, which resulted in a prevalence of 
hypoactive sexual desire disorder (HSDD) of 22%. In contrast, the prevalence of HSDD in trans 
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men was comparable to that in the general male population. Moreover, a small group of trans 
men (3.6%) even reported personal or relational distress due to high levels of sexual desire.  
Previous research from our center showed no associations between sexual desire and serum 
levels of sex steroids in trans women. In chapter 3.2 these potential associations between sexual 
desire and sex steroid levels were investigated in trans men. No direct associations were observed 
between testosterone levels and solitary or dyadic sexual desire (the desire to behave sexually by 
onseself or with a partner). However, an independent effect of LH levels on solitary sexual desire 
was found. Trans men with elevated levels of LH, indicating suboptimal testosterone therapy, 
reported significantly lower solitary sexual desire levels than those with low LH levels. 
Suppressed LH levels were also associated with having a higher need for sexual activities and a 
higher frequency of experiencing excessive sexual desire.  
Chapter 4 discusses QoL of trans persons after long-term hormonal treatment. Firstly, we 
compared QoL of trans persons to an age- and gender matched control population, recruited 
from a population based study on sexual health in Flanders (the‘Sexpert’-study). We showed that 
QoL of trans persons was poorer compared to our control population even after adjustment for 
important determinants of QoL such as age and socio-economical status. Both physical and 
mental functioning were significantly lower in trans persons, but the absolute difference in 
physical functioning was rather small, whereas it was marked for mental functioning. Secondly, 
we investigated the main determinants of QoL in trans persons. We showed that hormonal 
treatment satisfaction and employment status were independently associated with physical and 
mental functioning in both trans women and men. In trans women, having children and having 
undergone vaginoplasty were also negative determinants of physical functioning. However, the 
latter association was lost when we excluded trans women who underwent vaginoplasty very 
recently. Facial feminization surgery was also a positive predictor of mental functioning in trans 
women whereas having children was an additional independent positive determinant of mental 
functioning in trans men.  
Finally, in chapter 5, the main findings of our different studies are summarized and discussed, 
together with perspectives on future research topics.  
In conclusion, with this work, we have shown that current cross-sex hormone therapies are 
effective and safe at short-time follow-up. Alternatively, we showed that long-term cross-sex 
hormone therapy may be associated with important side effects such as osteoporosis and 
cardiovascular disease, especially in trans women. Besides these effects on physical health, we also 
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 observed important associations between cross-sex hormonal therapy, sexual functioning and 
QoL of trans persons.         
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Chapter 1. INTRODUCTION   
 
In this background chapter, we will give an overview on 
the prevalence, etiology, diagnosis and treatment of 
gender dysphoria. Further, we will summarize the 
regulation, synthesis and clinical effects of sex steroids 
as well as the clinical effects of cross-sex hormone 
therapy in trans persons. 
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Chapter  1. Introduction 
1.1 Gender  dysphoria 
1.1.1 Introduction 
Gender identity is defined as the individual’s personal sense and subjective experience as being 
male, female or in between.  
Gender role refers to the behaviors, attitudes and personality traits that a society, in a given 
culture and historical time, designates as masculine or feminine. Or that is seen as “more 
appropriate” or “typical of” the social role as men or as women.  
Variations in gender identity and gender role are evident in many cultures, but with considerable 
differences across cultures in how such individuals are perceived(1). In some cultures, gender non-
conforming individuals, for example Acault-men of Myanmar(2) and the Hijras of India, are very 
well accepted in the society. Other cultures, such as our Western Society have been unreceptive 
to gender non-conforming persons, and enforced a clear sexual dimorphism. Nevertheless, many 
stories of gender variation have been described in our society(3).  
In the beginning of the 20th century, Magnus Hirschfeld performed ground breaking work in this 
field and opposed against a clear male-female dichotomy. Together with Harry Benjamin, he 
initiated medical treatment of the “transsexual,” a term introduced by Hirschfeld in 1923, to live a 
gender-appropriate life(4, 5). Since then, the scientific, clinical and social acceptance have 
ameliorated and an increasing number of countries nowadays have well-organized gender teams 
to support trans persons in a multi-disciplinary setting.  
1.1.2 Definitions  and   diagnosis 
Gender nonconformity refers to the extent to which a person’s gender identity, gender role 
and/or gender expression differs from the cultural norms prescribed for people of a particular 
sex, within a certain society and time. This term incorporates a broad spectrum of gender 
variations, for example cross-dressers, androgynes, transsexuals and other individuals with a 
lower degree of gender dysphoria. The majority of research is based on the most extreme form of 
gender nonconformity, in literature described as gender dysphoria (DSM-5), gender identity 
disorder (DSM IV), or transsexualism (DSM III). They all refer to the distress that is caused by 
the discrepancy between a persons’ gender identity – the sense one has of being male or female 
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or in between – and the sex assigned at birth. It is important to note that only some gender 
nonconforming people will experience gender dysphoria at some point in their lives(6). 
The diagnosis of Gender Dysphoria relies on assessment by a mental health professional 
according to the criteria specified in the Diagnostic and Statistical Manual of Psychiatric Diseases 
(DSM III, DSM IV, DSM IV-TR, DSM-5)(7) or the tenth revision of the International 
Classification of Diseases (ICD-10)(8). As in this thesis participants have been diagnosed mainly 
based  DSM IV-TR criteria, both DSM IV-TR and DSM-5 criteria will be discussed.  
1.1.2.1 DSM IV-TR criteria 
A. A strong and persistent cross-gender identification (not merely a desire for any perceived 
cultural advantages of being the other sex). 
B. Persistent discomfort with his or her sex or sense of inappropriateness in the gender role of 
that sex. 
C. The disturbance is not concurrent with a physical intersex condition. 
D. The disturbance causes clinically significant distress or impairment in social, occupational, or 
other important areas of functioning. 
Specify whether (for sexually mature individuals): 
 Sexually attracted to males 
 Sexually attracted to females 
 Sexually attracted to both 
 Sexually attracted to neither 
1.1.2.2 DSM-5 criteria 
A. A marked incongruence between one’s experienced/expressed gender and assigned gender, of 
at least 6 months’ duration, as manifested by at least two of the following: 
A marked incongruence between one’s experienced/expressed gender and primary and/or 
secondary sex characteristics (or in young adolescents, the anticipated secondary sex 
characteristics).  
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A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a 
marked incongruence with one’s experienced/expressed gender (or in young adolescents, a desire 
to prevent the development of the anticipated secondary sex characteristics).  
A strong desire for the primary and/or secondary sex characteristics of the other gender.  
A strong desire to be of the other gender (or some alternative gender different from one’s 
assigned gender).  
A strong desire to be treated as the other gender (or some alternative gender different from one’s 
assigned gender). 
A strong conviction that one has the typical feelings and reactions of the other gender (or some 
alternative gender different from one’s assigned gender). 
B. The condition is associated with clinically significant distress or impairment in social, 
occupational, or other important areas of functioning. 
Specify if: With a disorder of sex development (e.g., a congenital adrenogenital disorder such as 
congenital adrenal hyperplasia or an androgen resistance syndrome). 
Specify if: Post transition: The individual has transitioned to full-time living in the desired gender 
(with or without legalization of gender change) and has undergone (or is preparing to have) at 
least one cross-sex medical procedure or treatment regimen - namely, regular cross-sex hormone 
treatment or gender reassignment surgery confirming the desired gender (e.g., penectomy, 
vaginoplasty in a natal male, mastectomy or phalloplasty in a natal female). 
1.1.2.3 ICD-10 criteria 
ICD-10 defines a range of gender identity disorders including Transsexualism(8), which has three 
diagnostic criteria: 
1. The desire to live and be accepted as a member of the opposite sex, usually accompanied 
by the wish to make his or her body as congruent as possible with the preferred sex 
through surgery and hormone treatment. 
2. The transsexual identity has been present persistently for at least two years. 
3. The disorder is not a symptom of another mental disorder or chromosomal abnormality. 
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1.1.3 Prevalence of Gender Dysphoria 
The prevalence of gender dysphoria is not well-known(9). Small sample studies have been 
conducted in several countries. De Cuypere and colleagues(10) reviewed several studies involving 
eight countries and also conducted their own research. They reported that the prevalence of 
gender dysphoria in Belgium ranged from 1:11,900 to 1:45,000 in trans women and 1:30,400 to 
1:200,000 in trans men. This wide variation between studies can be explained by use of different 
definitions as some prevalence numbers were based on the number of legal sex change as noted 
in the national register(11), (12), number of psychiatric diagnoses(13), number of persons using 
hormonal therapy(14-16), the number of applicants for sex reassignment surgeries (SRS)(17)or 
number of persons who underwent SRS(10, 18). This implies an important selection bias as only 
persons who undergo treatment are included in the current calculations. Population-based 
research is required for a more reliable estimation of the prevalence of gender dysphoria as not all 
persons have access to treatment. In addition, population based research can give us an 
estimation on the broader spectrum of gender nonconformity. Recently, we performed a 
population-based study in Flanders on the prevalence of gender nonconformity in the Flemish 
population. We found that gender incongruence was present in 0.7% of men and 0.6% of 
women. More information on this study can be found in the Addendum. 
1.1.4 Etiology  
The development of a person’s gender identity is a complex cognitive and affective learning 
process, influenced by biological factors such as genetics and pre- and post-natal hormonal 
environment and interactions with parents, peers, societal and cultural/religious norms and 
expectations(19). 
The development of a person’s gender identity and the sex development generally coincide. The 
actual cause of experiencing a discrepancy between a persons’ gender identity and the birth sex 
remains unknown. Several biological, psychological, and socio-cultural correlates have been 
related to the existence of gender dysphoria (for review see(20)) but none of these findings can 
give a formal explanation. The etiology of gender dysphoria is probably based on a complex 
interaction between all these biological, psychological and socio-cultural factors(20).  
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1.1.5 Treatment  
Once the diagnosis of gender dysphoria in adults is made, the therapeutic approach may include 
psychotherapy or counseling, cross-sex hormone therapy and surgery(6). The procedure of sex 
reassignment therapy is presented in Figure 1.1. 
 
 
 
 
Figure 1.1. Classical procedure of sex reassignment therapy 
 
1.1.5.1 Psychotherapy or counseling 
Psychotherapy is often the first intervention and is highly recommended by the World 
Professional Association of Transgender Health (WPATH) Standards of Care(6), but is not a 
requirement for hormone therapy neither for surgery in the new guidelines of the Standards of 
Care. The overall goal of psychotherapy is to help an individual to explore gender conflicts and to 
find ways to alleviate gender dysphoria by setting realistic life goals in their relationships, 
education and work.  
An important part of this exploration occurs by the real life experience. In this period, trans 
persons are asked to fully live in accordance with their desired gender and to inform their social 
environment. This real life experience is intended to confront the individual with the everyday life 
in the desired gender role before irreversible surgical changes are induced. Real life therapy is 
mostly started at the initiation of cross-sex hormone therapy. 
  
Clinical diagnosis 
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1.1.5.2 Hormonal therapy 
The two main goals of hormone treatment are to reduce endogenous hormone levels, and 
thereby the secondary sex characteristics of the individual’s biological sex and assigned gender; 
and to replace endogenous sex hormone levels with those of the desired sex. In addition to 
inducing physical changes, the act of using cross-sex hormones is itself an affirmation of gender 
identity in many trans persons. 
Trans women usually receive a combination of anti-androgen therapy together with estrogens to 
induce feminization. Testosteron therapy is used in trans men to induce masculinisation, often 
preceded by progestins to suppress menstruations. As, the focus of this thesis is to describe the 
clinical effects of cross-sex hormonal of trans persons, we will discuss this treatment in more 
detail in section 1.3. 
1.1.5.3 Surgery 
Sex reassignment surgery is often the last and the most considered step in the treatment process 
for gender dysphoria. Some trans persons live successfully in their desired gender role without 
surgery, for others surgery is needed to reduce their gender dysphoria. Surgery can involve many 
procedures (Table 1 and 2). SRS is the most relevant procedure and includes oophorectomy, 
penectomy and vaginoplasty in trans women and mastectomy, hysterectomy and ovariectomy in 
trans men. Trans men can proceed with a phalloplasty (creation of a full-sized phallus) or with 
metaidoioplasty (creation of a microphallus by surgical enhancement of the androgen dependent 
hypertrophy of the clitoris). Both procedures are generally combined with scrotoplasty and 
vaginectomy. Trans men who have a phalloplasty can proceed with the placement of an erection 
prosthesis. 
Table 1. Surgical  procedures   for  trans women  (adapted  from (5)) 
Breast surgery Genital surgery Non-genital, non-breast surgery  
Augmentation 
mammoplasty 
(implants/lipofilling) 
Penectomy 
Orchiectomy 
Vaginoplasty 
Clitoroplasty 
Vulvoplasty 
Facial feminization surgery 
Liposuction and lipofilling  
Voice surgery and/or thyroid cartilage 
reduction  
Gluteal augmentation 
(implants/lipofilling)  
Hair reconstruction 
Various aesthetic procedures 
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Table 2.  Surgical  procedures   for  trans men  (adapted  from (5)) 
Breast surgery Genital surgery Non-genital, non-breast surgery  
Subcutaneous 
mastectomy, creation 
of a male chest 
Hysterectomy 
Ovariectomy 
Metadoidioplasty  
Phalloplasty 
Vaginectomy 
Scrotoplasty 
Implantation of erection  
and/or testicular prostheses 
Voice surgery 
Liposuction or lipofilling 
Pectoral implants 
Various aesthetic procedures 
 
 
1.2 Sex steroids in   men and women 
Sex steroids are steroid hormones which play an essential role in sexual and reproductive 
functions as well as the development and maintenance of secondary sex characteristics. In 
addition, the sexual dimorphism of different organs and tissues also points out a major role for 
sex steroids in many other processes.  
1.2.1 Synthesis, secretion and regulation 
In both men and women, synthesis and secretion of sex steroids occurs in gonads and adrenal 
cortex and starts with the conversion of cholesterol into pregnenolone (Figure 1.2). After 
formation of pregnenolone, the specific hormones produced are dependent on the endocrine 
organ and cell type due to specific enzyme expression. In the adrenal cortex for example, zona 
glomerulosa and fasciculata lack different enzymes necessary for sex steroid production.  
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Figure 1.2. Major pathways in sex steroid synthesis (modified from(21)) 
 
While men and women both produce estrogens and androgens, the amount of sex hormone 
production is different and genetically predetermined. Prenatal sex steroid exposure in uterus 
plays a crucial role in the development of primary sex characteristics. Afterwards, production and 
secretion of sex steroids is very limited during childhood, apart from a transient ‘infant puberty’, 
whereas from puberty on the pulsatile frequency of gonadotropin-releasing hormone (GnRH) 
secretion triggers gonadotropin production, luteinizing hormone (LH) and follicle stimulating 
hormone (FSH). In general, the basic mechanisms of the hypothalamic-pituitary-gonadal axis are 
quite similar in women and men, but in women of reproductive age they are more complex due 
to the cyclical hormonal changes of the menstrual cycles imposed by the ovaries. 
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1.2.1.1 Regulation of the hypothalamic-pituitary-gonadal axis in women 
The menstrual cycle includes a follicular phase and a luteal phase. The follicular phase is 
characterized by recruitment of new follicles and maturation of a dominant follicle with 
progressive increase of follicular estrogen secretion towards the midcycle ovulation. After 
ovulation, the luteal phase is initiated which is characterized by the transformation of the follicle 
into a corpus luteum that secretes E1, E2 and progesterone. If no conception takes place, the 
cycle ends by the demise of the corpus luteum, with decrease of progesterone and estrogen 
secretion, which induces menstruation. 
This ovarian function is driven by coincidental pulsatile secretion of the pituitary gonadotropic 
hormones LH and FSH by the gonadotropes, which in turn is driven by release of the 
hypothalamic GnRH into the pituitary portal circulation. FSH is responsible for the early 
maturation of the ovarian follicles whereas both FSH and LH are needed for their final 
maturation. The midcycle surge of LH secretion induces ovulation and initiates the initial 
formation of the corpus luteum. LH stimulates conversion of cholesterol into androstenedione in 
the theca cell in the ovarian follicle and corpus luteum. The theca interna cell supplies 
androstenedione to the granulosa cell and the latter produce E1 and E2 through aromatization. 
FSH facilitates estrogen secretion by activation of FSH receptors on the granulosa cell. Mature 
follicles also express LH receptors and activation increases estrogen and progesterone synthesis.  
GnRH is normally secreted in episodic bursts, which is essential for normal secretion of 
gonadotropins. Besides this episodic secretion, fluctuations in both the frequency and amplitude 
of the GnRH bursts also play an important role in hormonal changes during menstrual cycle. 
These variations are induced, at least in part, by gonadal steroid feedback (Figure 1.3). The 
feedback of progesterone during the luteal phase lowers the frequency of episodic GnRH 
secretion, which in turn favours FSH relative to LH secretion by the pituitary gonadotropes and 
contributes to the recruitment of new follicles in the subsequent early follicular phase of the next 
cycle. The early follicular phase of the cycle consists of higher frequency low amplitude 
gonadotropin pulses, controlled by negative feedback action of E2 at both the pituitary and 
hypothalamic level. The FSH secretion is also regulated by negative feedback inhibition by 
inhibin B, a peptide hormone produced by the ovarian granulosa cells.  
The substantial progressive increase of E2 secretion by the dominant follicle towards midcycle 
results in a temporary reversal of negative feedback of E2 on gonadotropins into a positive 
feedback with massive secretion of gonadotropins of only a few hours duration. This so called 
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‘gonadotropin surge’ induces ovulation. During the subsequent luteal phase, the combined 
negative feedback effect of E2 and progesterone is to slow down the frequency of the 
hypothalamic GnRH pulse generator, with consequently a marked reduction of the frequency of 
gonadotropin pulses compared to the follicular phases. Because there is more time for 
accumulation of gonadotropins between pulses, they are of larger amplitude.  
After cessation of follicular ovarian activity at menopause or after removal of the ovaries, there 
are no longer cyclical changes in gonadotropin secretion and in absence of any substantial 
negative feedback by estrogens, mean gonadotropin levels are high and characterized by frequent 
large amplitude pulses; because of loss of negative feedback effect by inhibin B, FSH secretion is 
higher  than LH secretion.  
 
Figure 1.3 Regulation of the hypothalamic-pituitary-gonadal axis women (modified from(21)) 
 
More than 95% of E2 in the female circulation is produced in the ovary. In contrast to E2, 
approximately 50% of estrone is secreted in the ovary while the remaining is produced from 
peripheral conversion of mainly androstenedione, produced in the adrenal gland, and in a lesser 
extent E2. 
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The major androgens in the serum of women (with a normal menstrual cycle) are DHEAS, 
DHEA, androstenedione, T and dihydrotestosterone (DHT). DHEAS is almost exclusively 
produced in the adrenals whereas only half of the DHEA levels in women are produced in the 
adrenals. The remaining 50% are produced in the  the ovary (20%) or derived from peripheral 
conversion of DHEAS (30%). Half of serum T originates from conversion of these adrenal 
androgens whereas the ovaries and adrenals produce both 25% of serum T levels. 
1.2.1.2 Regulation of the hypothalamic-pituitary-gonadal axis in men 
In men, LH production and secretion, stimulates the Leydig cells to produce T where FSH 
stimulates spermatogenesis and inhibin B production by the Sertoli cells. The produced 
hormones are in turn involved in a negative feedback regulation of the gonadotropins (Figure 
1.4.) Androgens exert inhibitory actions on LH production at both the hypothalamic and 
pituitary level, whereas inhibin B is the main regulator of FSH secretion. Besides negative 
feedback by T itself on LH production, major negative feedback effects on LH secretion are in 
fact exerted by circulating E2 produced by aromatization of T
(22).  
 
Figure 1.4. Regulation of the hypothalamic-pituitary-gonadal axis in men 
 
Besides this production of T in testis, which accounts for 95% of serum T levels, 5% of T is 
secreted by the adrenals. In addition, the adrenals produce about 50% of androstenedione and 
almost all DHEA and DHEAS.  
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About 1% of the produced T in the testis is converted into E2 through conversion by the 
aromatase enzyme in peripheral tissues, which accounts for 80% of the circulating E2
(23). 
Aromatization mainly takes place in adipose tissue, but aromatase expression has also been 
observed in other tissues such as osteoblasts, muscle and brain(24). The remaining 20% of E2 in 
the male circulation is directly secreted by the testis through aromatization of androgens within 
the Leydig cells. In addition, a small fraction of E2 is derived from the conversion of E1, which 
itself is mainly derived from aromatization of androstenedione. Approximately 5% of T is 
converted to the more potent androgen, dihydrotestosterone DHT. This occurs by the 5α-
reductase enzyme at the tissue level in prostate, testis, skin and adrenal glands. A smaller amount 
of DHT is derived from peripheral conversion of androstenedione(25) or produced in the testis(26). 
1.2.2 Transport 
In the circulation, T and E2 are mostly bound to serum proteins: i.e., tightly bound to sex 
hormone binding globulin (SHBG) (40-60%), with much lower affinity to albumin (40-50%)  and 
a small fraction to corticosteroid-binding globulin (CBG) (<5%)(27). E2 binds to SHBG with a 
lower affinity than T. Only a small fraction (1-4%) of sex steroids is unbound, or "free"(28). The 
free fractions are directly available to enter the cell and initiate metabolic actions. In addition, 
some hormone fractions, weakly bound to serum albumin, may dissociate from the protein 
during passage in the tissues and enter the cells. Therefore, both unbound and albumin-bound 
sex steroids are seen as the biologically available T and E2 fractions
(29).  
1.2.3 Mechanism of action 
1.2.3.1 Nuclear binding of sex steroid hormones 
Action of sex steroids at cellular level occurs by binding to their respective nuclear receptor: 
estrogen receptor alpha (ERα) and beta (ERβ) for estrogens and the androgen receptor (AR) for 
T and DHT. The AR does not bind androstenedione or DHEA(S) and their androgenic effects 
are supposed by their local transformation to T. Binding of sex steroids with their respective 
receptor induces a conformational change in the receptors protein structure resulting in a 
dissociation of the AR from chaperone proteins. After dimerization, the activated receptor is 
translocated to the nucleus, where it binds to a specific AR- or ER-response element on the 
promoter regions of the target genes, stimulating transcription of a specific target gene. 
Additionally, specific co-regulators can enhance or reduce transcription activation(30). 
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1.2.3.2 Non-genomic effects of sex steroids 
Although sex steroids are known to exert most of their action through the classical genomic 
regulation of gene transcription, there is also evidence for rapid activation via 'non-genomic' 
pathways, which do not depend on gene transcription or protein synthesis but involve steroid-
induced modulation of cytoplasmic or cell membrane-bound regulatory proteins(31). Up till now, 
the receptor mechanisms mediating these rapid effects are still not entirely understood. 
 
Figure 1.5.  Nongenomic and genomic androgen mechanisms (modified from
(32)
) 
Left, Nongenomic effects of testosterone, which are triggered by binding to a still uncharacterized (nonclassical) 
membrane receptor. This activates second messengers including calcium and protein kinases, which produce typically 
rapid responses. Genomic effects are depicted in the middle and on the right. Testosterone (or other aromatizable 
synthetic androgens) crosses the cell membrane to be converted to estradiol (or the aromatic synthetic analog) by 
aromatase, which then binds to and activates ERα or ERβ. Right, DHT (or other nonaromatizable androgens) enters 
the cell to bind and activate the AR. Ligand-bound ER or AR dissociate their heat-shock protein (HSP), undergo 
conformational changes, dimerize, and translocate into the nucleus where they bind to specific sites known as 
estrogen response elements (ERE) or androgen response elements (ARE) located within the DNA of target nuclear 
genes to produce long-term genomic effects of testosterone. 
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1.2.4 Clinical effects of sex steroids 
Sex steroid receptors are widely spread throughout the body and are therefore responsible for the 
development and function of reproductive organs but also play a role in the development and 
function of many other tissues and systems, such as muscle, fat, bone, skin, the larynx, immune 
system, hematopoietic cells and cardiovascular system. Sex steroid receptors are also expressed in 
brain tissue and it is well-established that they play a major role on motivational aspects of sexual 
functioning. In the next section, these effects will be discussed in more detail. 
1.2.4.1 Sex steroids and the skin pilosebaceous unit 
Sex steroids are well-known to affect the skin pilosebaceous unit (PSU) and both androgen and 
estrogen receptors are expressed in the sebocytes and hair follicle dermal papilla(33, 34). The 
biological action of T on the skin and scalp, is mostly effected by its local conversion to the more 
potent DHT by 5α-reductase. Two isoforms have been described; type 1 is predominant in 
sebaceous and sweat glands, with lesser activity in epidermal cells and hair follicles(35). Type 2 
activity dominates in beard hair follicles. T can also be converted to E2 by the aromatase enzyme; 
the latter is also prominently present in the PSU(36). 
Androgens play a central role in the stimulation of the sebaceous gland growth and 
differentiation(37, 38). They exert also strong effects on hair growth by their effects through type 2 
5α-reductase and the AR on dermal papilla cells(37). Indeed, men with a deficiency of type 2 5α-
reductase have little or no beard growth and do not develop androgenetic alopecia(39). Also, the 
inhibition of type 2 5α-reductase by finasteride has been proven to slow the progression of 
androgenic alopecia(40). Androgens cause an increase in the size of hair follicles and the diameter 
of the hair in androgen-dependent areas (beard in male adolescents, axillary and pubic hair); 
However in scalp follicles of susceptible men androgens paradoxically foster miniaturization and 
shortage of hair in the anagen phase leading to androgenic alopecia(41). These contradictory effects 
may be explained by genetically determined differences in the response of papilla cells to 
androgens at different body areas(37). 
The effects of E2 on the PSU unit are less well-known
(42). Estrogens reduce the size and secretion 
of sebaceous glands indirectly by pituitary-gonadal suppression of androgen production(37). 
Estrogens are also known to play an important direct role in human hair growth control(42). They 
are thought to prolong the anagen phase of scalp hair growth by increasing cell proliferation rates 
and postponing their transition to the telogen phase(41). Also, low dose estrogen therapy has been 
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found to stimulate pubic and axillary hair growth of hypogonadal girls, independently of changes 
in androgen levels(43). Similar effects of E2 are described in pregnancy: due to high E2 levels, many 
scalp hair follicles remain in anagen phase(44). However, in the postpartum, a large number of hair 
follicles simultaneously advance into telogen phase due to a sudden decrease in E2 levels, causing 
loss of a large number of hairs, which is described as the postpartum telogen effluvium(45). 
As sex steroids strongly affect the skin pilosebaceous unit, several clinical conditions of the skin 
such as hirsutism, acne and androgenic alopecia are often treated with anti-androgenic and/or 
estrogenic medication (such as cyproterone acetate(46), 5α-reductase inhibitors(47) and combined 
oral contraceptives (COC’s)(48). 
1.2.4.2 Sex steroids, body composition, and bone 
1.2.4.2.1 Fat mass 
Gender differences in fat metabolism are well-recognized. Women generally have a higher 
amount of body fat mass than men(49). In addition, premenopausal women store fat mass 
preferentially in the subcutaneous areas, mainly at the gluteal and femoral regions, the so-called 
‘pear’ or gynoid body shape whereas men store predominantly visceral fat mass in the abdominal 
area (‘apple’ or android body shape)(49). It is well-known that mainly visceral fat mass is associated 
with detrimental effects such as dyslipidemia, insulin resistance, metabolic syndrome, systemic 
inflammation, diabetes, and cardiovascular disease(50-54). 
As  most of the differences between both genders occur from puberty on, important effects of 
sex steroids on body composition are suspected. Indeed, androgen receptors are expressed in 
both adipocytes and preadipocytes(55-56), with a higher expression in visceral compared to 
subcutaneous adipocytes and preadipocytes(57-58). Androgens inhibit the differentiation of 
preadipocytes and interfere with lipid metabolism: T inhibits lipid uptake and lipoprotein lipase 
activity, and stimulates lipolysis(59-60). Low T levels in men, for example in men treated by 
androgen deprivation therapy for prostate cancer, will enhance lipid uptake and decrease lipolysis 
mostly in the abdominal fat tissue resulting in a more centrally fat storage(59-63).   
Not only androgen receptors but also estrogen receptors (ERα and ERβ) are expressed in both 
visceral and subcutaneous fat tissue(64). Concerning ER-subtypes, it was found that the expression 
of ERα is much higher compared to ERβ. In contrast to the AR, no regional differences were 
found in ERα expression in subcutaneous versus visceral adipose tissue. 
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The important roles of estrogens are illustrated by observations in ERα KO mice and men with 
estrogen deficiency or resistance(65-68): they develop an increase in total body fat mass with 
profound insulin resistance and impaired glucose tolerance. ERβ KO mice have a similar body 
weight and an equal fat distribution in comparison to wild type mice(67) indicating that ERα is 
more important than ERβ in preventing fat tissue deposition. Reduced ERα expression and 
impaired ERα function as well as some polymorphisms of the human ERα gene have been linked 
with an increased prevalence of several aspects of the metabolic syndrome(65, 69-71). The molecular 
and cell-biological mechanisms underlying the metabolic actions of estrogen are still poorly 
understood(72) but evidence demonstrates that E2 has direct effects on cultured adipocytes with 
the overall effect of inhibiting lipogenesis and adipogenesis(73-74). Interestingly, although the 
overall effect of E2 is to decrease lipid deposition in adipose tissue, E2 is known to favour 
subcutaneous adipose tissue accumulation by central(75)and peripheral mechanisms(74, 76). The 
important role of estrogens on adipose tissue can also be seen in both animal- and clinical studies 
after oophorectomy. These studies show that women experience an increase in abdominal fat 
mass after oophorectomy, putting them at a risk for glucose intolerance and cardiovascular 
disease. Interestingly, when supplemented with estrogens, these effects can be reversed(77-78).  
The traditional view of adipose tissue as a passive reservoir for energy storage is no longer 
valid(79). Adipose tissue is also an important site of steroid hormone biosynthesis and metabolism. 
Several steroid metabolizing enzymes such as aromatase enzyme are expressed in adipose tissue. 
This local sex steroid conversion may contribute to effects of T and E2 on adipose tissue. 
Aromatase KO mice or patients lacking aromatase activity, with reduced endogenous production 
of estrogens, both show distinct metabolic phenotypes with an increased adiposity accompanied 
by decreased glucose tolerance and pronounced insulin resistance(65, 80-82). Besides sex steroids 
metabolism, adipose tissue expresses and secretes a wide variety of bioactive peptides, known as 
adipokines, which can act both at local or systemic level. These adipokines appear to be involved 
in a wide range of physiological processes such as haemostasis (e.g., plasminogen activator 
inhibitor 1), lipid metabolism (e.g., apolipoprotein E), blood pressure regulation 
(angiotensinogen), insulin sensitivity (e.g., adiponectin), inflammation (e.g., IL-6) and 
angiogenesis (e.g., vascular endothelial growth factor). In addition, a variety of receptors such as 
cytokine-, catecholamine-, and hormonal receptors are expressed,  allowing for communication 
with distant organs such as the central nervous system(79). 
Besides a determining role of sex steroids on body composition, there is also evidence for 
reciprocal effects of body composition on sex steroid levels. Obesity is for example associated 
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with a higher aromatase activity, resulting in an increased E2 production
(83-87). The latter will in 
turn decrease T levels due to suppression of the hypothalamic pituitary axis. Conversely, weight 
loss in obese men has been associated with increasing levels of T, and with decreasing levels of 
E2, reflecting lower aromatase activity due to decreasing levels of fat mass
(85). Furthermore, 
adiposity is a major determinant of serum SHBG concentrations and has therefore marked 
effects on total levels of circulating sex steroids with obesity characterized by low SHBG and 
(total) sex steroid levels. 
1.2.4.2.2 Muscle mass 
Similarly as for fat mass, muscle mass differs between men and women. In general, men have 
more muscle mass and greater muscle strength compared to women. Indeed, the anabolic effects 
of T on muscle metabolism are well-established and androgens are therefore widely used among 
athletes and bodybuilders. Both AR as well ER (both α and β) are expressed in muscle cells(88-89). 
Testosterone is found to increase myoblast protein synthesis, the cross-sectional area of muscle 
fibers (both type 1 and 2) and the number of myonuclei and satellite cells in a dose- and 
concentration-dependent manner(90-92). Estrogens are known to exert several effects on skeletal 
muscle mass and functions, such as on muscle contractile properties, reducing post-exercise 
muscle damage and infiltration of inflammatory cells, and increasing muscle repair and 
regenerative processes. But the exact molecular and cell-biological pathways remain poorly 
understood(93-94). 
Besides its role on locomotion and maintaining posture, skeletal muscle plays a key role in bone 
metabolism by its active loading on the bone surface and thereby stimulating bone mineralization 
and growth(95-96), which is also known as ‘the mechanostat theory’(97). In addition, muscle tissue 
contributes to glucose metabolism, as a major proportion of glucose utilization takes place in the 
muscles.  
The importance of sex steroid effects on muscle and fat mass and function, suggests that drastic 
changes in sex steroids may therefore have important metabolic consequences. 
1.2.4.2.3 Bone  
Sex steroids play a pivotal role in the regulation of bone formation by both direct and indirect 
effects on bone growth. Prepubertal boys and girls have in general a comparable bone mass and 
size. However, from puberty on, bone mass and size increase in boys and girls, but in boys this 
increase is on average 10% greater due to a higher rate of periosteal apposition and the longer 
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duration of pre- and intrapubertal growth in boys. Besides these differences in size and cortical 
thickness, long bones in boys also acquire a relatively larger marrow cavity compared to girls.  
Apart from the bone formation and achievement of peak bone mass, sex steroids also affect the 
maintenance of bone health through indirect effects and direct effects by AR’s as well as ER’s in 
osteoblasts, osteocytes and osteoclasts(98-101). This maintenance of the adult skeleton is achieved 
by a continuous process of renewal and repair, called the ‘bone remodeling’. This process occurs 
in basic multicellular units, which include osteocytes, osteoblasts and osteoclasts, localized within 
the bone remodeling cavity. Bone remodeling is strongly regulated by central, systemic and local 
factors and is characterized by a cycle of sequential periods of activation, bone resorption, 
reversal and bone formation within a basic multicellular unit. Osteocytes recruit osteoclasts to 
sites of microdamage and initiate bone resorption. The resulting defects are repaired by 
osteoblasts as they produce a new matrix which is mineralized afterwards. 
The actions of E2 on bone metabolism are multiple. In vitro research showed that E2 increases 
expression of osteoprotegerin in the osteoblast(102), while decreasing that of RANKL, resulting in 
decreased RANK-activation, which in turn reduces osteoclast activation(103-104). Other effects of E2 
include the reduction of osteoclastogenesis, stimulation of osteoclast apoptosis, and an increase 
of osteoblasts lifespan(105-107). Alternatively, androgens are found to stimulate the proliferation and 
differentiation of osteoblast precursor cells(108), and to inhibit osteoclastogenesis, directly(109)or 
through osteoblastic activity(109-110). Importantly, in a mice model it was found that androgens are 
exclusively responsible for trabecular bone development and maintenance, while both androgen 
and estrogen action are needed for the development and maintenance of cortical bone(111). 
The clinical effects of estrogen deprivation, as seen in postmenopausal women are well-known, 
with a manifest increase of bone remodeling, bone resorption and thus bone loss, resulting in a 
high prevalence of osteoporosis(112). A large number of studies have been conducted to evaluate 
the effect of estrogen administration on bone mass in postmenopausal women and generally all 
studies showed that estrogens (natural and synthetic, oral or transdermal) reduce bone 
remodeling and bone resorption and thus the loss of bone mass.  
Hypogonadal men also show significantly increased bone remodeling and bone resorption, 
resulting in lower bone density than age- and sex-matched controls, especially at trabecular 
skeletal site(113), but also at cortical sites. T replacement therapy in these men results in an increase 
in bone mineral density(114), which is mainly substantial in hypogonadal men before closure of the 
epiphyseal growth plates. The effects of T during bone acquisition and in maintenance of skeletal 
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integrity in adult men are due to direct effects of T on bone, indirect effects of T on bone after 
aromatization to E2, and indirect effect of T through increase and maintenance of muscle 
mass(115). 
1.2.4.3  Sex steroids and cardiovascular effects 
1.2.4.3.1 Sex steroids and cardiovascular risk factors 
Premenopausal women suffer less from cardiovascular disease than men, but the incidence of 
cardiovascular disease rises after menopause. Traditionally, the sex difference in cardiovascular 
morbidity and mortality has been attributed to the endocrine profiles of adult men and women, 
surmising that androgens are deleterious and estrogens favourable for cardiovascular health. 
However, this assumption is becoming increasingly questioned(116). Nevertheless, it is well-
recognized that sex steroids influence different cardiovascular risk factors such as lipids, blood 
pressure, hemostasis and risk of thrombosis, glucose metabolism and endothelial function. We 
will discuss these functions in more detail and will end with the overall relation between sex 
hormones and cardiovascular end points. 
1.2.4.3.1.1 Glucose metabolism 
As already mentioned in section 1.4.2.2.1. and 1.4.2.2.2, sex steroids exert important effects on 
muscle and fat mass and function, with important metabolic and cardiovascular consequences. 
The increase in visceral fat, as for example seen in hypogonadal men, has been related to 
dyslipidemia, insulin resistance, metabolic syndrome, systemic inflammation, diabetes, and 
cardiovascular disease(50-52). Apart from these indirect effects of sex steroids, some studies(117-118), 
but not all(119), showed evidence for direct effects of sex steroids on glucose metabolism. Acute T 
withdrawal in men, for example, was found to decrease insulin sensitivity in the absence of any 
detectable changes in body composition. Also, large epidemiological studies show that the 
association between low T levels and insulin resistance persists after adjusting for total body fat 
mass(120, 121). However, whether some of the effects of T on insulin resistance are related to 
peripheral conversion to E2, is still poorly understood
(118).  
Compared to their age-matched counterparts, premenopausal women (with a normal menstrual 
history) have enhanced insulin sensitivity. Menopause and ovariectomy result in a marked decline 
in insulin sensitivity, in parallel with an increase in fat mass and rise in lower low-density 
lipoprotein cholesterol (LDL-C), triglycerides and fatty acids(74); whereas restoration of E2 in 
physiological doses can maintain insulin action and glucose tolerance(122). Evidence for direct 
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effects of cross-sex hormones has also been described. Pregnancy and luteal phase of the 
menstrual cycle, both characterized by elevated E2 and progesterone levels, are associated with 
reduced insulin sensitivity(123-124).  Indeed, it is argued that E2 favours insulin sensitivity when E2 
levels stay within a tight physiological concentration(74). On the contrary, augmentation of E2 to 
supraphysiological levels were shown to induce insulin resistance by both hyperinsulinemia in the 
liver and reduction in GLUT 4 expression within the muscle(125). 
1.2.4.3.1.2 Lipids 
Women have a less proatherogenic plasma lipid profile than men. In particular, women have a 
higher high-density lipoprotein cholesterol (HDL-C) concentration and LDL-C, very low-density 
lipoprotein cholesterol (VLDL-C) and total plasma triglyceride concentrations compared to age-
matched men(126-128). In addition, the average size of circulating VLDL particles is smaller in 
women whereas the average size of LDL and HDL particles is larger in women than men(128-130). 
It is generally thought that these sex differences in plasma lipid profile are caused by differences 
in sex steroid levels, but this assumption has been questioned(128). The already mentioned 
important gender differences in body composition may also contribute as total body adiposity, 
visceral fat storage, and insulin resistance are associated with increased plasma triglyceride and 
LDL-C and decreased HDL-C concentrations(131). However, many other factors such as gender 
differences in insulin and adipokine action, gene expression and gene imprinting may also 
contribute(128). 
Our knowledge concerning the effects of E2 and T on lipid profile is mostly based on studies 
investigating the effects of hormone therapy in men and pre- and post-menopausal women. In 
Table 3, a summary of these effects can be found. These studies also show that the mode of 
administration(132-133), i.e., oral, intramuscular or  transdermal, plays an important role probably 
due the hepatic “first-pass” effect. In addition, different effects can be found in relation to the 
dosage as well as the chemical nature of the hormone preparations.  
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Table  3. Effects of sex steroid therapy on lipid metabolism (adapted from (126))  
 Estrogens Progestogens Non-aromatisable   Androgens 
 Oral parental Oral and  parental Men women 
Total and VLDL 
Triglycerideconcentrations 
↑↑ ↓ or ↔ ↓ ↔ ↔ 
VLDL triglyceride 
production 
↑↑ ? ↔ ? ? 
VLDL triglyceride removal ↔ ? ↑ ? ? 
HDL concentrations ↑↑ ↑ or ↔ ↓ ↓↓ ↓↓ 
HDL apolipoprotein A-I 
production 
↑↑ ↔ ↓↓ ↓↓ ↓↓ 
HDL apolipoprotein A-I 
removal 
↔ ↔ ↓ ↑↑ ↑↑ 
HDL apolipoprotein A-
2production 
↔ ? ? ? ? 
HDL apolipoprotein A-2 
removal 
↔ ? ? ? ? 
LDL concentrations ↓↓ ↓ or ↔ ↓ or ↔ ↑ or ↔ ↑ or ↔ 
LDL apolipoprotein B-100 
production 
↑ ↔ ↑ or ↔ ? ? 
LDL apolipoprotein B-100 
removal 
↑↑ ↔ ↑ or ↔ ? ? 
↑, Increase; ↓, decrease; ↔, no effect, ? unknown . Double arrows indicate more pronounced 
effects than single arrows. 
 
1.2.4.3.1.3 Endothelial function 
The endothelium plays a major role in vascular physiology and contributes to maintain vascular 
tone and non-thrombogenic properties of the endothelial surface. Atherosclerosis, a chronic 
inflammatory and multifactorial process, characterized by the formation of atheromatous plaques, 
arterial wall thickening, and lumen narrowing, is a consequence of endothelial dysfunction(134). 
Endothelial dysfunction is initiated by injury of the endothelium by shear stress and exposure to 
toxins (e.g., tobacco components) and atherogenic lipids. This dysfunctional endothelium is 
impaired to preserve vascular tone and its non-thrombogenic features. In addition, activated 
endothelial cells express selectins, integrins and adhesion molecules to which monocytes and T 
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lymphocytes bind before migration into the subendothelial space. Afterwards, monocytes 
differentiate into macrophages which take up modified lipoproteins, such as oxidized LDL, and 
further differentiate into foam cells. The latter, together with T lymphocytes, stimulate 
proliferation and migration of smooth muscle cells by release of inflammatory factors resulting in 
the so-called fatty streak, which further evolve into an atherosclerotic plaque. Endothelial 
function is regulated by many factors, including sex steroid hormones. ER’s and AR’s are present 
at the vascular endothelium and smooth muscle cell, but sex steroid functions are also mediated 
by non genomic effects(135-136). Importantly, aromatase, 5α-reductase and other steroid-modifying 
enzymes are also expressed at the vascular endothelium and smooth muscle cell as well as in 
macrophages and platelets(137-140). 
Studies in mice show mainly protective effects of E2 on endothelial function, including 
vasodilatation(141), promoting re-endothelialization, inhibiting smooth muscle cell proliferation(142) 
and matrix deposition following vascular injury, and attenuating atherosclerotic plaque 
progression(143). Importantly, different types of estrogens, estrogen dosages or route of 
administration may exert different effects(144). 
The effects of T are less well studied. While some animal and clinical studies suggest that T 
indeed exerts deleterious effects on the vascular wall by enhancing vascular tone(145-147),  others 
show that T is associated with protective effects by inducing vasorelaxation of vascular smooth 
muscle cells(148-150). Besides regulation of vascular tone, smooth muscle cells also contribute in the 
atherosclerosis process by proliferation, migration and matrix production. In contrast to the 
already mentioned inhibiting effects of E2 on smooth muscle cell proliferation and matrix 
deposition(142), some studies(151-152) but not all(153) showed that T increased proliferation and 
migration of smooth muscle cells. In addition, T may increase oxidation of LDL by macrophages. 
A summary of the metabolism and mode of action of sex steroids in the vascular cells can be 
found in Figure 1.6. 
  
   
 
41 
Chapter 1 . Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aromatse 
 
 
 
Figure 1.6.  Metabolism and mode of action of sex steroids in vascular cells (modified from(154)).      
SMC: smooth muscle cell, EC: endothelial cell. 
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Macrophages: decreased uptake oxLDL en 
cytokines    
 
DHEAS 
DHEA 
Estrone 
Estradiol 
17α-OH 
Progesterone 
Androstenedione 
Testosterone 
DHT 
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1.2.4.3.1.4 Blood pressure 
Men typically have higher blood pressures than premenopausal women. The sexual dimorphism 
in blood pressure begins at puberty and persists through adult age, until after menopause when 
the prevalence of hypertension is at least as prevalent in women as in age-matched men(155-157). 
These findings may suggest an important role of sex steroids. Effects of sex steroids on blood 
pressure can be mediated by effects on the vascular tone (cfr. above), vascular growth, kidney and 
sympathetic nervous system. Indeed, sex steroid receptors are present at the endothelium, 
smooth muscle cells, the kidney and sympathetic nervous system(148, 158-159). 
Support for the antihypertensive effects of E2  can be found in the observations that during the 
menstrual cycle, blood pressure is lower during luteal phase than follicular phase(157, 160-161) and that 
pregnancy is generally associated with lower blood pressure(157,162). In contrast, clinical studies on 
the effects of estrogen therapy such as combined oral contraceptives (COC) or postmenopausal 
hormone replacement therapy showed inconsistent results, with some studies showing a decrease 
of blood pressure(163-164), whereas others observed no effect(165-166) or an increase(167-169). Once more, 
these findings are complicated by differences in type, dosage and route of administration of 
estrogens.  
Few data are available on the associations between T and blood pressure in biological women. In 
women with or without PCOS (polycystic ovary syndrome), a positive association between serum 
androgen levels and blood pressure(170-171) whereas others were unable to show such an 
association(172). In contrast, in men several studies(173-175) found an inverse association between 
serum T levels and blood pressure; and low levels of T have been reported in men with 
hypertension(176, 177). Moreover, T substitution in hypogonadal men and patients with metabolic 
syndrome was found to decrease blood pressure levels(178-180). Concerning supraphysiological 
levels of T, as seen in anabolic-androgenic steroids users, some studies observed no change in 
blood pressure(181-183) whereas others found a significant increase(184-186).  
1.2.4.3.1.5 Hemostasis and thrombosis 
Estrogens are known to affect the coagulation system. High E2 levels, e.g., during pregnancy, are 
known to induce a prothrombotic state resulting in an increased risk for venous thrombosis(187). 
In addition, COC use and hormone replacement therapy are both associated with a higher risk 
for venous thrombosis(188-189). The haemostatic changes in women taking hormone replacement 
therapy and COC’s are characterized by changes in procoagulant- (e.g., prothrombin), 
anticoagulant- (e.g., protein S and tissue factor pathway inhibitor) and fibrinolytic parameters(190). 
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Thrombin generation-based activated protein C (APC) sensitivity is a global test for the overall 
prothrombotic effect and predicts the risk of venous thrombosis(191). Significant differences exist 
between different types of COC’s, with third generation COC’s with newer progestins showing a 
higher risk than second generation COC’s. In addition, COC’s with a higher estrogen dosage 
showed a higher risk than those with lower estrogen dosage(192). Of interest, use of COC’s 
containing cyproterone acetate may be associated with an excess risk for venous thrombosis 
comparable to third generation COC’s or even higher(193). As already mentioned, different effects 
can also be seen in relation to the route of administration. The transdermal route avoids the first 
pass effect of the liver and this may induce different metabolic effects. Indeed, a reduced 
activation of the haemostatic system in transdermal estrogens has been observed(194) and a lower 
venous thrombosis risk is described in women using transdermal than oral COC’s and HRT(195-
197).  
In men, abuse of anabolic-androgenic steroids by athletes has been associated with cardiovascular 
morbidity(198). T administration can induce erythrocytosis and affects the expression of platelet 
tromboxane A2 receptors(199), both pro-thrombotic factors. Interestingly, the risk for 
development of erythrocytosis during T treatment in men is greater in older men than in young 
men(200), and when administrating intramuscular T ester injections compared to oral or 
transdermal T therapy(201). Some studies observed a dose-dependent effect of T treatment(90), 
whereas others were unable to confirm this(200). Considering aromatase expression in vascular 
cells, some authors suggested that some pro-thrombotic effects of T therapy in men may be 
related to higher E2
(202). 
1.2.4.3.2 Sex steroids and cardiovascular morbidity 
As stated above, sex steroids strongly affect different cardiovascular risk factors. E2 was mainly 
associated with beneficial effects on cardiovascular system, whereas T was mostly related to 
deleterious effects on cardiovascular health. Whether these associations with cardiovascular risk 
factors can be translated into cardiovascular morbidity will be discussed below.  
Observations that cardiovascular morbidity rises after menopause, although not abruptly, are 
consistent with a protective cardiovascular effect of E2. About three decades ago, data from large 
observational studies also suggested that hormonal therapy resulted in a reduction in coronary 
heart disease and mortality(203-205). In contrast with these protective effects of estrogen treatment, 
data from the first large scale randomized controlled trials (The Women’s Health Initiative Trials) 
showed no coronary protective effects of hormone replacement therapy and even harmful effects 
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in some women(206). However, recent analyses show the importance of the relationship between 
timing of HRT initiation and underlying differences in vascular biology that exist between 
perimenopausal and older women. These showed that younger women at the start of menopause 
experienced beneficial effects from hormone replacement therapy whereas older women 
experienced harmful effects(207, 208). A recent randomized controlled trial (Danish Osteoporosis 
Prevention Study) also showed a reduction in a combined end-point of mortality and 
hospitalizations for congestive heart failure or myocardial infarction in women using hormone 
replacement therapy(209). Alternatively, women of reproductive age using COC’s were found to 
have a higher risk for myocardial infarction, in a dose-dependent way(210). In addition, the majority 
of evidence suggests a small but significant increase in ischemic stroke in women using COC’s(211) 
and in postmenopausal women (even younger ones) using oral estrogens(212). Concerning the 
associations between T levels and cardiovascular health in women, some studies(213, 214) but not 
all(215) have found a negative association with cardiovascular risk profile, but so far evidence for 
an association with cardiovascular events is lacking(216). 
In men, most cross-sectional studies have associated lower endogenous serum T levels in men 
with a higher prevalence of cardiovascular disease(217). Some prospective population-based studies 
showed no association(218), but the majority found a modest inverse association between T and 
cardiovascular disease in men(219-220, 203) (for review see(221)). Our knowledge concerning effects of 
T treatment on cardiovascular health is sparse with only a few, small sample size randomized 
controlled trials(221). With respect to the association of endogenous E2 and cardiovascular disease 
in men, a recent meta-analysis of prospective studies did not provide evidence for either 
protective or harmful effect of total E2 concentrations on risk for incident cardiovascular disease 
in men(222).  
1.2.4.4 Sex steroids, brain and behaviour 
Testosterone and E2 receptors are widespread throughout the entire brain
(223-225) and sex steroids 
are thought to be responsible, at least in part, for the sexual differentiation in brain and 
behaviour(226). Effects of sex steroids on the brain can be categorized as organizational or 
activational(226-227). Organizational effects refer to the ability of sex steroids to form nervous 
system structure during development. These effects are permanent and programs activitional 
responses to sex steroids. In contrast, activational effects of sex steroids are transient, depend on 
hormone levels and include the ability to change activity of cells which then facilitates certain 
behaviour(226, 227).  
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In this section we will elaborate on some effects sex steroids on mood and behaviour, more 
specifically we will discuss the effects of  T and E2  on  motivational aspects of sexual functioning, 
depressive mood and aggressive behaviour.  
1.2.4.4.1 Motivational aspect of sexual functioning 
T affects motivational aspects of sexual functioning such as sexual desire in men(228). Loss of 
sexual desire is one of the key clinical signs of hypogonadism and numerous studies consequently 
showed an increase in sexual desire during T administration in hypogonadal young and aging 
men(229-232). Whether supraphysiological levels of T affects sexual desire in men is not well-known, 
as some authors(232) described a significant increase whereas others did not(233- 234). In contrast, the 
role of androgens in female sexual desire is not well-known with inconsistent and often 
contradictory evidence(228). Some studies found a correlation between serum T levels and sexual 
desire in women(235-236), whereas other studies did not observe such an association(237-238). In 
addition, several studies(239-240), but not all(241), observed that T supplementation in women with 
surgical or natural menopause increased sexual desire.  
Effects of estrogens on sexual desire in men and women are poorly understood(228). Only a few 
studies examined the relation between sexual desire and circulating estradiol levels in men, but 
most studies observed no clear associations(242-243). In contrast, administration of exogenous 
estrogens has been used historically as an anti-androgen treatment in prostate cancer patients and 
sex offenders, in whom a reduction in sexual desire was observed(228). In women, some(244) but not 
all studies(245-246), observed associations between E2 levels and sexual desire. Several studies 
examining the effects of estrogen therapy in postmenopausal women found an increase in sexual 
desire(246-247). However, others reported that high doses of estrogens were associated with lower 
sexual desire(248-249). 
1.2.4.4.2 Depressive mood 
The lifetime prevalence of a major depressive disorder in women is almost twice that in men(250-
251). This has led to the hypothesis that sex steroids are involved in this sex difference.  
Hypogonadism in young men has been associated with depressive mood and T replacement has 
been found to improve mood of these men(252- 253). In older men this association between T levels 
and depressive symptoms is less clear with some(254) but not all(255-257) observing an association. 
Supraphysiological levels of T in healthy young men were found to increase ratings of manic 
symptoms, although most showed little change, while a few developed prominent effects(258). 
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Alternatively, depressive symptoms are commonly reported in men using anabolic androgenic 
steroids(259-260), but depression in these men can also be related due to withdrawing from 
steroids(259). 
The role of T on depressive mood in women is not well-known and some studies found inverse 
relationships between depressive symptoms and total and T levels(235) whereas others failed to 
show such an association(261). A recent randomized double blinded placebo controlled study 
observed no benefit of 150 µg T patch on mood in women with primary ovarian insufficiency(262),  
whereas a randomized double blinded placebo controlled study in androgen deficient women 
with hypopituitarism did show an improvement(263). In postmenopausal women treated with T 
patch, an improvement in depressive symptoms was found(241) whereas a prospective population 
based study in 3302 women showed that an increase in T levels from baseline were significantly 
associated with higher depression scores independently of multiple covariates and confounders 
including menopausal status and vasomotor symptoms(264). 
The role of E2 on depressive symptoms remains unclear. Some epidemiological and clinical 
studies have suggested that lower levels of E2 or a more pronounced decrease in E2 levels were 
associated with depressed mood(265,-266) whereas others were unable to find such an association(267-
268). In postmenopausal women an improvement in psychological well-being was reported after 
treatment with HRT(269-270).  
1.2.4.4.3 Aggressive behaviour 
In animals studies, the association between T and aggressive behaviour is well recognized(271- 272), 
whereas in humans this association is more controversial. Two meta-analyses observed an overall 
weak positive association between T and aggressive behaviour(272-273). 
Some studies(258) but not all(90, 274) found that supraphysiological levels of T, are associated with an 
increase in aggressive behaviour. In young men using (long-term) anabolic androgenic steroid 
use, aggressive behaviour is one of the most often reported side effects(258, 275). Moreover, young 
males who used anabolic androgenic steroids were more likely to engage in violent acts than were 
those that did not use(276). Importantly, it has also been described that these behavioural 
consequences are not simply determined by the presence of very high levels of androgens but 
through influence of the central nervous system and changes of the behavioural response to a 
variety of stimuli(277). 
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1.3 Cross-sex hormonal therapy in trans persons 
As stated above, cross-sex hormone treatment often plays a key role in the treatment of trans 
persons. The two main aims of hormone treatment are firstly to reduce endogenous hormone 
levels and thereby the secondary sex characteristics of the individual’s biological sex and assigned 
gender, and secondly to replace endogenous sex hormone levels with those of the desired sex by 
using cross-sex hormones. Besides inducing physical changes, the act of using cross-sex 
hormones is itself an affirmation of gender identity. In addition, cross-sex hormone therapy may 
help trans persons in changing their gender role, as many trans persons change their gender role 
around the time of starting hormonal therapy.  
1.3.1 Cross-sex hormone therapy in trans women 
As already mentioned, a combination of estrogens and ‘anti-androgens’ and/or androgen 
lowering therapy is the most commonly used and studied treatment regimen to obtain 
feminization in trans women. In the literature, a wide variation of types and doses of estrogens 
and anti-androgens and/or androgen lowering medication have been described, all resulting in 
feminization (Table 4). As up till now no randomized controlled trials have been performed, little 
information is available on the optimal formulations and dosages.  
Androgen deprivation can be achieved by reducing endogenous T levels and/or T activity by 
blocking androgen receptor or blocking the conversion of T to the more potent DHT. The use 
of anti-androgens and/or androgen lowering therapy permits lower doses of estrogen needed to 
suppress T, and so reduces the associated risks of high-dose exogenous estrogen exposure. 
Estrogens can be administered orally, transdermally or parentally using various types of 
estrogens. 
Anti-androgen therapy and/or androgen lowering therapy can be stopped after oophorectomy 
and some physicians also lower estrogen dosage at that time(278). Current endocrine guidelines also 
suggest adjusting the hormone dosage for comorbid health concerns, similar as in hormonal 
replacement therapy for hypogonadism(5).  
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Table 1.   Common hormone treatment regimens currently used in trans women  (adapted  from (5)) 
Anti-androgen and/or androgen lowering therapy Estrogen therapy  
Spironolactone 100-200 mg daily 
Cyproterone acetate 50-100 mg daily 
GnRH agonist 3.75 mg sc monthly 
Oral estradiol 
        Ethinyl estradiol 50-100 µg daily 
        Estradiol valerate 4-6 mg daily  
        Conjugated equine estrogens 1.5-5 mg daily 
Transdermal estradiol 
        Estradiol gel 4mg daily 
        Estradiol patch 100 µg/24 h 
Parental estradiol 
        Estradiol valerate 5-20 mg every 2 weeks 
        Estradiol cypionate 5-10 mg weekly 
 
The use of progestins, apart from cyproterone acetate, remains controversial(5). Since progestins 
play a role in mammary development in biological women, some clinicians believe they are 
necessary for full breast development(279-281). However, the available evidence does not provide 
support for better effects on breast size of adding progestogens to cross-sex estrogen 
administration in trans women(282). However, available evidence is quantitatively and qualitatively 
extremely poor, which hampers any firm conclusion at this time(283). Also, many centers use anti-
androgens with progestational action, which complicates the interpretation of current data. In 
addition, all progestogens by definition have some progestational activity but they differ in 
chemical structure, metabolism, pharmacokinetics, affinity, potency and intracellular action which 
can translate into very different biological and clinical effects(284). 
1.3.2 Cross-sex hormone therapy in  trans men 
Cross-sex hormone therapy in trans men mainly involves T therapy. Testosterone treatment can 
be given orally, transdermally, or parenterally (IM). Similar to the situation for trans women, no 
randomized controlled trails have been performed concerning T treatment in trans men and 
therefore variations in treatment modalities exist between centers (Table 5.). Besides T, 
progestins and GnRH agonists can be used for a short period of time to assist with menstrual 
cessation early during hormonal therapy. 
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Table 5.   Common hormone treatment regimens currently used in trans women  (adapted  from (5)) 
 Suppression of menses Testosterone therapy  
Progestagens 
GnRH agonist  
Oral Testosterone 
         Testosterone undecanoate 160-240 mg daily 
Transdermal Testosterone 
         Testosterone gel 1% 2.5-10 mg daily 
Parental Testosterone 
          Testosterone undecanoate 1000 mg every 12 weeks 
          Testosterone enanthate or cypionate every 2 weeks 
 
1.3.3 Clinical effects and side effects of cross-sex hormone therapy 
1.3.3.1 Physical changes induced by cross-sex hormone therapy 
Our knowledge concerning physical changes during cross-sex hormone therapy is largely based 
on clinical experience, rather than evidence based. Most physical changes occur during the first 
year of cross-sex hormone therapy. In trans women, a decreased facial and body hair, decreased 
skin oiliness, a fat redistribution and breast growth were observed(278, 285-288). Over a longer period 
of time, the prostate gland and testicles underwent hypotrophy(5, 289). 
Testosterone treatment in trans men is found to increase facial and body hair, skin oiliness, 
clitoral size and muscle mass. In addition, a redistribution of fat mass and induction of a 
deepened voice, breast atrophy and cessation of menses were reported(278, 285, 286, 288, 290-291). 
Large prospective studies examining both the short and long-term clinical effects of cross-sex 
hormone therapy are needed to improve our understanding in an evidence based way. 
1.3.3.2 Cardiovascular and metabolic effects 
1.3.3.2.1 Cardiovascular and metabolic factors 
As seen in 1.2.4.3., sex steroids can affect several cardiovascular risk factors. A summary of the 
literature concerning prospective changes in cardiovascular risk factors during cross-sex hormone 
therapy in trans women and men is shown in Table 6 and 7. 
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Anti-androgen and estrogen therapy in trans women and T therapy in trans men both improves 
and impairs some aspects of the profiles of cardiovascular risk factors. The majority of these data 
are based on older treatment modalities using high dose ethinyl estradiol and high dose 
cyproterone acetate in trans women and short-acting intramuscular T esters in trans men. 
Whether our newer treatment modalities in trans persons will induce similar changes in metabolic 
and cardiovascular parameters still needs to be examined. 
In addition, it is not well known how these effects on metabolic and cardiovascular factors can be 
translated into hard clinical endpoints. This will be discussed in the next section.
   
 
 
 
Table  6. Prospective  changes in  cardiovascular  risk  factors in trans women    (adapted   from (292)) 
Outcome variable  Observed  change Effect on  CV  morbidity References 
Body composition 
Weight 
Visceral fat 
Total body fat 
Insulin metabolism 
Fasting glucose 
Fasting insulin 
Insulin sensitivity 
Lipid spectrum 
Total cholesterol 
LDL cholesterol 
HDL cholesterol 
VLDL cholesterol 
Triglycerides 
Fish fatty acid (DHA) 
Other CVD risk factors 
Heart rate 
Diastolic blood pressure 
Systolic blood pressure 
Arterial stiffness 
Hemostasis/fibrinolysis 
Total homocysteine 
Inflammation marker 
 
Increase/no effect 
Increase 
Increase 
 
No effect 
Increase 
Decrease 
 
Decrease/no effect 
Decrease/no effect 
Increase/no effect 
No effect 
Increase/ no effect 
Increase 
 
Increase 
Increase/no effect 
Increase/no effect 
No effect 
Increase 
Decrease 
Increase 
 
 
↑/- 
↑ 
↑ 
 
- 
↑ 
↑ 
 
↓/ - 
↓/ - 
↑/ - 
- 
↑/- 
↓ 
 
? 
↑/ - 
↑ / - 
- 
↑ 
↓ 
↑ 
 
(293),(294),(295), (296) / (297), (298), (299) 
(293), (300), (295) 
(293), (300), (295), (296), (299) 
 
(300), (294) 
(300)-(295) 
(300), (295), (301) 
 
(300) / (297), (298), (302) 
(300) / (302) 
(300), (296), (299)/ (244) 
(300) 
(300), (296) / (297), 248) 
(300) 
 
(294) 
(300) /(294) 
(300)/(294) 
(294) 
(194), (296) 
(296), (302) 
(296), (303) 
  
  
 
Table  7. Prospective  changes  in  cardiovascular  risk  factors in  trans  men    (adapted from (292)) 
Outcome variable  Observed  change Effect on  CV  morbidity References 
Body composition 
Weight 
Visceral fat 
Total body fat 
Insulin metabolism 
Fasting glucose 
Fasting insulin 
Insulin sensitivity 
Lipid spectrum 
Total cholesterol 
LDL cholesterol 
HDL cholesterol 
VLDL cholesterol 
Triglycerides 
Fish fatty acid (DHA) 
Other CVD risk factors 
Heart rate 
Diastolic blood pressure 
Systolic blood pressure 
Arterial stiffness 
Hemostasis/fibrinolysis 
Total homocysteine 
Inflammation marker 
 
 
Increase/no effect 
Increase 
Increase 
 
No effect 
Increase 
Decrease 
 
Decrease/no effect 
Decrease/no effect 
Increase/no effect 
No effect 
Increase/ no effect 
Increase 
 
Increase 
Increase/no effect 
Increase/no effect 
No effect 
Increase 
Decrease 
Increase 
 
 
 
↑/- 
↑ 
↓ 
 
↓ 
- 
↓/ - 
 
↓/ - 
↓/ - 
↑/- 
- 
↑/- 
- 
 
- 
↑/- 
↑/- 
↑ 
- 
↑ 
↑ 
 
 
 
(290), (294), (295), (302), (304)/ (305),(306) 
(293), (300), (295) 
(290), (293), (300), (295), (307)/(305), (306) 
 
(300), (294), (304) / (295) 
(300), (295), (301), (304) 
(300), (301), (304) / (300), (295) 
 
(258, 259) / (300), (305), (304), (306) 
(300), 258, 259) / (239, (302), (306) 
(239, (300), (294), (305), (304)/ (306), (308), (309) 
(300) 
(290, 300), (305)/ (294), (295), (306), (309) 
(300) 
 
(300), (294) 
(290)/ (300), (294), (305) 
(290), (305)/ (300), (294),(243) 
(194, 295) 
(296), (302) 
(296), (303) 
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1.3.3.2.2 Cardiovascular morbidity 
1.3.3.2.2.1 Cardiovascular morbidity in trans women 
Current evidence suggests that cross-sex hormone therapy administration to trans women is 
associated with an increased risk for venous thrombosis (Table 8.)(310), (311). Two studies, assessing 
cardiovascular mortality in trans persons, observed an increased cardiovascular mortality in trans 
women compared to general population(312),(313). Interestingly, Kaplan Meier Curve diverged after 
about 10 years of follow-up, which could explain previous research that observed no higher 
cardiovascular mortality(310), (311).  
Table  8.  Studies on cardiovascular endpoints in trans women 
Study N Follow-up Treatment  regimen Outcome 
Asscheman 
1989
(310)
 
303 Median 
duration HRT of 
4.4 years*  
 
Ethinyl estradiol 100 μg/d 
and cyproterone acetate 
100 mg/d 
45-fold increase in VT 
and/or PE  
No increased 
cardiovascular morbidity 
and mortality 
 
Van 
Kesteren 
1997
(311)
 
816 Mean duration 
HRT of 9.5 
years 
  
 
Ethinyl estradiol 100 μg/d 
or transdermal 17β-
estradiol 100 μg/twice a 
week and cyproterone 
acetate 100 mg/d 
 
20-fold increase in 
venous thrombosis 
and/or pulmonary 
embolism 
No increased 
cardiovascular morbidity 
or mortality rate  
Asscheman 
2011
(312)
 
966 Median 
duration HRT 
of18.5 years* 
 
Ethinyl estradiol 100 μg/d 
or transdermal 17β-
estradiol 100 μg/twice a 
week and cyproterone 
acetate 100 mg/d 
 
Higher mortality due to 
ischemic heart disease; 
SMR 1.64 (1.43-1.87) 
Higher mortality due to 
CVD; SMR 2.11 (1.32-
3.21) in age group 40-64 
years 
Dhejne 
2011
(313)
 
191 Median time 
since SRS of 
9.1 years* 
 
Not specified Higher mortality due to 
cardiovascular disease 
compared to controls 
Bazarra 
Castro 
2012
(314)
 
58 Mean duration 
HRT of 6.5 ± 7.9 
years 
Different estrogen 
regimens and 
cyproterone acetate 
50mg/d 
Lower cardiovascular 
morbidity compared to 
control male and female 
population 
HRT: hormone replacement therapy; VT: venous thrombosis; PE: pulmonary embolism;  AMI: acute myocardial 
infarction; CVD: cerebrovascular disease; * not separately reported for trans men and trans women                                                                                         
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Despite mainly positive changes in cardiovascular risk factors, the majority of evidence suggests 
an increased cardiovascular risk in trans women. The interpretation of the increased 
cardiovascular risk during cross-sex hormone therapy in trans women is complicated because the 
chemical nature of the estrogen, the route of administration, cardiovascular health status of the 
patient and the dosage of estrogens, may all carry significant weight as seen from studies on 
COC’s and hormone replacement therapy. 
Chemical nature 
As no controlled trials or even large observational studies are available on cross-sex hormone 
therapy in trans persons, hard evidence concerning preference of one estrogen type above the 
others is lacking. However, different types of estrogens can exert different metabolic effects. 
Indeed, observational data suggested that use of high dose ethinyl estradiol (EE) was associated 
with a higher risk for venous thrombosis in trans women(311), which was also confirmed in the 
study from Toorians et al.(194) who found a higher APC resistance in trans women using oral EE 
than oral and transdermal 17-β E2. In addition, Asscheman and colleagues
(312) showed that current 
EE use was independently associated with a threefold increased risk for cardiovascular death.  
Route of administration 
As already mentioned, the transdermal route avoids the first pass effect of the liver with potential 
metabolic consequences. A lower venous thrombosis risk is described in women using 
transdermal contraceptives and HRT(195). In trans persons, an observational study(311) observed a 
decrease in venous thrombosis since the use of transdermal estrogens in trans women aged above 
40 years. Alternatively, although based on small sample size, Toorians and colleagues(194) observed 
no significant difference in APC resistance in trans women using oral than transdermal estrogens. 
In line with studies seen in women using hormone replacement therapy(144), Giltay and colleagues 
reported that oral EE increased CRP and tPA levels in trans women, whereas transdermal 
estrogens did not(303, 315). 
Estrogen dosage 
To our knowledge, not a single study investigated the effects of different estrogen dosages on 
cardiovascular morbidity or mortality in trans women. As already mentioned, in women using 
COC’s it has been observed that lower estrogen dosage showed a significant reduction in venous 
thrombosis(192) and some also found a lower risk for myocardial infarction and stroke(210). Whether 
these results can be extrapolated to trans women is not known, but as the estrogen dosage 
prescribed in trans women are higher than those used in contraceptives of HRT, it is 
undoubtedly of interest.  
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Cardiovascular risk factors and older age 
Safety of cross-sex hormone therapy in patients with established cardiovascular disease or 
increased cardiovascular risk, such as older age, is not known as studies in these patient 
populations are lacking. It is widely believed that cardiovascular risk factors should be managed 
as they emerge(5), but whether hormonal therapy should be stopped or a dosage reduction should 
be performed at a certain cardiovascular risk profile, remains uncertain.  
1.3.3.2.2.2 Cardiovascular morbidity in trans men 
Similar as in trans women, only a handful of studies have examined cardiovascular morbidity in 
trans men (Table 9.). These showed a lower or comparable risk for cardiovascular morbidity 
compared to control populations(310), (311). Concerning cardiovascular mortality, one study(263) 
found a higher cardiovascular mortality rate whereas others did not(310,312). In conclusion, in 
contrast to the situation in trans women, the majority of evidence suggests that T treatment in 
trans men is relatively safe at short and medium duration of follow-up, although it should be 
noted that outcome studies in trans men are performed on smaller sample sizes and at significant 
younger ages, compared to trans women.  
Table  9.  Studies on cardiovascular endpoints in trans men 
Study N Follow-up Treatment  regimen Outcome 
Asscheman 
1989 
(310)
 
122 
 
Median 
duration HRT of 
4.4 years* 
 
T esters 250 mg im every 
2 wks or T undecanoate 
120-160 mg/d 
No increased 
cardiovascular morbidity 
Van 
Kesteren 
1997
 (261)
 
293 
Mean duration 
HRT of 8.2 
years 
 
T esters 250 mg im every 
2 wks or T undecanoate 
160 mg/d 
No increased 
cardiovascular morbidity 
or mortality rate 
 
Asscheman 
2011
(312)
 
365 
Median 
duration HRT of 
18.5 years* 
 
T esters 250 mg im every 
2 wks or T undecanoate 
160 mg/d 
No increased 
cardiovascular mortality 
rate 
Dhejne 
2011
(267)
 
133 
Median time 
since SRS was 
9.1 years* 
 
Not specified 
Higher mortality due to 
cardiovascular disease 
compared to controls 
Bazarra 
Castro 
2012
(268)
 
37 
Mean duration 
HRT of  4.9 
years  ± 4.6 
 
Different T preparations 
No difference in 
cardiovascular morbidity 
compared to control men 
and women 
HRT: hormone replacement therapy                                                                                                                                                                                        
* not separately reported for trans men and trans women 
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1.3.3.3 Cancer 
Some tumors are hormone-dependent, therefore examining the incidence of cancer during cross-
sex hormone therapy is of interest. In the next section, a review of the literature on hormone-
dependent and reproductive organ carcinomas is given. A number of tumors (e.g., colon cancer) 
also show sex differences in their prevalence and it is reasonable to assume that sex steroids 
might be one of the factors to explain this sex difference, but so far no data are available 
concerning the incidence of these cancers during cross-sex hormone therapy(316). 
1.3.3.3.1 Cancer in trans women 
1.3.3.3.1.1 Breast cancer 
One of the major concerns of long-term cross-sex hormone therapy in trans women is the 
induction of cancers of estrogen-sensitive tissues, such as the breast(316). Up till now, eight 
individual breast cancer case reports have been reported in the literature (317-322). Given that only a 
few case reports have been reported and no cases were reported in large cohorts of trans women, 
the risk of breast carcinoma is likely to be very low at short-term follow-up; long-term follow-up 
data are presently not available. 
1.3.3.3.1.2 Lactotroph adenoma 
Several cases of lactotroph adenoma, also known as prolactinoma, during cross-sex hormone 
therapy in trans women have been described(323-328). Indeed, both estrogen and cyproterone 
acetate treatment were found to increase prolactin levels(329-331), although the exact onset and time 
course of hyperprolactinemia and development of prolactinoma during cross-sex hormone 
treatment in trans women is still not well-understood(5). Similarly, as for breast cancer, only a few 
case reports of prolactinoma’s have been reported and none were reported in large cohorts of 
trans women, suggesting a low risk. Current guidelines recommend to measure prolactin levels at 
baseline and then at least annually during the transition period and biannually thereafter(5). 
1.3.3.3.1.3 Prostate cancer 
The prostate is not removed during SRS, however, the risk of development of prostate cancer 
during anti-androgen and estrogen seems low, considering the important role of T in the 
development of clinical prostate cancer. Indeed, only four cases of prostate cancer in trans 
women have been reported(332-335), mostly hormone (T)-independent cancers with very high PSA 
values at diagnosis, and it is not clear whether these cancers were present prior to cross-sex 
hormone therapy. 
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1.3.3.3.2 Cancer in trans men 
As mentioned earlier, T treatment usually reduces breast glandular tissue and the vast majority of 
trans men undergo mammectomy early in the course of sex reassignment treatment. In addition, 
ovariectomy and hysterectomy are recommended in trans men when they are eligible for SRS. 
Therefore, the risk for development of these cancers seems low. Indeed, only a few cases of 
breast and ovarian cancer have been described before(336-338) and after mammectomy(339-340).  
Overall, the available evidence suggests that cancers related to cross-sex hormone treatment of 
trans persons are uncommon, but long-term follow-up studies addressing prevalence of cancer 
are scarce.  
1.3.3.4 Bone health 
Concerning bone health in trans women, most studies(289, 297-299, 307, 341-344) but not all(287, 345) 
demonstrated a maintained bone mineral density or even an increase in bone mineral density 
after several years of cross-sex hormonal therapy.  
In trans men, T treatment was found to prevent possible bone loss due to estrogen deficiency 
both after short(305, 307, 346) and longer-term T treatment(341-342, 347). However, most studies were 
rather small and long-term follow-up data are still lacking.  
1.3.3.5 Sexual desire and sexual desire problems 
In the past, transsexualism (especially male-to-female transsexualism) was often considered as a 
hyposexual condition and it was assumed that trans individuals had no sexual desire(348). 
Considering the important effects of sex steroids in men and women, a significant impact of 
cross-sex hormone therapy in trans persons can be expected. Aside from effects of cross-sex 
hormone therapy, the experience of genital surgery and postsurgical outcome may also affect 
sexual functioning in trans persons. Indeed, some studies already showed an important impact of 
sex reassignment therapy on sexual functioning(349-351). 
Yet, the effects of both hormonal therapy and SRS on sexual desire are not well-known, as 
prospective data concerning the frequency and intensity of sexual desire in trans men and women 
are currently lacking. In trans women, sexual desire is only investigated after SRS (Table 10), and 
the results can therefore be influenced by length of time since SRS and specific surgical 
techniques used. In addition, most studies were based on small samples and used indirect 
‘indicators’ of sexual desire, such as frequency of masturbation or frequency of sexual activity. 
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Furthermore, current evidence in trans women is conflicting, as some studies showed a 
decrease(349, 352) or  no change(353-354) whereas others showed an increase in sexual desire(350, 355-356). 
When sexual desire scores are compared to control women, one study(354) observed lower sexual 
desire scores in trans women, whereas another study showed that trans women had an equal 
prevalence of HSDD(357). 
Our knowledge on sexual desire in trans men is even more limited, since data from direct 
evaluations of sexual desire in trans men are non-existent. The available data can only be 
interpreted as an indication of sexual desire through measurement of the frequency of sexual 
activity or frequency of masturbation before and after SRS. In their sample of adult trans men, 
De Cuypere et al.(353) generally found an increase in frequency of masturbation after T treatment 
and SRS. Similarly, Lief and Hubschmann(355) reported an increase in sexual activity following 
SRS, whereas Smith et al.(352) and Cohen-Kettenis and van Goozen(349) reported no change or an 
increase in masturbation after T treatment and SRS in their adolescent trans men sample. 
   
 
 
Table  10.  Studies   concerning  sexual  desire   in   trans  women (adapted from (311)) 
Study N  Follow-up Oucome measue Outcome 
 
Sorenson et al.,1981(358) 
 
Mate-Kole et al., 1990 (350) 
 
Lief et al.,1993 (355) 
 
Cohen-Kettenis et al.,1997 (349) 
 
Rehman et al., 1999 (359) 
 
Schroder et al., 1999 (351) 
 
Smith et al., 2001(352) 
 
De Cuypere et al., 2005 (353) 
 
Lobato et al., 2006 (356) 
 
Elaut et al., 2008 (357) 
 
 
Weyers et al.,  2009 (354) 
 
23 
 
20 
 
14 
 
5 
 
28 
 
17 
 
7 
 
32 
 
18 
 
62 
 
 
50 
 
 
 
Postoperative, on average 6 years 
 
Postoperative, on average 2 years 
 
Post-operative, on average 33 
months  
Postoperative, on average 2.6 
years* 
Postoperative, at least 3 years 
 
Postoperative 
 
Postoperative, on average 1.3 
years* 
Postoperative, on average 3.8 
years 
Postoperative, on average 24.9 
months  
Postoperative, on average 5.2 
years 
 
Postoperative, on average 75.5 
months 
 
Frequency of masturbation 
 
Sexual desire 
 
Sexual activity 
 
Frequency of masturbation 
 
Sexual desire 
 
Frequency of sexual desire 
 
Frequency of masturbation 
 
Frequency of masturbation 
 
Sexual activity 
 
Prevalence of HSDD 
Association with T  
 
Comparison of sexual desire 
to control population 
 
Infrequent or low 
 
Increased 
 
Increased 
 
Decreased 
 
No change 
 
Low 
 
Decreased 
 
No change 
 
Increased 
 
No significant difference 
No significant association 
 
Low sexual desire in trans women 
 
*Not separately reported for trans men and trans women
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1.3.3.6 Other conditions 
1.3.3.6.1 Other conditions in trans women 
1.3.3.6.1.1 Liver problems 
Van Kesteren and colleagues(311) showed that approximately 3% of trans women experienced a 
transient elevation of the liver enzymes. Concerning persistent changes in liver enzymes, it was 
not clear wether these could be attributed to hepatitis B infection or alcohol rather than to the 
effects of hormonal treatment(311). 
1.3.3.6.1.2 Gallbladder problems 
Both observational studies as well as randomized controlled trials suggest that estrogen therapy 
carried an important risk for gallbladder disease(360, 361). Indeed, an increased risk for galbladder 
disease during cross-sex hormone therapy has already been described in trans women(310). 
1.3.3.6.1.3 Mood problems 
It is well-recognized that anti-androgen and estrogen therapy induces a calming effect in trans 
women(281). Besides these positive changes, Asscheman and colleagues(310) described that 
combined treatment with estrogen and cyproterone acetate in trans women was associated with a 
15-fold increase in depressive mood changes, but with few morbidity. In contrast, others(362) 
report that cross-sex hormone therapy lowers anxiety and depression scores, which is possibly 
related to a better mental health after initiation of cross-sex reassignment therapy. 
1.3.3.6.2 Other conditions in trans men 
1.3.3.6.2.1 Skin problems 
From clinical experience, it is known that acne is one of the most often reported side effects of T 
treatment in trans men, but so far only one study has investigated the effects of T treatment on 
the skin in trans men. Giltay and colleagues(286) examined sebum production and acne scores 
during the first year of cross-sex hormone therapy in 17 trans men treated with short-acting 
intramuscular T esters, and found indeed a significant increase in sebum production and acne 
scores during T treatment. The long-term dermatological effects of T treatment in trans men 
have not yet been addressed.  
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1.3.3.6.2.2 Liver problems 
Similar to trans women, periodic monitoring of the liver enzymes is recommended given that up 
to 15% of trans men treated with T experience transient elevations in liver enzymes(311).  
1.3.3.6.2.3 Mood problems 
As in trans women, cross-sex hormone therapy by itself was found to induce a calming effect on 
most trans men(281). However, some observed that the administration of androgens in trans men 
was clearly associated with an increase in anger proneness and aggression tendencies(363). 
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1.4 Quality of life in trans persons 
The World Health Organization (WHO) defines quality of life (QoL) as “an individual’s 
perception of their position in life in the context of the culture and value systems in which they 
live, and in relation to their goals, expectations, standards, and concerns”. QoL is therefore an 
evaluation of a personal well-being, including several aspects such as emotional, social and 
physical functioning. In health care, QoL is often measured to determine how the individual's 
well-being may be affected by a certain disease or its treatment. 
At this moment, only a few studies addressed QoL of trans persons (Table 11). Most studies(364-
366), but not all(354), found that QoL in trans persons was poorer when compared with a general 
population sample or control group, but in these studies no adjustments were made for well-
known determinants of QoL, such as age and socio-economic status, which can induce an 
important bias. Several follow-up studies have shown that cross-sex hormone therapy and SRS 
are related to favourable changes in many aspects of the individual’s life, such as gender 
dysphoria feelings, psychosocial and sexual functioning(353, 367-368). In the same way, cross-sex 
hormone therapy(365, 369, 370) and facial(366) and/or genital surgery(366, 371) were associated with better 
QoL scores. However, the main predictors of QoL in trans persons after SRS, after taking all 
these determinants into account, have not yet been investigated. 
Only recently, other determinants of QoL in trans persons were explored. Some(371, 372) found that 
socio economical factors (e.g., educational level, employment status, partnership) were associated 
with QoL scores whereas others were unable to find such associations(369). 
In summary, QoL is an underinvestigated area in transgender health care. Both hormonal 
therapy, facial and genital surgery have been associated with better QoL scores in trans persons in 
cross-sectional studies but prospective studies are still needed to confirm these observations. 
Little information is available on general determinants of QoL in trans persons and data 
concerning the main predictors of quality of life are lacking in trans persons after SRS.  
 
   
 
 
Table  11.  Studies   concerning   health    related   quality   of   life   in   adult   trans   persons 
Study Study population Follow-up Outcome measure  Ouctome 
Newfield et al. 
2006 
(365)
 
 
 
Weyers et al.  
2009 
(354) 
 
 
Kuhn et al. 
2009 
(364)
 
 
Ainsworth et al.  
2010 
(366)
 
 
Parola N et al. 
2010 
(373) 
 
Wierckx et al.  
2011
(372) 
 
 
Gorin-Lazard et al. 
2012 
(369)
 
 
 
 
Motmans et al. 
2012 
(371)
 
 
 
Gomez-Gil et al. 
2013 
(370) 
 
446 trans men 
 
 
 
50 trans women 
 
 
 
52 trans women 
3 trans men 
 
247 trans 
women 
 
15 trans men 
15 trans women 
 
50 trans men 
 
 
 
31 trans women 
30 trans men 
 
 
 
83 trans women 
65 trans men 
 
 
119 trans 
women 
74 trans men 
64.7% used HRT 
37% had top surgery 
 
 
Post SRS, on average 10 
years of HRT 
 
 
Post SRS (on average 
15 years) 
 
30.4% had FFS 
29% were post SRS 
 
Post SRS at least 2 
years; all used HRT 
 
Post SRS; on average 
10 years of HRT 
 
 
72.1% used HRT 
Median duration HRT 20 
months 
 
 
95.5% used HRT (on 
average 6.4 years )73.6 
% were post SRS 
 
62.2% used HRT 
Different surgeries 
Comparison with published norms 
Comparison depending on HRT  and top 
surgery status 
 
Comparison with published norms 
Associations with sociodemographic 
correlates 
 
Comparison with control population 
 
 
Comparison with published norms 
Association with FFS and SRS 
 
Retrospective evaluation; Associations 
with gender and the subject's personality 
 
Comparison with published norms 
Associations with sociodemographic 
correlates 
 
Comparison depending on HRT status 
Comparison with control population 
Associations with sociodemographic 
correlates 
 
Comparison with published norms 
Associations with SRT and 
sociodemographic correlates 
 
Associations with SRT and 
sociodemographic correlates 
Lower QoL scores in trans men 
Higher QoL scores in those using HRT and those 
who had top surgery 
 
No significant differences compared to controls 
 
 
 
Lower QoL scores compared to controls  
 
 
Lower QoL in trans women  
Positive association with FFS 
 
QoL improved after SRT Better QoL scores in trans 
men. No association with personality traits 
 
Lower mental health and vitality  
Postive association with relationship status 
 
 
Higher QoL scores in those using HRT. Comparable 
QoL scores except for role physical functioning 
(lower in trans) and general health (lower in general 
population) 
 
Similar QoL scores in trans women. Lower mental 
well-being in trans men.  Employment, education, 
income partnerschip were positively associated 
 
HRT, family support, working/studying ara positively 
associated with QoL scores 
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1.5 Research Objectives 
1.5.1 General aims 
Gender dysphoria is a condition in which a person experiences discrepancy between the sex 
assigned at birth and the gender they identify with, leading to extensive personal distress. 
Transsexualism is considered the most extreme form of gender dysphoria and is characterized by 
the wish to undergo treatment to conform with the other biological sex. Cross-sex hormone 
therapy is an important part of the medical treatment of trans persons. The above discussed 
profound effects of sex steroids on several tissues, organs and systems raise questions about the 
safety and effects of cross-sex hormone treatment in trans persons. Although this treatment has 
been used for several decades, our knowledge regarding short- and long-term effects and side 
effects of cross-sex hormone therapy, is extremely scarce. This is mainly due to the low 
prevalence of this diagnosis, the small number of subjects treated in each centre, the lack of 
prospective studies, the lack of long-term follow-up data and the wide variations in treatment 
modalities between centers. In the past years, the importance of patients’ QoL and its changes by 
medical treatment has become increasingly important, but these data are scarce in trans persons.  
Therefore the general aim of this thesis is two-fold: 
Firstly, we aim to investigate the short-and long-term physical changes, side effects and adverse 
events of cross-sex hormonal therapy in trans persons. 
Secondly, to study QoL of trans persons and to investigate the main determinants of QoL in 
trans persons. 
1.5.2 Specific aims 
Firstly, the short-term effects of anti-androgen and/or estrogen treatment in trans women and T 
treatment in trans men are investigated in a multi-center prospective study (chapter 2). In 
chapter 2.1, general clinical effects including hormonal and biochemical changes, 
anthropometrics (waist-hip ratio, total body fat mass and muscle mass), side effects (e.g., liver 
dysfunction, hypercholesterolemia and hypertension) and adverse events during the first year of 
cross-sex hormonal therapy, are addressed. In chapter 2.2 we focus on the changes in metabolic 
and cardiovascular risk factors (e.g., HOMA-IR, Matsuda index, lipid differentiation, body 
composition by DXA and pQCT) during the first year of hormonal therapy, whereas in chapter 
2.3 we investigate the dermatological changes (body hair and distribution, androgenetic alopecia 
and acne) in trans men. To address questions with respect to the long-term effects, side effects 
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and adverse events of cross-sex hormone therapy in trans women and men, two clinical studies 
and one large-sample questionnaire study were performed. In chapter 2.4 biochemical changes, 
anthropometrics, side effects and adverse events of cross-sex hormone therapy are investigated, 
whereas in chapter 2.5, cardiovascular and cancer morbidity of trans persons are compared to a 
control population recruited from a population-based study in Flanders.  
In chapter 3 (3.1 and 3.2), we focus on the effects of cross-sex hormone therapy on sexual 
desire, whereas in chapter 4, QoL of trans persons is compared to control men and women, and 
associations between sex reassignment therapy and QoL are investigated.  
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1.6 Studies 
1.6.1 Overview of the study populations 
A general overview on the different study populations is given in Figure 1.4. 
 
 
 
 
 
 
 
Figure 1.4. Overview of the study populations 
1.6.1.1 ENIGI: multicenter prospective study  
The ENIGI study or the European Network for the Investigation of Gender Incongruence is a 
multicenter prospective study involving four European institutions with established gender teams 
(Ghent, Oslo, Hamburg and Amsterdam), started by the psychologists and psychiatrists. The 
endocrinologists joined this project afterwards and developed a common standardized hormonal 
intervention protocol. Besides the four gender teams, Florence also joined this endocrinological 
protocol. 
The sample used in this thesis is based on the data of Ghent and Oslo. Between February 2010 
and June 2012, all patients diagnosed with gender dysphoria who were referred to our 
departments were invited to participate in this prospective study (N=152). Forty-five  persons 
Clinical 
studies 
Trans 
women 
N=50 
Trans   
men 
N=50 
 
TransBel 
Trans 
women 
N=214 
Trans   
men 
N=138 
 
ENIGI 
Trans 
women 
N=53 
Trans   
men 
N=53 
 
Prospective multi-center 
study in the first year of 
HRT 
Clinical study with 
hospital visit every 3 
months 
Aim: to investigate short-
term clinical effects and 
morbidity 
 
Cross-sectional single-
center study after on 
average 8.4 years of HRT 
Questionnaire study 
                                              
Aim: to investigate long- 
term morbidity znd 
quality of life 
 
Cross-sectional single-
center study after on 
average 10 years of HRT 
Clinical study with 
hospital visit 
Aim: to investigate long-
term clinical effects and 
morbidity 
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were excluded resulting in a total population of 53 trans women and 53 trans men in the current 
analyses. Patients are followed 3-monthly during the first treatment year. After 12 to 24 months 
of cross-sex hormone treatment, most trans persons at our centers usually undergo sex 
reassignment surgery. 
Trans women treated at the Ghent University Hospital were assigned to two different treatment 
modalities based upon the decision of the psychiatrist. Trans women who would favour a slower 
procedure received a dual-phase protocol. In the first phase, sex-specific features were 
suppressed by administration of cyproterone acetate 50 mg daily for about 3 months. In the 
second phase, estrogens were added to induce irreversible feminization. The other trans women 
received a combination of cyproterone acetate 50mg and estrogens at start. In both centers, trans 
women younger than 45 years received estradiol valerate 4mg daily; patients older than 45 years 
received transdermal estrogens (transdermal 17- β estradiol path 100µg/24h). In case of non 
tolerance, transdermal 17-β estradiol gel 2mg twice daily or EV 4mg was prescribed. All trans 
men received intramuscular T undecanoate 1000 mg (Nebido®) 3-monthly, whether or not 
preceded by progestin treatment to suppress menstruation. Short-acting intramuscular T esters 
250 mg 2-weekly were given, in case of non tolerance of intramuscular T undecanoate. The main 
goal of this study was to investigate effects, side effects and adverse events of standardized cross-
sex hormonal therapies at set time points during the first year of hormonal therapy. Clinical 
effects investigated in this study were changes in hair growth and distribution of body hair, acne, 
sexual desire, body composition, bone mass, cardiovascular risk factors, insulin sensitivity and 
biochemical parameters. This study complied with the recommendations of The Declaration of 
Helsinki and was approved by the Ethical Committee of the Ghent University Hospital and the 
University Hospital of Oslo. All participants gave written informed consent. Clinical trial number: 
NCT01072825. 
1.6.1.2 TransBel 
The TransBel study is a multicenter cross-sectional questionnaire study with the main aim to 
investigate the outcome of sex reassignment treatment. Further recruitment in other centers in 
Flanders and Wallonia is currently ongoing. Therefore, we included only data from our own 
center in this thesis. Inclusion criteria for this study were: diagnosis of gender dysphoria, use of at 
least 3 months cross-sex hormones and currently or formerly treated at the center for Sexology 
and Gender Problems at the Ghent University Hospital. Respondents received a paper version of 
the questionnaire or could choose to fill in the survey online. All surveys were collected between 
August and December 2012. We achieved a response rate of 54%, as 352 participants (214 trans 
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women and 138 trans men) agreed to participate in this study. This study was approved by the 
ethical review board of Ghent University Hospital, Belgium and all participants gave their 
consent for participation in the study. The main focus of this study was to investigate the 
morbidity and quality of life of trans persons during and after sex reassignment treatment. 
1.6.1.3 Clinical studies  
Two clinical cross-sectional studies were performed, one in 50 trans women and one in 50 trans 
men. Participants of both studies were Dutch-speaking, treated at the Center for Sexology and 
Gender Problems at the Ghent University Hospital and all underwent sex reassignment surgery. 
Both studies were approved by the ethical review board of Ghent University Hospital and all 
participants gave written informed consent. Response rate of the studies were 71.4% and  64% 
respectively. During a one day hospital visit, all participants received a fasting, morning blood 
sample, evaluation of anthropometrics, body composition, bone mineral density (dual energy x-
ray absorptiometry) and questionnaires on medical history, clinical effects, quality of life, sexual 
functioning and surgical results. The aims of these studies were to investigate antropometrics, 
body composition, bone mineral density, clinical effects and biochemical parameters after long-
term cross-sex hormone therapy. 
1.7 Methods 
1.7.1 Anthropometric characteristics and body composition 
Antropometrics and body composition were measured in the ENIGI study and in both clinical 
studies. Body weight (kilograms) was measured in light indoor clothing, without shoes. Standing 
height was measured to the nearest 0.1 cm using a wall-mounted Harpenden stadiometer (Holtain 
Ltd., Crymuch, UK). Body mass index (BMI) was calculated as body weight (kilograms) divided 
by the square of the body height (square meters). Waist-to-hip ratio is determined as the ratio of 
waist circumference, the abdominal circumference located midway between the lower rib margin 
and the iliac crest, over hip circumference, the widest circumference around the buttocks. As 
both WHR and BMI are only indicators of body composition, we also assessed fat and lean mass 
by measuring the whole body soft tissue composition using Dual-energy X-ray absoptiometry 
(DXA) (Hologic QDR-4500A device; software version 11.2.1; hologic Inc., Bedford, MA, USA). 
This technique allows us to make a distinction between fat and lean mass but also between 
truncal fat mass and appendicular fat mass. The coefficient of variation for both spine and whole-
body calibration phantoms was less than 1%, as calculated from daily and weekly measurements, 
respectively. 
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1.7.2 Evaluation   of   clinical  effects 
Clinical assessment of acne was performed  in each patient with the Gradual Acne Grading Scale 
(GAGS) in the ENIGI study and the clinical trans men study(374). This is a quantitative scoring 
system in which the total severity score is derived from the summary of six regional subscores. 
Each subscore is obtained by the score of the most heavily weighted lesion within each region (1 
for ≥ one comedone, 2 for ≥ one papule, 3 for ≥ one pustule and 4 for ≥ one nodule)  
multiplied by the factor for each region (factor for forehead and each cheek is 2, chin and nose is 
1 and chest and upper back is 3). A score between 6–18, 20-30 and 31-36  are considered as mild, 
moderate or severe acne respectively. 
The effects of T therapy on hair growth and distribution of body hair in trans men was 
evaluated by the Ferriman and Gallwey classification(375)for each patient in the ENIGI study and 
the clinical trans men study. This scale scores 9 androgen dependent areas on a 5-point Likert-
type scale (from 0= no to 4=very dense). A score for the androgen-dependent area of more than 
8 is considered indicative for hirsutism. 
Patients’ experienced treatment-related symptoms including hot flashes, palpitations, 
dizziness, sleeping problems, fatigue, abdominal complaints, hair loss, acne, cognition problems, 
mood swings, irritability, anxiety, panic attacks, low sexual desire, high sexual desire, headache, 
breast tenderness, joint pain and muscle soreness were investigated in the ENIGI and TransBel 
study using a four-point Likert-type scale (no, mild, moderate or severe complaints). 
Frequency of sexual desire was assessed in the TransBel study and clinical trans men study 
using a 5-point Likert-type scale as well as current sexual desire compared to after sex 
reassignment (5 point Likert-type scale, from ‘much higher’ to ‘much lower’). In the clinical trans 
men study, sexual desire was additionally measured using the Dutch version of the Sexual Desire 
Inventory(376). This self-report questionnaire contains 14 items. Subscales measure the intensity 
and frequency of the desire to behave sexually with a partner (dyadic sexual desire) or by oneself 
(solitary sexual desire). For the frequency-items, participants chose one out of seven options. For 
the strength items, participants scored their sexual desire on a 9-point Likert-type scale ranging 
from 0 (no desire) to 8 (strong desire). Participants were asked to take the previous month as a 
reference. Adding items resulted in a score for dyadic and solitary sexual desire. Higher scores 
indicate a higher level of sexual desire, with a maximum score of 62 for the dyadic subscale and 
23 for the solitary subscale. The Sexual Desire Inventory has a good reliability and validity(376). In 
the TransBel study, both trans men and women were additionally asked about the presence of 
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personal distress caused by sexual desire problems (yes or no) and to describe whether this 
caused distress for themselves, their partner, both of them and/or their relationship.  
All studies recorded clinical adverse events including cardiovascular events, cerebrovascular 
disease, venous thrombosis and/or pulmonary embolism, cancer. In addition,  in our clinical 
studies, reaching hormone target levels, normal for the desired gender  and supra-or subnormal 
serum of serum parameters; e.g., development of erythrocytosis, hyperprolactinaemia, 
hypercholesterolemia, and hyperglycemia were  also evaluated. 
1.7.3 Quality of life 
QoL was measured in the TransBel using the SF-12 questionnaire(377). This questionnaire includes 
12 questions with fixed response choices, organized in two scaled scores, based on the weighted 
sums of the questions in their section. These scores were converted into a summary score for 
each section: physical functioning and mental functioning, with higher scores indicating higher 
levels of functioning or well-being. The SF-12 questionnaire is the shorter version of the SF-36 
questionnaire.  
1.7.4 Biochemical analysis  
1.7.4.1 ENIGI study 
Venous blood was obtained at baseline and 12 months and serum was stored at -80 degrees until 
batch analysis. Routine clinical blood samples were drawn at the 3 months, 6 months and 9 
months time point. 
Luteinizing hormone (LH), follicle stimulating hormone (FSH), SHBG, insulin, DHEAS and, 
prolactin were measured by electrochemiluminiscence immunoassay (ECLIA); Modular, Roche 
Diagnostics, Mannheim, Germany.  The inter-assay CVs were as follows: LH and FSH, 2.19% 
and 2.55%, respectively; prolactin 4.8%, SHBG 2.8%, DHEAS 4.8% and insulin 2.3%. Estradiol 
(E2), estrone (E1), androstenedione, cortisol and testosterone were determined by liquid 
chromatography tandem mass spectrometry (AB Sciex 5500 triple-quadrupole mass 
spectrometer; AB Sciex, Toronto Canada). Serum limit of quantification was 0.3 pg/mL for E2 
and 0.5 pg/ml for E1, and the interassay CV were 4% at 21 pg/mL for E2 and 7.6% at 25 
pg/mL for E1. Serum limit of quantification was 1 ng/dL (35pmol/L) for T, and the interassay 
CV were 6.5% at 3 ng/dL. Dihydrotestosterone (DHT) was measured by liquid chromatography 
tandem mass spectrometry after paper chromatography. Serum limit of quantification was 5 
ng/dL for DHT, and the interassay CV were 6% at 11 ng/dL. Hemoglobin (Hb), hematocrit 
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(Hct), glucose, creatinin and liver enzymes glutamic-oxaloacetic transaminase (GOT), glutamic-
pyruvic transaminase (GPT), cholesterol (C), LDL-C, HDL-C, and triglycerides were measured 
using routine clinical chemistry methods. 
1.7.4.2 Clinical studies 
Venous blood samples were obtained between 08.00 and 12.00h after overnight fasting. All blood 
samples were stored at -80°C until batch analysis. 
Commercial kits for Radio-Immuno Assay (RIA) were used to determine the serum 
concentrations of total T and sex hormone binding globulin (Orion Diagnostica, Espoo, 
Finland); E2 (Clinical Assay, Diasorin s.r.l., Saluggia, Italy); LH, Insulin-like growth factor (IFG-
1), C-terminal telopeptides of type I collagen (CTX), 1 aminoterminal propeptide (P1NP) 
(electrochemiluminiscence immunoassay (ECLIA); Modular, Roche Diagnostics, Mannheim, 
Germany. Insulin-like growth factor-binding protein 3 (IGFBP3) was determined by an 
extraction method (DSL-5600; Diagnostic System Laboratories, Webster, 166 TX, USA). The 
intra- and interassay coefficients of variation for all assays were ≤ 10%. Hematocrit, total 
cholesterol, and creatinin were measured using routine clinical chemistry methods. 
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ABSTRACT 
Context 
Data on the effects of cross-sex hormone therapy (CHT) are limited due to the low prevalence of 
gender dysphoria, small number of subjects treated at each center, lack of prospective studies, 
and wide variations in treatment modalities. 
Objective 
To report the short-term effects of cross-sex hormone therapy on hormonal and clinical changes, 
side effects, and adverse events in trans men (female-to-male transsexuals) and trans women 
(male-to-female transsexuals)  
Design 
This was a multi-center 1 y prospective study.  
Setting 
University Hospital setting. 
Patients 
Fifty-three trans men and 53 trans women were included.   
Intervention 
Trans men received injections with testosterone undecanoate every 3 months. Trans women 
younger than 45 y received cyproterone acetate (CA) 50mg daily and 4mg estradiol valerate (EV) 
daily while those older than 45 y received CA 50mg daily together with transdermal 17-β estradiol 
100µg/24h. 
Main Outcome Measures 
Sex steroids, prolactin, liver enzymes, lipids, hematocrit, blood pressure, anthropometrics, 
Ferriman and Gallwey score, and global acne grading scale were measured. Side effects, adverse 
events, and desired clinical changes were examined.  
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Results 
No deaths or severe adverse events were observed one year after start of CHT. Two trans men 
developed erythrocytosis and two had transient elevation of the liver enzymes. Trans men 
reported an increase in sexual desire, voice instability, and clitoral pain (all p≤0.01). Testosterone 
therapy increased acne scores, facial and body hair, and prevalence of androgenetic alopecia. 
Waist-hip ratio, muscle mass, triglycerides, total cholesterol (C), and LDL-C increased whereas 
total body fat mass and HDL-C decreased. Three trans women experienced transient elevation of 
liver enzymes. A significant increase in breast tenderness, hot flashes, emotionality, and low sex 
drive (all p≤0.02). Fasting insulin, total body fat mass, and prolactin levels increased; and waist-
hip ratio, lean mass, total-C and LDL-C decreased. 
Conclusions 
Current treatment modalities were effective and carried a low risk for side effects and adverse 
events at short time follow-up.
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INTRODUCTION 
Trans persons undergo cross-sex hormone therapy (CHT) to induce the secondary sex 
characteristics of the desired sex while reducing those of the natal one[1]. The act of using cross-
sex hormones is also an affirmation of gender identity in many trans persons. The choice of type 
and dosage of hormones have not yet been established as randomized controlled trials and 
comparative studies are lacking[2], and so a variety of hormone preparations are currently used[3]. 
Female-to-male gender dysphoric persons, referred to as trans men, are treated with testosterone 
(T) preparations to induce virilization, sometimes preceded with progestagens to suppress 
menstruation[1]. To promote feminization, trans women (male-to-female gender dysphoric 
persons) usually receive estrogens in combination with anti-androgen and/or gonadal axis 
suppression medication to lower T levels and/or action[1].  
Many centers in Europe use cyproterone acetate (CA), a progestational agent with androgen 
receptor blocking properties[4-6] whereas spironolactone, a diuretic with anti-androgen action, is 
mostly used in the United States[7-8]. Other centers also use gonadotropin-releasing-hormone 
(GnRH) analogues[9-10], non-steroidal androgen receptor blockers, or 5-alpha reductase inhibitors. 
In addition, type of formulation, hormone dosage and route of administration (oral, transdermal 
or intramuscular) may differ between centers. These wide variations in treatment modalities and 
the low prevalence of transsexuality, and therefore small number of subjects treated in each 
center, hamper our knowledge on the effects and side effects of CHT. Furthermore, hormonal 
therapies have changed considerably in the past years, and most current evidence is based on 
older treatment regimens. The use of long-acting T preparations has significantly increased in 
trans men, and use of ethinyl estradiol (EE) has decreased in trans women due to the increased 
risk for cardiovascular disease[11].  
AIMS 
The aim of this study was to investigate the physical and physiological effects, side effects, and 
adverse events of commonly used cross-sex hormone therapies. We present the first multi-center 
prospective study in a well-described cohort of trans persons treated according to a standardized 
treatment protocol.  
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METHODS 
Study Population and sex hormone therapy 
This research is part of the European Network for the Investigation of Gender Incongruence 
(ENIGI), a collaboration of four major West European gender identity clinics (Amsterdam, 
Ghent, Hamburg and Oslo)[12] created to study the diagnostics and treatment of gender 
dysphoria. We present current data from the Department of Endocrinology at the Ghent 
University Hospital and the University Hospital in Oslo. All patients diagnosed with gender 
dysphoria and referred to our departments between February 2010 and August 2012 were invited 
to participate in this prospective study (N=152). We included only hormone naive trans persons. 
After screening, by thorough medical history and determination of serum sex steroids, 44 
individuals were excluded. A total of 53 trans men and 53 trans women participated in our study 
(figure 1). Patients were followed every 3 months during the first treatment year.  
 
Exclusions
• Previous or current
cross-sex hormone
administration
(N=23)
• Unwilling to 
participate (N=11)
• Other: (N=4)
Ghent University
Hospital admissions
(N=119)
Rikshospitalet Oslo 
admissions
(N=43)
Exclusions
• Previous or
current cross-sex
hormone
administration
(N=8)
• Unwilling to 
participate (N=0)
3-monthly 
intramuscular
testosterone
undecanoate
(N=27)
3-monthly 
intramuscular
testosterone
undecanoate
(N=26)
Trans men
(N=28)
Trans women
(N=53)
Trans men
(N=28)
Trans women
(N= 7)
Total inclusions
(N=81 )
Total inclusions
(N=35)
Other
protocol
(N=1)
Other protocol  (N=3)
Lost follow-up (N=3)
Trans women
CA OD and EV 
2mg BD
(N=34)
Trans women
CA OD and TE 
100µg/24h
(N=13)
Stop estrogen
therapy (N=1)
Trans women
CA OD and EV 
2mg BD
(N=6)
Lost follow-up 
(N=2)
Figure 1. Subject enrollment 
   
 
81 
Chapter 2 . Clinical effects 
Trans men received injections of 1000 mg intramuscular T undecanoate (Nebido®; Bayer, 
Germany) at the start of the study, after 6 weeks, and every 12 weeks thereafter. Before T 
initiation, progestagens were sometimes taken to suppress the menstrual cycle. In case of non 
tolerance, injections with intramuscular T esters (T decanoate 100 mg, T isocaproate 60 mg, T 
fenylpropionate 60 mg, T propionate 30 mg/ml) (Sustanon 250®; MSD; Netherlands) every 2 
weeks were prescribed. 
All trans women younger than 45 y (N=40) received 50 mg of CA (Androcur®; Bayer, Germany) 
in combination with 4 mg of estradiol valerate (EV) daily (Progynova®; Bayer). Patients older 
than 45 y (N=13) received 50 mg of CA daily in combination with 100 µg/24 h transdermal 17-β 
estradiol patch (Dermestril®; Besins, Belgium). In case of non-tolerance, 2 mg of transdermal 17-
β estradiol gel twice daily (Oestrogel®; Besins, Belgium) or 4 mg EV per day was given. Based on 
the decision of the mental health professional and patient, some trans women who favored a 
slower procedure and/or needed an extra diagnostic evaluation received a dual-phase protocol 
(N=16). In the first phase, sex-specific features were suppressed by administration of CA 50 mg 
daily for about 3 months, and estrogens were added to induce feminization in the second phase. 
This study complied with the recommendations of the Declaration of Helsinki and was approved 
by the ethical committee of the Ghent University Hospital and the University Hospital of Oslo. 
All participants gave written informed consent. Clinical trial number: NCT01072825. 
MAIN OUTCOME MEASURES 
Medical history and  examination 
Descriptive data was collected from all individuals, including physical and psychiatric medical 
history, current and past medication use, familial medical history, and lifestyle factors such as 
smoking and alcohol consumption. Information was compared to data from medical files for 
accuracy and corrected if necessary. 
Physical parameters 
Anthropometrics 
Standing height was measured to the nearest 0.1 cm using a Harpenden stadiometer (Holtain Ltd, 
Crymuch, United Kingdom). Body weight was measured in light indoor clothing without shoes to 
the nearest 0.5 kg. Waist circumference, defined as the smallest abdominal circumference, and hip 
circumference, defined as the largest hip circumference, were determined to the nearest 0.1 cm. 
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Body composition                                                                                                                 
Whole body lean mass and fat mass were measured using dual-energy X-ray absorptiometry 
(DXA) with Hologic Discovery (Hologic Inc., Bedford, MA) in Belgium and with Lunar Prodigy 
Advance (GE, Madison, WI) in Norway. 
Acne 
Clinical assessment of acne was performed every 3 months in each patient by the same 
endocrinologist with the Gradual Acne Grading Scale (GAGS)[13], a semi-quantitative scoring 
system in which the total severity score is derived from the summary of six regional subscores. 
Each subscore was obtained by the score of the most heavily weighted lesion within each region 
(1 for one or more comedones, 2 for one or more papules, 3 for one or more pustules, and 4 for 
one or more nodules) multiplied by the factor for each region (the factor for forehead and each 
cheek is 2, chin and nose is 1 and chest and upper back is 3). Scores between 6–18, 20–30, and 
31–36 were classified as mild, moderate or severe acne, respectively. 
Body hair and distribution 
The effects of testosterone therapy on hair growth and distribution of body hair in trans men was 
evaluated every 3 months using the modified Ferriman and Gallwey classification[14] in each 
patient by the same endocrinologist. This scale scores nine androgen-dependent areas on a 5 
point likert scale (from 0= no to 4=very dense). A score for an androgen-dependent area of more 
than 8 indicated hirsutism. Androgenetic alopecia was assessed using the Norwood/Hamilton 
classification[15]. 
We were unable to evaluate the effects of CHT on hair growth and distribution of body hair in 
trans women because almost all of them underwent laser epilation during the course of the study. 
Side effects  and  adverse  events 
Clinical adverse events, including cardiovascular events, venous thrombosis and/or pulmonary 
embolism, osteoporotic fractures, abnormal liver function tests, hypertension, and death 
(including suicide) were recorded. We also evaluated whether hormone levels reached the target 
values for the desired gender. Development of erythrocytosis, hyperprolactinaemia, 
hypercholesterolemia, and hyperglycemia was also assessed. 
We evaluated symptoms possibly related to hormonal status every 3 months, including hot 
flashes, night sweats, sleeping problems, fatigue, memory or cognition problems, mood swings, 
irritability, anxiety, low or high sexual desire, migraines, nail and gum problems, breast 
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tenderness, joint pain, and muscle soreness using a four-point Likert scale (no, mild, moderate or 
severe complaints). 
Biochemical determinations 
Venous blood was obtained at baseline and at 12 months, and serum was stored at −80˚C until 
hormones were analyzed in one batch. Blood samples for routine clinical parameters were drawn 
at the 3-, 6-, and 9-month time points. 
Luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin 
(SHBG), insulin, dehydroepiandrosterone sulfate (DHEAS), and prolactin were measured by 
electrochemiluminiscence immunoassay (ECLIA) (Modular, Roche Diagnostics, Mannheim, 
Germany). The inter-assay CVs were as follows: LH 2.19%, FSH 2.55%, SHBG 2.8%, prolactin 
4.8%, DHEAS 4.8%, insulin 2.3%. Estradiol (E2), estrone (E1), DHEAS, androsteendione, 
cortisol, and testosterone were determined using liquid chromatography tandem mass 
spectrometry (AB Sciex 5500 triple-quadrupole mass spectrometer; AB Sciex, Toronto Canada). 
The serum limit of quantification was 0.3 pg/mL for E2 and 0.5 pg/ml for E1, and the inter-
assay CVs were 4% at 21 pg/mL for E2 and 7.6% at 25 pg/mL for E1
[16]. Serum limit of 
quantification was 1 ng/dL (35pmol/L) for T, and the interassay CV was 6.5% at 3 ng/dL. 
Hemoglobin (Hb), hematocrit (Hct), glucose, creatinin, and the liver enzymes glutamic-
oxaloacetic transaminase (ASAT), glutamic-pyruvic transaminase (ALAT), cholesterol (C), LDL-
C, HDL-C, and triglycerides were measured using routine clinical chemistry methods.  
Statistical analysis 
Descriptive statistics were expressed as means and standard deviations, or medians [first to third 
quartiles] for in case of a non-normal distributions. Statistical analyses of categorical variables 
were carried out using χ2 and Fisher's exact tests as appropriate. Statistics of means in 
prospective data were carried out using the paired Student t tests or Wilcoxon signed-rank tests 
when variables were not normally distributed. Between two groups, statistics of means was 
evaluated using independent Student t tests and Mann-Whitney-U tests when variables were not 
normally distributed. Significance was set at p<0.05 (two-tailed). Data were analyzed using SPSS-
software, v.21 (SPSS Inc., Chicago, IL). For all analyses, missing values were excluded. 
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RESULTS 
General characteristics  
General characteristics of the study population are shown in Table 1. Trans women were 
significant older than trans men at the time of presentation (p<0.001). A significantly greater 
proportion of trans men were at the Oslo center, and the subjects were significantly older at the 
Ghent center. 
Table 1. Baseline  characteristics  of the study population 
 Trans women Trans men 
Ghent 
(N=47) 
Oslo 
(N=6) 
Ghent 
(N=27)  
Oslo 
(N=26) 
 
Age (years) 
Current smoker (%) 
Former smoker (%) 
Alcohol (U/week) 
Height (cm) 
Weight (kg) 
BMI (kg/m²) 
 
 
31.7 ± 14.8 
19.1 
38.3 
0 (0 - 7) 
178.4 ± 6.2 
76.1 ± 13.9 
23.9 ± 4.1 
 
19.3 ± 2.4 
0 
0 
0 (0 - 0) 
179.5 ± 3.8 
73.7 ± 18.5 
22.9 ± 5.7 
 
27.3 ± 8.5 
25.9 
33.3 
0 (0 – 0) 
163.4 ± 4.4 
65.7 ± 15.0 
24.5 ± 5.2 
 
21.7 ± 5.1 
14.4 
30.8 
0 (0 – 0.75) 
168.3 ± 6.0 
71.2 ± 15.9 
25.2 ± 5.5 
Data are presented as mean  ±S.D or median (first to third quartiles).  
 
Hormonal and  biochemical changes in trans men  
All trans men achieved T levels within the male reference range (321–1005 ng/dl) during 
treatment (Table 2). Three trans men (5.7%) had T levels that exceeded the upper limit of 1005 
ng/dl (1 at 3-month, 1 at 9-month and 1 at 12-month time point of treatment). Hct levels 
gradually increased during T treatment. Two trans men developed erythrocytosis according to 
male reference ranges (Hct levels above 52%), one developing it after 9 months and one after 12 
months of treatment. T levels were within the male reference range in these men. Erythrocytosis 
was present in 20.1% of trans men according to female reference ranges (Hct levels above 48%). 
E2, E1, prolactin, and SHBG decreased significantly, whereas DHEAS, androsteendione, and 
cortisol levels were not influenced by T treatment. Testosterone treatment induced a less 
favorable lipid profile, as total-C, LDL-C, and triglycerides increased whereas HDL-C decreased 
(Table 2). 
Hormonal and  biochemical changes in trans women  
All trans women achieved adequate gonadotropin and T suppression during anti-androgen and 
estrogen administration (Table 2). Two trans women (both on oral EV) who initially had an 
adequate T and gonadotropin suppression showed T levels within the normal male range at 12 
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months, possibly due to poor adherence to treatment. Gonadotropins, T, and androstenedione 
decreased during oral and transdermal estrogen therapy associated with CA, whereas E2 and E1 
increased.  
Trans women using oral EV, unlike those using transdermal estrogen, experienced a significantly 
increased SHBG, decreased DHEAS, and a trend toward increased cortisol levels. Prolactin levels 
significantly increased during both oral and transdermal estrogen treatments (figure 2A), and 
during 12 weeks of CA treatment alone (figure 2B).  
CHT induced a more favorable lipid profile, as total-C and LDL-C decreased during both oral 
and transdermal estrogen treatments. HDL decreased during both forms of estrogen treatment, 
and triglycerides decreased during transdermal but not oral estrogen treatment. No significant 
differences were observed between trans women initially treated with CA plus estrogens 
compared to those initially treated with CA alone (data not shown).  
Figure 2. Changes in prolactin levels during CA plus oral or transdermal estrogen treatment (A)/ 
Changes in prolactin levels during CA plus estrogens or CA alone. 
 
 
Figure 2A.  Data presented as median, error bars 
represent 95% CI. Dark grey square: cyproterone 
acetate (CA) plus oral estrogens; Light grey square: CA 
plus transdermal estrogens. We observed a comparable 
increase in prolactin levels during both oral and 
transdermal estrogen treatment (p<0.001 and p=0.002, 
respectively). 
Figure 2B.  Data presented as median, error bars 
represent 95% CI.  Dark grey square: cyproterone 
acetate (CA) plus estrogens; Light grey square: CA 
alone. 
We observed an increase in prolactin levels during 
CA + estrogen treatment (p<0.001) and during CA 
treatment alone (P=0.009). CA+ estrogen treatment 
induced higher prolactin levels compared to CA 
treatment alone (p=0.01). 
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Table 2. Hormonal and biochemical changes in trans persons 
 Trans women (N=53) Trans men (N=53) 
Oral  
estrogens  
(N=40) 
P Transdermal 
 estrogens  
(N=13) 
 
P Intramuscular T 
undeconoate 
(N=53) 
 
P 
Testosterone (ng/dl) 
       Baseline  
       12 month 
Estradiol (pg/ml) 
       Baseline  
       12 month 
Estrone (pg/ml) 
       Baseline  
       12 month 
SHBG (nmol/l) 
       Baseline  
       12 month 
LH (U/l) 
       Baseline  
       12 month 
FSH (U/l) 
       Baseline  
       12 month 
Prolactin (ng/ml) 
      Baseline  
       12 month 
DHEAS (µg/dl) 
       Baseline  
       12 month 
Androstenedione (ng/dl) 
       Baseline  
       12 month 
Cortisol (µg/dl) 
       Baseline  
       12 month 
Hematocrit (%) 
       Baseline  
       12 month 
Fasting glucose (mg/dl)* 
       Baseline  
       12 month 
Fasting insulin (mU/l)* 
       Baseline  
       12 month 
Creatinin (mg/dl) 
       Baseline  
       12 month 
GOT (U/L) 
       Baseline  
       12 month 
GPT (U/L) 
       Baseline  
       12 month 
Total C (mg/dl) 
       Baseline  
       12 month 
LDL-C (mg/dl) 
       Baseline  
       12 month 
HDL-C (mg/dl) 
       Baseline  
       12 month 
Triglycerides (mg/dl) 
       Baseline  
       12 month 
 
517.5 (419.2-631.9) 
10.7 (8.3-14.3) 
 
19.1 (15.3-24.9) 
56.5 (42.3-70.8) 
 
29.8 (24.1-40.1) 
360.9 (253.3-485.3) 
 
31.2 (24.0-40.1) 
41.7 (25.8-50.7) 
 
4.8 (3.7-6.4) 
0.1 (0.1-0.1) 
 
3.5 (2.8-5.3) 
0.2 (0.1-0.4) 
 
8.1 (6.3-11.3) 
20.6 (16.7-28.9) 
 
289.9 (253.1-401.7) 
236.8 (192.9-348.5) 
 
101.2 (77.0-121.3) 
56.2 (43.4-76.4) 
 
15.2 (12.9-18.7) 
15.7 (12.8-20.8) 
 
45.2 ± 2.5 
42.0 ± 5.7 
 
0.83 ± 0.1 
0.84 ± 0.1 
 
7.2 (4.9-9.7) 
9.3 (7.2-11.3) 
 
0.9 ± 0.1 
0.8 ± 0.1 
 
24.1 ± 9.2 
17.7 ± 3.6 
 
25.0 ± 17.4 
18.6 ± 9.5 
 
171.5 ± 32.7 
152.3 ± 28.3 
 
99.4 ± 29.0 
92.3 ± 28.9 
 
52.9 ± 13.5 
45.7 ± 9.2 
 
79.5 (54.7 -108) 
70.8 (50-133.1) 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
0.06 
 
 
0.003 
 
 
0.78 
 
 
0.019 
 
 
0.001 
 
 
<0.001 
 
 
0.01 
 
 
0.001 
 
 
0.03 
 
 
<0.001 
 
 
0.1 
 
567.0 (484.8-678.2) 
14.0 (12.4-17.2) 
 
23.6 (18.3-29.3) 
95.4 (58.5-127.6) 
 
45.8 (33.8-50.3) 
57.8 (47.3-90.7) 
 
50.3 (36.0-59.7) 
48.1 (29.0-90.7) 
 
5.5 (3.5-6.8) 
0.1 (0.1-0.1) 
 
5.4 (3.5-6.8) 
0.2 (0.1-0.4) 
 
6.6 (4.1-9.3) 
26.2 (18.6-36.2) 
 
285.9 (220.4-404.5) 
275.6 (171.9-410.3) 
 
117.4 (94.6-161.4) 
69.6 (55.9-106.7) 
 
15.4 (13.4-19.9) 
15.0 (11.8-18.9) 
 
45.5 ± 1.7 
42.0 ± 2.3 
 
0.92 ± 0.06 
0.88 ± 0.1 
 
7.3 (6.6-18.7) 
12.0 (9.1-17.0) 
 
0.93 ± 0.1 
0.85 ± 0.1 
 
26.8 ± 8.3 
19.6 ± 4.8 
 
29.9 ± 15.3 
21.0 ± 10.1 
 
227.2 ± 35.6 
181.3 ± 20.6 
 
138.3 ± 24.8 
106.3 ± 20.4 
 
58.2 ± 15.2 
54.8 ± 15.7 
 
87.0 (68.0-176.5) 
85.0 (70.0-110) 
 
0.001 
 
 
0.001 
 
 
0.028 
 
 
0.33 
 
 
0.001 
 
 
0.001 
 
 
0.001 
 
 
0.42 
 
 
0.001 
 
 
0.28 
 
 
<0.001 
 
 
0.25 
 
 
0.1 
 
 
0.011 
 
 
0.013 
 
 
0.12 
 
 
0.004 
 
 
0.001 
 
 
0.26 
 
 
0.03 
 
30.2 (20.4-39.9) 
595.8 (481.1-715.7) 
 
50.3 (24.2-99.3) 
29.4 (21.7-34.7) 
 
51.7 (30.3-80.9) 
45.5(32.9-53.8) 
 
51.6 (23.0-81.2) 
25.1 (19.7-34.0) 
 
6.7 (4.2-9.9) 
2.4 (0.7-5.8) 
 
4.8 (3.4-7.3) 
4.2 (1.2-6.6) 
 
13.7 (9.3-19.9) 
9.6 (7.9-14.4) 
 
254.0 (170.1-351.4) 
257.6 (174.1-355.7) 
 
113.9 (90.9-150.5) 
113.8 (80.2-151.9) 
 
13.3 (8.9-16.0) 
11.8 (9.4-15.2) 
 
40.8 ± 2.9 
45.8 ± 3.0 
 
0.80 ± 0.1 
0.77 ± 0.1 
 
9.1 (5.8-16.3) 
7.5 (5.2-13.2) 
 
0.74 ± 0.1 
0.84 ± 0.1 
 
20.0 (17-23) 
24 (18-29.5) 
 
16.0 (11.5-20) 
20 (15-25) 
 
171.9 ± 28.1 
178.2 ± 30.6 
 
98.4 ± 26.3 
116.1 ± 28.9 
 
56.3 ± 12.7 
47.8 ± 10.7 
 
69.0 ( 51.7-89.5) 
81.1 (65.3-124.6) 
 
<0.001 
 
 
0.001 
 
 
0.01 
 
 
<0.001 
 
 
<0.001 
 
 
0.02 
 
 
<0.001 
 
 
0.97 
 
 
0.42 
 
 
0.42 
 
 
<0.001 
 
 
0.28 
 
 
0.02 
 
 
<0.001 
 
 
0.01 
 
 
0.02 
 
 
0.04 
 
 
0.006 
 
 
<0.001 
 
 
<0.001 
Data are presented as mean  ±S.D or median (first to third quartiles) P value results from paired T-test or Wilcoxon 
signed rank test             * based on subsample (N=44) 
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Physical changes  
Trans men 
Total body weight significantly increased due to an increase in total lean mass, whereas total fat 
mass decreased. An android pattern of fat distribution was observed as the waist-hip ratio 
increased during treatment (p=0.02), mainly due to reduced hip circumference (Table 3). As 
expected, Ferriman and Gallwey score significantly increased (p<0.001), with a wide between-
subject variability ranging from 2 to 28.  
Trans women 
In contrast to trans men, total body weight remained unchanged for trans women, although they 
experienced an increase in total body fat mass and a decrease in total body lean mass. A gynoid 
pattern of fat distribution was induced in trans women, as the waist-hip ratio decreased during 
treatment (Table 3).  
Anti-androgen with estrogen treatment resulted in a significant increase (average 3.3 cm) in breast 
circumference at the nipple, with a wide inter-individual range of increase (p<0.004). Trans 
women using oral estrogens experienced similar changes in physical measures as those using 
transdermal estrogens (Table 3). No significant differences were observed between trans women 
treated with CA plus estrogens from start compared to those initially treated with CA alone (data 
not shown), although the former tended to have a larger breast circumference (p=0.06). 
Side effects and adverse events  
Trans men 
We recorded no deaths, cardiovascular events, osteoporotic fractures, venous thromboses, or 
pulmonary embolisms in trans men. Two were switched to short-acting intramuscular T esters 
after 9 and 12 months, respectively, of T undecanoate therapy mainly because of muscle and joint 
aches. Liver enzymes increased during T therapy, but only 1.9% of trans men had liver enzymes 
values exceeding twice the upper limit of normal according to female reference ranges. No 
subject had liver enzymes values exceeding twice the upper limit of normal levels according to 
male reference ranges. 
Blood pressure increased slightly during treatment, but none of subjects developed hypertension 
during our observation. Fasting insulin levels decreased (p=0.02), and nobody developed type 2 
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diabetes. GAGS acne scores increased (p<0.001), but the majority of trans men (94.3%) had mild 
acne lesions. The remaining 5.7% had moderate acne lesions after 12 months of therapy, and no 
individuals had severe or very severe acne lesions. Eighteen persons (34.0%) initiated topical or 
oral acne treatment.  
Seventeen percent of trans men developed androgenetic alopecia. No indication of troublesome 
aggression, hostility, or sleep apnea was present. All trans men reported loss of vaginal bleeding 
during treatment. Spotting was reported in about one third of participants, generally limited to 
the first 6 months of treatment (figure 3).  
Trans women  
Similar to trans men, no deaths, cardiovascular events, osteoporotic fractures, venous 
thromboses, or pulmonary embolisms were observed in trans women. One trans woman had to 
stop estrogen treatment due to major depression and was excluded from our analyses. Serum 
prolactin levels exceeding twice the upper limit of normal were observed in 15.7% and 3.9% 
according to the male and female reference range, respectively. One trans woman experienced 
galactorea, which spontaneously stopped after several weeks. Transient elevation of the liver 
enzymes exceeding twice the upper limit of normal was observed in 5.7% and 1.9% according to 
the female and male reference ranges, respectively. One trans woman developed hypertension 
during the study observation (defined as a systolic blood pressure above 140 mmHg or diastolic 
above 90 mmHg at three different time points). Fasting insulin increased during anti-androgen 
and estrogen treatment (p=0.005), but no subject met criteria for diagnosis of type 2 diabetes. 
Two trans women using transdermal estrogen patches (15.4%) were switched to other therapies 
because of skin irritation after 3 and 9 months of treatment, respectively. 
Treatment-related symptoms 
Trans men 
Treatment-related symptoms were investigated every 3 months in a subsample of trans men 
(N=25). The vast majority of the trans men reported an increase in sexual desire (figure 3). 
Testosterone treatment resulted in variable levels of voice deepening and an increased voice 
instability (p=0.024). About 20% of trans men reported clitoral pain, with a peak incidence 
observed at 6 months of treatment. Symptoms of emotionality decreased (p=0.01). 
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We observed no changes in symptoms of night sweats, hot flashes, abdominal pain, anxiety, 
breast tenderness, irritability, palpitations, joint pain, muscle soreness, headache, mood swings, 
fatigue, concentration difficulties, memory, or sleep-related problems (data not shown).  
Trans women 
We examined treatment-related symptoms every 3 months in a subsample of trans women 
(N=30) treated with 50 mg of CA daily in combination with estrogens from the start. A 
significant increase in breast tenderness, emotionality, low sexual desire, and hot flashes was 
observed (p<0.001, p=0.001, p<0.001, and p=0.02, respectively)(figure 3).  
We found no changes in night sweats, abdominal pain, anxiety, irritability, palpitations, skin 
dryness, joint pain, muscle soreness, headache, mood swings, fatigue, concentration difficulties, 
memory or sleep-related problems (data not shown). 
No significant differences in the presence of treatment-related symptoms at the 3-month time 
point between trans women treated with oral or transdermal estrogen. No significant differences 
were observed at the 3-month time point between trans women treated with CA plus estrogens 
from start compared to those initially treated with CA alone (data not shown), except for a higher 
prevalence of breast tenderness in those women treated with CA plus estrogens (p=0.001). 
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Table 3. Physical  changes in  trans  persons 
  
Trans women (N=53) 
 
Trans men (N=53) 
Oral 
estrogens 
(N=40) 
p 
Transderma
l estrogens 
(N=13) 
p 
Intramuscular 
T undeconoate 
(N=53) 
p 
Weight (kg) 
     Baseline 
    12 months 
BMI (kg/m²) 
     Baseline 
     12 months 
Total body fat mass (kg) 
     Baseline 
     12 months 
Total body lean mass (kg) 
     Baseline 
     12 months 
Waist circumference (cm) 
     Baseline 
     12 months 
Hip circumference (cm) 
     Baseline 
     12 months 
Waist-hip ratio 
     Baseline 
     12 months 
Breast circumference (cm) 
     Baseline 
     12 months 
Systolic blood pr (mmHg) 
     Baseline 
     12 months 
Diastolic blood pr (mmHg) 
     Baseline 
     12 months 
Ferriman and Gallwey 
score 
     Baseline 
     12 months 
Acne score 
     Baseline 
     12 months 
 
73.3 ± 13.8 
74.6 ± 14.3 
 
23.1 ± 4.2 
23.7 ± 4.4 
 
15.4 ± 7.4 
20.0 ± 8.1 
 
5.6 ± 7.5 
5.3 ± 8.0 
 
81.2 ± 10.1 
79.7 ± 10.5 
 
94.2 ± 9.3 
98.1 ± 9.3 
 
0.9 ± 0.1 
0.8 ± 0.1 
 
92.9 ± 10.0 
95.7 ± 11.2 
 
125.1 ± 13.8 
118.8 ± 13.9 
 
76.8 ± 10.8 
75.7 ± 10.6 
 
- 
- 
 
2 (0-7) 
0 (0-0) 
 
0.10 
 
 
0.42 
 
 
<0.001 
 
 
<0.001 
 
 
0.21 
 
 
<0.001 
 
 
<0.001 
 
 
0.03 
 
 
0.005 
 
 
0.32 
 
 
- 
- 
 
<0.001 
 
 
82.1 ± 13.1 
82.1 ± 11.6 
 
26.1 ± 3.5 
26.1 ± 3.4 
 
16.6 ± 5.4 
18.7 ± 4.6 
 
62.6 ± 9.3 
59.7 ± 8.1 
 
91.6 ± 11.1 
90.9 ± 10.1 
 
96.9 ± 7.8 
100.4 ± 7.1 
 
0.94 ± 0.06 
0.91 ± 0.07 
 
98.2 ± 9.0 
101.2 ± 9.0 
 
131.6 ± 15.8 
128.8 ± 15.5 
 
76.7 ± 9.0 
79.7 ± 9.3 
 
- 
- 
 
0 (0-0) 
0 (0-0) 
 
0.99 
 
 
0.91 
 
 
0.01 
 
 
0.02 
 
 
0.50 
 
 
0.07 
 
 
0.07 
 
 
0.09 
 
 
0.47 
 
 
0.43 
 
 
- 
- 
 
1.0 
 
 
68.4 ± 15.5 
70.6 ± 13.2 
 
24.8 ± 5.3 
25.6 ± 4.4 
 
22.9 ± 11.4 
19.9 ± 9.7 
 
43.0 ± 6.6 
48.3 ± 5.6 
 
80.3 ± 13.6 
80.1 ± 11.2 
 
97.3 ± 10.5 
95.4 ± 9.2 
 
0.82 ± 0.09 
0.84 ± 0.08 
 
- 
- 
 
111.5 ± 12.6 
115.6 ± 11.7 
 
70.2 ± 10.5 
72.5 ± 9.2 
 
0 (0-2) 
10 (6-16) 
 
2 (0-5) 
7.5 (2-11.8) 
 
0.01 
 
 
0.01 
 
 
<0.001 
 
 
<0.001 
 
 
0.74 
 
 
0.02 
 
 
0.03 
 
 
- 
 
 
0.05 
 
 
0.18 
 
 
<0.001 
 
 
<0.001 
 
Data are presented as mean  ±S.D or median (first to third quartiles) in case of non-Gaussian distribution; P value 
results from paired T-test or Wilcoxon signed rank test in case of non-Gaussian distribution 
*Based on sub sample (n= 20) 
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Figure 3. Prevalence of symptoms in trans men (A) Prevalence of symptoms in trans women (B) 
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DISCUSSION 
We presented the first multi-center prospective study describing the effects of current CHT on 
hormonal and clinical changes, side effects, and adverse events in trans men and trans women. 
The main findings of our study were that our therapies (injections with T undecanoate every 3 
months in trans men, and 50 mg CA plus either 4 mg oral EV or 100 µg/24 h transdermal 17-β 
estradiol daily in trans women) were effective and safe. The majority of trans persons had desired 
levels of sex steroids according to the Endocrine Society Guidelines[1] and developed the 
secondary sex characteristics of the desired sex. Trans men experienced cessation of menses and 
developed a male body habitus with an android pattern of fat distribution, a deepening of the 
voice, an increase in lean mass, male pattern baldness, and both facial and body hair. Trans 
women experienced an increase in fat mass with a gynoid pattern of fat distribution, and an 
increase in breast circumference. 
None of the trans persons experienced severe adverse events such as cardiovascular events or 
death. These findings are in line with previous reports that demonstrated T treatment for trans 
men was effective and relatively safe in the short-term[17-19]. The results in trans women confirm a 
recent study[10] showing a low risk for adverse events at short-time follow-up, but contrasts earlier 
reports that have indicated a high incidence of venous thrombosis and/or pulmonary embolism 
during the first year of CHT[17, 19]. Current treatment modalities in trans women, including the 
avoidance of EE usage and using transdermal estrogens in older trans women, may therefore be 
less detrimental to the coagulation system. Indeed, Toorians and colleagues[20] described a higher 
activated protein C (APC) resistance with oral EE compared to oral EV and transdermal 17-β 
estradiol usage. In addition, Van Kesteren et al.[17] reported a decreased incidence of venous 
thrombosis with the use of transdermal estrogens in older trans women.  
Similar to Mueller and colleagues[18], we observed a small but significant increase in systolic blood 
pressure during T therapy. However, considering the small increase (about 3.5%) we observed, it 
is likely that sample sizes in other studies[21-22] were too small to detect a statistically significant 
difference. Importantly, no subject developed a clinically significant blood pressure increase 
during our study observation. T treatment also increased liver enzymes in our study, similar to 
the study from Mueller and colleagues[18], although the clinical relevance of this finding remains to 
be determined.  
Previous studies have not investigated systematically treatment-related symptoms during T 
therapy in trans men. However, the majority of trans men reported an increase in voice 
instability, acne, and sexual desire. Most acne cases were mild and none were severe or very 
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severe according to the GAGS. Nevertheless, about a third of our patients underwent acne 
treatment, indicating that even mild and moderate acne lesions were clinically relevant. 
One trans woman discontinued treatment because of depression. Indeed, it has been previously 
reported that CHT increases depression risk [19]. However, others show CHT lowers anxiety and 
depression scores, possibly due to improvements in mental health after initiation of cross-sex 
reassignment therapy[23]. Similar to others[17, 19], we found a transient elevation of the liver enzymes 
during anti-androgen and estrogen treatment, although generally a decrease in liver enzymes is 
observed[24].  
Concerning the risk for hyperprolactinemia during CHT in trans women, our findings 
substantiate most other studies  showing an increase in prolactin levels during administration of 
CA combined with estrogen therapy[1, 17, 25-28] and CA alone[25, 27]. However, our previous 
retrospective follow-up studies do not show a further increase in the long-term[5, 29]. Moreover, 
the clinical relevance of increased prolactin levels during CHT remains undetermined. Although a 
few case reports of prolactinomas have been reported following CHT, none were reported in 
large follow-up studies, perhaps suggesting a low risk associated with CHT. 
Trans women also reported treatment-related symptoms. Although some of them such as breast 
tenderness and low sexual desire were well-known from our clinical practice, subjects 
unexpectedly reported a significant increase in hot flashes during anti-androgen and estrogen 
treatment. Because we did not use validated questionnaires or objective measurements to analyze 
these symptoms, further exploration and characterization is needed. 
Investigation of cardiovascular risk factors during CHT is important, as recent studies show that 
trans women have an increased cardiovascular morbidity[30] and mortality[11, 31] compared to the 
general population. Similar to previously published studies using EE plus CA, we found a 
reduction in LDL-C and an increase in fat mass and fasting insulin during the first year of CHT 
in trans women[21, 32]. Estrogen therapy increases removal of LDL apolipoprotein B-100[33], but 
the pathophysiological mechanism of increased insulin resistance during anti-androgen and 
estrogen therapy is not fully understood. CHT induces important changes in body composition, 
with an increase in fat mass, which may affect glucose metabolism. Sex steroids may also exert 
direct effects, as acute T withdrawal in men decreases insulin sensitivity in the absence of any 
detectable changes in body composition[34]. Augmentation of E2 to supraphysiological levels may 
also induce insulin resistance through liver hyperinsulinemia and reduced GLUT 4 expression 
within the muscles[35].  
 94 
In line with Dittrich and colleagues[10], we observed no increase in body weight, triglycerides, or 
blood pressure in trans women. These findings differ from a previously published study using EE 
plus CA [21], and are likely to be related to differences in type of estrogen used. Different types of 
estrogen exert divergent metabolic effects. EE has a stronger hepatic impact due to its 17α-
ethinyl group, which prevents the inactivation of the molecule and results in a slower 
metabolism[36-37]. Additionally, the higher estrogen dosage in the study by Elbers and colleagues[21] 
may also contribute to differences in these health outcomes. 
HDL-C decreased in trans women (in both oral and transdermal group), which was somewhat 
unexpected under estrogen therapy. A potential explanation for these findings may be found in 
the progestagenic effects of cyproterone acetate, as progestogens decrease HDL-C 
concentrations[38]. Decreased HDL-C levels have been previously shown in trans women using 
transdermal estrogen therapy[39-40]. Because the transdermal route avoids the first pass effect of 
the liver, it may have different metabolic effects than oral estrogen therapy. Decreased 
triglycerides were also observed with transdermal, but not oral estrogen therapy. In addition, 
trans women using oral EV showed significantly higher E1/E2 ratio than those using 
transdermal therapy. A lower E2/E1 ratio has been reported in postmenopausal women 
receiving transdermal hormone replacement therapy[41]. No other differences were observed 
between these two modes of estrogen treatment, suggesting both are equally effective.  
Testosterone undecanoate treatment decreased fat mass but induced a less favorable lipid profile 
and an android pattern of fat distribution in trans men. Although these changes were also seen in 
studies using 2- or 3-weekly injections of intramuscular T esters[42-43], most of the evidence 
suggests that T treatment is relatively safe at short- and medium-term follow-up[17-19]. However, 
outcome studies in trans men are generally performed in much smaller sample sizes and at 
younger ages compared to trans women. Large, long-term (>20 y) follow-up studies are needed 
to investigate the cardiovascular safety of T therapy in trans men. 
As previously described[12], the age and sex ratio differed significantly between our two centers. 
This age difference should be kept in mind in future outcome studies, as older age may be 
associated with a worse cardiovascular outcome[44].  
The strengths of the present study were its relatively large sample size compared to most other 
prospective studies; the use of widely prescribed (but scientifically not well documented) 
treatment modalities; our detailed description of adverse events, side effects and treatment-
related symptoms; and the use of a mass spectrometry-based methodology to measure serum sex 
steroid levels in trans persons. Although we did not use a validated questionnaire to measure 
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treatment-related symptoms, we were the first to examine these symptoms systematically. 
Validation of such a questionnaire may be valuable for future studies, as no standardized 
assessment of symptoms exists presently. Secondly, our treatment protocol was to administer oral 
EV to trans women younger than 45 y and transdermal estrogen therapy to those over 45 y. This 
age discrepancy may have influenced the difference in treatment response between the two 
groups. In addition, some trans women initially received CA alone without concomitant estrogen 
use. This may have influenced our results, although no significant differences were observed 
between these two groups. Moreover, the lack of difference between the groups may indicate that 
most relevant changes occur during the first 9 months of CHT. Thirdly, we did not have a 
blinded clinician to determine the clinical effects of the treatment, which may possibly induce a 
bias. Finally, we described average differences associated with each treatment, but we observed 
large between-subject differences in clinical outcome measures, which may be due to differences 
in sex steroid metabolism or sensitivity.  
CONCLUSION  
We observed that our current treatment modalities in both trans men and women are effective 
and carry a low risk for side effects and adverse events at short-time follow-up.
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2.2 Sex steroids and cardiometabolic risk factors: lessons from the 
treatment of trans women and men 
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ABSTRACT 
Introduction 
Sex steroids may explain part of the between-sex variation in cardiovascular risk. This study 
aimed to investigate associations between sex steroids and cardiometabolic factors and to explore 
the changes in cardiovascular risk profile during cross-sex hormone therapy (CSH) in trans 
persons. 
Methods 
In this prospective intervention study, we examined cardiometabolic factors in 40 trans women 
(male-to-female transsexual persons) and 20 trans men (female-to-male transsexual persons) 
before and after 12 months of CSH. Trans men received injections with testosterone (T) 
undecanoate every 3 months. Trans women <45y received cyproterone acetate (CA) 50mg daily 
and estradiol valerate 4mg daily while those >45y received CA 50mg daily together with 
transdermal 17-β estradiol 100µg/24h. 
Main outcome measures 
Glucose metabolism (oral glucose tolerance test) and detailed lipid profile were examined.Total 
body fat, trunk fat mass and lean body mass were determined by dual X-ray absorptiometry. 
Regional fat and muscle area at the forearm and calf by peripheral quantitative computed 
tomography.  
Results 
In trans women, an increase in total body fat mass, trunk fat mass and cross-sectional fat area at 
proximal forearm and tibia and decrease in total body lean body mass and cross-sectional muscle 
area at forearm was seen. Trans men experienced an increase in lean mass and a decrease in total 
body fat percentage. Fasting insulin levels and HOMA-IR increased during anti-androgen with 
estrogen treatment, but decreased during T therapy in trans men.  
Fasting glucose, Matsuda index and AUC for insulin and glucose remained unchanged during 
CSH both in trans women and men. In trans women, all serum lipids levels lowered during CSH, 
apart from an increase in free fatty acids. During T therapy triglycerides, LDL cholesterol and 
ApoB levels increased, whereas HDL cholesterol decreased.  
No associations were found between changes in sex steroid levels and changes in body 
composition, glucose metabolism or lipid profile. Older age was significantly associated with an 
increased AUC of insulin after one year in trans women.  Measures of adiposity were associated 
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with impaired lipid profile and glucose metabolism in trans women and with an impaired lipid 
profile in trans men. 
Conclusions 
CSH increased insulin resistance but favourably affected the lipid profile in trans women, 
whereas it improved insulin resistance but worsened lipid profile. Adiposity was associated with a 
less favourable outcome in both trans women and men. In trans women, older age was related to 
an impaired glucose tolerance.These findings suggest that the between-sex variation in 
cardiovascular risk is mainly due to effects of sex steroid exposition on body composition. 
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INTRODUCTION 
Women have a more favourable cardiovascular risk profile compared to their age- matched male 
counterparts, including a less proatherogenic plasma lipid profile, less visceral fat mass and a 
lower prevalence of impaired glucose tolerance and arterial hypertension[1-4]. Whether these sex 
differences in cardiovascular risk factors are simply caused by differences in sex steroid levels is a 
matter of debate; and the role of non-hormone mediated effects of genes located on the sex 
chromosomes has been put forward[5-7]. Some also suggested that sex differences in the 
relationship between cardiovascular risk factors (e.g., impact of insulin resistance on 
cardiovascular disease) may explain the advantage of young women compared to men[8]. The 
effects of cross-sex hormone therapy in trans persons may offer new perspectives on these sex 
differences and the role of sex steroids herein. 
Current knowledge in the field of transsexualism is hampered by a lack of prospective studies, 
small study samples and wide variations in treatment modalities between centers. In addition, 
most previous studies investigating changes in lipid profile and insulin sensitivity[9-12], used former 
treatment modalities in male-to-female transsexual persons (trans women) including high dose 
cyproterone acetate (CA) and high dose oral ethinyl estradiol (EE). However, since the 
observations that this estrogen type was associated with a higher risk for venous thrombosis and 
increased cardiovascular mortality[13-15], its use has been abandoned.  Most studies in female-to-
male transsexual persons (trans men) used short acting T esters[9-12], instead of long-acting 
intramuscular T undecanoate, that was more recently marketed. The latter is increasingly used, as 
the long intervals between intramuscular injection make this formulation attractive for T 
supplementation, particularly in these healthy, young persons who will need life-long treatment. 
The aims of this study were twofold: (1) to investigate possible associations between sex steroids, 
body composition, insulin sensitivity and lipid profile in trans persons, and (2) to evaluate 
changes in cardiovascular risk profile during treatment with current cross-sex hormone therapies. 
METHODS 
Study Population and sex hormone therapy 
This study is conducted at the department of Endocrinology at the Ghent University Hospital. 
Between February 2010 and September 2012, all adult patients diagnosed with gender dysphoria 
referred to our department were invited to participate in this prospective study (N=119). After 
screening by thorough medical history and determination of serum sex steroids, participants were 
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excluded because of current or previous use of cross-sex hormone therapy (n=23), unwillingness 
to participate (n=11), pre-existent impaired glucose tolerance (n=7), anorexia (n=2) and other 
reasons (n=3). In addition, four participants were excluded due to protocol violation and another 
four trans persons were lost to follow-up. Baseline results were not statistically different when 
participants who were lost to follow-up were excluded (data not shown). A total number of 40 
trans women and 20 trans men were included in the current study. 
All trans women younger than 45y (n=29) received cyproterone acetate (CA) 50mg daily 
(Androcur®; Bayer, Germany) in combination with estradiol valerate (EV) 4mg daily 
(Progynova®; Bayer, Germany). Patients older than 45y (n=11) received CA 50mg daily in 
combination with transdermal 17-β estradiol patch 100µg/24h (Dermestril®; Besins, Belgium). 
In case of non-tolerance due to allergic skin reaction, transdermal 17-β estradiol gel 2mg twice 
daily (Oestrogel®; Besins, Belgium) (n =1) or EV 4mg was prescribed (n=1). Generally, CA and 
estrogens were given from start (treatment protocol 1; n=24). Based upon the decision of the 
mental health professional and patient, some trans women who favoured a slower procedure 
and/or need an extra diagnostic evaluation received a dual-phase protocol (treatment protocol 2; 
n=16). In the first phase, sex-specific features were suppressed by administration of CA 50 mg 
daily for a median duration of 16 weeks whereas in the second phase, estrogens were added to 
induce feminization. 
All trans men received injections with intramuscular T undecanoate 1000mg every 3 months 
(Nebido®; Bayer, Germany), sometimes preceeded by progestagens to suppress the menstrual 
cycle. In case of non-tolerance, 2-weekly injections with intramuscular T esters (T decanoate 100 
mg, T isocaproate 60 mg, T fenylpropionate 60 mg, T propionate 30 mg/ml) (Sustanon 250®; 
MSD; Netherlands) was prescribed (n=1).This study complied with the recommendations of The 
Declaration of Helsinki and was approved by the Ethical Committee of the Ghent University 
Hospital and the University Hospital of Oslo. All participants gave written informed consent. 
Clinical trial number: NCT01072825. 
MAIN OUTCOME MEASURES  
Medical history and examination 
Descriptive data were collected from all individuals including: physical and psychiatric medical 
history, current and past medication use, familial medical history, and lifestyle factors including 
smoking and alcohol consumption. Information was compared to data from medical files for 
accuracy and corrected if necessary. 
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Antropometrics 
Standing height was measured to the nearest 0.1 cm using a Harpenden stadiometer (Holtain Ltd, 
Crymuch, United Kingdom). Body weight was measured in light indoor clothing without shoes to 
the nearest 0.1 kg. Waist circumference, defined as the smallest abdominal circumference and hip 
circumference, defined as the largest hip circumference, were determined to the nearest 0.1 cm.  
Body composition 
Body composition (whole body lean mass, fat mass, trunk fat mass and appendicular fat mass) 
was determined using dual-energy X-ray absorptiometry (QDR-4500 A, software version 11.2.1; 
Hologic, Inc., Bedford, MA, USA). We used quantitative computed tomography (XCT-2000, 
Stratec Medizintechnik, Pforzheim, Germany) to measure cross-sectional muscle area (muscle 
CSA) and fat area (fat CSA) at dominant forearm and lower leg (66% from distal end). This fat 
CSA at the forearm and tibia is a measure of subcutaneous fat. 
Glucose metabolism 
After an overnight fast, a two-hour oral glucose (75 g) tolerance test (OGTT) was carried out at 
baseline and after 12 months of hormonal therapy, with glucose, insulin and triglycerides 
measured at 0, 30, 60, and 120 minutes. Postprandial hypertriglyceridemia was also found to be 
an independent cardipovascular risk factor.  
To evaluate the degree of glucose tolerance and β-cell function, several indexes derived from 
either fasting or OGTT-stimulated measurements were used: homeostatic model assessment of 
insulin resistance (HOMA-IR)[16], Matsuda index[17] and incremental glucose and insulin areas 
under the curve (AUC glucose/insulin). 
Biochemical   determinations 
Fasting venous blood samples were obtained at baseline and 12 months between 08.00 and 
10.00h and stored at -80 degrees until batch analysis. 
Luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin 
(SHBG) and insulin were measured by electrochemiluminiscence immunoassay (ECLIA); 
Modular, Roche Diagnostics, Mannheim, Germany.  The inter-assay CVs were as follows: LH 
and FSH, 2.19% and 2.55%, respectively; SHBG 2.8%, insulin 2.3%. Estradiol (E2), and 
testosterone (T) were determined by liquid chromatography tandem mass spectrometry (AB 
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Sciex 5500 triple-quadrupole mass spectrometer; AB Sciex, Toronto Canada). Serum limit of 
quantification was 0.3 pg/mL for E2 and 35pmol/L for T , and the interassay CV were 4% at 21 
pg/mL for E2 and 6.5% at 3 ng/dL. Radioimmunoassays were used for leptin (Bio-connect 
diagnostics, Huissen, the Netherlands) and insulin-growth factor 1 (IGF1) (Cisbio diagnostics, 
Codelet France).  
Hemoglobin (Hb), hematocrit (Hct), glucose, creatinin, cholesterol (C), LDL cholesterol (LDL-
CH), HDL cholesterol (HDL-C), triglycerides (TG), Apolipoprotein (apo)A1, ApoA2, ApoB, 
free fatty acids, C-reactive protein (CRP) and uric acid were measured using routine clinical 
chemistry methods.  
Statistical analysis 
Data are expressed as mean ± standard deviation or median [1st–3rd quartile] when criteria for 
normality were not fulfilled. Statistical analyses of categorical variables were carried out using χ² 
and Fisher's exact tests as appropriate. Statistics of paired data were carried out using the paired 
Student t test and Wilcoxon rank sum tests when variables were not normally distributed. We 
calculated the differences between year one and baseline, denoted as ∆, for lipids, glucose 
metabolism parameters, body composition parameters (total body fat, subcutaneous and trunk fat 
mass). We created a multiple regression model using ∆lipids and ∆glucose and ∆insulin and 
∆body composition as dependent variables and age, ∆body composition and treatment protocol 
(this only for trans women) as independent variables in multiple linear regression analysis 
(stepwise). Significance was set at p<0.05 (two-tailed). Data were analyzed using SPSS-software, 
version 21 (SPSS Inc., Chicago, IL). For all analyses, missing values were excluded. 
RESULTS 
General characteristics  
Table 1 summarizes the general characteristics of the study population and hormone levels at 
baseline and after 12 months of cross-sex hormone therapy. In trans women, gonadotropins, T, 
hematocrit and creatinine decreased, whereas E2, leptin and IGF1 increased during anti-androgen 
with estrogen therapy (all p<0.01). Changes were comparable in both treatment protocols (data 
not shown). 
Trans men achieved T levels within the male reference range (321-1005mg/dl) during treatment. 
Hematocrit and creatinin levels increased whereas E2, prolactin, gonadotropins, SHBG and leptin 
decreased. IGF1 levels were not influenced by T treatment. 
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Systolic blood pressure decreased during treatment in trans women, whereas no change was 
observed in trans men. 
 
Table   1.  Demographics and hormone measurements at baseline and after 12 months  of HRT  
 Trans  women  (N=40) P Trans  men (N=20) P 
 
Age at baseline (years) 
Current smoker at baseline (%) 
Alcohol at baseline (U/week) 
Systolic blood pressure (mmHg) 
          Baseline 
         12 months 
Diastolic blood pressure (mmHg) 
         Baseline 
         12 months 
Mean arterial blood pressure  
         Baseline 
         12 months 
Hematocrit % 
          Baseline  
          12 months 
Creatinin (mg/dl) 
          Baseline  
          12 months 
Testosterone (mg/dl) 
          Baseline  
          12 months 
Estradiol (pg/ml) 
          Baseline  
          12 months 
SHBG (nmol/l) 
          Baseline  
          12 months 
LH (U/l) 
         Baseline  
          12 months 
FSH (U/l) 
          Baseline 
          12 months 
Leptin (ng/ml) 
          Baseline 
          12 months 
IGF1 (ng/ml) 
          Baseline 
        12 months 
 
 
31.5 ± 12.9 
17.5 
0 (0-6) 
 
128.2 ± 14.3 
122.7 ± 12.6 
 
77.8 ± 9.7 
76.8 ± 9.0 
 
94.6 ± 9.5 
91.2 ± 10.5 
 
45.5 ± 2.4 
41.6 ± 2.4 
 
0.94 ± 0.1 
0.84 ± 0.1 
 
543.5 (433.7-676.7) 
12.0 (10.2 -15.5) 
 
20.5 (16.7 - 28.6) 
57.5 (40.7 -78.6) 
 
35.2 (25.3-41.8) 
42.4  (27.1-51.4) 
 
4.5 (3.7- 6.4) 
0.1 (0.1 -0.1) 
 
3.6 (2.8-5.8) 
0.2 (0.1 -0.4) 
 
4.7 (2.8-7.8) 
11.0 (7.0- 16.0) 
 
224.1 (182.5-307.2) 
287.2 (210.1-320.0) 
 
- 
- 
- 
 
0.020 
 
 
ns 
 
 
ns 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
0.009 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
25.6 ± 8.0 
20.02 
0 (0-0) 
 
114.1 ± 12.3 
119.5 ± 14.4 
 
71.2 ± 11.6 
74.2 ± 10.6 
 
85.4 ± 11.5 
89.3 ± 10.0 
 
41.2 ± 3.0 
45.0 ± 2.8 
 
0.79 ± 0.1 
0.86 ± 0.1 
 
30.0 (19.6-35.8) 
647.2 (492.6-
795.9) 
 
69.3 (24.6-113.2) 
31.2 (23.8- 36.1) 
 
74.5 (46.9-86.2) 
37.2 (20.2-45.8) 
 
4.8 (3.7-7.2) 
1.9 (0.1-4.3)  
 
4.3 (2.9-6.2) 
4.6 (1.0-6.7) 
 
9.5 (6.6-14.1) 
5.3 (2.8-6.5) 
 
287.4 ± 109.7 
285.4 ± 83.6 
 
- 
- 
- 
 
ns 
 
 
ns 
 
 
ns 
 
 
<0.001 
 
 
0.03 
 
 
<0.001 
 
 
0.006 
 
 
<0.001 
 
 
0.006 
 
 
ns 
 
 
<0.001 
 
 
ns 
Data are presented as mean  ±S.D or median (first to third quartiles); P value: from paired T-testa or Wilcoxon 
signed rank testb 
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Anthropometrics and body composition  (Table 2).  
In trans women, there was an increase in total body fat mass, trunk fat mass and fat CSA at 
proximal forearm and tibia. Total body lean mass and muscle CSA at proximal forearm 
decreased, hip circumference increased and waist-hip ratio decreased during treatment. During T 
therapy, trans men experienced an increase in whole body lean mass and a decrease in fat 
percentage, but no changes in total body fat mass, trunk fat or appendicular fat mass were seen. 
Fat CSA at the tibia decreased whereas muscle CSA at forearm and tibia increased.  
Table   2.  Antropometrics and body composition at baseline and after 12 months  of HRT 
 
Trans  women  
(N=40) 
P Trans  men (N=20) P 
BMI (kg/m²) 
          Baseline  
          12 months 
Whole body fat mass (kg) 
          Baseline  
          12 months 
Whole body percentage fat (%) 
          Baseline  
          12 months 
Whole body trunk fat mass (kg) 
          Baseline  
          12 months 
Whole body lean mass (kg) 
          Baseline  
          12 months 
Waist (cm) 
          Baseline  
          12 months 
Hip (cm) 
          Baseline  
          12 months 
Waist-hip ratio 
          Baseline 
          12 months 
Proximal forearm fat CSA (cm²) 
          Baseline 
          12 months 
Proximal forearm muscle CSA (cm²) 
          Baseline 
          12 months 
Proximal tibia fat CSA (cm²) 
          Baseline 
          12 months 
Proximal tibia muscle CSA (cm²) 
          Baseline 
          12 months 
 
23.8 ± 4.3 
24.2 ± 4.4 
 
15.1 ± 6.6 
18.9 ± 7.0 
 
19.3 ± 5.5 
24.1 ± 5.1 
 
7.1 ± 3.7 
8.2 ± 3.8 
 
58.1 ± 9.2 
55.4 ± 8.9 
 
83.8 ± 11.3 
82.9 ± 11.4 
 
95.5 ± 9.1 
99.6 ± 8.6 
 
0.88 ± 0.1 
0.83 ± 0.1 
 
8.6 ± 5.0 
12.8  ± 5.2 
 
41.5 ± 8.3 
37.0 ± 8.3 
 
17.3 ± 9.2 
22.8 ± 7.7 
 
78.8 ± 16.4 
76.7 ± 15.0 
 
ns 
 
 
<0.001 
 
 
<0.001 
 
 
0.001 
 
 
<0.001 
 
 
ns 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
ns 
 
22.6 ± 3.2 
24.6 ± 3.2 
 
16.6 ± 5.6 
16.2 ± 5.2 
 
27.1 ± 6.0 
24.1 ± 5.3 
 
6.6 ± 2.9 
6.4 ± 2.8 
 
41.6 ± 5.2 
47.5 ± 5.4 
 
73.0 ± 9.4 
75.0 ± 9.8 
 
95.9 ± 4.1 
95.9 ± 5.8 
 
0.76 ± 0.1 
0.78 ± 0.1 
 
10.7 ± 3.4 
9.7 ± 3.4 
 
28.0 ± 4.1 
33.0 ± 4.1 
 
27.4 ± 9.2 
24.5 ± 9.7 
 
64.3 ± 12.0 
72.6 ± 11.1 
 
0.02 
 
 
ns 
 
 
0.04 
 
 
ns 
 
 
<0.001 
 
 
ns 
 
 
ns 
 
 
ns 
 
 
ns 
 
 
<0.001 
 
 
0.02 
 
 
<0.001 
 
Data are presented as mean  ±S.D or median (first to third quartiles); P value: from paired T-testa or Wilcoxon 
signed rank testb; CSA: cross-sectional area 
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Glucose  metabolism  and  lipid  metabolism (Table 3) 
Serum fasting glucose levels remained unchanged both in trans men and trans women     
(Table 3). Fasting insulin levels and HOMA-IR increased during anti-androgen with estrogen 
treatment, and decreased during T therapy in trans men.  
 
Table   3.  Serum  lipids at baseline and after 12 months of cross-sex hormone therapy 
 Trans  women  (N=40) P Trans  men (N=20) P 
Total-CH (mg/dl) 
          Baseline 
           12 months 
LDL-CH (mg/dl) 
          Baseline 
          12 months 
ApoB  (mg/dl) 
          Baseline 
          12 months 
ApoA1 (mg/dl) 
          Baseline 
          12 months 
ApoA2 (mg/dl) 
          Baseline 
          12 months 
HDL-CH (mg/dl) 
          Baseline 
          12 months 
VLDL-CH (mg/dl) 
          Baseline 
          12 months 
TG (mg/dl) 
          Baseline 
          12 months 
FFA (µEq/L) 
          Baseline 
          12 months 
Uric acid (mg/dl) 
          Baseline 
          12 months 
HOMA-IR 
          Baseline 
          12 months 
Matsuda index 
          Baseline 
          12 months 
 
183.5 ± 39.1 
159.9 ± 30.2 
 
115.7 ± 34.4 
100.3 ± 27.4 
 
70.6 ± 21.5 
61.8 ± 16.5 
 
137.0 ± 27.7 
125.6 ± 25.4 
 
0.30 ± 0.05 
0.28 ± 0.06 
 
44.9 ± 10.8 
41.4 ± 9.8 
 
23.2 ± 16.7 
19.5 ± 13.4 
 
87 (58 -121.8) 
74.5 (54.3 – 90.5) 
 
481 (359.8-570.5) 
627.5 ( 437.5-729) 
 
5.5 ± 1.0 
4.3 ± 0.8 
 
0.7 (1.2-2.0) 
2.0 (1.4-2.9) 
 
4.4 (3.7-6.6) 
3.9 (2.7-6.0) 
 
<0.001 
 
 
<0.001 
 
 
0.001 
 
 
0.01 
 
 
0.07 
 
 
0.01 
 
 
0.02 
 
 
0.02 
 
 
0.05 
 
 
<0.001 
 
 
0.02 
 
 
ns 
 
162.5  ± 19.6 
173.3 ± 27.4 
 
98.8 ± 19.8 
112.5 ± 23.6 
 
54.8 ± 13.2 
72.0 ± 20.3 
 
129.4 ± 29.1 
135.0 ± 24.7 
 
0.3 ± 0.06 
0.3 ± 0.06 
 
49.5 ± 11.5 
42.5 ± 6.8 
 
14.3 ± 3.6 
18.2 ± 9.6 
 
65.5 (48.5-77.5) 
66.5 (53.3-102.0) 
 
504 (367.8-605.3) 
430 (333.5-504.3) 
 
3.9 ± 0.6 
5.1 ± 0.8 
 
1.7 (1.0-3.1) 
1.4 (1.0-2.3) 
 
4.4 (3.3-6.2) 
4.4 (3.2-6.3) 
 
0.1 
 
 
0.008 
 
 
0.005 
 
 
ns 
 
 
ns 
 
 
0.01 
 
 
0.06 
 
 
0.06 
 
 
ns 
 
 
<0.001 
 
 
0.05 
 
 
ns 
Data are presented as mean  ±S.D or median (first to third quartiles); P value: from paired T-test or Wilcoxon signed 
rank test; CH: cholesterol; APO: apolipoprotein; LDL: low density lipoprotein; HDL: high density lipoprotein; 
VLDL: very low density lipoprotein;TG: triglycerides; FFA: free fatty acids; HOMA: homeostatic model assessment 
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Matsuda index, reflecting whole-body insulin sensitivity, and AUC for insulin and glucose 
remained unchanged during cross-sex hormone therapy both in trans women and trans men. 
In trans women, apart from increasing free fatty acids, all levels of lipids and uric acid lowered 
during treatment.  
In trans men, TG at all time points of the OGTT, LDL-CH, ApoB and uric acid increased, 
whereas HDL-CH decreased after 1 year of testosterone therapy. CRP remained unchanged in 
both groups. 
 
Associations  between   sex steroids,  body composition, lipid  profile, AGE  and glucose metabolism  in 
trans women  
Age 
Older age was significantly associated with a greater decrease in LDL-CH and total-CH and 
increased AUC of insulin after 12 months (respectively p=0.003, βsd=-0.461 and p=0.001, βsd=-
0.514 and p=0.003, βsd=0.410, p=0.003, βsd=0.486) and a less increased fat mass and percentage 
fat, and less decreased lean body mass percentage during treatment (respectively p=0.028, βsd=-
0.348, p=0.004, βsd=-0.442 and p=0.003, βsd=0.458).  
Type of hormonal treatment 
No major differences were found between ∆lipids, ∆glucose metabolism parameters and ∆body 
composition parameters and oral or transdermal estrogen treatment (data not shown). 
Changes were comparable in both treatment protocols but participants in treatment protocol 1 
showed a tendency towards greater increase in total body fat mass (p=0.05), trunk fat mass 
(p=0.09), appendicular fat mass (p=0.03), hip circumference (p=0.08) and proximal forearm fat 
(p=0.06).  
Changes in total-CH, LDL-CH, VLDL-CH, HDL-CH were comparable in trans women 
receiving treatment protocol 1 or 2 (data not shown), but ApoA1, A2 and ApoB were more 
markedly decreased in treatment protocol 2 vs. 1, which remained after adjustment for total fat 
mass and age.  
No differences were observed in glucose metabolism changes in trans women receiving treatment 
protocol 1 or 2 (data not shown). 
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Fat mass 
A greater increase in total body fat mass and trunk fat mass (but not subcutaneous fat mass) was 
associated with increased AUC of insulin (both p=0.001, βsd=0.561 and p=0.004, βsd=0.458), 
decreased Matsuda index (both p=0.030, βsd=-0.574 and p=0.016, βsd=-0.399) and increased 
leptin (both p<0.001; βsd=0.492 and p<0.001, βsd=0.477), increased ApoA2 (both p=0.001, 
βsd=0.499 and p<0.001, βsd=0.528) and ApoB (both p=0.001, βsd=0.524 and p<0.001, 
βsd=0.537).  
The ratio of trunk fat over appendicular fat (as measured by DXA) was positively associated with 
changes in fasting TG, VLDL-CH, ApoA2, ApoB and uric acid and negatively with HDL-CH 
(data not shown).  
Sex steroids 
After adjustment for age, no associations were found between sex steroid changes (E2, T and 
SHBG) and changes in lipids, glucose metabolism and body composition. 
Associations   between  sex steroids, body composition, lipid  profile, AGE and glucose metabolism  in 
trans men  
Age  
No associations were found between age and changes in lipids, glucose metabolism and body 
composition in trans men (data not shown). 
Fat mass 
No associations were found between measures of body composition and changes in glucose 
metabolism in trans men (data not shown). A smaller decrease in all measures of fat mass (total 
body fat, trunk fat as well as subcutaneous fat mass) was associated with a greater increase in 
ApoB changes during testosterone therapy (after adjustment for age: all p<0.05 and βsd>0.473). 
Changes in trunk fat mass were negatively associated with ∆HDL-CH (p=0.035, βsd=-0.486) and 
positively with ∆leptin (p=0.036, βsd=-0.483), which remained after correction for age. 
Sex steroids 
No associations were found between sex steroid changes (E2, T and LH) and changes in lipids, 
glucose metabolism and body composition. 
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DISCUSSION  
The present study investigated possible associations between sex steroid levels and 
cardiometabolic factors and explored changes in cardiovascular risk profile during cross-sex 
hormone therapy in trans persons. Our results demonstrate that CSH has important effects on 
body composition, glucose metabolism and lipid profile. In trans women, anti-androgen and 
estrogen therapy increased in insulin resistance and generally improved lipid profile, whereas T 
therapy showed opposite effects in trans men. 
Our observation that insulin resistance increased during treatment in trans women corroborates 
with previous studies using high dose CA and EE[10, 12]. Cross-sex hormone therapy in trans 
women induces a decrease in lean mass and an increase in fat mass, which is hypothesized to 
deteriorate glucose metabolism. Some[18, 19] but not all[20] studies also demonstrated that sex 
steroids may exert direct effects in the absence of any detectable changes in body composition. 
Our results generally support the first hypothesis, as we found that changes in total body fat mass 
and trunk fat mass (but not subcutaneous fat mass) were associated with these less favourable 
changes in insulin sensitivity, whereas no associations were found with serum sex steroid levels. 
However, the variable timing of sampling in relation to the last dosing may have obscured 
possible associations.  
Similar as for glucose metabolism, less favourable changes in lipid profile such as increased ApoB 
and TG and decreased HDL-CH concentrations were not related to individual sex steroid levels 
but were associated with changes in trunk fat or the ratio of trunk fat over appendicular fat in 
both trans men and women. This again underscores the importance of body composition 
changes during cross-sex hormone therapy.  
In line with Dittrich and colleagues[21], significant differences were observed compared to 
previously published studies using EE plus CA[10] as we observed no increase in body weight and 
TG in trans women. These discrepancies may be related to differences in type of estrogen as it 
has been shown that EE has a stronger hepatic impact due to its 17α-ethinyl group that prevents 
the inactivation of the molecule and results in a slower metabolism[22, 23]. In addition, the higher 
estrogen dosage used in the study by Elbers and colleagues[10] may also contribute to these 
previous findings. 
In trans men, our observations that T treatment decreased insulin resistance in trans men are in 
contrast with previous reports showing no change[10] or increase[12] in insulin resistance. The 
beneficial changes in body composition in this study with an increase in percentage lean mass, a 
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decrease in percentage body fat and no change in trunk fat mass and waist circumference, may be 
an explanation for our findings, even though we were unable to show such a significant 
association. In contrast, others showed an increase in visceral fat mass during the first 12 months 
of T therapy[10] and a larger waist circumference compared to natal females after long-term T 
therapy (mean 9.9 years)[24]. The different type and dosage of T administered may give an 
explanation. Short-acting intramuscular T esters are known to induce more sub- and 
supraphysiological T levels compared to long-acting intramuscular T undecanoate[25]. In young 
healthy men, changes in T concentrations were found to be associated with dose-dependent and 
region-specific changes in total body lean and fat mass[26]. Future randomized controlled trials are 
needed to investigate this hypothesis.  
Trans men developed a less favourable lipid profile with higher fasting TG, LDL-CH and ApoB 
and lower HDL-CH levels. These results largely confirm those from Mueller and colleagues[27] 
who also observed an increase in TG’s and decrease in HDL-CH levels. The observed increase in 
LDL-CH levels in our study are in contrast with other studies in trans men showing no change[9, 
28] or decrease[10, 29]. However, studies in women receiving T therapy mainly showed an increase or 
no change in LDL-CH[7, 30- 31]. Similar as in trans women, changes in body composition were also 
associated with the lipid profile alterations. Although T therapy induced a lower fat percentage 
overall, trans men that had less decreases in fat mass, had higher levels of ApoB and lower levels 
of HDL-CH after 12 months of T therapy. ApoB is present as a single molecule in LDL, IDL 
and VLDL lipoproteins and a growing body of evidence has now demonstrated the superiority of 
apoB measurement over that of LDL cholesterol for assessment of CVD risk[32]. 
From our study we can derive several clinical implications. Firstly, in comparison with older 
treatment modalities in trans women and short-acting intramuscular T esters in trans men, it 
seems that the current treatment modalities displayed a more favourable cardiovascular risk 
profile: we observed no increase in TG and total body weight in trans women and an reduction 
of insulin resistance in trans men. The question remains whether these more favourable effects 
on cardiovascular risk profile will also be translated into a lower risk for cardiovascular disease 
during long-term follow-up.  
Secondly, we found that a higher body fat mass was associated with less favourable 
cardiometabolic factors in both trans women and men. Therefore, avoiding obesity is also 
important to improve the cardiometabolic risk profile of trans persons, and weight management 
should be a part of the entire endocrine treatment plan. 
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Thirdly, older age at treatment initiation was associated with more detrimental changes in glucose 
metabolism in trans women despite more modest changes in body composition, and there should 
be a low threshold to screen for impaired glucose tolerance in older trans persons. 
The strengths of the present study are our detailed descriptions of lipid profile, the use of pQCT 
to measure subcutaneous fat mass, the use of increasingly used state-of-the-art treatment 
modalities and the use of mass spectrometry to measure serum sex steroid levels. Our study is 
hampered by a relatively small sample size, although we achieved a larger sample size in 
comparison with most other prospective studies. Recruitment is continuously ongoing. Finally, 
our comparisons between both treatment modalities in trans women are hampered by the age 
difference between the two groups, which is inherent to the treatment protocol. 
In conclusion, we showed that cross-sex hormone therapy in trans women increased insulin 
resistance and generally improved lipid profile, whereas trans men experienced less insulin 
resistance but a worsening of lipid profile. Adiposity was associated with a less favourable 
outcome in both trans women and men. These findings suggest that the between-sex variation in 
cardiovascular risk is mainly due to effects of sex steroid exposition on body composition. 
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ABSTRACT 
Introduction 
Our knowledge concerning the effects of testosterone (T) therapy on the skin of trans men 
(female-to-male transsexuals) is scarce. 
Aim 
To evaluate the short and long-term clinical effects of T treatment on the skin of trans men. 
Methods 
We conducted a prospective intervention study in 20 hormone naïve trans men and a cross-
sectional study in 50 trans men with an average of 10 years on T therapy. 
Main outcome measures 
Acne lesions were assessed using the Gradual Acne Grading Scale, hair patterns using the 
Ferriman and Gallwey classification (F&G), and androgenetic alopecia using the Norwood 
Hamilton Scale.  
Results 
T treatment increased facial and body hair growth. The F&G score increased progressively from 
a median value of 0.5 at baseline to a value of 12 after 12 months of T administration. After long-
term T treatment, all but one transman achieved an F&G score indicative of hirsutism in women, 
with a median value of 24. Only one transman acquired mild fronto-temporal hair loss during the 
first year of T treatment, whereas 32.7% of trans men had mild frontotemporal hair loss and 31% 
had moderate to severe androgenetic alopecia after long-term T therapy. The presence and 
severity of acne increased during the first year of T therapy, and peaked at 6 months. After long-
term T treatment, most participants had no or mild acne lesions (93.9%). Dermatological 
outcome was not demonstrably related to individual serum T or dihydrotestosterone levels. 
Conclusions 
T treatment increased facial and body hair in a time-dependent manner. The prevalence and 
severity of acne in the majority of trans men peaked 6 months after beginning T therapy. Severe 
skin problems were absent after short- and long-term T treatment.  
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INTRODUCTION 
Androgens and estrogens are known to affect the skin pilosebaceous unit (PSU), and both 
androgen and estrogen receptors are expressed in the sebocytes and hair follicle dermal papilla[1-2]. 
The biological action of testosterone (T) on peripheral tissues, such as the scalp, is in part 
affected by its local conversion to dihydrotestosterone (DHT) by 5α-reductase (type 1 and 2). T 
can also be converted to estradiol (E2) by the aromatase enzyme, which is also prominently 
present in the PSU[3]. Androgens are required for sexual hair and sebaceous gland development 
and play a central role in stimulation of sebaceous gland growth and differentiation[4, 5]. In 
addition, androgens have been shown to increase the size of the hair follicle, the diameter of the 
hair, and the proportion of time that terminal hairs spend in the anagen phase[4-5, 6]. The effects of 
E2 on the PSU unit are less understood but estrogens are known to play an important role in 
human hair growth control[7]. Furthermore, given that T is aromatized into E2 in many tissues, it 
may be possible that some effects of T on the PSU unit are mediated by E2. Alternatively, the 
local balance between E2 and androgens may determine local E2 and androgen action[7-8]. 
Androgen excess in women is associated with important dermatological effects, such as acne 
vulgaris, hirsutism, and androgenetic alopecia[9-11], with potentially important psychological 
disturbing effects[12]. However, androgens are not the sole contributors in to the pathogenesis of 
these disorders[4, 13], and wide inter-individual variability in androgen effects has been described. 
Susceptible persons may experience these pathologies with normal female androgen levels 
whereas others experience no skin problems with markedly elevated androgen levels[4, 13-14].  
Female-to-male transsexual persons (herein referred to as trans men) receive T treatment to 
induce virilization and suppress menstruation[15]. Given the important effects of sex steroids on 
sebum production and distribution as well as on the growth of body and scalp hair, 
dermatological changes during cross-sex hormone treatment are important to address. However, 
to our knowledge, only one study has previously investigated the effects of T treatment on the 
skin in trans men. Giltay and colleagues[16] examined the changes of hair growth and sebum 
production during the first year of cross-sex hormone therapy in 17 trans men, all treated with 
intramuscular T esters every 14 days. However, the short-term dermatological effects of T 
undecanoate, a long-acting depot preparation administered every 3 months, has not been 
previously addressed in trans men. In addition, long-term dermatological outcomes of T 
treatment have not yet been described in this patient population.  
The aim of the current study is to investigate the short- and long-term dermatological effects of T 
treatment in a relatively large group of trans men. 
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METHODS 
Study population and study procedures 
All trans participants were diagnosed with Gender Identity Disorder (Diagnostic and Statistical 
Manual of Mental Disorders- III-R and DSM-IV, 302.85) and were treated at the center for 
Sexology and Gender Problems at the Ghent University Hospital (Ghent, Belgium). Two 
different studies were performed. 
Prospective intervention study 
Twenty Caucasian trans men before start of cross-sex hormone therapy and sex reassignment 
surgery were included in this study. All men received intramuscular T undecanoate (1000 mg) 
(Nebido®) every 3 months. Patients were followed and monitored every 3 months during the 
first treatment year (Clinical trial number: NCT01072825). 
Cross-sectional study  
This study included 50 trans men who underwent sex reassignment surgery (SRS), including 
hystero-oophorectomy and mastectomy. On average, participants were 8.7 years after SRS (range, 
9 months to 22 years). All started hormonal therapy at least 2 years before SRS. The majority of 
participants were Belgians (n=48), with one Dutch subject and one Iranian subject. Detailed 
descriptions of this study population can be found elsewhere[17-18]. 
Trans men had been using T treatment for an average of 9.9 years, (range, 3.2 to 27.5 years). 
Current cross-sex hormonal therapy consisted of intramuscular T treatment with either a mixture 
of T esters (T decanoate 100 mg, T isocaproate 60 mg, T fenylpropionate 60 mg, and T 
propionate 30 mg/ml) every 2 or 3 weeks (n=35), T undecanoate (1000 mg) every 12 weeks 
(n=7), or transdermal T (50 mg) daily (n=8). One participant used both oral T undecanoate (40 
mg, once daily) and T gel (50 mg per 5 g, 50 mg daily). All trans men had physiological male T 
levels. Exclusion criteria for both studies included treatments or disorders affecting sex hormone 
status: untreated hypo- or hyperthyroidism, Cushing syndrome, alcohol abuse, mucoviscidosis, 
malabsorption, cirrhosis, chronic kidney failure, or current (<2 years) or prolonged use of 
corticosteroids, anabolic steroids, and anti-androgens. Both studies complied with the 
recommendations of the Declaration of Helsinki and were approved by the Ethics Committee of 
the Ghent University Hospital. All participants gave their written informed consent. 
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Main Outcome Measures  
Medical history 
In both studies, a self-constructed questionnaire was completed with questions pertaining to 
medical history, current and past hormonal treatment, medication use, and dermatological 
history. 
Degree of hair growth  
The degree of hair growth was subjectively assessed according to the modified Ferriman and 
Gallwey method (F&G)[19] in which nine sites (lip, chin, chest, upper back, sacroiliac region, 
upper abdomen, lower abdomen, arm, and medial thigh) are graded according to the following: 
0=none, 1=slight, 2=moderate, 3=dense, and 4=very dense. The F&G score has a minimum 
value of 0 and a maximum of 36. Only terminal hair growth is considered in the scoring. A score 
of greater than 8 in an androgen-dependent area was considered indicative of hirsutism.                                                                                                                   
Androgenetic alopecia was assessed using the Norwood/Hamilton classification[20].  
Satisfaction   male  hair  pattern 
Satisfaction with the male hair pattern was assessed using a five point Likert scale from very 
unsatisfied to very satisfied. 
Acne  evaluation 
Clinical assessments of current acne lesions were performed on the face and back of subjects 
according to the Global Acne Grading Scale (GAGS)[21]. The GAGS considers six locations on 
the face and chest/upper back, with a factor for each location based roughly on surface area, 
distribution, and density of pilosebaceous units. The borders on the face are delineated by the 
hairline, jaw line, and ears. No magnifying glass or skin stretching is allowed and good lighting is 
taken into account. The chest and upper back have been included because they are critical in 
order to assess the severity of the acne. Each of the six locations is graded separately on a 0-4 
scale, with the most severe lesion within a location determining the local score. These grading 
scores are then multiplied by the factor of each location (forehead 2, right cheek 2, left cheek 
2, nose 1, chin 1, chest and upper back 3). The global score is the summation of all the local 
scores (=grades  factors). The global scores are subdivided into categories: no active acne 
lesions (score=0), mild active acne lesions (score=1-18), moderate active acne lesions (score=19-
30), severe active acne lesions (score=31-38), and very severe acne lesions (score>39).  
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Sebum  production  and  acne  scar  evaluation  
In the cross-sectional study, we additionally evaluated sebum production using the Dual Tape 
Sebum Test Kit, Cortex Technology (Cuderm Corporation, www.cortex.dk) 1 hour after 
thorough alcohol cleansing. The Sebutape technique provides information about sebaceous gland 
function expressed in a score ranging from 1 to 10: low production of sebum (values 1, 2, or 3), 
normal production of sebum (values 4, 5, 6 or 7) and high production of sebum (values 8, 9, or 
10). The area in the midline of the forehead was tested because this is an area where sebaceous 
glands are the largest and most numerous. In this study, we also assessed acne scarring on the 
face of subjects according to the Échelle d’evaluation Clinique des cicatrices d’acné (ECCA) 
grading scale (min score=0; max score=540)[22]. 
Biochemical  determinations 
In all subjects, venous blood samples were obtained between 0800 and 1000 h. Using these blood 
samples, hematocrit (Sysmex-XE-2100 Hematology Analyzer, Goffin Meyvis, Etten-Leur, 
Netherlands), creatinine, and total cholesterol (Cobas C501 + Modular, Roche Diagnostics, 
Mannheim, Germany) were determined in the serum. Commercial immunoassay kits were used 
to determine serum concentrations of sex hormone-binding globulin (SHBG) (Orion 
Diagnostica, Espoo, Finland), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and 
estradiol (Modular; Roche Diagnostics, Mannheim, Germany). Baseline T levels in hormone 
naïve trans men were determined by using liquid chromatography-mass spectrometry (LC-MS; 
AB Sciex 5500 triple-quadrupole mass spectrometer, AB Sciex, Toronto, Canada). T levels within 
the male range were determined using immunoassay kits (Modular; Roche Diagnostics, 
Mannheim, Germany). DHT was measured by LC-MS after paper chromatography. The intra- 
and interassay coefficients of variation for all assays were ≤ 10%. 
Statistical  analyses 
The normal distribution of all variables was tested using the Kolmogorov-Smirnov one-sample 
test. Variables with a normal distribution were described in terms of the mean and standard 
deviation or in the case of non-normal distribution, the median [first to third quartiles]. 
Correlations between normally distributed parameters were calculated using Pearson’s correlation 
coefficient and Spearman’s correlation coefficient. Analysis of variance (ANOVA) tests for 
repeated measurements were used to explore dermatological changes during the first year of T 
treatment. We used multiple regression analyses with absolute changes in dermatological variables 
as the dependent variable and absolute changes in endocrine measurements as the independent 
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variable to investigate associations of changes in endocrine measurements with dermatological 
changes. PASW 21.0 software package (SPSS Inc., Chicago) was used for all analyses. A P value 
<0.05 was considered statistically significant all P values were two-tailed.  
RESULTS 
The general characteristics of the study populations are summarized in Table 1.  
Table   1.  General characteristics  of the study population 
 
Prospective study  baseline visit 
(N=20) 
Cross-sectional study 
(N=50) 
Age (years) 
Age at SRS (years) 
Height (cm) 
Weight (kg) 
BMI (kg/m²) 
Use of hormone therapy (%) 
Current smoking (%) 
T (ng/dl) 
DHT (ng/dl) 
Estradiol (pg/ml) 
SHBG (nmol/l) 
LH (U/l) 
Creatinin (mg/dl)  
Hematocrit (%)  
Total cholesterol (mg/dl) 
 
26.6 ± 8.3 
– 
163.7 ± 4.7 
63.9 ± 14.0 
23.7 ± 4.5 
100 
25.0 
30.3 (20.6 – 46.5) 
13.1 (9.1–18.7) 
88.3 (44.6 – 140) 
67.7 (17.8 – 84.5) 
5 (3.7 – 8.1) 
0.8 (0.7 – 0.8) 
41.6 ± 3.0 
172.2 ± 29.1 
37 ± 8.2 
30 ± 8.2 
165 ± 6.7 
67.5 ± 11.5 
24.8 ± 3.8 
100 
28 
631.1 (466.0 – 1019.2) 
64.5 (46.3 – 117.3) 
34.4 (24.7 – 49.7) 
30.1 (22.5 – 38.5) 
3.7  (0.2 – 28.5) 
0.9 (0.9 – 1.0) 
48.8 ± 2.8 
207 ±  35 
 
Data are presented as mean  ±S.D or median (first to third quartiles) in case of non-Gaussian distribution. 
Hair   growth   and   hair  distribution 
Prospective study 
T treatment increased facial and body hair growth in all subjects. The F&G score increased 
progressively from a median of 0.5 at baseline to 12.0 after 12 months of T administration (Table 
2.) After 6 months of T treatment, more than half of the participants (53.8%) had scores >8, 
which indicates hirsutism in women. After 12 months, the majority of trans men (80.0%) had 
scores >8 (Figure 1). Wide inter-individual variability was observed as the absolute increase in 
F&G scores ranged from 2 to 25. 
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Cross-sectional study 
All but one participant (n=49) acquired an F&G score >8, with a median score of 24 (range: 6- 
34) (Figure 1). The subject with an F&G score of 6 had been on T therapy for 43 months. 
Satisfaction with the obtained male hair pattern was positively associated with the F&G score 
(r=0.49, P<0.001). No associations were observed between duration of T therapy, and type of T 
therapy, and F&G score (data not shown). 
 
Figure 1. Ferriman and Gallwey scores during T treatment 
Data are presented as the median F&G score; error bars represent 95% confidence intervals (CI). Long-term T 
treatment represents median F&G scores from the cross-sectional study. P value results from ANOVA repeated 
measures analyses 
Evaluation  of androgenetic alopecia 
Prospective study 
One subject developed a mild frontotemporal hair loss during the first year of T treatment 
(Norwood/Hamilton score ӀӀ). 
Cross-sectional study 
Eighteen participants (36.7%) experienced no scalp hair loss (Norwood/Hamilton score Ӏ), 
whereas 32.7% (n=16) had mild frontotemporal hair loss (Norwood/Hamilton score ӀӀ). Fifteen 
participants (31%) had moderate to severe alopecia (Norwood/Hamilton score ≥ III). A 
significant correlation between alopecia and age was observed (r=0.31, P=0.03). No associations 
were observed between duration of T therapy, and type of T therapy, and alopecia (data not 
shown). 
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Acne  evaluation 
Prospective study 
At baseline, 35% of the subjects had facial acne and 15% had acne on the back and/or chest. 
After 6 months of androgen administration, facial acne was present in 82.4% of subjects and in 
88.2% of subjects on the back and/or chest. After 12 months of androgen therapy, facial acne 
was still present in 55% of participants and 50% of participants on the back and/or chest. The 
presence of acne, as well as the severity increased during T administration (Figure 2). However, 
during our observations, the majority of trans men had mild acne lesions, 20% had moderate 
acne lesions, and none had severe or very severe acne lesions according to the GAGS. 
During the first year of androgen treatment, 50% of trans men used one or more topical product 
[benzoyl peroxide (5% gel) (n=6), adapalene (0.1%) and benzoyl peroxide (2.5%) gel (n=6), or 
over the counter topical products (n=4)]. Three subjects used oral antibiotics during the course 
of the study to treat acne.  
Cross-sectional study 
Participants had a median total GAGS of 3.0 (range 0-24) (Figure 2C). According to this scale, 
the majority (63.3%) had mild acne lesions. Three participants (6%) had moderate acne scores, 
and 15 participants (30.6%) had no active acne lesions. Younger participants had more acne 
lesions (P=0.05). The majority of participants (65%) had no acne scars, according to the ECCA 
grading scale. The mean score was 12.55 (SD: 25.4; range 0-115).  
Sebum  production  evaluation  in the cross-sectional study 
Sebum production was performed using the Sebutape technique on the forehead in 40 trans men. 
A median value of 2.0 was observed with a range from 1 to 9. Twenty-five participants (62.5%) 
had a low sebum production one hour after alcohol cleansing; however, up to 95% of all 
participants (n=38) had low to normal sebum production (value 1 to 6). Only two subjects 
showed elevated levels of sebum production. No significant associations were found between 
sebum production and acne lesions, duration of hormonal therapy, and type of hormonal therapy 
(data not shown).  
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Associations  between dermatological  outcome and sex steroids 
Prospective study 
No associations were observed between absolute changes in F&G scores, male pattern baldness, 
acne lesions, and absolute changes in LH, T, DHT, E2, or SHBG (data not shown).  
Cross-sectional study 
No significant associations were found between F&G scores, male pattern baldness, sebum 
production, acne lesions, and LH, T, DHT, E2, or SHBG apart from a positive between F&G 
scores and E2 (linear regression; P=0.03). 
CONCLUSIONS 
This study investigated the short- and long-term dermatological effects of T treatment in trans 
men. We observed that the majority of trans men acquired an F&G score indicative of hirsutism 
in biological women during the first year of T therapy. These findings corroborate those from 
Giltay and colleagues[16]. As expected, long-term T administration further increased F&G scores. 
All but one participant achieved an F&G score >8, with wide inter-individual variability. Our 
results therefore suggest that substantial changes in hair growth and hair distribution occur 
during the first year of T treatment. However, slower but important increases in hair growth can 
be expected after. Moreover, the further increase in F&G scores contributes to increased patient 
satisfaction because it was strongly associated with the obtained male hair pattern. 
With respect to the dermatological side effects of androgen therapy, we observed that the 
presence and severity of acne lesions increased during T treatment. However, most men 
developed only mild acne and none suffered from severe or very severe acne according to the 
Global Acne Grading Scale. However, the fact that half our participants began using topical 
agents or oral antibiotics during our study period shows that, although mild and moderate, these 
acne lesions are clinically significant.   
Similar to the observation of Giltay and colleagues[16], we found that most acne lesions occurred 
within the first 6 to 9 months of treatment, with a decrease at 12 months. These results may be 
related to the acne treatment used by several of our patients. Alternatively, it may indicate that the 
initial increase in sebum production and the associated acne lesions resulting from male T levels 
in biological females attenuate over time. Indeed, our long-term observations also show markedly 
lower median acne scores compared to scores during the first year of treatment. Furthermore, 
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after long-term T therapy, the vast majority of trans men had no or mild acne scars, suggesting 
that the long-term dermatological side effects related to acne are relatively rare in this specific 
patient population.  
It was also found that the risk of developing androgenetic alopecia was low during the first year 
of T administration. However, as expected, with longer T exposure, the prevalence of 
androgenetic alopecia increased. The prevalence of moderate or severe androgenetic alopecia 
after a mean T treatment period of 10 years in trans men between the ages of 18 and 50 (25%) 
was significantly lower compared to the general population, in which approximately 42% of 
males aged between 18 and 50 years suffer from this condition[23]. It is likely that shorter exposure 
times of T may explain these observations and that further increases can be expected with longer 
durations of T administration. Another possible explanation might be that the age at which T 
exposure is commenced may play a significant role in the pathogenesis of androgenetic alopecia. 
Alternatively, because aromatase levels in the frontal hair follicles from women were found to be 
approximately six times higher than those in males, it is possible that natal women are less prone 
to develop androgenetic alopecia due to differences in local T and E2 ratios[24]. However, whether 
this is the case in trans men after long-term T treatment remains unknown. 
As expected, we observed no associations between serum T or DHT and dermatological 
outcome considering the single-point measurements of T in these men, the differences in types 
of T administration, and the variable timing of sampling in relation to the last T dosing in our 
cross-sectional study. Furthermore, most studies have described a wide inter-individual variability 
and observed only weak or no association between T and DHT levels and acne or hirsutism 
scores[14, 16]. The variability in PSU responsiveness to androgens may be related in part to 
variations in androgen metabolism; for example, variations in 5α reductase activity, 3β-
hydroxysteroid dehydrogenase activity, aromatase activity, or differences in androgen receptor 
sensitivity[14-25].  
Interestingly, a positive relationship was observed between E2 and F&G score in our cross-
sectional study. One explanation could be that given the variability of T levels due to single-point 
measurements of T, the differences in the types of T administration and the variable timing of 
sampling in relation to the last T dosing, E2 may be a more stable marker of T exposure in trans 
men.  
Some limitations of our study need to be addressed. First, we used the modified F&G method to 
evaluate hair growth and hair distribution. This method has some limitations, such as its 
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subjective nature, the failure to account for a focally high score, and the lack of consideration of 
other androgen sensitive areas (for example, sideburns and buttocks)[26]. Objective tools are 
available to examine hair growth and distribution, such as determining the density of terminal 
hairs by direct counting[27] or photography[28]. However, these techniques are predominantly 
useful for assessing hair growth rates and the extent of terminal hair density in a specific body 
area. They are considered much less useful to assess the extent of total body hair or face terminal 
hair density[29], which was the main aim of our study.  
Secondly, the cross-sectional design of our long-term follow-up study implies no causal 
relationships can be drawn. A long-term prospective study is preferable. Nevertheless, because 
this is the first study addressing long-term dermatological outcomes in trans men, our findings 
add valuable information. 
In conclusion, T treatment time-dependently increased facial and body hair. The prevalence and 
severity of acne in the majority of trans men peaked at 6 months after beginning T therapy. 
However, severe skin problems were absent after short and long-term T treatment. 
Dermatological outcome was not demonstrably related to individual serum T or DHT. The 
observed significant association with E2 remains to be established. 
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Figure 2. Acne scores during T treatment  
Data are presented as the median score; error bars represent standard error. Long-term T treatment represents the 
median score from the cross-sectional study. P value results from ANOVA repeated measures analyses.  
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2.4 A long-term evaluation of cross-sex hormone treatment in transsexual 
persons. 
 
Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, T’Sjoen G 
Journal of  Sexual Medicine 2012; 9(10):2641-2651 
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ABSTRACT 
Introduction 
Long-term effects and side effects of cross-sex hormone treatment in transsexual persons are not 
well-known. 
Aim 
The aim of this study is to describe the effects and side effects of cross-sex hormone therapy in 
both transsexual men and women. 
Main  Outcome Measures 
Hormone levels were measured by immunoassays. Physical health was assessed by physical 
examination and questionnaires on general health and specific side effects, areal bone parameters 
by dual energy X-ray absorptiometry. 
Methods 
Single center cross-sectional study in 100 transsexual persons post-sex reassignment surgery and 
on average 10 years on cross-sex hormone therapy. 
Results 
Transsexual men did not experience important side effects such as cardiovascular events, 
hormone-related cancers, or osteoporosis. In contrast, a quarter of the transsexual women had 
osteoporosis at the lumbar spine and radius. Moreover, 6% of transsexual women experienced a 
thromboembolic event and another 6% experienced other cardiovascular problems after on 
average 11.3 hormone treatment years. None of the transsexual women experienced a hormone-
related cancer during treatment. 
Conclusion 
Cross-sex hormone treatment appears to be safe in transsexual men. On the other hand, a 
substantial number of transsexual women suffered from osteoporosis at the lumbar spine and 
distal arm. Twelve percent of transsexual women experienced thromboembolic and/or other 
cardiovascular events during hormone treatment, possibly related to older age, estrogen 
treatment, and lifestyle factors. In order to decrease cardiovascular morbidity, more attention 
should be paid to decrease cardiovascular risk factors during hormone therapy management. 
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INTRODUCTION 
The current treatment regimens for transsexual persons usually involve hormonal therapy as well 
as sex reassignment surgery (SRS). In 1986, at the start of our multidisciplinary team, a dual-phase 
hormonal schedule was used. First, during the reversible part, sex specific features were 
suppressed using cyproterone acetate 50–100 mg, together with starting the real-life test. 
Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone and acts primarily as an 
androgen receptor antagonist. It has also a progestational and weak glucocorticoid activity that 
inhibits luteinizing hormone (LH) releasing and in turn reduces testosterone levels. After 6 
months up to 1 year treatment with cyproterone acetate, cross-sex hormones were added[1]. 
Recently, we changed our hormonal protocol, and we now prescribe antiandrogens (mostly 
cyproterone acetate 50 mg) and estrogens simultaneously to the majority of transsexual women 
(male-to-female transsexual persons). However, some transsexual women favour a slower 
procedure, and they receive the dual-phase hormonal protocol. Also, the type and doses of 
estrogens have changed during the past years. Currently, at the start of cross-sex hormone 
treatment, ethinyl estradiol and conjugated estrogens are rarely prescribed, and below the age of 
40, estradiol valerate 4 mg daily is now recommended. After the age of 40, transdermal estrogens 
(17β estradiol gel 2 mg daily or 17β estradiol patch 100mg twice a week) is usually recommended. 
In transsexual men (female-to-male transsexual persons), testosterone administration has been 
and is currently started after suppression of the menstruation by a progestin.The goals of 
hormonal treatment are to induce the development of the secondary characteristics of the new 
sex and to diminish those of the natal sex[2]. Consequently, transsexual men are treated with 
testosterone to induce virilization, which includes the development of a male hair growth pattern 
and body composition, cessation of menses, a deepening of the voice, and clitoral enlargement. 
To obtain feminization, transsexual women at our center receive a combination of antiandrogen 
therapy and estrogen therapy. Feminization consists of breast formation, reduction of masculine 
hair growth, and a more female fat distribution. 
A number of studies demonstrated the efficacy of several hormonal preparations to induce 
masculinization and feminization in transsexual persons[3–6]. After SRS, which usually involves 
gonadectomy, hormone treatment is continued life-long to maintain virilization and feminization 
in transsexual men and women, respectively, and to avoid signs or symptoms of hormone 
deficiency. Follow-up data on the long-term effects and side effects of hormone treatment on 
physical health are still scarce in this specific population[7,8] and, as no randomized controlled 
trials are available, the optimal formulations and dosages of cross-sex hormone treatment are 
unknown at present. Current treatment modalities for hormonal replacement therapy are similar 
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to those of hypogonadal persons and aim at hormone values in the normal physiological range[2]. 
Sustained supraphysiological levels of both testosterone and estrogen increase the risk for serious 
adverse reactions such as thrombosis, whereas subphysiological levels may induce the effects 
known from hypogonadal states. Although based on limited evidence, a serum concentration of 
LH within the normal range may be a reliable marker of adequate dosing[8,9]. In this study, we will 
describe the long-term effects and side effects of hormonal therapy in a relatively large number of 
transsexual men and women. 
METHODS 
Study Population and Study Procedures 
 
We performed two independent studies. First, in 2007, all Dutch-speaking transsexual women 
who underwent SRS at least 6 months before recruitment and who consulted a member of the 
gender team for treatment or follow-up during 2006 were invited by mail (N = 70).We had no 
further inclusion criteria, and we included 50 transsexual women in our study. The others did not 
respond (N = 17) or declined to participate because they wished not to be reminded of their past 
(N = 3)[9,10]. Second, in 2010, all Dutch-speaking transsexual men who underwent SRS between 
1987 and 2009 at our hospital (N = 79) received a written invitation in which they were asked to 
confirm their participation by telephone or electronic mail. Fifty individuals agreed to 
participate[11–13]. Two participants could not be reached because of change of address. The others 
were not willing to participate. 
All transsexual women underwent SRS (orchidectomy and phallectomy in combination with 
vaginoplasty) at least 6 months before recruitment and after at least 2 years of hormonal 
treatment. All but two women received breast augmentation. Before SRS, hormonal therapy had 
been initiated using antiandrogen therapy (cyproterone acetate 50–100 mg/day) up to a 
maximum of 1 year, followed by the addition of exogenous estrogen administration (different 
formulations). Post-SRS, all but three participants received estrogen treatment. On average, 
transsexual women were 6.3 years after SRS, with a minimum of 6 months and a maximum of 
32.2 years. All transsexual men except for one underwent ablative SRS (hystero-oophorectomy 
and mastectomy) at least 2 years before inclusion in this study. Almost all (N = 46) participants 
underwent phalloplasty, eight of whom had a previous metaidoioplasty, one person had 
metaidoioplasty alone, and three participants expressed no wish for further genital surgery. All 
started testosterone therapy at least 2 years before SRS. On average, participants were 8.7 years 
after SRS, with a minimum of 9 months and a maximum of 22 years. 
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Study Procedures 
 
Transsexual women received questionnaires on medical history, dermatological features, changes 
in voice, quality of life, sexual functioning, surgical results, and psychological functioning during 
their hospital visit. They completed their study protocol between March and June 2007. 
Transsexual men who agreed to participate in the study received questionnaires on medical 
history, dermatological changes, voice, quality of life, sexual functioning, fertility wish, surgical 
results, and psychological functioning by regular mail. Subsequently, they visited Ghent 
University Hospital between November 2009 and April 2010 for further evaluation. Both studies 
were approved by the ethical review board of Ghent University Hospital, Belgium. All 
participants gave written informed consent for participation in the study. 
MAIN OUTCOME MEASURES 
Medical History and Examination 
 
As sex steroid treatment is known to be associated with specific side effects, data relevant to the 
long-term use of estrogen and testosterone therapy were collected from both samples. A self-
constructed questionnaire was completed concerning medical history, experience of adverse 
effects (such as hormone-related cancers and thromboembolic and other cardiovascular events), 
current and past hormonal treatment, medication use, and smoking habits. Information was 
compared with data from medical files for accuracy and corrected if necessary. 
Anthropometry, Areal Bone Mineral Density, and Body Composition 
 
Body weight and anthropometrics were measured in light indoor clothing without shoes. 
Standing height was measured using a wall-mounted Harpenden stadiometer (Holtain, Ltd, 
Crymuch, UK). Areal BMD at the lumbar spine, at the proximal femur (total hip region), and at 
both distal forearms were measured using dual energy X-ray absorptiometry (DXA) with a 
Hologic QDR-4500A device (software version 11.2.1; Hologic, Bedford, MA, USA). T- and Z-
scores for areal BMD were calculated using controls provided by the National Health and 
Nutrition examination Survey-0 (NHANES-0) study group for the hip[14] and by the 
manufacturer for the lumbar spine, distal forearm, and total body BMD[15]. Male references were 
used in transsexual women and female references for transsexual men as all participants 
underwent normal pubertal development, with well-known effects on bone mass and size. The 
coefficient of variation (CV %) was <1% as calculated from daily spine phantom measurements. 
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Biochemical Determinations 
 
Venous blood samples were obtained between 08.00 AMand 12.00 AMafter overnight fasting. All 
blood samples were stored at -80°C until batch analysis. Commercial kits for radioimmuno assay 
were used to determine the serum concentrations of total testosterone (T) and sex hormone 
binding globulin (SHBG) (Orion Diagnostica, Espoo, Finland); estradiol (E2) (Clinical Assay, 
Diasorin s.r.l., Saluggia, Italy), according to amodified protocol that doubles the serum amount[16]; 
LH, insulinlike growth factor, C-terminal telopeptides of type 
I collagen (CTX) as a marker of bone resorption, protocollagen 1 aminoterminal propeptide 
(P1NP), which reflects bone formation (electrochemiluminiscence immunoassay [ECLIA]; 
Modular, Roche Diagnostics, Mannheim, Germany). Insulin-like growth factor-binding protein 3 
(IGFBP3) was determined by an extraction method (DSL-5600; Diagnostic System Laboratories, 
Webster, TX, USA).The intra- and interassay coefficients of variation for all assays were ≤10%. 
For all measurements, samples from transsexual men and transsexual women were assayed in a 
same assay run. Serum free T was calculated from the total serum hormone concentration, serum 
SHBG, and serum albumin, using a validated equation derived from the mass action law[15]. We 
defined supra- and subphysiological levels of T, estradiol, and LH as hormone levels exceeding 
the upper or lower limit of the reference ranges according to values from our local laboratory. 
Hematocrit, total cholesterol, and creatinin were measured using routine clinical chemistry 
methods. Prolactin and prostate-specific antigen (PSA) were additionally investigated in 
transsexual women. 
Statistical  Analysis 
 
Descriptive statistics are expressed as means and standard deviations, or, in case of a non-normal 
distribution. Between-group differences of categorical variables were calculated with x2 tests, or a 
Fisher exact test was used. Differences between both groups of linear variables were calculated 
using the student T-test or linear regression analysis while covarying for age, weight, and/or 
height. Significance was set at P < 0.5 (two-tailed). Data were analyzed using PASW-software, 
v.18 (SPSS Inc., Chicago, IL, USA). For all analyses, missing values were excluded. 
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Table   1.  General characteristics  and biochemical levels of the study population  
 
Transsexual men 
(N=50) 
Transsexual women 
(N=50) 
P 
Age at time of the interview  (ys) 
Age at SRS (ys) 
Height (cm) 
Weight (kg) 
Use of hormone therapy (%) 
 
Testosterone (ng/dl)
a
 
Free testosterone (ng/dl)
a
 
Estradiol (pg/ml)
a
 
SHBG (nmol/l)
a
 
LH (U/l)
a
 
 
Creatinin
 
(mg/dl)
a
  
Hematocrit %  
IGF1 (ng/ml) 
PSA (ng/ml)
a
 
Prolactin (ng/ml)
a
 
37 ± 8.2 
30 ± 8.2 
165 ± 6.7 
67.5 ± 11.5 
100 
 
631.1 [466.0-1019.2] 
15.5 [9.2-25.0] 
34.4 [24.7-49.7] 
30.1 [22.5-38.5] 
3.7  [0.2-28.5] 
 
0.9 [0.9-1.0] 
48.8 ± 2.8 
225.5 ± 65 
- 
- 
43.0 ± 10.4 
36.7 ± 9.8 
175.1 ± 8.3 
77.8 ± 18.3 
94.0 
 
29.6 [21.8-38.2] 
0.3 [0.18-0.49] 
50.9 [27.7-73.7] 
66.1 [48.0-110.3] 
27.0 [17.5-39.4] 
 
0.8 [0.7-0.9] 
41.0 ± 2.4 
229.1± 103 
0.003 [0.03-0.09] 
9.1 [6.0-12.2] 
0.003 
0.001 
<0.001 
0.01 
0.24 
 
<0.001
a
 
<0.001
 a
 
0.012
 a
 
<0.001
 a
 
0.001
 a
 
 
<0.001 
<0.001 
0.713 
- 
- 
 
Data are presented as mean  ±S.D or median (first to third quartiles) in case of non-Gaussian distribution. 
Categorical variables using chi-square-test; Linear variables using Linear regression analysis  a adjusted for age, height, 
and weight. 
RESULTS 
General Characteristics 
 
General characteristics of the study population (N = 100) are summarized in Table 1. All 
transsexual men were on testosterone replacement therapy for about 10 years (Figure 1); in total 
496 hormone treatment years.Three transsexual women were not on estrogen therapy because of 
previous thromboembolic events and were therefore excluded from further hormonal, 
biochemical, and bone measurements. The remaining transsexual women were on average 9.2 
years on hormone therapy (in total 473 hormone treatment years). Most transsexual men used 
intramuscular testosterone treatment (parental testosterone esters 250 mg/2 or 3 weeks;N = 35 
or testosterone undecanoate 1000 mg/12 weeks; N = 7), while seven men applied transdermal 
testosterone gel (50 mg daily). One participant used both oral testosterone undecanoate 40 mg 
(daily) and transdermal testosterone gel 50 mg daily. Transsexual women used transdermal 
estradiol (17β estradiol gel 1.5 mg/24u:N = 22; estradiol patch 50 mg/24u: N = 3) or oral 
estrogens (estradiol valerate 2 mg: N = 19; estriol 2 mg: N = 1; ethinyl estradiol 50 mg: N = 1; 
ethinyl estradiol 120 mg: N = 1). Participants using ethinyl estradiol (N = 2) were excluded from 
estradiol analysis as this compound is not measured in the assay. 
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Figure 1. Duration of cross-sex hormone therapy 
 
Hormonal and Biochemical Parameters 
 
Given that the goal of hormone treatment in transsexual men and women is to obtain hormonal 
concentrations in the normal physiological range for natal men and women, respectively, 
hormonal levels differed significantly between both groups (Table 1). At the time of 
measurement, 8.9% of transsexual men exhibited levels below the reference values of our 
laboratory (testosterone<321 ng/dL), whereas 26.7% exceeded the upper limit of 1005 ng/dL. 
Sixty-three percent of transsexual women had estrogen levels below the lower limit (estradiol <55 
pg/mL) and 11.5% above the upper limit (200 ng/L). When compared directly, transsexual 
women had higher LH levels compared with transsexual men (85% vs. 42%, respectively). In 14 
transsexual men (28.5%), we observed hematocrit levels above 50%, eight of whom (16.3%) had 
erythrocytosis (hematocrit levels above 52%) with one participant having a hematocrit level of 
55%. Hematocrit levels in transsexual men were negatively associated with LH levels (linear 
regression: P = 0.021; β = -0.35), but not with other hormonal parameters (testosterone, SHBG) 
or age (data not shown). Hematocrit levels were significantly higher in participants who used 
conventional intramuscular testosterone esters compared with those who used intramuscular 
testosterone undecanoate or transdermal testosterone (linear regression: P = 0.042; β = 0.29). 
Four transsexual women (8.2%) had slightly elevated prolactin levels (range: 21.4–30.5 ng/mL) 
compared with the normal male range at our laboratory (4–17 ng/mL). Only one transsexual 
woman had a prolactin level above the normal female range (6–30 ng/mL). None had elevated 
PSA levels. 
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Hormone-Related Cancers 
Transsexual men did not experience hormonerelated cancers during hormone treatment, whereas 
one transsexual woman had a macroprolactinoma. As this patient’s macroprolactinoma was 
diagnosed before the start of cross-sex hormone treatment, she was excluded from prolactin 
analyses. 
Cardiovascular  Risk Factors 
Cardiovascular risk factors were comparable in both groups, although transsexual women 
evidenced lower mean arterial blood pressure and lower serum triglycerides levels (Table 2). A 
similar number of transsexual men and women were overweight (24% vs. 22%) or obese (14% 
vs.14%). Three transsexual women had a body mass index above 35 kg/m2 as compared with 
none of the transsexual men. Hypercholesterolemia (cholesterol >190 mg/dL) was observed in 
60% of transsexual women and 64% of men. A comparable number of transsexual women and 
men had an elevated blood pressure at the time of investigation and/or used antihypertensive 
medication (26% vs. 28%). 
Table   2.  Cardiovascular  risk factors 
 
Transsexual men 
(N=50) 
Transsexual women 
(N=50) 
P 
Current smoking (%) 
Smoking years  
Sports activity (%) 
BMI (kg/m
2
) 
Total Cholesterol (mg/dl) 
Triglycerides (mg/dl) 
Systolic Blood pressure (mmHg) 
Diastolic Blood pressure (mmHg) 
Mean arterial blood pressure (mmHg) 
  
34.7 
11.6 ± 14.0 
50.0 
24.8 ± 3.8 
199.1 [185.0 -220.0] 
114.5 [85.5-182.0] 
124.7  ± 14.4 
81.3 ± 10.7 
95.8 ± 10.1 
36.0 
15.7 ± 14.3 
40.0 
  25.3 ± 5.4   
198.0 [168.0 -227.3] 
83.0 [64.3-127.8] 
 124.8 ± 16.6 
77.1 ± 10.1 
93.0 ± 11.2 
0.39 
0.15 
0.32 
0.80 
0.44
a
 
0.001 
a
 
0.208 
0.002
 a
 
0.008
 a
 
 
Data are presented as mean ± S.D.  Non-Gaussian distribution: data presented as median (first to third quartiles) 
Categorical variables using chi-square test; Linear variables using Linear Regression analysis a Adjusted for age and 
weight. 
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Thromboembolic and  Cardiovascular  Events 
No transsexual men reported cardiovascular events such as myocardial infarction (MI), 
cerebrovascular disease, or deep venous thrombosis. Three transsexual women experienced 
thromboembolism (two cerebral and one deep venous thrombosis) during hormone treatment 
(Table 3). One participant experienced deep venous thrombosis and pulmonary embolism before 
starting of cross-sex hormone treatment. Estrogen treatment was given in combination with 
anticoagulants. Additionally, four transsexual women experienced other cardiovascular diseases: 
transient ischemic attack (TIA) (N = 1), venous ulcer (N = 1), and MI (N = 2). One participant 
experienced MI prior to hormone therapy. Another transsexual woman underwent surgery for 
peripheral arterial disease during the course of hormone treatment, but the presence of diabetes 
mellitus was a likely cause in this woman. All participants except one, who experienced 
thromboembolic or other cardiovascular events, were smokers at the time of event (on average 
24 smoking years). 
Areal Bone Mineral Density Using DXA 
Transsexual women experienced significantly more osteoporosis and osteopenia as 
comparedwith transsexual men. In transsexual men, no osteoporosis (T-scores< -2.5) was 
diagnosed, while in transsexual women, osteoporosis was observed in 23.4% of patients at the 
lumbar spine, 8.7% at femoral neck, 2.1% at the total hip, and 25.5% at the left radius. In 
addition, the mean Z-scores in transsexual women were negative at all sites (at the lumbar spine: -
1.0 ± 1.4, total hip: -0.4 ± 1.0, femoral neck: -0.7 ± 1.0, distal radius: -1.3 ± 1.3, and total body: -
1.0 ±1.0). No differences in bone density were found between patients using transdermal or oral 
estrogen administration (data not shown). Finally, no associations were found in bone mineral 
density at lumbar spine, femoral neck, total hip and serum testosterone, LH, or estradiol levels in 
both transsexual women and men (data not shown). Compared with the normal male range at 
our laboratory (<0.58 ng/dL), all but four transsexual women had normal CTX levels (range: 
0.62– 1.24 ng/dL), while two transsexual women had higher P1NP levels above the normal male 
range (102 ng/mL) (range: 106–125 ng/mL). 
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Table 3. Tromboembolic and  other cardiovascular events in transsexual women (n=6) 
 
Event 
Age at  event 
(year) 
Duration of HRT 
at event 
(years) 
Type of estrogen therapy at event 
(all oral administration, daily intake) 
Smoking years 
at event 
Current smoker 
 
Thromboembolic events 
DVT* 
Cerebral thrombosis** 
Cerebral thrombosis 
TIA at SRS* 
 
Other cardiovascular events 
Peripheral arterial disease 
Venous ulcer 
MI 
 
 
 
52 
58 
46 
33 
 
 
46 
45 
43 
 
 
 
21 
20 
1 
2 
 
 
8 
7 
21 
 
 
 
Conjugated estrogens 0.625 (Premarin®) 
Ethinyl estradiol 50 µg 
Cyproterone acetate 50 mg 
Conjugated estrogens 0.625 + cyproterone 
acetate 50 mg 
 
Estradiol valerate 2 mg
b
 
Ethinyl estradiol 20 µg 
Estrogen therapy
a
 
 
 
 
18 
45 
- 
18 
 
 
18 
13 
31 
 
 
No 
Yes 
Yes 
No 
 
 
Yes 
Yes 
Yes 
DVT: deep venous thrombosis, MI: myocardial infarction, TIA: transient ischemic attack. a Not further specified b Diagnosis of  type 2 diabetes 9 years before event                         
* same participant           ** homozygeous carrier mutant methylhydrofolatereductase (MTHFR) allele                                                                                                                                                                                                                                                                                                                
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DISCUSSION 
This study presents follow-up data on physical health after hormone therapy and SRS (on 
average after 10 treatment years) in transsexual men and women.We demonstrate that at our 
center, transsexual men are less at risk for severe side effects than transsexual women. In 
addition, we found that none of the transsexual men experienced cardiovascular events or 
hormone-related cancers. These findings are in line with previous studies, which demonstrated 
that cross-sex hormone treatment was acceptably safe in the short- and medium-term for 
transsexual men[17,18]. However, risks may become more apparent as subjects grow older and the 
duration of hormone exposure increases[6,18]. Moreover, the presence of several cardiovascular 
risk factors such as obesity, poorer lipid profile, or elevated serum hematocrit raises the concern 
for possible future cardiovascular events[4]. Several risks factors were present in a substantial part 
of our group of transsexual men at the time of investigation: being overweight (24%), obesity 
(14%), hypercholesterolemia (64%), smoking (30%), erythrocytosis (14.3%), and elevated blood 
pressure (22.5%). Long-term studies are needed to provide specific data on the effects of 
hormonal treatment in transsexual men on cardiovascular health[6]. A healthier lifestyle may 
reduce the impact of these risk factors, while some risk factors such as erythrocytosis are related 
to the specific pharmacokinetic effects of the type of testosterone therapy[19,20] and can be 
avoided. In contrast with previous findings in natal men[20], older age was not associated with a 
higher risk of erythrocytosis during testosterone administration. However, in comparison with 
the study by Coviello et al. [20], none of our transsexual men were aged between 60 and 75 years. 
Transsexual women showed a similar number of cardiovascular risk factors compared with 
transsexual men in the current sample. Except for smoking, which occurred more in the 
transgender participants, similar or even less cardiovascular risk factors were present in 
comparison with the general Belgian population[21–25]. Nevertheless, 12% of transsexual women 
experienced thromboembolic and/or other cardiovascular complications during hormone 
treatment after a mean duration of 11.4 hormone treatment years. For a comparable duration of 
hormone treatment years, cross-sex hormone treatment seems to have more harmful effects in 
transsexual women than in men. This is in line with Asscheman et al.[26], who observed higher 
cardiovascular mortality after an average of 20 years of cross-sex hormone therapy in transsexual 
women, but not transsexual men, as compared with the general population. Whether these 
thromboembolic and other cardiovascular events are caused by cross-sex hormone therapy, older 
age of transsexual women, or represent the preexisting sex differences in cardiovascular events, 
remains to be determined. Long-term prospective studies in a larger study sample are needed in 
this regard. 
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The incidence of venous thrombosis in the present study (2% or estimated 21/10,000 user years) 
was lower than the one reported by Van Kesteren et al.[17]. Their study[17] showed that 6.4% 
(58/10,000 user years) in their group of transsexual women experienced a deep venous 
thrombosis or pulmonary embolism thrombosis during hormonal therapy, which was a 20-fold 
increased incidence compared with the general Dutch male population. However, a more 
appropriate control group might be women using estrogens and/or progestagens such as 
hormone replacement therapy (HRT) or combined oral contraceptives (COCs). COC therapy 
and HRT are both associated with an increased risk of venous thromboembolism[27-28]. A recent 
Danish population study[29] found that the incidence of venous thromboembolism in women 
using COC was 3.01/10,000 user years, which is still significantly lower than the risk observed in 
transsexual women. The estrogen levels of many of our transsexual women were below the 
normal female range. This may be a reason why relatively few transsexual women experienced 
venous thrombosis and pulmonary embolism compared with other centers. However, inadequate 
estrogen levels can cause side effects known from hypogonadal states. As we felt the need to 
increase the estrogen dosage in our treatment protocol in the past years, we chose 17β estradiol 
as this formulation is thought to induce less changes in hemostatic factors[30]. Currently, more 
attention is also paid to monitor LH levels especially when estradiol levels cannot be measured 
by the immunoassay. Also, in the presence of low bone density, clearly supraphysiological LH 
levels will influence our decision on estrogen dosage. 
We observed a higher incidence of cerebrovascular disease in our transsexual women compared 
with the general male and female population[31]. 
Both COC and HRT are known to increase the risk for cerebrovascular disease[32,33]. However, 
other factors such as smoking, hypercholesterolemia, or hypertension are even more 
detrimental[34]. Indeed, the majority of transsexual women who experienced cerebrovascular 
complications had other important risk factors besides estrogen therapy including genetic 
predisposition, smoking, and hypercholesterolemia. Although we always strongly recommend to 
all transsexual women to quit smoking, it appeared that many individuals continued despite prior 
experience of a thromboembolic or cardiovascular event. In our clinical experience, it remains 
difficult to convince transsexual women to discontinue smoking but also to adopt a healthier 
lifestyle. Importantly, during and after transition, more attention should be paid to treat 
cardiovascular risk factors such as hypercholesterolemia and hypertension. 
One patient developed a TIA at SRS, and perioperative thromboses in transsexual women have 
been described in other centers as well[17,35]. As surgery and immobilization are well-known risk 
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factors for development of thrombosis, we currently advise to discontinue hormonal therapy at 
least 2 weeks before SRS or other elective surgery and to restart at mobilization. However, the 
existing evidence regarding the necessity to discontinue hormonal therapy before surgery in 
transsexual women remains limited. Also, the time period hormonal therapy should be 
discontinued is presently unknown. In our current treatment regimens especially ethinyl estradiol 
is no longer used given possible association with higher thromboembolic risks[30,35]. 
With regard to hormone-related cancers, it should be noted that all transsexual men treated at 
our center receive bilateral mastectomy, hysterectomy, and ovariectomy, within 1 year of 
testosterone treatment, so that risk of development of related cancers in these areas is very low. 
However, breast cancer has been reported in one transsexual man after bilateral mastectomy 
under long-term hormone treatment as well as development of an ovarian cancer in another 
transsexual man during hormone treatment and before ovariectomy[36,37]. None of the transsexual 
women developed hormone-related cancers during hormone therapy. So far, only a few case 
reports of prolactinomas, breast cancers, and prostate carcinomas in transsexual women have 
been reported[38]. Nevertheless, it deserves mention that the incidence of hormone-related 
cancers can increase as the duration of hormone exposure increases[38]. Moreover, it is possible 
that transsexual persons feel uncomfortable with medical exams concerning their native sex such 
as prostate examinations in transsexual women or gynecological examinations in transsexual men 
leading to an underinvestigation of cancers in these subjects. However, with appropriate care, 
these medical checkups are possible[39]. All transsexual women had normal PSA levels and only 
one participant developed a slightly elevated prolactin level compared with normal female range. 
This is in line with Dietrich et al.[40], who did not find an increase in prolactin levels in 60 
transsexual women treated with monthly injections of gonadotropin-releasing hormone analogue 
(GnRH) analogs and oral estradiol valerate 6 mg daily, but it is in contrast with Asscheman et 
al.[35], who observed that more than 50% of trans women experienced elevated prolactin levels 
under cross-sex hormone treatment (mostly cyproterone acetate 100 mg and 100 mg 
ethinylestradiol daily). The time course and exact mechanism of increased prolactin levels during 
cross-sex hormone treatment in transsexual women has not been fully elucidated. Type and dose 
of HRT are likely to be at least partly responsible for the observed differences, but head-to-head 
comparisons of different treatment regimens are to be performed. 
Finally, long-term bone health is also a matter of concern in the treatment of transsexual 
persons. In line with most[41–43] but not all studies[44], we found that cross-sex hormone therapy 
maintained areal bone mineral density in all transsexual men, possibly due to a direct effect of 
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testosterone on bone and/or an indirect effect of testosterone after aromatization to estradiol. In 
contrast to most other studies[45–48], but consistent with previous results from our center[49], we 
observed a high prevalence of osteoporosis and osteopenia in our group of transsexual women. 
However, the prevalence of osteoporosis and osteopenia is also dependent based on which 
gender (natal or desired) is used as a reference. As all our transsexual men and women 
underwent normal puberty, with well-known effects on bone mass and size, we generally 
recommend the use of the natal gender as a reference. Although this can be debated especially in 
adolescent transsexual persons. Data on bone health in transsexual women compared with 
control men are extensively described elsewhere[10]. Multiple causes might explain the high 
number of osteoporosis in our transsexual women compared with other centers. First, it is 
possible that our treatment regimen in the past using cyproterone acetate alone up to a 
maximum 1 year without concomitant use of exogenous estrogen therapy has led to a decrease in 
bone mineral density as cyproterone acetate decreases testosterone levels. Previous studies in 
men treated for prostate cancer[50,51] support these findings and show a decrease in BMD during 
androgen deprivation therapy. Moreover, men with prostate cancer treated with androgen 
deprivation therapy exhibited a higher fracture risk compared with those not receiving this 
therapy[52,53]. In sex offenders, treatment with cyproterone acetate was also associated with 
significant bone loss[54]. Second, given the use of a cross-sectional design in the present 
investigation, it cannot be ruled out that our study group differed at baseline because of cultural 
differences in physical activity, height, or calcium intake. Lower levels of physical activity in 
Belgium as compared with other European as well as non-European countries have been 
described in both female and male adults and adolescents[55–57]. Finally, low estrogen levels and 
high gonadotrophines in our participants might indicate inadequate estrogenization. However, 
the rather high SHBG levels and the absence of clinical symptoms of insufficient treatment such 
as hot flushes do not support this hypothesis. The normal values for markers of bone turnover 
in this study population are also not suggestive for a state of estrogen deficiency with active bone 
loss, characterized by an increased bone turnover. Future prospective studies examining bone 
health in transsexual women may clarify the current findings. Studies comparing treatment 
regimens of cyproterone acetate with or without concomitant estrogen administration, as well as 
multicenter studies with adjustment for confounding effects (e.g., physical activity, height and 
calcium intake), may solve these questions. 
Our study has several limitations. The relatively small sample size disallows us to provide 
accurate prevalence and incidence rates of morbidity. Comparisons with the general population 
therefore need to be interpreted with caution. Also, some adverse events based on biochemical 
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variations and osteoporosis may be explained to some extent by increased screening. Third, as in 
all follow-up studies, selection bias of our participants cannot be excluded. Participants who 
agreed to this study may have a more favourable outcome than those who refused to participate. 
Fourth, as older age is associated with a higher morbidity, it should be noted that transsexual 
women in our sample were on average 6 years older than transsexual men. However, given that 
transsexual men mostly seek treatment at younger ages, transsexual women will be older if a 
comparable duration of hormone therapy is evaluated[58]. Finally, the nature of the cross-sectional 
design implies that we cannot draw any causative conclusions. In addition, given the absence of a 
baseline measurement, we cannot rule out that some of the findings were already present before 
cross-sex hormone therapy. Yet, despite these limitations, we feel that the present data 
contribute to the investigation of the effects and side effects of hormone therapy in transsexual 
persons, especially as follow-up data on hormone administration in this specific group remain 
scarce. 
CONCLUSIONS 
In conclusion, we have shown that after an average of 10 years of cross-sex hormone treatment, 
transsexual men did not experience important side effects such as hormone-related cancers or 
cardiovascular events. Osteoporosis was also absent in transsexual men. On the other hand, a 
substantial number of transsexual women suffered from osteoporosis at the lumbar spine and 
distal arm. Twelve percent of transsexual women experienced thromboembolic and/or other 
cardiovascular events during hormone treatment, possibly related to older age, estrogen 
treatment, and lifestyle factors. In order to decrease cardiovascular morbidity, more attention 
should be paid to decrease cardiovascular risk factors during hormone therapy management. 
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2.5 Prevalence of cardiovascular disease and cancer during cross-sex 
hormone therapy 
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ABSTRACT  
Objective  
This study evaluates the short- and long-term cardiovascular- and cancer-related morbidities 
during cross-sex hormone therapy in a large sample of trans persons. 
Methods 
A specialist centre cross-sectional study compared 214 trans women (male-to-female transsexual 
persons) and 138 trans men (female-to-male trans persons) to an age- and gender-matched 
control population (1 to 3 matching). Participants were on cross-sex hormone therapy for an 
average of 7.4 years. We assessed physical health and possible treatment-related adverse events 
using questionnaires. 
Results 
Five percent of trans women experienced venous thrombosis and/or pulmonary embolism 
during hormonal therapy. Five of these adverse events occurred during the first treatment year, 
while another 3 occurred during sex reassignment surgery. 
Trans women experienced more myocardial infarctions compared to control women (P=0.001) 
but a similar proportion compared to control men. Cerebrovascular disease prevalence was 
higher in trans women compared to control men (P=0.03). Trans men had similar rates of 
myocardial infarction and cerebrovascular disease compared to control male and female subjects. 
Type 2 diabetes prevalence was higher in both trans men and women compared to their 
respective controls, whereas cancer rates were similar to control men and women.  
Conclusion 
Morbidity rate during cross-sex hormone therapy was relatively low, especially in trans men. We 
observed a higher prevalence of venous thrombosis, myocardial infarction, cerebrovascular 
disease and type 2 diabetes in trans women compared to control population. Trans men had 
similar morbidity rates compared to controls aside from increased type 2 diabetes prevalence.
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INTRODUCTION 
Hormonal therapy is an established part of gender identity disorder treatment and induces 
secondary sex characteristics development of the desired gender while reducing those of the 
natal sex[1]. Female-to-male transsexual persons, denoted as trans men, generally receive 
progestins to suppress menstruation and intramuscular testosterone preparations to induce 
virilisation. Male-to-female transsexual persons (trans women) generally receive anti-androgen 
therapy together with oral or transdermal estrogens to induce feminization. Optimal 
formulations and dosages of cross-sex hormone treatment are unknown at present[2], but current 
guidelines recommend aiming for hormonal levels within the normal physiological range[3]. 
Sustained supraphysiological levels of sex steroids increase the risk of adverse events such as 
thrombosis[3], whereas subphysiological levels may induce the effects of a hypogonadal state. 
Although cross-sex hormone therapy can induce several side effects; it is surprising that only a 
handful of studies[4-9] have examined morbidity and mortality in trans persons. In general, current 
evidence suggests that testosterone administration in trans men is not very harmful[10]. However, 
anti-androgen and estrogen administration may negatively impact cardiovascular health in trans 
women[2]. Both anti-androgens and estrogens increase the risk of venous thrombosis and/or 
pulmonary embolism[7], and two recent mortality studies showed a higher cardiovascular 
mortality rate in trans women compared to the general population[4-5]. However, the relationship 
between cross-sex hormone treatment and cardiovascular risk profile in trans women is complex, 
as the chemical nature of the estrogens[5], the route of administration[11], the dosage of 
estrogens[12-13], and the patient’s cardiovascular health status may all have an effect. 
Cancer has not been reported frequently in trans individuals[2, 14]. However, because some 
tumours are hormone-dependent, examining the incidence of cancer during cross-sex hormone 
therapy may be important[15].  
The aim of this study was to examine the prevalence of cardiovascular- and cancer-related 
morbidity during cross-sex hormonal therapy in the patients treated at our centre since 1986.  
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SUBJECT AND METHODS 
Study population and study procedures 
All persons diagnosed with Gender Identity Disorder (GID) (Diagnostic and Statistical Manual 
of Mental Disorders- III-R and DSM-IV, 302.85; International Classification of Diseases, 10th 
revision, F64.0) at the Center for Sexology and Gender Problems at the Ghent University 
Hospital (Ghent, Belgium) between 1986 and June 2012 and underwent at least 3 months of 
cross-sex hormonal therapy were invited by letter to participate in this study. Respondents 
received a paper version of the questionnaire by post or filled out the survey online. A reminder 
message was sent to non-responders. All surveys were collected between August and December 
2012. We achieved a response rate of 54% as 352 participants, including 214 trans women and 
138 trans men, agreed to participate in this study (Figure 1). Ten of the invited persons died 
during the follow-up period.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Subject enrollment 
Total gender dysphoria patients 
treated with ≥ 3 months of cross-
sex hormones (N=665) 
Trans men 
(N=236) 
Trans women 
(N=429) 
Trans men 
(N=235) 
Trans men 
(N=420) 
Deceased 
(N=1) 
Deceased 
(N=1) 
No contact 
(N=35) 
No contact 
(N=66) 
Not willing to 
participate 
(N=62) 
Not willing to 
participate 
(N=140) 
Trans men 
(N=138) 
Trans men 
(N=214) 
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Ten trans women were no longer on estrogen therapy due to previous thromboembolic events 
(n=5), dissatisfaction (n=2) or other reasons (n=3). The remaining trans women were on 
hormone therapy for an average of 7.7 years (range: 3 months-35 years) (Figure 2). In trans 
women, current cross-sex hormonal therapy consisted of transdermal estradiol [17-β estradiol gel 
1.5 mg/24u (n= 76; 35.5%); estradiol patch 50 µg/24u (n=29;13.6%); or daily intake of oral 
estrogens; estradiol valerate 2 mg (n=91; 42.5%), estriol 2 mg (n=1; 0.4%), ethinyl estradiol 50 
µg (n=2; 0.9%), and oral contraceptive ethinyl estradiol 30-50µg (n=5; 2.3%)]. A majority of the 
trans women (n=129; 65%) in our study underwent orchiectomy. 
Trans men were on testosterone replacement therapy for an average of 9.4 years (range: 3 
months to 49 years). Cross-sex hormonal therapy in trans men consisted of intramuscular 
testosterone treatment with either a mixture of testosterone esters (testosterone decanoate 100 
mg, testosterone isocaproate 60 mg, testosterone fenylpropionate 60 mg, testosterone propionate 
30 mg/ml) every 2 or 3 weeks (n=64; 46.4%); testosterone undecanoate 1000mg per 12 weeks 
(n=62; 44.9%); transdermal testosterone 50 mg daily (n=9; 6.5%); or oral testosterone 
undecanoate (n=2; 1.4%). Eighty-six percent of trans men (n=118) underwent 
hysterectomy/ovariectomy.  
 
Figure 2. Duration of hormonal therapy 
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Participants were questioned about their physical health, incidence of possible treatment-related 
adverse events, socio-demographic status, health-related quality of life (QOL), treatment-related 
symptoms, surgical results, and satisfaction with hormonal and surgical treatment. Data 
concerning QOL, treatment satisfaction, and sexual desire are addressed elsewhere[16-17]. For both 
trans men and women, age-matched female and male control groups were used to compare data 
concerning cardiovascular and cancer morbidities. We focused on relatively common morbidities 
in the general population to provide accurate estimates of their prevalence. We also studied 
morbidities that could be assessed reliably by a questionnaire. The control group for trans 
women consisted of 619 women and 640 men, and the control group for trans men consisted of 
414 women and 414 men. This control group was randomly selected (3 control men and 3 
control women for each subject) and was recruited from a population-based study in Flanders. 
Methods for this study are described elsewhere[18]. Briefly, the control population was recruited 
from a survey of sexual health characteristics and bio-medical, psychological, demographic and 
socio-cultural correlates in persons between 14 and 80 years. Data were collected on 1832 
respondents (response rate: 40.0% of the eligible respondents) between February 2011 and 
January 2012. Respondents were randomly drawn from the Belgian National Register. All data 
were gathered via face-to-face interviews using a combination of computer-assisted personal 
interviewing (CAPI) and computer-assisted self-interviewing (CASI). Both studies were 
approved by the ethical review board of Ghent University Hospital, Belgium. All participants 
gave their consent to participate in the study. 
MAIN OUTCOME MEASURES 
Physical health and incidence of possible treatment related adverse events 
Medical history, medication use, smoking habits, weight, height, current and past hormonal 
treatment, and clinical adverse events (e.g. acute myocardial infarction, venous thrombosis 
and/or pulmonary embolism, type 2 diabetes, transient ischemic attack, stroke, and cancer) were 
addressed using a questionnaire that we developed. Morbidity data before the start of hormonal 
therapy were retrieved from medical files. Medical information was corrected from medical files.  
Statistical analysis 
Descriptives were expressed as mean and standard deviation (SD) or median (first to third 
quartile) when criteria for normal distribution were not fulfilled. Linear regression analyses were 
used to compare linear variables between groups with group being the independent variable. 
Dichotomous and categorical variables were analyzed using logistic regression and chi-square 
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tests, respectively. Morbidity, QOL, and physical symptoms comparisons between groups were 
adjusted for age. Data were analyzed using PASW-software, v.19 (SPSS Inc., Chicago, IL).  
Statistical significance was set at P < 0.05, and all tests were two-tailed. 
Results 
General characteristics 
General characteristics of the study population are described in Tables 1 and 2.  
Almost 30% (n=179) of the women in the trans women control group used sex steroid 
medication, including oral contraceptives (n=93; 15%), hormonal coil (n=33; 5.9%), hormonal 
replacement therapy (n=21; 34%), vaginal ring (n=14; 2.3%) or others (n=17; 2.8%). One man 
in the trans women control group used oral testosterone undecanoate and another used 
intramuscular testosterone esters. 
In the control group of the trans men, 36.2% (n=150) of women used sex steroid medication, 
including oral contraceptives (n=89; 21.5%), hormonal coil (n=34; 8.2%), hormonal replacement 
therapy (n=8; 1.9%), vaginal ring (n=9; 2.2%), or others (n=10; 2.4%). One man in this control 
group used intramuscular testosterone esters. 
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Table   1.  General characteristics of trans women and their control group 
 
Trans  
women 
(N=214) 
Control 
men 
(N=640) 
Control 
 Women 
(N=619) 
P  
men 
P 
women 
Age at time of study (years) 
Current in a relationship (%) 
Work status (%) 
Unemployed 
Employed 
Retired 
Student 
Unable to work 
              Household 
Income (%) 
≤999 euro 
1.000-1.999 euro 
2.000-2.999 euro 
3.000-5.999 euro 
≥ 6.000 euro 
Educational level (%) 
               School going 
               None / Primary School 
               Primary High School 
               Secondary High School 
               Bachelor/master 
BMI (kg/m²) 
SRS (%) 
Time since SRS (years) 
Duration HRT (years) 
Sex steroid therapy (%) 
43.7 ± 12.6 
47.2 
 
14.2 
55.9 
9.5 
5.2 
13.7 
1.4 
 
10.3 
42.2 
27.5 
16.7 
3.4 
 
5.2 
6.1 
17.3 
29.4 
41.1 
24.4 [21.7-27.9] 
64.8 
6.0 [2-11] 
6.0 [3-11] 
95.3% 
43.4 ± 13.7 
82.7 
 
1.8 
77.2 
10.3 
9.0 
1.7 
0 
 
0.2 
16.6 
29.0 
49.2 
5.1 
 
3.8 
13.0 
24.8 
27.0 
31.5 
24.8 [22.7-27.4] 
- 
- 
- 
0.3 
43.1 ± 13.1 
83.9 
 
7.2 
70.8 
6.2 
8.4 
4.3 
7.4 
 
2.9 
20.9 
28.5 
44.8 
2.9 
 
4.1 
16.7 
19.6 
23.0 
36.7 
23.5 [21-26.5] 
- 
- 
- 
29.1 
 
NS 
<0.001 
 
<0.001 
 
 
 
 
 
 
<0.001 
 
 
 
 
 
NS 
 
 
 
 
0.07 
- 
- 
- 
<0.001 
 
 
NS 
<0.001 
 
<0.001 
 
 
 
 
 
 
<0.001 
 
 
 
 
 
NS 
 
 
 
 
NS 
- 
- 
- 
<0.001 
 
Data are presented as mean (S.D) or median (first to third quartiles) in case of non-Gaussian distribution. Categorical variables using 
Chi Square; Linear variables using ANOVA analysis.  NS: not significant; SRS: sex reassignment surgery 
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Table   2.  General characteristics of trans men and their control group 
 
Trans  
men 
(N=138) 
Control 
men 
(N=414) 
Control 
 Women 
(N=414) 
P  
men 
P 
women 
 
Age at time of study (years) 
Current in a relationship (%) 
Children (%)        
Work status (%) 
                 Unemployed 
                 Employed  
                 Retired 
                 Student 
                 Unable to work 
                 Household 
Income (%) 
                 ≤999 euro 
                1.000-1.999 euro 
                2.000-2.999 euro 
                3.000-5.999 euro 
                ≥ 6.000 euro 
Educational level (%) 
               School going 
               None / Primary School 
               Primary High School 
               Secondary High School 
               Bachelor/master 
BMI 
SRS (%)  
Time since SRS (years) 
Duration HRT (years) 
Sex steroid therapy (%) 
 
37.5 ± 11.0 
62.3 
23.9 
 
9.4 
64.5 
1.5 
13.0 
9.4 
2.2 
 
14.2 
35.8 
24.6 
23.9 
1.5 
 
13.1 
8.7 
10.2 
28.3 
39.3 
24.3 [22.2-27.5] 
85.5 
7.0 [4-13] 
7.0 [4-13] 
100% 
 
37.1± 11.9 
77.3 
44.1 
 
1.3 
77.2 
2.3 
18.2 
1.0 
0 
 
0 
14.0 
28.3 
52.6 
5.1 
 
8.6 
9.6 
22.6 
26.7 
32.5 
23.1 [20.9-26.2] 
- 
- 
- 
0.2 
 
37.4 ± 10.1 
82.6 
58.1 
 
4.2 
69.6 
2.0 
16.5 
3.7 
4.0 
 
1.5 
18.1 
25.1 
52.6 
2.6 
 
9.3 
11.2 
17.6 
24.7 
37.2 
24.2 [22.2-26.6] 
- 
- 
- 
36.2 
 
NS 
<0.001 
<0.001 
 
0.001 
 
 
 
 
 
 
<0.001 
 
 
 
 
 
NS 
 
 
 
 
NS 
- 
- 
- 
<0.001 
 
NS 
<0.001 
<0.001 
 
0.02 
 
 
 
 
 
 
<0.001 
 
 
 
 
 
NS 
 
 
 
 
0.02 
- 
- 
- 
<0.001 
Data are presented as mean (S.D) or median (first to third quartiles) in case of non-Gaussian distribution. Categorical variables using 
Chi Square Test; Linear variables using ANOVA analysis.  NS: not significant; SRS: sex reassignment surgery 
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Morbidity in trans persons compared to control population 
Cardiovascular disease and cancer-related morbidities in trans women and men and their 
respective control groups are shown in Table 3 and 4, respectively. 
Table 3.  Prevalence of morbidity in trans women compared to an age-matched control population 
 
 
Trans  women 
before HRT* 
Trans 
women 
Age-
matched 
Control men 
Age-matched 
Control 
women 
P 
men 
P 
women 
 
VT and/or PE 
Myocardial infarction 
TIA/CVD 
Obesity 
Diabetes Mellitus type 2 
Cancer 
 
9.2 
4.7 
4.7 
56.0 
37.3 
18.7 
60.7 
18.7 
23.4 
116.8 
42.0 
28.0 
- 
12.5 
9.4 
92.0 
6.2 
21.9 
- 
0 
14.9 
107.6 
14.9 
24.9 
- 
NS 
0.03 
NS 
0.04 
NS 
- 
0.001 
NS 
NS 
0.021 
NS 
Data are presented cases/1000 persons; logistic regression adjusted for age          
NS: not significant; VT: venous thrombosis; PE: pulmonary embolism; TIA: transient ischemic attack; CVD: 
cerebrovascular disease                                                                                                                                                                                                                            
* retrieved from patient files 
Eleven trans women (5.1%) experienced venous thrombosis and/or pulmonary embolism during 
hormonal therapy. Almost half of these incidents occurred during the first treatment year (n=5), 
another three at the time of sex reassignment surgery (SRS), one after 3 years of hormonal 
therapy, another after 11 years, and one after 22 years of hormonal therapy. In all but one 
incident, one or more of the following risk factors was present: smoking (n=7), immobilization 
(n=3), and/or clotting disorder (n=1). Hormonal treatment at the time of the incident consisted 
of 50 mg cyproterone acetate (n=2), 4 mg estradiol valerate in combination with 50mg 
cyproterone acetate  (n=2), 4mg estradiol valerate  (n=1), 2mg transdermal 17β estradiol  (n=3), 
50 µg ethinyl estradiol (n=1), 0.625mg conjugated equine estrogens (n=1), or unknown (n=1). 
Three cases of acute myocardial infarction were diagnosed within the first 2 years of combined 
anti-androgen and estrogen treatment. Patients were 48 years old on average at the time of the 
event (Table 5). 
Transient ischemic attack (TIA) or cerebrovascular disease (CVD) was diagnosed in 5 trans 
women after an average of 7.2 years of hormonal therapy (range 2-20). Patients were 51 years old 
on average at the time of event (Table 5). 
Trans women had a similar BMI compared to control men and women (data not shown). Trans 
men had a similar BMI as control men but a higher BMI compared to control women (P=0.02). 
Prevalence of obesity in trans women and men was similar to the control population. Trans 
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persons had a similar prevalence of cancer compared to control men and women. Three cases of 
colon carcinoma, 2 cases of melanoma, and 1 case of lymphoma were diagnosed in trans women. 
None of our trans men experienced cancer during follow-up. 
Table 4.   Prevalence of morbidity in trans men compared to an age-matched control population 
 
 
Trans 
 men 
before HRT* 
Trans  
men 
Age-
matched 
Control men 
Age-matched 
Control 
women 
P 
men 
P 
women 
 
VT and/or PE 
Myocardial infarction 
TIA/CVD 
Obesity 
Diabetes Mellitus type 2 
Cancer 
 
14.5 
0 
0 
79.7 
14.5 
0 
14.5 
0 
0 
137.7 
36.2 
0 
- 
7.3 
7.3 
92.0 
7.3 
19.2 
- 
0 
7.3 
118.6 
0 
21.4 
- 
NS 
NS 
NS 
0.06 
0.05 
- 
NS 
NS 
NS 
<0.001 
0.04 
Data are presented cases/1000 persons; logistic regression adjusted for age                   
NS: not significant; VT: venous thrombosis; PE: pulmonary embolism; TIA: transient ischemic attack;     
CVD:cerebrovascular disease                                                                                                                                                                                                                            
* retrieved from patient files 
 
Mortality in trans persons 
Ten trans persons (one transman and nine trans women) died during our follow-up. Causes of 
death were suicide (n=6), cardiovascular disease (n=2), cancer (n=1), and unknown (n=1). Three 
patients committed suicide during hormonal therapy and before SRS, while three committed 
suicide after SRS. 
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Discussion 
This study presents follow-up data related to cardiovascular disease and cancer-related 
morbidities during short- and long-term cross-sex hormone therapy administration in a large 
group of trans persons. Similar to others[7, 9], we observed a relatively high risk of venous 
thrombosis and/or pulmonary embolism during cross-sex hormone therapy in trans women. 
The incidence of venous thrombosis and/or pulmonary embolism in our study (5.1%) was lower 
than Van Kesteren and colleagues[7], who showed that 6.4% of their sample experienced this 
during hormonal treatment. The use of high-dose oral ethinyl estradiol (100µg OD) may explain 
the higher incidence in the latter study, as this estrogen type and route of administration is 
known to affect the coagulation system negatively[5, 19-20]. However, Ott and colleagues[21] did not 
observe any venous thrombosis and/or pulmonary embolism incidents during their follow-up 
study of 162 trans women (mean age 36 years) who received transdermal 17β estradiol for an 
average of 4.4 years. This may be a safer  type of estrogen and route of administration although 
37% of the trans women who experienced venous thromboses in our sample received 
transdermal 17β estradiol. The older age of our participants and longer follow-up period in our 
study may also contribute to the higher incidence of these events.  
The increased risk of cerebrovascular diseases in trans women compared to control men 
corroborates with our previous follow-up study[6] and with Asscheman and colleagues[5]. The 
latter found a higher mortality rate due to cerebrovascular disease in trans women aged between 
40 and 64 years. Use of oral contraceptives and hormonal replacement therapy are associated 
with an increased risk of cerebrovascular disease[22-23], and our results suggest this may also be 
true for cross-sex hormone therapy in trans women.  
We also showed that trans women had a higher prevalence of myocardial infarction compared to 
control women, but similar compared to control men. Asscheman and colleagues[5] also observed 
that long-term hormonal replacement therapy does not decrease the risk of coronary events in 
trans women compared to community dwelling men. It may be that these results represent the 
pre-existing gender differences in coronary events[24] as a considerable part of this discrepancy in 
cardiovascular health cannot be explained by lifestyle or other cardiovascular risk factors. 
Moreover, we observed in our previous follow-up study that aside from a higher smoking rate, 
trans persons had a similar number or fewer cardiovascular risk factors compared to the general 
population[6]. Another explanation may be that similar to the timing hypothesis in 
postmenopausal women[25-26], estrogen therapy effects in trans women may depend on the 
individual’s cardiovascular health at the start of the therapy. Estrogen therapy can aggravate 
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preexisting cardiovascular disease in older trans women, whereas it may exert beneficial 
cardiovascular effects in young and healthy trans women. Our results, may support this 
hypothesis as the majority of trans women who experienced myocardial infarction or 
cerebrovascular disease were aged over 50 years, had one or more cardiovascular risk factors 
(mainly smoking), and had undergone cross-sex hormone therapy for a short duration. Although 
cardiovascular risk factors should be managed in trans women[3], current guidelines do not 
specify at what age and how patients with cardiovascular risk factors should be treated. Based on 
these preliminary results, we may recommend that older trans women with well-known 
cardiovascular risk factors, especially smoking, should be closely monitored, in particular at the 
start of cross-sex hormone treatment. Furthermore, cardiovascular risk factors including 
hypertension, hypercholesterolemia, and smoking should be managed before initiating cross-sex 
hormone therapy in trans women at risk for cardiovascular disease. Further research is needed to 
investigate possible mechanisms contributing to increased cardiovascular disease risk during 
cross-sex hormone treatment, as well as the safety of different cross-sex hormone therapies in 
older trans women.   
Similar to others[7-9], we found that testosterone treatment in trans men was relatively safe in 
relation to short- and medium-term cardiovascular health. However, risks may become more 
apparent as subjects grow older and the duration of hormone exposure increases[27-28]. 
To our knowledge, previous morbidity studies[7, 9] have not investigated the prevalence of type 2 
diabetes in trans persons compared to control individuals. We discovered both trans men and 
women had a higher prevalence of type 2 diabetes compared to control men and women, with 
almost all diagnoses made before starting hormonal therapy in trans women. Because trans 
persons are carefully screened by endocrinologists before hormonal therapy, the presence of type 
2 diabetes may be diagnosed more frequently. Incidence of type 2 diabetes during hormonal 
therapy was also higher in trans men compared to control men and women, although the overall 
number of cases we observed was relatively low. Hyperandrogenism in biological women has 
been associated with an increased insulin resistance due to direct effects on skeletal muscle and 
adipose tissue insulin action[29-30], altered adipokine secretion, and increased visceral adiposity[31]. 
Furthermore, one study investigating the effects of androgen administration on insulin 
sensitivity, evaluated by euglycemic clamp[32], observed that testosterone treatment significantly 
decreased insulin-mediated glucose disposal in trans men, although another study from the same 
group[33] was unable to reproduce these findings. Trans men also had a higher BMI compared to 
control women. This suggests lifestyle differences between the groups may contribute to this 
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discrepancy, although obesity prevalence was not different between trans men and control 
women. 
We saw no difference in cancer incidence in trans persons compared to our control population, 
which are in line with the results from Asscheman and colleagues[5]. However, Dhejne and 
colleagues[4] found the cause-specific risk of death from neoplasms in trans persons was double 
that of control individuals, although this was unlikely to be related to cross-sex hormonal 
treatment. Although the incidence of hormone-related cancers was not higher in the trans groups 
at either short- or medium-term follow-up, the incidence of hormone-related cancers may 
increase with longer duration of hormone treatment[10].  
Trans women had a higher mortality rate compared to trans men, although the number of 
mortalities was relatively small. Similar to others[5, 7], we found that prevalence of suicide in trans 
persons (902/100 000 persons), was higher compared to the general Belgian female (12.8/ 100 
000 persons) and male population (34.9/100 000 persons) within the same age category, 
especially in trans women[34]. Even though cross-sex reassignment therapy has been associated 
with better functioning in terms of gender dysphoria relief, QOL improvement, psychological 
functioning, and decrease in suicide attempts[35-39], the relatively high suicide rate during and after 
transition shows the fragile psychological position of some trans persons.  
The main limitation of this study is the possible selection bias as we had a modest response rate 
of 54 %. Furthermore, the relatively small sample size prevents us from determining accurate 
prevalence of morbidity and mortality. Joining databases from other specialized centres may help 
solve these problems and improve the safety and clinical care related to cross-sex hormone 
therapy. Additionally, because many of the women in the control groups used hormonal therapy, 
we may be underestimating the observed differences in trans person morbidities compared with 
the control population. However, because the control population was randomly drawn from the 
national register, we assume a representative population sample was used in our analysis.  
In conclusion, the data of the current study indicates relatively low morbidity rates during cross-
sex hormone therapy, especially in trans men. We observed a higher cardiovascular morbidity in 
trans women compared to female and male controls.  
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ABSTRACT 
Introduction 
Sex steroids and genital surgery are known to affect sexual desire, but little research has focused 
on the effects of cross-sex hormone therapy and sex reassignment surgery on sexual desire in 
trans persons. We aim to explore associations between sex reassignment therapy (SRT) and 
sexual desire in a large cohort of trans persons. 
Methods 
A cross-sectional single specialized center study including 214 trans women (male-to-female 
trans persons) and 138 trans men (female-to-male trans persons). 
Main   outcome  measures 
Questionnaires assessing demographics, medical history, frequency of sexual desire, hypoactive 
sexual desire disorder (HSDD) and treatment satisfaction. 
Results 
In retrospect, 62.4% of trans women reported a decrease in sexual desire after SRT. Seventy-
three percent of trans women never or rarely experienced spontaneous and responsive sexual 
desire. A third reported associated personal or relational distress resulting in a prevalence of 
HSDD of 22%. Respondents who had undergone vaginoplasty experienced more spontaneous 
sexual desire compared to those who planned this surgery but had not yet undergone it (P=0.03). 
In retrospect, the majority of trans men (71.0%) reported an increase in sexual desire after SRT. 
Thirty percent of trans men never or rarely felt sexual desire; 39.7% from time to time and 
30.6% often or always. Five percent of trans men met the criteria for HSDD. Trans men who 
were less satisfied with the phalloplasty had a higher prevalence of HSDD (P=0.02). Trans 
persons who were more satisfied with the hormonal therapy had a lower prevalence of HSDD 
(P=0.02).  
Conclusion 
HSDD was more prevalent in trans women compared to trans men. The majority of trans 
women reported a decrease in sexual desire after SRT, whereas the opposite was observed in 
trans men. Our results show a significant sexual impact of surgical interventions and both 
hormonal and surgical treatment satisfaction on the sexual desire in trans persons. 
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INTRODUCTION 
Hormonal therapy is an established part of Gender Dysphoria treatment and induces secondary 
sex characteristics development of the desired sex while reducing those of the natal sex[1]. Trans 
women (male-to-female transsexual persons) at our center generally receive cyproterone acetate 
together with oral or transdermal estrogens to induce feminization[1]. Female-to-male transsexual 
persons, denoted as trans men, generally receive progestins to suppress menstruation and 
intramuscular testosterone preparations to induce virilisation[1-2].  
It is well-known that sex steroids play a role in motivational aspects of sexual functioning such as 
sexual desire, particularly in cisgender men[3]. Numerous studies have observed an improvement 
in sexual desire during T administration in hypogonadal young and aging men[4-6] but not in 
eugonadal men[7]. Whether T treatment resulting in supraphysiological levels of testosterone 
increases sexual desire is less clear as one study[8] observed a significant increase whereas another 
did not[9].  
In contrast, our current knowledge about the role of androgens in female sexual desire is still 
scarce with inconsistent and often contradictory evidence[3]. In epidemiological studies, serum T 
levels were not correlated with sexual desire in cisgender women[10-11] whereas other studies did 
observe an association[12-13]. Also, evidence concerning the effects of oral contraceptives on 
sexual desire, which are known to decrease free T levels[14], are conflicting[15]. Furthermore, 
several studies[16-17], but not all[18], observed that T supplementation in surgical or natural 
menopausal women increases sexual desire. 
Effects of estrogens on sexual desire in both cisgender men and women are poorly understood[3]. 
Given that T is aromatized into estradiol (E2) in many tissues, it may be possible that effects of T 
on sexual desire are mediated by E2. Only a few studies examined the relation between sexual 
desire and circulating E2 levels in cisgender men but most studies observed no clear 
associations[19-20]. However, as E2 is known to exert an important role in the negative feedback of 
T in men at both the hypothalamic and pituitary level, administration of exogenous estrogens has 
been used historically as an anti-androgen treatment in prostate cancer patients and sex 
offenders, where a reduction in sexual desire was observed[3]. In cisgender women, some[21] but 
not all[22-23] studies, observed associations between E2 levels and sexual desire. Several studies 
examining the effects of estrogen therapy in postmenopausal women found an increase in sexual 
desire[23-24]. However, others reported that high doses of estrogens were associated with lower 
sexual desire[25-26]. 
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In view of the effects of sex steroids on sexual desire in cisgender men and women, several 
effects of cross-sex hormone therapy on sexual desire in trans persons can be hypothesized. In 
trans women,  a decline in serum T levels or T action together with increased SHBG and high E2 
levels may lower sexual desire; while in trans men, increasing serum T levels may facilitate sexual 
desire. However, these theoretical effects may be influenced in trans persons due to prior brain 
masculinization or feminization. Aside from effects of cross-sex hormone therapy, the 
experience of breast augmentation and removal, genital surgery and postsurgical outcome clearly 
affects sexual functioning in trans persons[27-32]. Sex reassignment surgery (SRS) in trans women 
consists of orchidectomy, penectomy and vaginoplasty. SRS in trans men includes mastectomy, 
hysterectomy and oophorectomy. Due to availability and extensive experience at our center, 
most trans men proceed immediately with phalloplasty (creation of a full-sized phallus)[33].                                       
Considering the important potential effects of both hormonal treatment and genital surgery, the 
current knowledge of the effect of sex reassignment therapy on sexual desire is limited and based 
on small sample studies. Evidence concerning sexual desire in trans women is conflicting as 
some studies using direct or indirect measures of sexual desire observed no change[34-35] or 
decrease[27-28; 36] whereas others observed an increase after sex reassignment treatment[29; 37-38]. In 
trans men a single study investigated sexual desire directly[39] whereas others used indirect 
measures such as frequency of masturbation[27, 35-36] and sexual activity[37].  
The present study aimed to investigate the effects of sex reassignment therapy on sexual desire in 
a well-described, large cohort of both trans men and women almost all treated by the same 
endocrine and surgical team.  
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METHODS 
Study Procedures and population 
All persons who were diagnosed with Gender Dysphoria/ Transsexualism (Diagnostic and 
Statistical Manual of Mental Disorders- DSM-5/International Classification of Diseases, 10th 
revision, F64.0) at the Center for Sexology and Gender Problems at the Ghent University 
Hospital (Ghent, Belgium) between1986 and June 2012 and underwent at least 3 months of 
cross-sex hormonal therapy were invited by letter to participate in this study. Respondents 
received a paper version of the questionnaire by post or filled out the survey on-line. A reminder 
message was sent to non-responders. All surveys were collected between August and December 
2012. Three hundred fifty two participants including 214 trans women and 138 trans men agreed 
to participate in this study resulting in a total response rate of 54% (51% in trans women and 
58.7% in trans men). Ten of the invited persons had died by the time of the follow-up (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Subject enrollment 
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This study was part of a multi-disciplinary study in which participants were questioned about 
their physical health and incidence of possible treatment related adverse events, socio-
demographic status, health-related quality of life (QoL), and treatment related symptoms such as 
changes in sexual desire, surgical results, and satisfaction with hormonal and surgical treatment. 
Data concerning morbidity and QoL are addressed  in other articles[40-41].  
The trans women were on hormonal therapy for a median duration of 7 years (range: 3 months - 
35 years). One hundred thirty-nine trans women (65%) underwent SRS (orchidectomy, 
penectomy and vaginoplasty), 60 trans women (28%) had plans for this surgery in the future, 4 
(1.8%) were still in doubt. The others (n= 11; 5%) did not wish this surgery or did not undergo it 
for medical reasons. About half of trans women (53.5%) underwent breast augmentation, 17.8% 
underwent vocal cord surgery or cricoid reduction and 21.5% had facial feminizing surgery.  
Trans men were on testosterone treatment for a median duration of 6 years (range 3 months - 49 
years). Eighty-six percent of the trans men underwent hysterectomy/oophorectomy. Seventy-six 
men (59.4%) had undergone phalloplasty. Nine men were treated with metoidioplasty, 8 of 
whom subsequently underwent a phalloplasty. Sixty-three percent of those who had undergone a 
phalloplasty, had an erection prosthesis implanted (n=48). 
This study was approved by the ethical review board of Ghent University Hospital, Belgium. All 
participants gave their consent to participate in the study.  
MAIN  OUTCOME MEASURES 
General  characteristics 
Civil status, current working situation, current job and household income were addressed. All 
participants were asked whether they had children (yes/no) and if so, to describe the method of 
conception for each child. 
Sex reassignment treatment 
Current and past hormonal treatments were addressed through a self-developed questionnaire. 
Patients were questioned about the medical procedures they underwent during transition. 
Satisfaction with different surgical procedures was evaluated by the participants on a 5-point 
Likert scale from very unsatisfied to very satisfied. Moreover, trans men were asked whether they 
had experienced surgical complications of metoidioplasty, phalloplasty or implantation of 
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erection prosthesis. Trans women were asked whether they had experienced surgical 
complications of the vaginoplasty procedure. 
Definition of HSDD  
The definition of Hypoactive Sexual Desire Disorder (HSDD) in this particular patient 
population is difficult. The renewed definitions of HSDD in women and men that will be used in 
DSM-5 may not be applicable for trans persons given the important interference of sex 
reassignment treatment with the potential to experience genital arousal in these patients. Indeed, 
previous research from our center observed that the female sexual functioning index (FSFI) was 
not unequivocally suitable for trans women, especially concerning sexual arousal[42].  
We evaluated HSDD in trans women as defined by Elaut and colleagues[43] who used the Sexual 
Function Health Council’s consensus definition[44]. They defined HSDD as ‘the persistent or 
recurrent deficiency (or absence) of sexual fantasies, thoughts, desire for sexual activity alone or 
with a partner and the inability to respond to sexual cues that would be expected to trigger 
responsive sexual desire. These symptoms must be causing personal distress’. 
Sexual desire in trans women was therefore assessed by the evaluation of spontaneous and 
responsive sexual desire in the past month using a 5-point scale from never to almost always. In 
addition, respondents were asked about the presence of distress caused by low sexual desire (yes 
or no) and to describe whether this caused distress for themselves, their partner, and/or their 
relationship. Respondents met the distress level when they experienced personal or relational 
distress. HSDD in trans women was scored when a participant indicated that (1) she 
never/rarely experienced either spontaneous (2) or responsive sexual desire, and when this was 
(3) causing her personal or relational distress.  
HSDD in trans men was defined according to DSM-IV-TR. HSDD was scored when a 
participant indicated that (1) he never/rarely experienced sexual desire in the past month, and 
when this was (2) causing him personal or relational distress. 
Relational and sexual functioning 
Participants also reported on the following items: marital status, duration of relationship, current 
sexual orientation (5 point scale from only attracted to men to only attracted to women or 
other), comparison of sexual desire before and after SRS (5-point scale from much higher to 
much lower), frequency of experiencing too low sexual desire in the past month (5-point scale 
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from never to almost always, experience of symptoms of high sexual desire, experience of 
symptoms of low sexual desire (4-point scale from no to severe). 
Physical and mental functioning 
Quality of life (QOL) was measured using the Dutch version of the Short Form-36 Health 
Survey (SF-12). This questionnaire includes 12 questions with fixed response choices, organized 
in 2 scaled scores, based on the weighted sums of the questions in their section. These scores 
were converted into a summary score for each section: physical functioning and mental 
functioning, with higher scores indicating higher levels of functioning or well-being [45]. Internal 
consistency with the SF-12 was high (total group: Cronbach’s α = 0.8). 
Statistical analysis 
The normal distribution of all variables was tested by the Kolmogorov-Smirnov one-sample test. 
Normally distributed variables were described in terms of mean and standard deviation (SD) and 
skewed variables in terms of median, first and third quartiles. Comparisons of continuous 
variables between trans women and men were made by linear regression analyses with group as 
independent variable. Dichotomous and categorical variables were analyzed using respectively 
logistic regression and Chi Square test. Data were analyzed using PASW-software, v.19 (SPSS 
Inc., Chicago, IL). Statistical significance was set at P < 0.05 and all tests were two tailed. Given 
the well-known association between age and sexual desire, linear and logistic regression analyses 
were adjusted for age. 
 190 
RESULTS 
Patient Characteristics 
Patient characteristics are summarized in Table 1. 
Table 1.  General characteristics of the study population 
 
 
Trans women 
(N=214) 
Trans men 
(N=138) 
P 
 
Age at time of study (years) 
Nationality (%) 
                 Belgian 
                 Other 
Civil status (%) 
                  Married/living together 
                  Not married or living together 
                Divorced 
                Widow      
Children (%) 
                 Birth before HRT (%) 
Work status (%) 
                 Unemployed 
                 Employed  
                 Retired 
                 Student 
                 Unable to work 
                 Household 
Monthly income (%) 
                 ≤999 euro 
                1.000-1.999 euro 
                2.000-2.999 euro 
                3.000-5.999 euro 
                ≥ 6.000 euro 
SRS (%) 
Time since SRS (years) 
Duration of hormonal therapy (years) 
Active smoking (%) 
BMI 
 
45 [32.8-52] 
 
86.0 
14.0 
 
36.0 
36.4 
25.2 
2.3 
41.1 
81.8 
 
14.2 
55.9 
9.5 
5.2 
13.7 
1.4 
 
10.3 
42.2 
27.5 
16.7 
3.4 
64.8 
6.0 [2-11] 
6.0 [3-11] 
29.9 
24.4 [21.7-27.9] 
37.5 ± 11.0 
 
87.0 
12.5 
 
44.5 
47.4 
8.0 
0 
23.9 
36 
 
9.4 
64.5 
1.5 
13.0 
9.4 
2.2 
 
14.2 
35.8 
24.6 
23.9 
1.5 
85.5 
7.0 [4-13] 
7.0 [4-13] 
29.4 
24.3 [22-27.5] 
<0.001 
 
NS 
 
<0.001 
 
 
 
 
<0.001 
<0.001 
0.001 
 
 
 
 
 
 
NS 
 
 
 
 
 
<0.001 
NS 
0.041 
NS 
NS 
Data are presented as % or median (first to third quartiles). Categorical variables using Chi square test; Continuous 
variables using linear regression analysis. NS: not significant; SRS: sex reassignment surgery (defined as 
orchidectomy/penectomy/ vaginoplasty in trans women and hysterectomy/ovariectomy in trans men)  
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Ten trans women were no longer on estrogen therapy due to previous thromboembolic events 
(N=5), dissatisfaction (N=2) or another cause (N=3). Current hormonal treatment in trans 
women mostly consisted of transdermal estradiol [17-β estradiol gel 1.5 mg/24u (n= 76; 35.5%); 
estradiol patch 50 µg/24u (n=29;13.6%); or daily intake of oral estrogens; estradiol valerate 2 mg 
(n=91; 42.5%), estriol 2 mg (n=1; 0.4%)), ethinyl estradiol 50 µg (n=2; 0.9%), and oral 
contraceptive ethinyl estradiol 30-50µg (n=5; 2.3%)]. Cross-sex hormonal therapy in trans men 
consisted of intramuscular testosterone treatment with either a mixture of testosterone esters 
(testosterone decanoate 100 mg, testosterone isocaproate 60 mg, testosterone fenylpropionate 60 
mg, testosterone propionate 30 mg/ml) every 2 or 3 weeks (n=64; 46.4%); testosterone 
undecanoate 1000mg per 12 weeks (n=62; 44.9%); transdermal testosterone 50 mg daily (n=9; 
6.5%); or oral testosterone undecanoate (n=2; 1.4%).  
Sexual desire in trans women 
Sexual desire and HSDD in trans women 
The majority of trans women (83.4%) never or rarely experienced spontaneous sexual desire; 
whereas 6.5% often or always experienced spontaneous sexual desire. Almost seventy-six percent 
(75.8%) never or rarely experienced responsive sexual desire. Fourteen percent experienced 
responsive sexual desire from time to time, 10.1% often or always. Seventy-three percent never 
or rarely experienced either spontaneous or responsive sexual desire. About one in three trans 
women, who never or rarely experienced either spontaneous or responsive sexual desire, 
indicated to be distressed by this, personally or within the relationship, resulting in a prevalence 
of HSDD of 22.1%. (Figure 2). However, the vast majority of trans women did not experience 
this lack or absence of sexual desire as distressing. 
Of the trans women who reported to experience spontaneous sexual desire often or always 
(6.5%), only one reported associated personal or relational distress. 
One fourth of trans women (24.2%) often or always experienced too low sexual desire (Table 2). 
In retrospect, the majority of trans women (69.7%) described their current sexual desire lower or 
much lower as compared to before sex reassignment therapy. In contrast, 17.4% reported no 
change in sexual desire and 13% of participants described an increase in sexual desire (Figure 3). 
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Table 2.   Sexual desire  in  trans  persons 
  
Trans women 
(N=214) 
Trans men 
(N=138) 
P 
Current in relationship (%)  
 
yes 
no 
 
47.2 
52.8 
62.3 
37.7 
 
<0.001a 
Duration of relationship (%) 
 
< 6 months 
6-12 months 
1-2 years 
2-5 years    
> 5 years             
7.1 
4.0 
14.1 
16.2 
58.6 
4.7 
5.8 
14.0 
19.8 
55.8 
NS b 
Sexual orientation (%) 
 
 
 
 
Current sexual desire (%)  
compared to sexual desire 
 before sex reassignment  
treatment 
 
 
(mainly) attracted to males 
bisexual 
(mainly) attracted to females 
Other 
 
Much higher 
Higher 
Equally 
Lower 
Much lower 
36.0 
11.2 
47.7 
5.1 
 
5.5 
7.5 
17.4 
26.4 
43.3 
10.2 
6.5 
81.8 
1.4 
 
31.3 
39.7 
16.8 
9.2 
3.1 
<0.001b 
 
 
 
 
<0.001b 
Frequency of experience of  
too low sexual desire (%) 
Almost never or never 
Rarely 
From time to time 
Often 
Almost always or always 
46.0 
19.7 
10.1 
10.1 
14.1 
74.0 
15.3 
5.3 
4.6 
0.8 
<0.001b 
 
 
 
Experience of symptoms of 
low sexual desire (%) 
 
 
 
Experience of symptoms of 
high sexual desire (%) 
 
 
 
 
No  
Mild 
Moderate  
Severe  
 
No  
Mild  
Moderate  
Severe  
 
40.8 
16.8 
15.2 
27.2 
 
82.3 
9.2 
4.9 
3.8 
 
 
81.6 
13.2 
4.4 
0.9 
 
31.6 
35.1 
22.8 
10.5 
 
<0.001b 
 
 
<0.001b 
Hypoactive sexual desire 
disorder (%) 
Yes 
No 
22.2 
77.8 
5.0 
95.0 
<0.001a 
Data are expressed as %; logistic regression analyses are adjusted for age; NS: not significant     
a Logistic regression analysis; b Chi Square Test 
 193 
Chapter 3 . Sexual desire 
Associations between sexual desire and sex reassignment treatment in trans women 
Cross-sex hormonal therapy 
Type of hormonal therapy, duration of hormonal therapy and satisfaction with hormonal therapy 
were not associated with frequency of spontaneous or responsive sexual desire or prevalence of 
HSDD (data not shown).  
Sex reassignment surgery 
Respondents who already had undergone a vaginoplasty, experienced more spontaneous sexual 
desire (P=0.002) compared to those who were still scheduled for this surgery. Satisfaction with 
genital reassignment surgery and experience of complications of vaginoplasty were not associated 
with sexual desire scores (data not shown). 
. 
. . 
Experience of personal 
and/or relational 
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25.6% 
 
 
 
Never/rarely 
experience of 
spontaneous sexual 
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83.4% 
 
25.6% 
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25.6% 
 
 
 
 
25.6% 
 
21.1% 
 
 
 
 
73.4% 
 
 
 
 
24.1% 
 
 
 
 
21.0% 
 
 
 
 
FFFigure 3. Prevalence of HSDD in trans women 
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Sexual orientation and relationship 
Involvement in a romantic relationship or relationship duration were not related to frequency of 
spontaneous or responsive sexual desire (data not shown) but respondents involved in a 
relationship had a higher prevalence of HSDD (P<0.001). Trans women (mostly) attracted to 
men had higher levels of spontaneous and responsive sexual desire compared to trans women 
(mostly) attracted to women (P=0.008 and P=0.009, respectively) (Figure 4A and 4B) but sexual 
orientation was not associated with prevalence of HSDD (data not shown).  
General characteristics 
Age was negatively associated with frequency of spontaneous and responsive sexual desire 
(P=0.008 and P<0.001, respectively). Employment status, having children, physical and mental 
well-being were not associated with frequency of  sexual desire or prevalence of HSDD (data not 
shown).  
 
Figure 4. Frequency of sexual desire according to sexual orientation in trans women/ Bars 
represent mean and whiskers 2 standard error of mean. P value result from post-hoc ANOVA. 
Sexual desire in trans men 
Sexual desire and HSDD in trans men 
Forty percent of trans men reported experiencing sexual desire from time to time whereas 30.6% 
often or always experienced this. Thirty percent of trans men never or rarely experienced sexual 
desire and about one in six trans men in our sample indicated to be distressed by this, personally 
or within the relationship, resulting in a prevalence of 5.0% of HSDD in our sample of trans 
men. 
 195 
Chapter 3 . Sexual desire 
Of the trans men who reported experiencing sexual desire often or always (30.6%), a majority 
reported no associated distress (76.9%), 12.8% reported personal or relational distress and 10.3% 
expressed that this caused no personal distress but exclusively stress for their partners. Of the 
total sample, 3.6% of trans men often or always experienced sexual desire and reported this 
caused personal or relational distress.  
In retrospect, the majority of trans men (71.0%) reported an increase in sexual desire after sex 
reassignment treatment, whereas 12.3% reported a decrease. Almost 17% experienced no change 
in sexual desire.           
 
Figure 3. Current sexual desire in trans men and women compared to sexual desire before sex 
reassignment treatment 
Associations between sexual desire and sex reassignment treatment in trans men 
Cross-sex hormonal therapy 
Shorter duration of testosterone treatment was significantly associated with more symptoms of 
high sexual desire (P=0.005). We observed no associations between type of hormonal therapy 
and satisfaction with  HRT and sexual desire scores (data not shown).  
Sex reassignment surgery 
Whether or not trans men had undergone phalloplasty surgery and/or the implantation of an 
erection prosthesis did not affect sexual desire scores. In addition, time since genital surgery, 
satisfaction with genital reassignment surgery and experiences of complications of phalloplasty 
and/or erection prosthesis were not associated with frequency of experiencing sexual desire (data 
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not shown). However, HSDD was more prevalent in trans men who were less satisfied with their 
phalloplasty (Fisher exact; P=0.02). 
Sexual orientation and relationship  
Shorter relationship duration was associated with a higher frequency of experiencing sexual 
desire (P=0.03). No associations were found between sexual orientation, involvement in a 
relationship and frequency of sexual desire and HSDD in trans men (data not shown).  
General characteristics 
No association was observed between age and frequency of sexual desire (data not shown) in 
trans men. Having children, physical and mental well-being were not associated with frequency 
of sexual desire or prevalence of HSDD (data not shown). Unemployed trans men had a lower 
frequency of sexual desire (P=0.015). 
Sexual desire  in total transsexual sample 
Comparison between trans women and trans men 
A comparison between trans women and trans men on relational and sexual desire parameters 
are shown in Table 2. Trans men were more frequently involved in a romantic relationship 
compared to trans women. More symptoms of high sexual desire were observed in trans men, 
whereas trans women reported more symptoms of low sexual desire. HSDD was more prevalent 
in trans women compared to trans men (P<0.001). We observed no difference in satisfaction 
with surgical reassignment of genitalia between trans men and women (data not shown). 
Associations between sexual desire and sex reassignment treatment in total transsexual 
sample 
Cross-sex hormonal therapy 
Dissatisfaction with hormonal therapy was associated with a higher prevalence of HSDD 
(P=0.02) (Figure 5). No association was observed between sexual desire scores and duration of 
hormonal therapy in the total trans sample (data not shown). 
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Sex reassignment surgery 
We observed no association between sexual desire scores and satisfaction with surgical 
reassignment of genitalia in the total transsexual sample.  
Relationship 
Trans persons involved in a romantic relationship had higher levels of sexual desire (P=0.02) 
and also had a higher prevalence of HSDD (P=0.001). 
General characteristics 
Age was negatively associated with frequency of  sexual desire (respectively: P<0.001). 
Employment status, having children, physical and mental well-being were not associated with 
frequency of  sexual desire or prevalence of HSDD (data not shown).  
 
Figure 5. Hormonal satisfaction in trans men and women and prevalence of HSDD / Bars 
represent percentage. We observed a higher ratio of trans persons experiencing HSDD in trans 
persons who are dissatisfied with the hormonal therapy. 
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DISCUSSION 
The present study described the sexual desire frequency (and prevalence of HSDD) and 
associations between sex reassignment treatment and sexual desire in a large, well-described 
group of both trans women and men. We observed that almost three quarters of trans women 
rarely or never experienced spontaneous and responsive sexual desire. About a third of these 
women with low sexual desire reported associated distress and met criteria for HSDD, a ratio 
also reported by studies in cisgender women[46-47]. We observed a lower prevalence of HSDD in 
trans women (22%) compared to a previous multi-center study[43] in 62 trans women (33%), 
possibly related to methodological differences. Trans women in our study had a higher 
prevalence of HSDD compared to male and female population studies using a similar definition, 
taking distress levels into account, as they found that between 0.5 and 6% of men and 3 to 
14.2% of women reported HSDD[48-52]. In trans men, a similar prevalence of HSDD was found 
(5.0%) compared to the general male population (range: 0.5-6%)[48-50, 52].  
Trans women had a higher prevalence of HSDD and described more often a decrease in sexual 
desire after sex reassignment therapy compared to trans men. Sexual desire is a multifaceted 
process, resulting from the triggering of a sexual response system with a specific arousability 
based on genetics, the presence of sex steroids and neurotransmitters as well as by lifelong 
psychosocial learning experiences. Those sexual stimuli can be both internal (such as sexual 
thoughts) or external cues (sensory stimuli experienced as erotic)[53]. Since trans women have 
mostly grown up with a highly testosterone dependent sexual response system and have often 
had sexual experiences in the male gender role, it requires a certain ‘reconditioning’ of the sexual 
response system within a less androgenic hormonal milieu. The fact that two in three trans 
women in our group did not experience this lack or absence of sexual desire as distressing, points 
to the presence of factors that might be compensating for the loss of the ‘androgen-driven 
sexuality’. This might consist of factors the current study could not assess, such as an 
increasingly positive self-image due to the transition and a boosted self-esteem from being 
recognized as female. 
Regarding determinants of sexual desire, it was found that trans women attracted to women 
experienced lower levels of sexual desire. These findings support previous results from Weyers 
and colleagues[42]. Interestingly, no differences in distress levels were observed between trans 
women attracted to men or attracted to women suggesting that trans women attracted to women 
may be less interested in sexual activity or are less open to sexually adequate stimuli compared to 
those attracted to men. Indeed, it has already been observed[42] that trans women attracted to 
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women attributed the lowest importance to sex in comparison with the others. These results may 
also corroborate with observations in lesbian women, as the latter had lower levels of sexual 
desire compared to heterosexual women[54]. Similar to studies in the general population, it was 
found that respondents involved in a partner relationship had higher distress levels[46] resulting in 
a higher prevalence of HSDD.  
Concerning the associations between cross-sex therapy and sexual desire, it was observed that 
trans women who had undergone vaginoplasty experienced higher levels of sexual desire 
compared to those who were scheduled to undergo this surgery. It is likely that the relief of 
gender dysphoria due to a body image more congruent with the gender identity has positive 
effects on sexual functioning or the other way around that the presence of male genitalia has 
negative effects on sexual functioning. As a result, trans women may experience more satisfying 
sexual relationships after genital surgery. In contrast, no associations were found between type of 
surgery and sexual desire scores in trans men, but satisfaction with phalloplasty was negatively 
associated with prevalence of HSDD. Interestingly, no associations were observed between 
surgical satisfaction and sexual desire scores in trans women. 
These different associations between trans women and trans men are not well-understood. One 
explanation could be that trans men attribute a higher degree of importance to functionality of 
their newly-formed genitalia compared to trans women. Many underlying factors may contribute 
to these findings such as differences between functional and esthetical surgical satisfaction, body 
image, self-esteem etc. This is a point for further exploration and study. 
Hormonal therapy satisfaction was related to a lower prevalence of HSDD in the total 
transsexual sample. Overall the results underline the importance of different surgical 
interventions and treatment satisfaction on sexual desire in trans persons. In earlier research in 
the same cohort, we observed that both hormonal and surgical satisfaction were strongly related 
to mental and physical well-being[40]. The current results underline the importance of high quality 
sex reassignment treatment on the sexual well-being of trans persons. 
As to the limitations of this study, we had a modest response rate (54%) and selection bias 
cannot be excluded. As in most follow-up studies, respondents who participated in this study 
may have experienced a more favourable outcome than those who refused. Secondly, our 
observations on changes in sexual desire after sex reassignment treatment in both trans men and 
women are based on retrospective data, and should be interpreted with caution; prospective 
studies are needed to confirm our results. Thirdly, the aim of this study was to investigate the 
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associations between sex reassignment treatment and sexual desire. However, we are aware that 
the subjective experience of sexual desire for an individual results from a complex interaction 
between the individuals’ sexual response system and adequate sexual stimuli and consequently 
can be affected by many biological, psychological, social, sexual and relational factors[53], which 
were not all addressed in the current study. Also, gender differences in intrinsic and extrinsic 
factors affecting sexual desire have led to another conceptualization of sexual desire in men and 
women[55]. Given these gender differences in sexual desire, distinct definitions of HSDD in men 
and women have been proposed[56-57]. We defined HSDD in trans women and trans men 
according to the definition of the desired gender, due to changes in both hormonal environment 
and/or genital anatomy and function in combination with transitioning to the desired gender 
role. However, this approach has certain limitations considering the presence of male or female 
genetics, gender differences in imprinting of brain systems, and lifelong psychosocial learning 
experiences in the natal gender role. In addition, because of surgical availability and expertise, 
and a well-organized health insurance system, allowing coverage for sex reassignment surgery, 
the majority of trans persons at our center who receive cross-sex hormone therapy undergo sex 
reassignment surgery. Also, postoperative sexual functioning is highly dependent on the quality 
of, and satisfaction with surgery[34] and this may differ from center to center. These factors may 
hamper the generalizabililty of our results. 
CONCLUSION  
Trans women had a higher prevalence of HSDD compared to what has been reported in 
previous research for cisgender women, while trans men had  similar or lower prevalence rates of 
HSDD in comparison with cisgender men. Most trans women reported a decrease in sexual 
desire after sex reassignment treatment whereas the opposite was observed in trans men. Our 
results point out a significant sexual impact of surgical procedures and both hormonal and 
surgical treatment satisfaction on the sexual desire in trans persons.
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3.2  Sexual desire in female-to-male transsexual persons: an exploration of 
the role  of  T replacement. 
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ABSTRACT 
Objective 
To describe sexual desire in female-to-male transsexual persons post sex reassignment surgery 
(SRS). The associations between serum androgen levels and sexual desire are examined. 
Design 
Single center cross-sectional study. 
Methods 
Forty-five female-to-male transsexual persons post SRS completed a standardized questionnaire 
assessing sexual desire (Sexual Desire Inventory). In addition, participants were asked questions 
on sexual desire before starting hormone treatment and having SRS. Serum levels of 
testosterone, LH and sex hormone-binding globulin were measured on fasting morning serum 
samples. 
Results 
In retrospect, 73.9% of the participants reported an increase in sexual desire after hormone 
treatment and SRS. Solitary sexual desire scores were significantly correlated with frequency of 
masturbation (r=0.835; P<0.001), whereas frequency of sexual intercourse with a partner was 
not. No direct associations were found between testosterone and solitary or dyadic sexual 
desire. However, ANOVA showed an independent effect of LH on solitary sexual desire 
(P<0.001). Post hoc analysis revealed that female-to-male transsexual persons with elevated 
levels of LH, indicating suboptimal testosterone therapy, reported significantly lower solitary 
sexual desire levels (than those with low LH levels; P=0.007). Suppressed LH levels were also 
associated with having a higher need for sexual activities (P=0.009) and a higher frequency of 
excessive sexual desire (P=0.007). 
Conclusion  
Most female-to-male transsexual persons report on a marked increase in sexual desire after 
testosterone treatment and SRS. No direct associations between levels of testosterone and 
solitary or dyadic sexual desire were found. However, measures of sexual desire were inversely 
associated with LH levels. 
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INTRODUCTION 
It is now widely believed that testosterone (T) plays an important role in motivational aspects of 
sexual functioning as sexual desire[1]. Testosterone therapy seems to enhance the frequency of 
sexual thoughts and the intensity of sexual feelings, especially in young hypogonadal men[2-3]. 
During the process of sex reassignment, transsexual persons receive cross-sex hormone 
replacement which transforms their hormonal milieu. After sex reassignment surgery (SRS), 
which often includes gonadectomy, cross-sex hormone treatment is continued as in other 
hypogonadal subjects. In view of a possible impact of T on sexual desire, it has been suggested 
that the effect of continuous T administration in female-to-male transsexual persons might lead 
to an increase in sexual desire[4]. Also, care givers working in treatment centers for gender 
dysphoria sometimes encounter complaints of low sexual desire in male-to-female transsexual 
persons while this is hardly the case in female-to-male transsexual persons. A previous study 
from our group found that hypoactive sexual desire was reported in one-third of transsexual 
women. While levels of free T in the group of male-to-female transsexual persons were markedly 
lower, the intensity and frequency of sexual desire was very similar to control women not using 
hormonal contraception. These findings argue against a major role of T in the sexual desire in 
male-to-female transsexuals[5]. In a pilot study, Kronawitter et al.[6] treated hypoactive sexual 
desire in male-to-female transsexual persons with a T patch. A significant improvement in sexual 
desire (as measured by the Brief Profile of Female Sexual Function (B-PFSF) was observed. 
Our knowledge on sexual desire in female-to-male transsexual persons is even more limited since 
data from validated questionnaires on sexual desire in female-to-male transsexual persons are 
non-existent[4]. The available data can only be interpreted as an indication of sexual desire 
through measurement of the frequency of sexual activity or frequency of masturbation before 
and after SRS. In their sample of adult female-to-male transsexual persons, De Cuypere et al.[7] 
generally found an increase in frequency of masturbation after T treatment and SRS. Similarly, 
Lief and Hubschmann[8] mentioned an increase in sexual activity following SRS. In their 
adolescent female-to-male sample, Smith et al.[9] and Cohen-Kettenis and van Goozen[10] 
reported no change or an increase in masturbation after T treatment and SRS. The present study 
aimed at providing a validated measure of sexual desire in this population[11]. Additionally, we 
hypothesized a marked association between serum androgen levels and levels of sexual desire in 
female-to-male transsexual persons. 
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MATERIAL AND METHODS 
Study population  
All Dutch speaking female-to-male transsexual persons who received SRS between 1987 and 
2009 at our hospital were invited by letter (n=79), in which they were asked to confirm their 
participation by telephone or electronic mail. Two participants could not be reached due to 
change of address. Those who had not replied after one month were contacted by telephone or 
were left a voice message as a reminder. If necessary, potential participants were contacted a 
second time. A total number of 47 persons agreed to participate in the study, consisting of one 
day hospital visit, which resulted in a response rate of 64%. Three participants, were informed by 
others and offered to participate in the study themselves, resulting in a study sample of 50.  
Exclusion criteria included treatments or disorders affecting sex hormone status, body 
composition and bone metabolism: untreated hypo- or hyperthyroidism, Cushing syndrome, 
alcohol abuse, mucovisidosis, malabsorption or eating disorders, cirrhosis, chronic kidney failure, 
auto-immune rheumatoid arthritis,  the current (<2 years) or prolonged use of corticosteroids, 
estrogens, anti-androgens, bisphosphonates, calcitonine and fluorides. The first year after SRS is 
often called the honeymoon period; a period which does not represent a realistic picture of long-
term sexual and psychological status. Participants who underwent SRS during the last year, were 
therefore excluded. One participant had to be excluded based on these criteria. Further, four 
participants were not willing to complete the Sexual Desire Inventory, resulting in a final study 
population of 45 for the current paper.  
In our center, female-to-male transsexual persons are treated through a multidisciplinary 
approach consisting of hormone therapy and SRS for most. SRS in female-to-male transsexual 
persons includes mastectomy, hysterectomy and bilateral ovariectomy. Due to the extensive 
experience in phalloplasty at our center[12-13], most female-to-male transsexual persons in this 
study (n=38) immediately preceeded with a phalloplasty and less frequently, with 
metaidoioplasty. The majority of participants who initially chose for metaidoioplasty (n=9) 
preceeded towards phalloplasty afterwards (n=8). Two female-to-male transsexual persons had 
not yet made up their minds about having further genital surgery. All participants started 
hormonal therapy at least two years before SRS. On average, participants were 8 years after SRS, 
with a minimum of 2 and a maximum of 22 years. All participants were on long-term T therapy. 
While current cross-sex hormone therapy was not standardized, almost all participants were 
treated by the same endocrinologist. Cross-sex hormone therapy consisted of: intramuscular T 
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treatment (parental T esters 250 mg/2 or 3 weeks; n=32); T undecanoate 1000 mg/12 weeks 
(n=7) and transdermal T gel (50mg daily; n=5). One participant used both oral T undecanoate 
40 mg (daily) and transdermal T gel 50 mg daily.  
We chose not to include community dwelling men, women or male-to-female transsexual 
persons as a control group since hormonal status, psychosocial factors and sexual functioning 
are very specific in this study population.  
To contextualize the levels of sexual desire in the present sample, we will use previous data of 
our research group on sexual desire in community dwelling men[14] and male-to-female 
transsexual persons[5] using the same validated questionnaire. The data on sexual desire in 
community dwelling men consist of baseline measures collected during a study in 55 
heterosexual couples in which the effect of three different forms of hormonal contraception on 
female sexual desire was assessed[14]; data from the male-to-female transsexual persons were 
collected during a previous study of our group on sexual desire and the association with T[5].  
Study Procedures 
Female-to-male transsexual persons, who agreed to participate in the study, received all 
questionnaires by regular mail. Subsequently, they visited the Ghent University Hospital between 
November 2009 and April 2010 for further evaluation. The visit  included a fasting morning 
blood sample, dermatologic, urological, speech, bone and body composition evaluations; data 
that will be reported in other publications[15].  
This study complied with the recommendations of The declaration of Helsinki and was 
approved by the Ethical committee of the Ghent University Hospital. Informed consent was 
obtained from all participants. 
Measures 
Sexual desire was measured using the Dutch version of the Sexual Desire Inventory[11]. This self-
report questionnaire contains 14 items. Subscales measure the intensity and frequency of the 
desire to behave sexually with a partner (dyadic sexual desire) or by oneself (solitary sexual 
desire). For the frequency-items, participants chose one out of seven options. For the strength 
items, participants scored their sexual desire on a 9-point Likert scale ranging from 0 (no desire) 
to 8 (strong desire). The participants were asked to take the previous month as a reference. 
Adding items resulted in a score for dyadic and solitary sexual desire. Higher scores indicate a 
higher level of sexual desire with a maximum score of 62 for the dyadic subscale and 23 for the 
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solitary subscale. The Sexual Desire Inventory has a good reliability and validity[11]. Internal 
consistency in the present study population was high (Cronbach’s α=0.89). 
Other items concerning sexual desire and sexual functioning in the past month were added: 
frequency of experiencing sexual desire, frequency of experiencing sexual desire towards their 
partner, frequency of sexual activities, frequency of masturbation (5 point Likert-scale from not 
at all to daily), current sexual desire compared  to after sex reassignment (5 point Likert-scale 
from much higher to much lower), frequency of experiencing excessive sexual desire (5 point 
Likert-scale from almost never to almost always), time one can live without any sexual activities  
(9 point Likert-scale from always to less than a day), sexual satisfaction with the current partner 
(5-point Likert scale from very unsatisfied to very satisfied, or not applicable). 
Biochemical determinations 
Venous blood samples were obtained between 0800 and 1200 h after overnight fasting, due to 
practical reasons regardless of the timing of T administration. All blood samples were stored at -
80 °C until batch analysis. Commercial kits for Radio-Immuno Assay (RIA) were used to 
determine the serum concentrations of  total T and sex hormone binding globuline (SHBG) 
(Orion Diagnostica, Espoo, Finland); Luteinizing hormone (LH) (electrochemiluminiscence 
immunoassay (ECLIA); Modular, Roche Diagnostics, Mannheim, Germany.  Intra- and 
interassay coefficients of variations were less than 10 en 15% for all measurements respectively. 
For all measurements, samples from female-to-male transsexual persons were assayed in a same 
assay run. Serum free T was calculated from the total serum hormone concentration, serum 
SHBG and serum albumin, using a validated equation derived from the mass action law[15]. We 
defined supra- and subphysiological levels of T and LH as hormone levels exceeding the upper 
or lower limit of the reference ranges according to values of our local laboratory.  
Statistical analysis  
The normal distribution of all variables was tested by the Kolmogorov-Smirnov one-sample test. 
Normally distributed variables were described in terms of mean and standard deviation and 
skewed variables in terms of median, first and third quartiles. Kruskall Wallis tests were used to 
determine differences in the hormone levels according to type of T treatment and to determine 
differences in sexual desire between female-to-male transsexual persons, male-to-female 
transsexual persons and community dwelling men. ANOVA was used to explore associations 
between hormonal levels (T, free T and LH) and measures of sexual desire. Post hoc analyses 
were performed by LSD tests. Mann Whitney U tests were used to test differences in sexual 
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desire between participants with T levels above the P75 and below P25, participants with supra 
or sub physiological levels of T and the rest of the group. 
All hypothesis tests were two-sided. The level indicating statistical significance was 0.05. Internal 
consistency within a set of items was assessed through Cronbach’s alpha metric. Statistical 
analyses were performed using PASW (version 18, 0; SPSS Inc., Chicago, IL). 
RESULTS 
Patient Characteristics 
Patient characteristics are summarized in Table 1. 
Twelve participants reported one or more chronic disease(s): autoimmune hypothyroidism 
(n=3), hypercholesterolemia (n=2), obesity (n=2), hypertension (n=3), liver function problems 
(n=2), epilepsy, migraine, colitis ulcerosa, psoriasis, Graves’ disease, chronic fatigue syndrome, 
unspecified disease (n=1).   
Table 1.  Patient  characteristics 
 Mean (S.D.) Range 
 
Age (years) 
Age at time of SRS (years) 
Height (cm) 
Weight (kg) 
BMI (kg/m²) 
Active smoking (%) 
Stopped smoking (%) 
Use of testosterone therapy (%) 
Duration of Ttherapy (years) 
37 (8.17) 
30 (7.68) 
165.11 (6.73) 
69.17 (12.04) 
25.33 (3.88) 
37 
34.8 
100 
9.42 (5.82) 
22-54 
16-44 
147.4-183.9 
45.0-98.5 
18.3-34.0 
28 
 
 
3.0-27.0 
 
Sexual desire and sexual functioning 
All but four participants completed the Sexual Desire Inventory. In two questionnaires one item 
was missing, we inserted there the personal mean of the other items of this subscale. The 
majority of the participants mentioned an increase in sexual desire after SRS: 38.6% (n=17) 
described the current sexual desire as much higher; 34.1% (n=15) as higher. In contrast, 25.0% 
(n=11) described no change in sexual desire after SRS and one participant mentioned a decrease 
in sexual desire. One participant was not willing to answer this question. Most participants 
masturbated after SRS. Sixty percent expressed to masturbate weekly or daily. A quarter 
expressed to masturbate once or twice a month. A minority masturbated less than monthly 
(4.4%) or not at all (11.1%). Frequency of masturbation was strongly correlated with solitary 
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(r=0.803; P<0.001) and dyadic sexual desire (r=0.466; P=0.001). Up to one third (32.1%) of the 
participants currently in a relationship reported to have sexual intercourse several times a week. 
Almost half of the participants (48.1%) reported to have sexual intercourse once or twice a 
month. Twenty-two percent of the participants were not sexually active with their partner in the 
past month. Frequency of sexual intercourse was not correlated with either dyadic (r=0.201; 
P=0.315) nor solitary sexual desire (r=0.204; P=0.307). Sixty-four percent of the participants 
currently in a relationship expressed their satisfaction with their sexual life, 18% remained 
neutral, whereas 18% expressed to be (very) unsatisfied. Comparison of female-to-male, male-to-
female transsexual persons and community dwelling men shows a difference in dyadic sexual 
desire (Kruskal-Wallis test; P<0.001) but not in solitary sexual desire (Kruskal-Wallis test; 
P=0.074). Further analysis shows that female-to-male transsexual persons score significantly 
higher on solitary and dyadic sexual desire compared to male-to-female transsexual persons but 
score similarly as community dwelling men. 
 
Figure 1. Sexual desire scores. Dark green square: dyadic sexual desire; Light green square: 
solitarysexual desire. * Mann-Whitney U test between female-to-male transssexuals and 
community dwelling men or male-to-female transsexuals 
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Hormonal data 
As expected, the time between the last T administration and the date of visit was significantly 
different according to the type of T replacement therapy (P < 0.001). Consequently further 
ANOVA analyses were corrected for this parameter. We could not detect a statistical difference 
in the levels of total T, calculated free T, LH and hematocrit between groups based on the type 
of T replacement therapy (Table 2).   
Testosterone treatment in female-to-male transsexual persons aims at T concentrations in the 
normal physiological T range for men. At the time of measurement, almost nine percent (8.9%) 
had levels below the reference values of our laboratory (T < 321 ng/dl), whereas 26.7% 
exceeded the upper limit of 1005 ng/dl. All participants with T values below 321 ng/dl were 
treated with classical T esters. No difference was observed in type of T therapy in participants 
with T above the upper limit. 
Table 2. Serum hormone levels according to the  type  of  testosterone replacement therapy  
 
T undecanoate 
1000 mg 
N=7 
Parental Testers 
250 mg 
N=32 
Transdermal T 
gel 
N=6 
P* 
Reference 
values ** 
 
T (ng/dl) 
Mdn 
IQR 
 
Free T (ng/dl) 
Mdn 
IQR 
 
SHBG (nmol/l) 
M 
SD 
 
LH (U/L)    
Mdn 
IQR 
 
Hematocrit (%) 
M 
SD 
 
 
878.9 
527.1-1161.0 
 
 
20.1 
13.8-30.2 
 
 
31.0 
8.9 
 
 
6.8 
0.1-17.5 
 
 
48.5 
2.2 
 
549.75 
393.9-1033.2 
 
 
13.5 
8.1-25.5 
 
 
31.0 
11.9 
 
 
3.5 
0.44-28.4 
 
 
49.0 
2.8 
 
807.7 
574.4-1405.5 
 
 
20.7 
15.7-38.2 
 
 
30.8 
11.8 
 
 
20.5 
0.4-49.1 
 
 
46.1 
2.4 
 
0.11 
 
 
 
0.11 
 
 
 
0.91 
 
 
 
0.50 
 
 
 
0.078 
 
321-1005 
 
 
 
6-25 
 
 
 
16-61 
 
 
 
1-9 
 
 
 
39.8-52.2 
Note. IQR: interquartile range; M: mean; Mdn: median; SD: standard deviation                                      
To convert T and FT to nanomoles per liter, multiply by 0.0347. 
 *Kruskall-Wallis test ** Reference values based on males values at local laboratory 
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Association between sexual desire and hormonal levels. 
No associations were found between levels of free T and solitary or dyadic sexual desire using 
ANOVA after correction for the type of T replacement therapy and time since last T 
administration (Testosterone undecanoate 1000 mg: P=0.885; Parental testosterone esters 
250mg: P=0.316; Transdermal testosterone gel: P= 0.709). 
Also, no significant associations were observed between total T and solitary or dyadic sexual 
desire (data not shown). We found no differences in measures of solitary or dyadic sexual desire 
between participants with total or free T levels below P25 and higher than P75 (Mann Whitney 
U test; TT: P=0.30; P=0.60 FT: P=0.24; P=0.40). Also, no differences were observed in 
measures of sexual desire between participants with supra or sub physiological T levels in 
comparison with T levels within the normal range (data not shown).  
Supraphysiological LH levels are assumed to reflect inadequate hormone therapy while 
suppressed levels indicate an excess of sex hormone substitution. Hence, we explored the 
associations between sexual desire scores and LH by ANOVA: this shows an independent 
association of LH on solitary and dyadic sexual desire after adjustment for age and weight (P< 
0.001; P=0.024 respectively). 
Post hoc analysis showed that female-to-male transsexual persons with low LH levels have 
significantly higher levels of solitary sexual desire than participants with higher LH levels (Figure 
2). Participants with LH levels above P75 reported a significantly lower solitary sexual desire than 
those with LH levels below P25, but a similar level to those with LH levels within the P25-P75 
range. Post hoc analysis for dyadic sexual desire demonstrated only a significant difference 
between those with LH levels above P75 and P50-75 (P=0.046) and below P25 and P50-75 
(P=0.011). 
LH levels were also inversely associated with a higher frequency of experiencing excessive sexual 
desire (ANOVA; P= 0.007). Post hoc analysis showed that participants with LH levels below 
P25 reported more frequent excessive sexual desire than participants with LH levels between 
P25-50 (LSD; P= 0.001) or LH levels above P75 (LSD; P= 0.001). LH levels were also inversely 
associated with a shorter time of being able to live without any sexual activities (ANOVA; 
P=0.009). Participants with LH levels below P25 reported having a higher need of sexual 
activities than those with LH levels between P50-75 (LSD; P= 0.004) or LH levels above P75 
(LSD; P= 0.005). 
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DISCUSSION 
Almost three quarters of our participants mentioned an increased sexual desire after SRS. This 
could be attributed to many changes associated with a sex reassignment procedure: improvement 
in general well being due to relief of gender dysphoria, T therapy, or more satisfactory sexual 
relationships after SRS. Furthermore, the majority of the participants currently in a relationship 
reported a satisfactory sexual life. These findings are in line with previous studies who generally 
found an improvement in sexual functioning after SRS[7; 9-10; 14].  
To our knowledge, this is the first study investigating sexual desire in female-to-male transsexual 
persons using a validated questionnaire. We found a correlation between the desire to behave 
sexually by oneself (solitary sexual desire) and frequency of masturbation, but no relation 
between the desire to behave sexually with a partner (dyadic sexual desire) and frequency of 
sexual activities with a partner. Female-to-male transsexual persons experience significantly 
higher frequency and intensity of sexual desire than male-to-female transsexual persons, a finding 
also reported in literature on sexual desire differences in biological men and women[16-17]. The 
higher level of androgens after sex reassignment in comparison with male-to-female transsexual 
persons might be one explanation for this finding. However, many biological, psychological as 
well as socio-cultural factors have been proposed to explain gender differences in sexual desire 
and motivation[18-19].  
With regard to the hormonal levels, we observed no statistical differences between the levels of 
total T, calculated free T, LH and hematocrit according to the type of T replacement therapy. 
However, borderline significance is observed for (free) testosterone and hematocrit. The 
differences in sample size according to the type of T therapy as well as the limited power of this 
study should be considered in this regard. Almost 9% of our participants reached the cut off 
levels of hypogonadism. This finding can be explained as blood sampling was performed 
regardless of the moment of last administration of T (Testosterone undecanoate 1000mg 
median: 37 days, range: 1-97 days; Parental testosterone esters 250 mg median: 9 days, range: 1-
30 days). However, the higher LH levels measured in these participants indicate the need to 
optimally adjust T dosage. In contrast, more than a quarter of our participants exceeded the 
upper limit of 1008ng/dl.  
In this study, we could not establish a direct association between sexual desire and T levels in 
female-to-male transsexual persons. However, we found an inverse association between solitary 
sexual desire and LH levels. Similarly, Van kesteren et al.[20] observed in their study on the effect 
of sex steroid treatment on bone health of transsexual persons that LH was a more adequate 
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indicator than the levels of sex steroids themselves. Inadequate T therapy, as indicated by high 
LH levels were associated with lower levels of solitary sexual desire compared to participants 
with low LH levels, but not than those with LH levels within the normal range. Participants with 
LH levels below P25 (all below the lower limit of our laboratory indicating an excess of T 
replacement therapy) scored significantly higher on solitary sexual desire than those with LH 
levels within the normal range. Furthermore, participants with LH levels below P25 reported 
more often an excessive sexual desire and a having greater need of sexual activities than the 
others.  
The reasons for not establishing a direct association between sexual desire and T in female-to-
male transsexual persons could be multiple. First, the differences in sample size between the 
types of T therapy in our participants could have hampered finding a relation, especially 
considering the relatively small sample size. Second, the response to T supplementation may 
differ individually[21-22], further complicating finding an association. Third, several studies have 
indicated that T levels above a certain threshold value of T do not have a significant impact on 
sexual functioning[23-26]. Fourth, serum androgen levels are only one aspect in the androgen 
cascade. Other factors, such as genetic variation of the transcriptional activity induced by the 
androgen receptor may modify T action[27-28]. 
Hormonal therapy in female-to-male transsexual persons aims at T levels within the normal male 
physiological range[29]. Adequate hormone therapy in female-to-male transsexual persons is 
needed to maintain for instance bone mass[20,30]. However, supraphysiological doses of T 
increases the risk of adverse effects as erythrocytosis and liver dysfunction[31]. Notably, the 
findings of our study reveal the importance of adequate T therapy for a satisfactory sexual life 
since suppressed LH levels are associated with increased frequency of excess of sexual desire and 
higher LH levels with lower measures of sexual desire. Further investigation of these 
observations in larger prospective samples are needed to confirm our findings as well as 
investigating the clinical relevance of experiencing high or low levels of sexual desire, as could be 
indicated by the levels of distress. 
Certain limitations of this study should be noted. First, the power of this study was limited, 
despite the fact that we were able to study a substantial number of female-to-male transsexual 
persons. Secondly, the cross sectional design implies that no causal relations could be drawn. 
Third, we could only establish a difference in sexual desire between participants with LH below 
P25 and the others. We found no difference between participants with LH levels above P75 and 
LH levels between P25-50 and P50-75. However, the high variance in sexual desire scores in the 
 220 
group with LH levels above P75 as well as the limited power of this study should be considered. 
Also, selection bias of our study is another possible limitation. As in all follow-up studies, 
participants who agreed to this study may have a more favourable outcome than those who 
refused to participate. Nevertheless, the response rate is relatively high with 64% of those 
contacted willing to participate in a study that required a full day hospital visit. Finally, sexual 
functioning after SRS is partly dependent on the quality of and satisfaction with surgery which 
hampers generalization to all centers.  
In conclusion, the data of the current study indicate the majority of the participants reported an 
increase in sexual desire after cross sex hormone treatment and SRS. No direct associations 
between levels of T and measures of sexual desire were found. However, measures of sexual 
desire were inversely associated with LH levels.  
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Chapter  4. QUALITY OF LIFE 
4.1 Quality of life in trans persons: a  case control study. 
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ABSTRACT 
In this cross-sectional study, we (1) compared the quality of life (QoL) of trans individuals 
during and after sex reassignment with an age- and sex-matched control population and (2) 
investigated the predictors of QoL in trans persons. Participants included 352 adults diagnosed 
with gender dysphoria (214 natal males, 138 natal females) who were treated at the Ghent 
University Hospital in Belgium. QoL was assessed with the SF-12 questionnaire. Possible 
predictors of QoL included age, sex, sexual orientation, partnership and parenthood status, 
education, employment, income, satisfaction with hormonal and surgical treatments, SRS, 
phalloplasty, erection prosthesis, facial feminization surgery, breast augmentation surgery, and 
occurrence of surgical complications. We found that trans women had lower physical and mental 
functioning scores compared with age-matched male and female counterparts, even after 
correcting for socio-economic status. Similarly, trans men had lower mental functioning scores, 
but not physical functioning scores, compared with control individuals after correcting for socio-
economic status. Multivariate regression analysis revealed that hormonal treatment satisfaction 
and employment status were independent positive predictors of physical and mental functioning 
in trans women and men. In trans women, having children and undergoing vaginoplasty were 
negative predictors of physical functioning, whereas facial feminization surgery was a positive 
predictor of mental functioning. In trans men, having children was another independent positive 
predictor of mental functioning. Therefore, these predictors should be considered within efforts 
to enhance QoL among trans individuals. 
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INTRODUCTION 
Gender dysphoria refers to the incongruence individuals experience between their assigned sex 
and their gender identity—the sense one has of being male, female, or in between—which causes 
extensive personal distress. Characteristic symptoms include strong and persistent cross-gender 
identification and a sense of inappropriateness toward one’s gender. Therapeutic approaches to 
gender dysphoria may include psychotherapy or counseling, cross-sex hormone therapy, and 
surgery[1]. 
Quality of life (QoL) is an individual’s perception of their position in life in the context of the 
culture and value systems in which they live and in relation to their goals, expectations, 
standards, and concerns. In health care, QoL is often measured to determine how an individual's 
well-being is affected by a disease or condition and its treatment. Little information is currently 
available on how QoL differs between trans persons and the general population. In general, QoL 
in trans persons has been found to be poorer than that compared with control groups of the 
general population[2-5]. However, none of these studies corrected for age, gender, or socio-
economic status, which are well-known determinants of QoL in the general population [6-7], 
thereby possibly introducing a bias. Yet, a good comparison between trans persons and the 
general population is required to inform health care providers, policy makers, and the general 
public about the needs of the trans population. 
Most research on self-reported QoL shows that trans persons who receive cross-sex hormone 
therapy [2, 8-9] facial feminization and genital surgery[5,10] had better QoL scores compared to those 
who did not receive these therapies. QoL refers to the general well-being of individuals and 
includes many aspects such as emotional, social and physical functioning. Apart from these 
clinical factors, QoL in trans individuals may also be related to other determinants such as social 
and economic factors. Some of these determinants have only recently been explored in the group 
of trans persons. Overall, most studies show that better employment status, social status, and 
social support are associated with higher QoL scores [8-10]. A better understanding of the 
strongest predictors of QoL in trans persons can help health care providers and policy makers 
utilize resources more effectively. However, this information is scarce and only available from 
trans individuals before sex reassignment surgery [8-9]. 
Thus, the aims of this study were two-fold: (1) to compare QoL between trans individuals and a 
control population after correcting for age, gender, and socio-economic status and (2) to 
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investigate the contribution of clinical and general determinants of QoL in trans persons after 
cross-sex hormone therapy and/or sex reassignment surgery.  
METHODS 
Study Population  and study procedures 
All persons who were diagnosed with gender dysphoria/transsexualism (Diagnostic and 
Statistical Manual of Mental Disorders-5, 302.85/ International Classification of Diseases, 10th 
revision, F64.0), treated at the Center for Sexology and Gender problems at the Ghent 
University Hospital (Ghent, Belgium) between January 1986 and June 2012, and who used cross-
sex hormones for at least 3 months were invited to participate in this study. Respondents 
received a paper version of the questionnaire by post or could choose to complete the survey on-
line. A reminder message was sent to non-responders. All survey responses were collected 
between August and December 2012. Our response rate was 54% (51% for trans women, 58.7% 
for trans men), with a final total of 352 participants (214 trans women, 138 trans men) (Figure 1).  
Participants were 41 years old on average (range: 18-86 years). Some trans women were not on 
estrogen therapy due to previous thromboembolic events (N=5), dissatisfaction (N=2), or other 
reasons (N=3), but the majority of trans women had been on hormonal therapy for a median 
duration of 7 years (range: 3 months–35 years). Cross-sex hormonal therapies were transdermal 
estradiol (17-β estradiol gel, 1.5 mg/24 h;  (N=76, 35.5%), estradiol patch (50 µg/24 h;  N=29, 
13.6%), or daily intake of oral estrogens (estradiol valerate, 2 mg; N=91, 42.5%), estriol (2 mg; N 
=1, 0.4%), ethinyl estradiol (50 µg; N=2, 0.9%), or oral contraceptives (N = 5, 2.3%). Among 
trans women, 139 (65%) underwent sex reassignment surgery (SRS; orchidectomy, penectomy, 
and vaginoplasty), 60 (28%) were planning for this surgery, 4 (1.8%) were in doubt, and 11 (5%) 
did not want surgery or did not undergo surgery for medical reasons. About half of the trans 
women (53.5%) underwent breast augmentation, 17.8% underwent vocal cord surgery or cricoid 
reduction, and 21.5% underwent facial feminizing surgery 
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Figure 1. Subject enrollment 
Trans men had been on testosterone replacement therapy for an average of 9.4 years (range: 3 
months–49 years). Cross-sex hormonal therapies were intramuscular testosterone treatment with 
a mixture of testosterone esters (testosterone decanoate, 1000 mg; testosterone isocaproate, 60 
mg; testosterone fenylpropionate, 60 mg; and testosterone propionate, 30 mg/ml; treatment 
every 2 or 3 weeks; N = 64, 46.4%), testosterone undecanoate (1000 mg for12 weeks; N = 62, 
44.9%), transdermal testosterone (50 mg/24 h; N = 9, 6.5%), or oral testosterone undecanoate 
(N = 2, 1.4%). Among trans men, 119 (86%) underwent hysterectomy/oophorectomy, 76 
(59.4%) underwent phalloplasty, and 9 (0.06%) underwent metaidioplasty, 8 of whom 
subsequently underwent phalloplasty. Forty-eight (63%) trans men who underwent phalloplasty 
had an erection prosthesis implanted. 
For both trans men and women, we used age-matched (± 3 years) female and male control 
subjects to compare QoL scores. These subjects were randomly selected (3 control men and 3 
control women for each patient) and were recruited from Sexpert, a population based study on 
sexual health in Flanders. Methods of this study are extensively described elsewhere[11].  Briefly, 
control individuals were recruited from a population (range: 14–80 years of age) who completed 
a survey containing extensive information on sexual health characteristics and biomedical, 
Total gender dysphoria patients 
treated with ≥ 3 months of cross-
sex hormones (N=665) 
Trans men 
(N=236) 
Trans women 
(N=429) 
Trans men 
(N=235) 
Trans men 
(N=420) 
Deceased 
(N=1) 
Deceased 
(N=1) 
No contact 
(N=35) 
No contact 
(N=66) 
Not willing to 
participate 
(N=62) 
Not willing to 
participate 
(N=140) 
Trans men 
(N=138) 
Trans men 
(N=214) 
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psychological, demographic, and socio-cultural correlates. Control data were collected between 
February 2011 and January 2012. The final database consists of 1832 respondents (response rate: 
40% of eligible respondents). Respondents were randomly drawn from the Belgian National 
Register. All data for this study were collected from face-to-face interviews and a combination of 
computer-assisted personal interviewing and computer-assisted self-interviewing. Both studies 
were approved by the ethical review board of Ghent University Hospital in Belgium, and all 
participants gave informed consent for participation in this study. 
Outcome measures 
Physical health and incidence of possible treatment related adverse events 
Medical history, medication use, smoking habits, weight, height, current and past hormonal 
treatment and clinical adverse events were addressed by a specifically designed questionnaire.  
Sociodemographic variables 
Information on age, sexual orientation (five-point scale from only attracted to men to only 
attracted to women or other), marital status, educational level (ISCED codes), employment 
status, and household income was collected. All participants were asked whether they were 
currently involved with a partner (yes/no) and the length of the relationship. Participants were 
also asked whether they had children (yes/no) and to describe the method of conception for 
each child. 
Health-related quality of life 
QOL was measured using the SF-12, a brief 12-item version of the Short Form-36 Health 
Survey (SF-36). All items had fixed response choices and were organized into two sections 
(physical functioning and mental functioning), with scores based on the weighted sums of 
responses (1–100) in each section. Participants were asked to answer the questions based on 
their experiences within the previous month. Higher scores indicate higher levels of functioning 
or well-being[12]. Internal consistency for the SF-12 was high (total group: Cronbach’s α = .8). 
Surgical results       
Participants evaluated their satisfaction with the outcome of transition-related surgical 
procedures using a five-point scale from very unsatisfied to very satisfied. Trans men were asked 
whether they experienced complications related to metaidioplasty, phalloplasty, or implantation 
of an erection prosthesis (yes/no). Trans women were asked whether they experienced 
complications related to vaginoplasty (yes/no). 
Statistical analysis 
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Continuous variables were expressed as mean and standard deviation (SD) or median (first to 
third quartile) when criteria for normal distribution were not fulfilled. Qualitative variables were 
expressed as percentages. Comparisons of linear variables between groups were performed using 
independent Student’s t-tests (parametric) or Mann-Whitney U tests (non-parametric). 
Dichotomous and categorical variables were analyzed using chi-square tests. Internal consistency 
within questionnaire scales used was assessed using Cronbach’s α. Univariate associations with 
QoL scores were determined by one-way analysis of variance (ANOVA). Multiple linear 
regression analysis was performed to determine which variables were independently associated 
with mental and physical functioning scores. Variables were included in the regression model 
based on their clinical interest and association with QoL in the univariate analysis (age, genital 
surgery, surgical satisfaction, hormonal treatment satisfaction, facial feminization surgery, 
partnership status, having children, educational level, and income). In Figure 3, bars represent 
means, and whiskers indicate 95% confidence intervals. Statistical significance was set at p < .05, 
and all tests were two-tailed. Data were analyzed using SPSS software, v.21 (SPSS Inc., Chicago, 
IL). 
RESULTS 
General characteristics 
General characteristics of the study population are described in Table 1. About half of trans 
women (47.7%) were mainly attracted to females, 36% were mainly attracted to males and 11.2% 
were equally attracted to females and males. Majority of trans men (81.8%) were mainly attracted 
to females, 10.2% were mainly attracted to males and 6.5% were equally attracted to females and 
males. 
Treatment satisfaction  
Most trans women (79.8%) were very satisfied or satisfied with vaginoplasty, whereas some 
(8.3%) were unsatisfied or very unsatisfied. Some (16%) also experienced one or more 
complications after vaginoplasty. Satisfaction with vaginoplasty was negatively associated with 
the occurrence of complications (p < .001). Almost all trans men were very satisfied with 
hysterectomy and ovariectomy. The vast majority (84.9%) who underwent phalloplasty were very 
satisfied or satisfied, although many (54.7%) reported having one or more postoperative 
complications. Over half of trans men who received an erection prosthesis (57.4%) felt very 
satisfied or satisfied, whereas nearly a quarter (24.1%) were very dissatisfied or dissatisfied. A 
third (33%) experienced one or more postoperative complications. Occurrence of phalloplasty- 
or erection prosthesis-related complications was negatively associated with surgical satisfaction (p 
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< .001 and p = .001, respectively). In both trans women and men, satisfaction with hormonal 
therapy was high (78% vs. 87.7%), but trans women were more often dissatisfied with hormonal 
therapy than trans men (9.8% vs. 2.1%, p = .002). We observed no association between type of 
hormonal therapy and treatment satisfaction (data not shown). 
Table 1.  General characteristics of the study population 
 
Trans women 
(N=214) 
Trans men 
(N=138) 
P 
 
Age at time of study (years) 43.7 ± 12.6 37.5 ± 11.0 <0.001 
Nationality(%) 
Belgian 
Other 
86.0 
14.0 
87.0 
12.5 
NS 
Civil status (%) 
               Married/living together        
               Not married or living together 
               Divorced 
               Widow 
 
36.0 
36.4 
25.2 
2.3 
 
44.5 
47.4 
8.0 
0 
<0.001 
Children (%) 
                Children born before HRT (%) 
41.1 
81.8 
23.9 
36.0 
<0.001 
<0.001 
Work status (%) 
                Unemployed 
                Employed 
                Retired      
                Student 
                Unable to work 
                Household 
14.2 
55.9 
9.5 
5.2 
13.7 
1.4 
9.4 
64.5 
1.5 
13.0 
9.;4 
2.2 
 
 
0.001 
 
 
 
 
Monthly income (%) 
                ≤999 euro 
                1000-1999 euro 
                2000-2999 euro 
                3000-5999 euro 
                ≥ 6000 euro 
10.3 
42.2 
27.5 
16.7 
3.4 
 
14.2 
35.8 
24.6 
23.9 
1.5 
NS 
SRS (%) 64.8 85.5 <0.001 
Time since SRS (years) 6.0 [2-11] 7.0 [4-13] NS 
Duration of HRT (years) 6.0 [3-11] 7.0 [4-13] 0.02 
Mental functioning 58.4 ± 14.8 60.8 ± 14.3 0.11 
Physical functioning 71.5 ± 23.6 78.3 ± 21.5 0.003 
Data are presented as %, medium ± s.d. or median (first to third quartiles). Categorical variables using Chi square 
test; Continuous variables using independent student T test or Mann-Whitney-U test. NS: not significant; SRS: sex 
reassignment surgery (defined as orchidectomy/penectomy/ vaginoplasty in trans women and 
hysterectomy/ovariectomy in trans men)  
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Quality of life compared to age-matched control population 
Trans men and women were less likely to be involved in a relationship, less likely to be 
employed, and had lower incomes than age-matched male and female control counterparts 
(p<.001). No difference in educational level was observed between trans and control individuals 
(data not shown). Compared to control men and women, trans women had lower physical and 
mental functioning scores (p < .001) (Figure 2AB), even after adjusting for age, partnership 
status, having children, employment status, educational level, and income (physical functioning: p 
< .001, βst = .21 (control men) and p = .003, βst = .13 (control women); mental functioning: p 
< .001, βst = .54 (control men) and p <  .001, βst = .30 (control women)). 
Physical functioning scores for trans men were similar to those for control women but lower 
than those for control men (p = .003) (Figure 2C). Trans men had lower mental functioning 
scores compared with those for control women and men (ps < .001) (Figure 2D). After adjusting 
for age, partnership status, having children, employment status, educational level, and income, 
trans men had lower mental functioning scores but not physical functioning scores compared to 
control men and women (physical functioning: p = .2, βst = .06 (control men) and p = .6, βst = 
-.04 (control women); mental functioning: p < .001, βst = .50 (control men) and p < .001, βst = 
.24 (control women)). 
 
Physical functioning Mental functioning 
 
Figure 3A and 3B. Physical and mental functioning of trans women compared to control 
population. Bars represent mean and 95% confidence interval. p value result from post-hoc 
ANOVA. 
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Physical functioning Mental functioning 
 
Figure 3C and 3D. Physical and mental functioning of trans men compared to control 
population. Bars represent mean and whiskers 95% confidence interval. P value result from post-
hoc ANOVA. 
Univariate associations with general and clinical determinants of QoL in trans persons 
The results of univariate analysis are presented in Table 2.  
Among all trans individuals, physical functioning scores were negatively associated with age and 
positively associated with educational level. Employment status and higher household incomes 
were positively associated with physical and mental functioning scores. Participants who lived 
with a partner had higher mental functioning scores than those who did not live with a partner. 
For trans men, having children was positively associated with mental functioning scores, whereas 
no such association was found for trans women. Having undergone SRS was associated with 
lower physical functioning scores. When only trans persons who had undergone SRS more than 
1 year ago were included, this association was no longer statistically significant (F = 3.3, p = .07). 
Trans women who underwent breast augmentation or vocal cord surgery had similar  
QoL scores compared with those who did not undergo surgery (data not shown). Facial 
feminization surgery was associated with higher mental functioning scores (F = 4.4; p = .04). 
Trans men who underwent phalloplasty had higher physical and mental functioning scores (F = 
5.8, p = .02 and F = 4.6, p = .03, respectively). Phalloplasty-related complications were 
negatively associated with mental functioning scores (F = 6.5, p = .001). Also, trans men with an 
erection prosthesis had a tendency toward higher mental functioning scores (F = 3.3, p= .07). 
Erection prosthesis-related complications were not associated with QoL scores (data not shown). 
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Table 2. Univariate   association   between QOL scores and  general and  clinical  determinants  
 Trans women Trans men Total trans sample 
 
Physical 
functioning 
Mental 
functioning 
Physical 
functioning 
Mental 
functioning 
Physical 
functioning 
Mental 
functioning 
Living with partner 
       No  
       Yes  
       F 
Children  
      No  
      Yes 
      F 
Employment 
      No 
      Yes 
       F 
Household Income  
       < mean 
       ≥ mean 
       F 
Sexual orientation 
     Same birth sex 
     Other birth sex 
     Other 
      F 
Satisfaction HRT 
     (very) dissatisfied  
      Neutral  
      (very) satisfied 
      F 
SRS 
      No  
      Yes 
      F 
Complication SRS 
      No  
      Yes 
       F 
Satisfaction SRS 
     (very) dissatisfied  
      Neutral  
     (very) satisfied 
      F 
Duration HRT 
       < 6 years  
       ≥ 6 years 
       F 
Time since surgery 
       < 6 years 
        ≥ 6 years 
       F 
 
71.2 ± 24.1 
72.1 ± 22.7 
0.0 
 
76.1 ± 20.9 
65.1 ± 25.6 
10.0 ** 
 
54.3 ± 26.9 
77.1 ± 18.9 
9.5*** 
 
66.8 ± 25.2 
76.3 ± 20.4 
8.4 ** 
 
72.1 ± 23.7 
67.1 ± 27.5 
73.3 ± 22.3 
0.6 
 
46.5 ± 27.4 
66.1 ± 22.4 
75.0 ± 21.5 
14.1 *** 
 
77.2 ± 17.7 
68.4 ± 25.8 
6.6 ** 
 
70.1 ± 24.9 
66.3 ± 27.0 
0.7 
 
62.5 ± 32.8 
71.7 ± 26.3 
68.4 ± 25.2 
0.4 
 
75.7 ± 20.6 
67.4 ± 25.6 
6.4 * 
 
71.3 ± 24.8 
65.5 ± 26.6 
1.7 
 
57.8 ± 15.1 
59.4 ± 14.1 
0.5 
 
59.2 ± 15.3 
57.3 ± 14.0 
2.7 
 
56.4 ± 16.3 
59.9 ± 13.4 
3.4* 
 
56.7 ± 15.5 
60.1 ± 14.1 
2.5 
 
56.5 ± 14.7 
57.7 ± 16.7 
60.1 ± 13.9 
1.3 
 
45.1 ± 14.1 
51.7 ± 13.6 
60.8 ± 14.0 
12.5 *** 
 
59.2 ± 13.7 
58.0 ± 15.4 
0.3 
 
59.0 ± 15.4 
56.5 ± 15.4 
0.8 
 
52.8 ± 15.6 
52.1 ± 16.4 
59.3 ± 15.0 
2.2 
 
55.7 ± 14.2 
58.1 ± 15.3 
0.0 
 
60.0 ± 14.4 
55.9 ± 16.2 
2.4 
 
75.9 ± 23.2 
81.3 ± 18.9 
2.0 
 
78.8 ± 21.3 
76.9 ± 22.1 
0.2 
 
69.4 ± 25.0 
83.0 ± 17.7 
15.3*** 
 
73.6 ± 23.9 
82.6 ± 17.9 
0.9 
 
78.8 ± 20.6 
69.4 ± 33.2 
78.9 ± 19.5 
0.8 
 
58.3 ± 26.0 
59.9 ± 33.7 
80.7 ± 18.7 
7.0 *** 
 
80.6 ± 18.4 
77.9 ± 22.0 
0.3 
 
85.2 ± 13.3 
79.0 ± 19.8 
2.4 
 
75.0 ± 26.5 
77.1 ± 25.2 
82.0 ± 16.6 
0.5 
 
75.0 ± 24.1 
79.9 ± 20.4 
0.1 
 
78.8 ± 21.8 
77.9 ± 21.4 
1.4 
 
57.8 ± 16.1 
64.5 ± 10.6 
7.8 ** 
 
59.5 ± 14.8 
64.8 ± 11.7 
3.5 ¥ 
 
55.1 ± 15.5 
63.9 ± 12.6 
7.1*** 
 
58.1 ± 15.7 
63.2 ± 12.3 
4.4 * 
 
60.9 ± 14.6 
54.2 ± 15.5 
64.0 ± 9.9 
1.3 
 
47.5 ± 15.6 
51.0 ± 17.2 
612.0 ± 13.4 
4.8 ** 
 
62.1 ± 12.1 
60.6 ± 14.6 
0.2 
 
66.5 ± 12.1 
60.3 ± 13.4 
4.6 * 
 
52.5 ± 17.7 
59.2 ± 15.3 
63.5 ± 12.6 
1.7 
 
58.3 ± 16.1 
62.1 ± 13.5 
0.0 
 
61.1± 14.8 
60.6 ± 14.0 
1.9  
 
72.9 ± 23.8 
76.3 ± 21.4 
1.7 
 
77.3 ± 21.1 
68.4 ± 25.2 
10.8 ** 
 
66.1 ± 26.3 
79.6 ± 18.6 
23.3*** 
 
69.4 ± 24.9 
78.9 ± 19.6 
14.8 *** 
 
76.2 ± 22.1 
67.8 ± 28.6 
73.9 ± 22.0 
1.9  
 
48.2 ± 27.0 
63.8 ± 26.8 
77.4 ± 21.0 
21.9 *** 
 
77.9 ± 17.6 
72.8 ± 24.5 
3.3 ¥ 
 
74.3 ± 23.2 
72.6 ± 24.4 
0.3  
 
73.9 ± 23.1 
73.6 ± 25.6 
66.3 ± 30.5 
0.6 
 
76.8 ± 21.0 
72.1 ± 24.4 
3.5 ¥ 
 
72.8 ± 24.5 
72.8 ± 24.6 
0.0 
 
57.8 ± 15.5 
61.8 ± 12.8 
5.9 * 
 
59.3 ± 15.1 
59.4 ± 13.8 
0.5 
 
55.9 ± 16.0 
61.6 ± 13.2 
9.9 *** 
 
57.3 ± 15.2 
61.4 ± 13.4 
6.6 ** 
 
59.2 ± 14.5 
56.7 ± 16.2 
60.5 ± 13.5 
0.9  
 
45.5 ± 13.9 
51.4 ± 14.7 
61.3 ± 13.8 
18.1 *** 
 
59.8 ± 13.2 
59.2 ± 15.1 
0.1  
 
61.2 ± 14.9 
58.4 ± 14.5 
2.0  
 
61.1 ± 14.2 
54.5 ± 16.1 
52.7 ± 15.5 
3.8 * 
 
59.5 ± 14.5 
59.2 ± 14.8 
0.0 
 
59.3 ± 15.1 
59.1 ± 15.1 
0.0 
One-way anova; *significant at the level p ≤ .05; ** significant at the level p ≤ .01; ** significant at the level p <.001; 
¥ significant at the trend level
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Table 3. Predictive   factors   for   QOL   in t  rans   persons (multivariate regression analysis) 
 Total trans sample Trans women Trans men 
 Physical 
functioning 
Mental 
functioning 
Physical 
functioning 
Mental 
functioning 
Physical 
functioning 
Mental 
functioning 
 
 
 
General determinants 
Age 
Living with partner (yes) 
Children (yes) 
Employed (yes) 
Above mean income  (yes) 
 
Clinical determinants 
Hormonal satisfaction 
SRS (yes) 
 
FFS (yes) 
 
Phalloplasty (yes) 
Erection prosthesis (yes) 
R² = .27 
F = 9.7*** 
βsd 
 
-0.16* 
-0.04 
-0.12* 
0.26*** 
0.13¥ 
 
 
0.32*** 
-0.10* 
 
- 
 
- 
- 
R² = .17 
F = 5.1*** 
βsd 
 
-0.07 
-0.06 
0.04 
0.15* 
0.04 
 
 
0.28*** 
-0.02 
 
- 
 
- 
- 
R² = .27 
F = 8.7*** 
βsd 
 
-0.07 
-0.05 
-0.20* 
0.25*** 
0.12 
 
 
0.29*** 
-0.16* 
 
-0.03 
 
- 
- 
R² = .14 
F = 3.6*** 
βsd 
 
-0.02 
-0.04 
-0.04 
0.08 
0.00 
 
 
0.30*** 
-0.05 
 
0.14¥ 
 
- 
- 
R² = .31 
F = 6.2*** 
βsd 
 
-0.29*** 
-0.02 
-0.05 
-0.30*** 
-0.10 
 
 
0.32*** 
-0.13 
 
- 
 
0.11 
-0.10 
R² = .25 
F = 4.6*** 
βsd 
 
-0.26** 
-0.14 
0.15 
-0.26** 
-0.07 
 
 
0.26** 
-0.14 
 
- 
 
0.16 
-0.03 
β= Standardized beta coefficient; F: F test                                                  
*significant at the level p ≤ .05; ** significant at the level p ≤ .01; ** significant at the level p <.001; ¥ significant at the trend level         
SRS= sex reassignment surgery; FFS= facial feminization surgery 
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Multivariate regression analysis in trans persons 
Results of multivariate regression analysis in total trans sample, trans women and trans men can 
be found in Table 3.  
Among all trans individuals, the regression model accounted for 27% of the variance in physical 
functioning scores and 17% of the variance in mental functioning scores. Employment status 
and hormonal treatment satisfaction contributed to both QoL sub-scores. Age, having children, 
and undergoing SRS were also independent predictors of physical functioning scores. In trans 
men, having children was an independent positive predictor of mental functioning scores. In 
trans women, having children and vaginoplasty were negative predictors of physical functioning 
scores, whereas facial feminization surgery was a positive predictor of mental functioning scores. 
Surgery satisfaction and complication rate were excluded from the model due to an interaction 
with the occurrence of genital surgery. A model including surgery satisfaction or complication 
rate instead of genital surgery showed similar results (data not shown). Surgery satisfaction and 
complication rate were not independent predictors of QoL scores (data not shown). 
DISCUSSION 
This study was designed to improve our understanding of health-related QoL in trans persons 
during and after sex reassignment by (1) comparing QoL between trans persons and an age-
matched population and (2) investigating the main predictors of QoL in trans persons. Our 
findings are consistent with previous studies[2-5] showing lower QoL scores in trans persons 
during and after sex reassignment compared to the general population. We found that trans 
persons had markedly poorer socio-economic status, were less likely to be involved in a 
relationship, were more likely to be unemployed, and had lower income. To evaluate whether 
differences in QoL scores among trans and control populations could be attributed to 
differences in socio-economic status, we corrected our analyses for these variables and found 
that trans men and women still had lower QoL scores.  
Of note, both physical and mental functioning scores were significantly lower in trans persons 
compared with control individuals, but the absolute difference between groups was smaller for 
physical functioning scores than for mental functioning scores. First, although cross-sex 
hormone therapy and SRS induce important physical changes and are associated with side effects 
and/or complications, these drastic outcomes do not seem to considerably affect physical 
functioning in the majority of trans persons. Second, although that sex reassignment therapy 
generally improves mental well-being of trans persons[8; 13-14] trans persons still have lower mental 
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functioning scores after this treatment. Minority stress couls also explain the lower mental 
functioning scores due to social stigma, prejudice, and discrimination in response to gender 
nonconformity. Minority stress includes actual experiences of rejection and discrimination, 
perceived rejection and expectations of being stereotyped or discriminated, and hiding minority 
status and identity out of fear of harm[15-16]. It is indeed reported that the majority of trans 
individuals experienced discrimination and the majority of them even experienced violence 
(verbal (78.9%), physical (26.8%) or sexual (31.6%) because of their gender identity or 
presentation[17-19]. 
Alternatively, trans persons may experience co-existent psychiatric morbidity prior to sex 
reassignment and therefore may be more prone to psychiatric problems after treatment[20-23]. 
However, a recent multi-center European study has shown that mainly affective and anxiety 
disorders were more prevalent in trans persons[23]. The incongruence trans persons experience 
between their gender identity and social life and/or bodily characteristics can cause much 
“dysphoria” that may lead to anxiety and effective problems or even disorders. In addition, the 
phenomenon of minority stress can also give explanation for the increased prevalence of 
affective disorders[23-24].  
Providing a better understanding of the strongest predictors of QoL in trans persons may also 
help health care providers and policy makers utilize resources more effectively. Therefore, we 
investigated the main determinants of QoL in trans persons using a regression model including 
both clinical and socio-demographic determinants. We found that hormonal treatment 
satisfaction and employment status were independent predictors of QoL in both trans women 
and men. To the best of our knowledge, previous studies have not investigated the main 
predictors of QoL in trans persons after SRS. However, two previous studies that assessed 
predictors of QoL in trans persons before SRS[8-9] report that hormonal therapy was an 
independent predictor of QoL. As almost all our respondents were on hormonal therapy, we 
were unable to investigate this hypothesis, but our findings seem to confirm the importance of 
hormonal therapy on the QoL of trans persons, even after SRS. Indeed, a recent prospective 
study also showed that cross-sex hormonal treatment is associated with better mental health in 
both trans men and women as lower levels of anxiety, depression, psychological symptoms and 
functional impairment were reported after 12 months of hormonal therapy[24]. Cross-sex 
hormone therapy is an essential part of the medical treatment of trans persons and induces body 
features and shape of the desired gender, which results in a reduction of self-reported distress[25]. 
Besides inducing physical changes, the act of using cross-sex hormones is itself an affirmation of 
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gender identity. In addition, many trans persons change gender role around the time of starting 
hormonal therapy, which could also improve social and mental functioning[24]. Our results show 
that not only the initiation of cross-sex hormone therapy but also satisfaction with the outcome 
of hormonal treatment is important for QoL. Trans persons who were more dissatisfied with 
their hormonal therapy might be less satisfied with their body changes or more likely to have 
experienced bothersome side effects, which could reduce mental and physical functioning. 
Therefore, further investigations of the predictors of hormonal treatment satisfaction, such as 
body image, expectations of hormonal effects and the experience and severity of side effects, is 
of clinical interest.  
Depression[8] as well as family support and working status[9] were previously found to be 
independent predictors of QoL in trans persons. Diagnosis of depression and strength of social 
support were not considered in our study, but we did observe an impact of family structure on 
QoL. Specifically, parenthood negatively affected QoL in trans women but positively affected 
QoL in trans men. A possible explanation for this finding may be that the majority of children of 
trans women (82%) were conceived before sex reassignment therapy, whereas the opposite was 
true for trans men (36%). As it is well-known that trans men present themselves at a younger age 
than trans women[27-28], our finding may thus reflect higher numbers of familial difficulties 
encountered by trans women due to sex reassignment treatment.  
In line with previous studies, we observed that employment status was an independent predictor 
of both physical and mental functioning. For instance, Motmans et al. (2012)[10] also found that 
trans persons who were employed had better general health, less bodily pain, greater physical 
functioning, and fewer role-physical and role-emotional problems. From clinical practice, it is 
known that trans persons experience more problems finding employment than the general 
population, especially during sex reassignment. Therefore, the enhancement of employment 
programs for trans persons may improve their QoL.  
Somewhat unexpectedly, surgical satisfaction and surgical complication rate were not found to 
be independent predictors of QoL scores. However, it should be noted that complication rate 
was only assessed as a binary variable. That is, minor adverse events, such as genital tract 
infections, may have been reported as complications[4] and thus may have influenced our results. 
Thus, other conclusions could have been reached had the severity of complications been taken 
into account. Future studies should take this into account. Also, we found a significant negative 
association between SRS and physical functioning, but this association disappeared after 
excluding trans individuals who had recently undergone SRS. Furthermore, our results 
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concerning mental functioning are in line with our previous survey[10] which showed no 
association between QoL and having undergone SRS, phalloplasty and erection prosthesis. These 
findings may be explained by the fact that many participants, who did not have these surgeries, 
were already planned for these surgeries in the near future. As previously suggested[10], another 
explanation may also lie in the state funded care (genital surgery and breast augmentation are for 
a large part reimbursed in Belgium) and in the quality and experience of caregivers. At our 
center, trans persons receive at least 6 contacts with mental health practitioners during the 
diagnostic phase, contacts that are continued throughout hormone therapy and before and after 
surgery. Surgery is generally performed after two years of cross-sex hormone therapy but this is 
no longer required according to the Standards Of Care[1] and has become more of a personal 
choice.   
In line with Ainsworth and Spiegel (2010)[5], it was found that trans women who underwent facial 
feminization surgery had a better QoL compared to those who did not. We also observed that 
facial feminization surgery was an independent positive predictor of mental functioning. This 
may be due to the better passability of trans women who underwent facial feminization surgery 
and/or improvements in body image and self-esteem. Moreover, better passability was recently 
found to be associated with less experience of violence[19]. 
Strengths of the present study are its relatively large sample size and the comparison of QoL 
between trans individuals and a representative control population after correcting for age, sex, 
and socio-economic status. Also, we were able to investigate predictors of QoL in trans persons 
after SRS. However, our study is hampered by our limited response rate, which may have 
resulted in selection bias, as trans persons who participated in this study may have had a better 
outcome than those who refused. However, compared to other long-term follow-up studies, we 
achieved similar[13] or even better response rate[29]. In addition, the generalizability of our results 
to other centers may be limited considering the availability of surgery and expertise in our center 
and the well-organized health insurance system in Belgium, which covers most of the costs of 
SRS. Another limitation of this study is that we measured only family status but did not examine 
perceived social support, which should be taken into account in future studies. Finally, 
considering our relatively large sample size, we may have found statistically significant results that 
may not be clinically relevant. However, to our knowledge, no information is available indicating 
what changes in QoL can be considered clinically relevant. 
In conclusion, our findings are consistent with the results of most other retrospective follow-up 
studies in that they indicate poorer QOL in trans persons compared with the general population, 
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even after adjusting for key determinants such as age, gender, and socio-economic status. 
Hormonal treatment satisfaction and employment status were the strongest predictors of 
physical and mental functioning of trans persons during and after sex reassignment.
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Chapter  5. SUMMARY OF CONTRIBUTIONS AND GENERAL  
DISCUSSION 
 
Gender dysphoria is a condition in which a person experiences discrepancy between the sex 
assigned at birth and the gender they identify with, leading to extensive personal distress. 
Transsexualism is considered the most extreme form of gender dysphoria and is characterized by 
the wish to undergo treatment to conform to the other sex. Cross-sex hormone therapy is an 
important part of this medical treatment, when desired, and aims to acquire the secondary sex 
characteristics of the desired sex while reducing those of the natal one.  
Besides these effects on secondary sex characteristics, sex steroids are also known to play an 
important role in many other tissues and systems such as muscle, fat, bone, skin, the larynx, the 
immune system, hematopoietic cells, brain cells and the cardiovascular system. This implies that 
cross-sex hormone therapy can induce important side effects. Despite the widespread use of this 
therapy, data concerning its effects and side effects are scarce due to the low prevalence of this 
diagnosis, the small number of subjects treated in each centre, the lack of prospective studies and 
the lack of long-term follow-up studies. In this thesis, we investigated both short- and long-term 
safety of cross-sex hormone therapy in trans women and men. In addition, as treatment related 
QoL is becoming increasingly important, we also examined QoL of trans persons and its 
associations with cross-sex reassignment therapy. 
5.1 Main findings and general discussion 
5.1.1 Short-term effects and safety of cross-sex hormone therapy 
The physical and physiological effects, side effects and adverse events of currently used cross-sex 
hormone therapies in both trans women and men were investigated in the ENIGI study (chapter 
2.1). The main findings of this study were that cyproterone acetate 50 mg daily with estrogen 
treatment (< 45y estradiol valerate 4mg daily and ≥ 45y 17β estradiol patch 100 µg/24h) in trans 
women and injections with T undecanoate 1000 mg every 3 months in trans men, were effective 
and safe therapies. All trans persons acquired adequate sex steroid levels and secondary sex 
characteristics of the desired sex. Importantly, none of the trans participants experienced severe 
adverse events such as cardiovascular events or death. These findings were in line with previous 
reports in trans men, which showed that T treatment was effective and acceptably safe in the 
short-term(290,311). Our results in trans women confirmed those from Dittrich and colleague(297), 
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indicating a low risk for adverse events at short-time follow-up. However, these findings were in 
contrast with earlier reports showing a high incidence of venous thrombosis and/or pulmonary 
embolism during the first year of cross-sex hormone therapy(310-311). This may suggest that current 
treatment modalities in trans women, which avoid the use of high dose EE and use transdermal 
estrogens in older trans women, may induce less detrimental effects on the coagulation system. 
Indeed, it has been previously found that EE induced a more pronounced APC resistance 
compared to other estrogen types(194). In addition, our colleagues in Amsterdam also observed a 
lower incidence of venous thrombosis since the introduction of transdermal estrogens in older 
trans women(311).  
Beside this increased risk for thromboembolic disease, anti-androgen and estrogen therapy may 
induce liver dysfunction and hyperprolactinemia(5). Indeed, our findings corroborate with 
previous studies using other treatment modalities(310-311) showing a risk for transient elevation of 
the liver enzymes and hyperprolactinemia. Importantly, the clinical relevance of these elevations 
during the first year of hormonal therapy seemed limited. Similar as in trans women, a small risk 
for transient elevation of the liver enzymes was found in trans men. In addition, a small increase 
in blood pressure was observed during T therapy as also observed by Mueller and colleagues(290).  
It is known that androgen excess in women is associated with important dermatological effects, 
such as acne vulgaris, hirsutism, and androgenetic alopecia with potentially important 
psychological disturbing effects. As only one study(286), using short-acting T esters, previously 
addressed this topic, we also aimed to investigate dermatological changes during treatment with 
long-acting intramuscular T undecanoate (chapter 2.3). We observed a rather low risk for 
development of androgenetic alopecia but a high risk for acne during the first 12 months of T 
therapy. Both incidence and severity of acne lesions increased during T treatment but most men 
developed only mild acne and none suffered from severe or very severe acne according to the 
Global Acne Grading Scale. Importantly, half our patients initiated acne treatment during this 
study period and showed that, although mild and moderate, these acne lesions are of clinical 
significance. Similar to the observations of Giltay and colleagues(286), we observed that most acne 
lesions occurred within the first 6 to 9 months of treatment, with a decrease at 12 months. These 
results may indicate that the initial increase in sebum production and the associated acne lesions 
resulting from male T levels in biological females, attenuate over time. A wide between-subject 
variability was found which suggests an important variability in PSU responsiveness to androgens 
due to variations in androgen metabolism; for example, variations in 5α reductase activity, 3β-
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hydroxysteroid dehydrogenase activity, aromatase activity, or differences in androgen receptor 
sensitivity. 
Clinicians working with trans persons will acknowledge that many trans persons attribute 
complaints to their hormonal therapy. As this was not addressed in a structured manner in 
previous research, we examined prospectively both the incidence and severity of possible 
hormone-related symptoms in the ENIGI study. The majority of trans men experienced voice 
instability with a peak incidence observed at 6 months, whereas a quarter of them experienced 
clitoral pain, which also peaked at 6 months. Trans men also reported a decrease of emotionality 
and an increase in sexual desire whereas trans women reported the opposite. In addition, many 
trans women experienced breast tenderness and hot flashes. The observed increase in hot flashes 
was somewhat unexpected under estrogen therapy. However, as no validated questionnaires or 
objective measurements were used in this study, further exploration and characterization is 
needed. The exact mechanism of hot flashes is still not fully understood, but it seems that 
complex neuroendocrine pathways involving norepinephrine, E2, T and endorphins are involved 
in regulating the thermoregulatory nucleus at the hypothalamus. Therefore, it may be possible 
that the profound changes in sex steroids levels in trans women also affect these neuroendocrine 
pathways. Whether these hot flashes will diminish over time also needs to be examined. Future 
research may also evaluate possible treatments. 
Finally, in view of recent studies showing an increased cardiovascular mortality in trans 
women(312-313), one of the main aims of this thesis was to investigate possible changes in 
cardiovascular risk factors during cross-sex hormone therapy (chapter 2.1 and chapter 2.2). 
Changes in cardiovascular risk factors during T therapy in men have been previously investigated, 
but most studies had a rather small sample size and used short-acting T esters instead of long-
acting intramuscular T undecanoate, which are more recently marketed. The latter are 
increasingly used as the long intervals make this formulation attractive for T supplementation, 
particularly in these healthy, young persons who will need lifelong treatment. We showed, in line 
with studies using 2 or 3-weekly injections of intramuscular T esters, that this treatment induced 
favourable changes in cardiovascular risk factors including a decrease in total body fat mass and 
an increase in lean body mass. Alternatively, unfavourable changes such as worsening of the lipid 
profile and an android pattern of fat distribution were also induced. Our findings concerning 
glucose metabolism, showing an improvement in insulin sensitivity, contrasts with studies in trans 
men using 2 or 3-weekly injections of intramuscular T esters, showing no changes(300) or a 
worsening in insulin sensivity(301). The beneficial changes in body composition with an increase in 
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muscle mass and a decrease in total body and trunk fat mass in the ENIGI study may be an 
explanation for our findings, even though we were unable to show such a statistical significant 
association in our sample, possibly due to insufficient power. In contrast, others(300) observed an 
increase in visceral fat mass during T therapy. Whether these differences may be related to 
differences in type of T or other factors, remains unknown and needs to be explored in future 
studies. 
In trans women, most evidence concerning changes in cardiovascular risk factors are also based 
on older regimens using high dose cyproterone acetate and high dose EE(295, 300). Given that 
different types and dosages of estrogens can exert different metabolic effects, we aimed to 
investigate changes in cardiovascular risk factors induced by our current treatment modalities. On 
the one hand, we confirmed findings from studies using EE, showing a reduction in LDL 
cholesterol and an increase of total body and trunk fat mass and insulin resistance during the first 
year of cross-sex hormone therapy in trans women(295, 300). On the other hand, in contrast to most 
previous research, we observed no increase in body weight, triglycerides or blood pressure during 
the first year of therapy, which may suggest more favourable changes with these newer 
treatments. However, it is clear that randomized controlled trials are needed in this field to 
compare the benefit and harm of different types of cross-sex hormone therapies, both on 
intermediate and hard clinical end points. 
Of note, we observed that a higher adiposity was associated with poorer cardiometabolic factors 
in both trans women and men. Therefore, avoiding obesity is also in trans persons an important 
way to improve the cardiovascular and metabolic risk profile, and weight management should be  
considered as an important part of the entire endocrine treatment plan. In addition, older age was 
also associated with more detrimental changes in glucose metabolism in trans women, which 
implies that screening for impaired glucose tolerance in the older trans population should not be 
forgotten. 
5.1.2 Long-term effects and safety of cross-sex hormone therapy  
Cross-sex hormone therapy is generally continued after SRS and it has been assumed that the 
principles of this treatment are similar to those of other hypogonadal persons aiming at sex 
steroids levels within the physiological range of the desired sex. Whether in the long-term all 
functions of sex steroids in trans persons are effectively covered by cross-sex hormones and 
whether the administration of these therapies is appropriately safe, remains unknown(292). 
Therefore, we also aimed to investigate the longer term clinical effects, side effects and safety of 
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cross-sex hormone therapy in both trans women and men (chapter 2.3, chapter 2.4 and 2.5). In 
chapter 2.4, we examined 100 trans persons post SRS and on average 10 years on cross-sex 
hormone therapy. We observed that 11.5% of trans women and 26.7% of trans men had 
supraphysiological levels according to reference values of the desired sex, which may increase the 
risk for cardiovascular events. In contrast, 63% of trans women and 8.9% of trans men exhibited 
subphysiological sex steroid levels which put trans persons at risk for side effects known from 
hypogonadal states. Indeed, an important finding of these studies was that a high number of trans 
women (about 25%) experienced osteoporosis at the lumbar spine, hip, or radius whereas in trans 
men no osteoporosis was diagnosed. Our results in trans men substantiated others whereas our 
findings in trans women are in contrast to most other studies(289, 297-299, 307, 341-344). This may be 
related to past treatment regimens where cyproterone acetate was generally prescribed alone for 
12 months without concomitant use of estrogens as it is well-established that androgen 
deprivation induces bone loss. Another explanation could be that trans women had an inadequate 
estrogenization, given the low estrogen and high gonadotropin levels observed in these women. 
However, the absence of clinical symptoms and high SHBG levels did not suggest this. 
Biochemical  markers of bone turnover were also not increased in these women and were 
therefore not suggestive for an increased bone turnover. Finally, given our cross-sectional study it 
may be that trans women at our center had low bone mass before the start of cross-sex hormone 
therapy. Indeed, our research group recently found that trans women, before any treatment, had 
a higher prevalence of osteoporosis compared to age-matched control men, possibly related to 
the lower physical activity and lower vitamin D levels found in trans women compared to 
controls(378). Why trans women in our center experience more osteoporosis compared to other 
centers, is not well-known. One could speculate that trans women in Belgium might have a lower 
physical activity rate compared to those in other centers as lower levels of physical activity were 
observed in the Belgian population compared to most other European countries(379, 380). But 
future multicenter studies such as the ENIGI study are needed to investigate the underlying 
mechanisms of the higher prevalence of osteoporosis at our center. 
In chapter 2.1 and chapter 2.2, we described that anti-androgen and estrogen therapy in trans 
women and T therapy in trans men both improved and impaired some aspects of the profiles of 
cardiovascular risk factors during the first year of treatment. How long-term cross-sex hormone 
therapy affects cardiovascular risk factors, was addressed in our clinical studies (chapter 2.3.). We 
observed that trans women had a similar prevalence of cardiovascular risk factors including 
hypercholesterolemia, hypertension, smoking and obesity compared to trans men. Additionally, 
we compared these prevalence rates to published ones of the general population and found that 
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similar or even less cardiovascular risk factors were present apart from smoking, which occurred 
more in trans persons. In spite of these relative comparable cardiovascular risk factors and 
comparable duration of cross-sex hormone therapy, 12% of trans women in this study 
experienced a cardiovascular adverse event during hormonal therapy compared to not a single 
trans man. The younger age of trans men may be a possible explanation as for a comparable 
duration of hormonal therapy, trans women will be significant older in comparison with trans 
men. Indeed, it is well-established that trans men present themselves at younger ages(381), which 
was also confirmed in our ENIGI study. Nevertheless, others also found that cross-sex hormone 
therapy in trans men was acceptably safe whereas trans women exhibited a higher rate of 
cardiovascular disease(241, 261). With regard to hormone related cancers, we observed none in our 
clinical studies in both trans women and men.  
Because the sample sizes were rather small in our clinical studies and the lack of an age-matched 
control group to compare morbidity rates of trans persons to the general population, we initiated 
the TransBel study. This is a multicenter cross-sectional study in Belgium, with the aim to 
investigate morbidity of trans persons in Belgium. As recruitment in other centers is still ongoing, 
we presented in this thesis data from our center and compared it to an age- and gender-matched 
control population recruited from a population based study on sexual health in Flanders (Sexpert 
study). We presented one of the largest samples published in literature including 352 trans 
persons who were on average 7.4 years on hormonal therapy (chapter 3.4). We confirmed the 
results from our clinical studies, showing a low risk for cardiovascular events and cancer in trans 
men whereas our results in trans women suggest no higher risk for cancer but an increased risk 
for cardiovascular disease.   
Firstly, a relatively high incidence of venous thrombosis (5%) was observed in our TransBel 
study, with half of these events occurring during the first year of therapy. This is in contrast with 
our prospective ENIGI study, where not a single case was observed during our 12 month 
observation. As already mentioned, these results may suggest that our newer treatment regimens, 
which avoid the use of EE and use transdermal estrogens in older trans women, have less 
detrimental effects on the coagulation system. In line with others(260-261), we observed an increased 
risk for venous thrombosis and/or pulmonary embolism at the time of SRS, which confirms the 
well-known risk for major abdominal and pelvic surgery and immobilization on thrombosis 
development. Alternatively, it is well-known that oral contraceptives and hormone replacement 
therapy increase the risk of thrombosis during and after surgery. However, the existing evidence 
regarding the necessity to discontinue hormonal therapy before surgery in trans women remains 
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limited, as there are no general guidelines available at this moment. Nevertheless, we currently 
advise to discontinue hormonal therapy at least two weeks before SRS or other elective surgeries 
and to restart at mobilization. However, it may be that this time period is too short, as it is not 
well-known at which time point changes in clotting factors are restored after stopping cross-sex 
hormone therapy. Future studies are needed to resolve this research question. 
Secondly, the majority of trans women in our study, who experienced myocardial infarction or 
cerebrovascular disease were aged over 50 years, had one or more cardiovascular risk factors 
(mainly smoking), and had undergone cross-sex hormone therapy for a short duration. These 
findings may possibly suggest that estrogen therapy can aggravate pre-existing cardiovascular 
disease, which has also been described in postmenopausal hormone replacement therapy in older 
women as suggested by the “timing hypothesis”. One potential explanation for these findings 
may be that besides beneficial changes such as in lipid status, estrogen therapy also increases 
proinflammatory factors such as matrix metalloproteinase 9, which destroy the matrix of the 
atheromatous plaque causing instability and rupture(382-383). In younger women, estrogen therapy 
also increases these proinflammatory factors, but in the absence of a significant plaque there is no 
substrate on which these proinflammatory factors would act(384).  
This brings us to the safety of cross-sex hormone therapy in women with established 
cardiovascular disease and older trans women. Unfortunately, studies in these populations are 
currently lacking, but it is widely believed that cardiovascular risk factors should be managed 
before the start of cross-sex hormone therapy and when they emerge(5). However, whether 
hormonal therapy should be stopped or a dosage reduction needs to be performed depending on 
certain cardiovascular risk profiles, is uncertain. In trans persons, the decision to stop or lower 
estrogen dosage is also complicated by the explicit wish of many trans women to continue high 
dose estrogen therapy. Based on our data we may recommend that older trans women or women 
with known cardiovascular risk factors, especially smoking, should receive low dose estrogens, as 
higher estrogen dosages were found to be associated with a higher risk of cardiovascular disease 
in women using COC’s and hormone replacement therapy. It may also be that these women may 
benefit from the transdermal route of administration of estrogen therapy as the latter induces 
fewer changes in proinflammatory markers. However, data concerning the effects of transdermal 
estrogens on cardiovascular end points in women using COC’s and hormonal replacement are 
conflicting. A nested case control study on hormonal replacement therapy in postmenopausal 
women observed that users of high dose transdermal estrogen therapy had a higher stroke risk 
compared to those on high dose oral estrogens, but that low dose transdermal estrogen therapy 
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had a lower risk, than low dose oral estrogen treatment(385), whereas another national 
observational study in almost 700 000 Danish women aged between 51 and 69 found a lower risk 
for myocardial infarction in women using transdermal HRT compared to those on oral HRT(386). 
In women of reproductive age, use of transdermal contraceptives was associated with a similar 
risk for development of MI(210, 387). Concerning the risk for thrombotic stroke, a recent large 
population study observed a higher risk in women who used contraceptive patches or a vaginal 
ring(210) in comparison with those on oral treatment. Nevertheless, there is a need for studies 
determining the safety of different cross-sex hormone therapies in older patients and patients 
with established cardiovascular risk factors and disease. In addition, guidelines are needed to 
assist clinicians in follow-up and management of cardiovascular risk factors during cross-sex 
hormonal therapy.  
Our findings concerning cancer in trans persons after long-term cross-sex hormone therapy are 
in line with others, indicating a low risk risk for development of hormone related cancers. 
Moreover, the prevalence of cancer was even lower in trans men compared to the control 
population in our TransBel study. Because of the bilateral mammectomy, oophorectomy and 
hysterectomy, trans men have a lower risk for development of these cancers, which are 
commonly diagnosed in cisgender women. Nevertheless, some cases of breast and ovarian cancer 
have already been described before surgery(336-338) and after mammectomy(339-340). Several important 
notes should be made concerning cancers in trans persons. Firstly, the current evidence is mainly 
based on trans persons who almost all underwent SRS. Therefore, these results cannot be 
extrapolated to trans persons who do not undergo SRS due to personal convictions or financial 
restraints. As T can also be aromatized to E2, the endometrium of trans men without 
hysterectomy for example is exposed to unopposed action of estrogens and the latter is known to 
increase the risk for endometrial carcinoma. Caregivers and trans persons themselves should be 
aware of this, and trans persons should be screened conform the biological sex if reproductive 
organs have not been surgically removed. Given the discomfort that trans persons experience 
with medical exams concerning their native sex, such as gynecological examinations in trans men, 
it is unlikely that many trans persons themselves will take initiative for screening. 
In addition, it is likely that the current follow-ups were too short as it takes years to induce 
cancers. Therefore, the incidence of hormone related cancers may possibly increase with longer 
hormone exposure time. This hormone exposure time will also drastically increase in the future, 
as presently, adolescent trans persons can be eligible for hormonal treatment and trans persons 
often receive hormonal therapy beyond menopausal age. This leads us to the point how long 
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hormonal therapy should be continued in trans persons. No guidelines for this issue are presently 
available, but this matter will become increasingly relevant as the trans population ages. An 
important consideration in this discussion is whether the guidelines for hormone treatment of 
postmenopausal women can be applied to trans women or likewise those for T treatment in 
elderly males, to trans men.  
Nevertheless, as stated above, it may be that longer sex steroid exposure increases the risk for 
hormone dependent cancers. Indeed, in postmenopausal hormone replacement therapy it was 
found that breast cancer incidence increased in women receiving about 7 years of hormone 
replacement therapy, compared to those receiving placebo. This would argue in favour of 
estrogen treatment cessation at a certain age or duration of hormonal therapy in trans women. As 
already mentioned, how long-term cross-sex hormone therapy affects cardiovascular health, 
remains to be determined. Alternatively, one can speculate that stopping hormonal therapy in 
trans women, who underwent gonadectomy, will increase the prevalence of hot flashes. In 
addition, stopping hormonal therapy will drastically decrease bone mineral density as observed 
for example in women receiving treatment for cancer, who experience a more profound estrogen 
depletion compared to postmenopausal women. Keeping in mind the already high prevalence of 
osteoporosis before the start of treatment, this would mean that many trans women might 
experience severe osteoporosis. However, besides hormonal therapy, other treatment options are 
currently available for osteoporosis prevention and treatment.  
Although cross-sex reassignment therapy has been associated with better functioning in terms of 
gender dysphoria relief, psychological functioning, and decrease in suicide attempts(367, 388) we 
observed a high number of suicide in trans persons, especially in trans women. Our results 
hereby confirm others(310, 312) showing an increase of suicide in this specific patient population. 
Moreover, the strikingly high prevalence of suicide attempts of 41% reported in a recent nation-
wide U.S.-based survey of 6456 self-identified transgender/gender non-conforming 
individuals(389) shows the fragile position of many trans persons. In general, this phenomenon has 
been related, at least in part, to minority stress caused by a number of factors such as 
discrimination, stigma and rejection. This also implies that clinicians working in trans persons 
such as endocrinologists should be thoughtful about this, especially as many trans persons quit 
psychological follow-up after transition. Hopefully, research such as ours, will add to respect in 
the scientific community for this patient group. This may reflect in political and juridic actions 
and eventually society’s view on gender dysphoria, and lead to the amelioration of QOL of trans 
persons. 
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5.1.3 Sexual desire 
Sexual health is an important element of general health, also for trans persons. However, despite 
major effects of both hormonal and surgical therapy on sexual functioning of trans persons, this 
is still an underexposed topic by health care professionals dealing with trans individuals. From a 
previous study of our center(353), it was found that transsexuals’ expectations were less met at a 
sexual level in comparison with a social or emotional level, indicating the need to counsel trans 
persons about possible sexual changes. Therefore, we also aimed to investigate possible effects of 
cross-sex hormone therapy on sexual desire of trans women and men, as it is known from 
cisgender men and women that sex steroids strongly affect sexual desire. 
Previous cross-sectional studies concerning the effects of cross-sex reassignment therapy on 
sexual desire in trans women showed conflicting results with some observing an increase, 
whereas others described a decrease or no effect. In trans men, not a single study investigated the 
effects of T therapy on sexual desire specifically. We are the first to present a prospective 
evaluation of sexual desire during the first year of cross-sex hormone therapy and described that 
trans women experienced significant lower levels and trans men significant higher levels of sexual 
desire (chapter 2.1). These results were also confirmed in our TransBel study as trans women 
reported a decrease of sexual desire since the start of cross-sex hormone therapy whereas trans 
men mentioned an increase (chapter 3.1). Moreover, in the TransBel study, 73% of trans women 
never or rarely experienced spontaneous and responsive sexual desire. A third of these women 
also reported associated personal or relational distress which results in a prevalence of HSDD of 
22%. This prevalence is higher compared to the general male and female population. In contrast, 
the prevalence of HSDD in trans men was comparable to the general male population. 
Moreover, a small group of trans men (3.6%) even reported personal or relational distress due to 
high levels of sexual desire. Whether sexual desire levels in trans men are related to sex steroid 
levels, was not addressed previously. Therefore ,we investigated these potential associations in the 
clinical trans men study (chapter 3.2). No direct associations were observed between T and 
solitary or dyadic sexual desire, but an independent association of LH on solitary sexual desire 
was found. Trans men with elevated levels of LH, indicating suboptimal testosterone therapy, 
reported significantly lower solitary sexual desire levels than those with low LH levels. 
Suppressed LH levels were also associated with having a higher need for sexual activities and a 
higher frequency of experiencing excessive sexual desire. In general, our results suggest an 
important impact of cross-sex hormones on sexual desire in both trans women and men, with the 
majority of trans women experiencing a decrease of sexual desire whereas the opposite was found 
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in trans men. This implies that trans persons and their partners should also be counseled about 
the changes in sexual desire when choosing cross-sex hormone therapy. The old paradigma of no 
sexual desire in trans persons can be rejected. Although a previous study from our center was 
unable to show associations between serum T levels and sexual desire in trans women(357), larger 
scale studies using LC-MS MS and standardization of blood sampling relative to timing of 
treatment administration are needed to fully confirm this observation. In addition, randomized 
studies are needed to determine whether low dose T therapy in trans women suffering from 
HSDD after starting cross-sex hormonal therapy may benefit these patients.  
5.1.4 Quality  of  life  after  sex reassignment treatment 
QoL is an evaluation of personal well-being and includes several aspects such as emotional, social 
and physical functioning. In health care, QoL is often measured to determine how the 
individual’s well-being may be affected by a certain disease or its treatment. Most previous 
studies(364-366) showed that QoL in trans persons was poorer when compared with a general 
population sample or control group but previous studies made no adjustments for well-known 
determinants of QoL such as age, gender and socio-economic status. In Chapter 4, we compared 
QoL of trans persons to an age- and sex matched control population and found, in line with 
previous studies, that QoL of trans persons was indeed poorer compared to our control 
population, even after correction for socio-economical status. Both physical and mental 
functioning were significantly lower in trans persons, but the absolute difference in physical 
functioning was rather small, whereas it was marked for mental functioning. This may suggest 
two things. First, cross-sex hormone therapy and SRS induce important physical changes and 
both therapies are associated with side effects and adverse events, but these drastic effects do not 
seem to affect physical functioning considerably in the majority of trans persons. Secondly, 
although it is generally acknowledged that sex reassignment therapy improves mental well-being 
of trans persons, trans persons still had a clinically significant poorer mental health also after 
these treatments.  
As mentioned earlier, one explanation can be found in the minority stress transgender people 
face due to social stigma, prejudice and discrimination because of their gender nonconformity. It 
is indeed known that the majority of trans individuals have reported discrimination. This social 
discrimination is also suggested by our findings that trans persons had a marked lower socio-
economical position despite a similar or even higher educational level. In addition, many trans 
persons even experienced violence (both verbal as physical) because of their gender identity or 
presentation. Motmans and colleagues(390) recently reported that 78.9% of trans individuals (living 
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in Belgium, the Netherlands or France) experienced verbal violence whereas more than a quarter 
experienced physical (26.8%) and sexual violence (31.6%). Considering the minority stress model, 
increasing public policy initiatives are needed to change the social norms, attitudes and structures, 
in order to reduce psychological distress and improve QoL of trans individuals. In addition, 
efforts to prevent discrimination and violence towards trans individuals are urgently needed.  
Providing a better understanding of the strongest predictors of QoL in trans persons may also 
help health care providers and policy makers to make the best use of resources. Therefore, we 
also investigated the main determinants of QoL in trans persons using a regression model 
including both clinical and socio-demographic correlates, as this was not addressed previously in 
trans persons after sex reassignment therapy. It was found that hormonal treatment satisfaction 
and employment status were independent predictors of QoL in trans persons. These findings 
corroborate with those from Gómez-Gil et al.(370) and Gorin-Lazard et al.(369), who have assessed 
the predictors of QoL in trans persons before SRS as they both observed  that hormonal therapy 
was an independent predictor of QoL. We were unable to investigate this hypothesis, as almost 
all our respondents were on hormonal therapy, but our findings seem to confirm the importance 
of hormonal therapy on the QoL of trans persons, even after SRS. Cross-sex hormone therapy is 
an essential part of the medical treatment of trans persons and induces body features and shape 
of the desired gender, which results in a reduction of self-reported distress. Besides inducing 
physical changes, the act of using cross-sex hormones is itself an affirmation of gender identity. 
In addition, many trans persons change gender role around the time of starting hormonal 
therapy, which could also improve social and mental functioning. Our results show that not only 
the initiation of cross-sex hormone therapy is important, but also the satisfaction with hormonal 
treatment. Trans persons who were more dissatisfied with their hormonal therapy might have 
been less satisfied with their body changes or experienced bothersome side effects, which could 
all affect mental and physical functioning. Future research investigating the main predictors of 
hormonal therapy satisfaction is of interest; this may include body image satisfaction, experience 
of side effects, severity of side effects, duration of hormonal therapy etc.  
In addition, it was previously found that family support and working status were independent 
predictors of QoL in trans persons. Strength of social support was not investigated in our study, 
but we also found the importance of family structure: parenthood was negatively associated with 
QoL scores in trans women, whereas the opposite was seen in trans men. A possible explanation 
may be that the majority of children in trans women (82%) were conceived before sex 
reassignment therapy, whereas in trans men the opposite is the case (36%). It is well-known that 
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trans men present themselves at a younger age compared to trans women and our findings may 
thus reflect the higher numbers of familial difficulties trans women encounter due to sex 
reassignment treatment. In line with others, we also observed that working status was an 
independent predictor of both physical and mental functioning scores. From clinical practice it is 
well-known that many trans persons experience problems finding a job, especially during sex 
reassignment. A potential way to improve QoL is the stimulation of employment programs for 
this population.  
In line with others, we observed that trans women who underwent facial feminization surgery 
had a better QoL compared to those who did not. Moreover, we observed that facial 
feminization surgery was an independent positive predictor of mental functioning in trans 
women. The better passability of trans women who underwent facial feminization surgery may 
improve body image satisfaction and self-esteem, but recent research also showed that a better 
passability was associated with less experience of discrimination and violence(390). For that reason, 
reimbursement of this surgery might also be considered to improve QoL of trans women.  
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5.2 Limitations and perspectives 
We provided in this thesis several findings concerning the short- and long-term clinical effects, 
side effects and adverse events of cross-sex hormone therapy in trans men and women and its 
associations with QoL. From these findings, we are already able to inform our future clients, their 
families, and other caregivers more accurately on the desired effects, side effects, and adverse 
events of these therapies in our daily practice. Nevertheless, the overall knowledge concerning 
this topic remains scarce when compared to other patient groups. Firstly, we presented one of 
the largest prospective and cross-sectional samples published in literature so far, but our sample 
sizes were still too limited to provide accurate estimates of morbidity rates. To this end, we plan 
to continue and expand our ENIGI study and several other gender clinics such as Amsterdam 
and Florence recently joined this study. In addition other centers such as Tel Aviv and 
Copenhagen showed interest. Also in the TransBel study, recruitment in other Belgian centers is 
ongoing with the aim to increase our statistical power. Upon completion, TransBel will be the 
first nationwide study available.  
In light of the aging trans population, safety of both short- and long term hormone therapy use 
needs to be examined in older trans persons, especially considering our observations that older 
trans women experienced a higher risk for cardiovascular disease. In this regard, we will further 
include trans persons in our ENIGI study, with additional attention to the aging group, and we 
will also continue to invite them for follow-up measurements in the next years.  
Further, during the ENIGI study we aimed to describe effects of currently used treatment 
modalities and we compared our results with previously published findings. From this it seems 
that, especially in trans women, newer treatment modalities may be associated with fewer risks. 
However, to prove the benefit of certain types and dosages of anti-androgens, estrogens and T 
therapies above others, randomized controlled trials are needed. A detailed study protocol for a 
randomized trial conducted in several European gender clinics is already available, but 
implementation is hampered at this moment due to financial restraints.  
In addition, we observed that breast development was not satisfactory to many trans women. It 
has been recently suggested(391) that excessive estrogenic action may negatively affect breast 
development. This brings up the question whether a step up dose of estrogens would be 
preferable to enhance breast development in trans women. No data are currently available 
regarding the effects of this treatment on breast development of trans women, but step up 
dosages of unopposed estrogens are usually prescribed for puberty induction, for example in 
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Turner girls. This therapy is mainly prescribed to avoid acceleration of bone maturity by high 
dose estrogen treatment resulting in a reduced final height. But, beneficial effects on breast 
development have been suggested, although rather clinical than experienced based. Considering 
the importance of breast development for many trans women, future studies are needed to 
examine this research question. In this regard, studies in adolescent trans women may also be of 
interest. 
Finally, we have identified many clinical effects, side effects but also adverse effects of cross-sex 
hormone therapy. Nevertheless, we certainly did not study all possible effects in this work. Sex 
hormones may, for example, also influence brain and behavior as distinct sex differences have 
been described on both structural and functional MRI data. To date, the exact psychological and 
cognitive effects and side-effects of cross-sex hormonal treatment are not clear. To further 
examine these potential effects, we have very recently performed a cross-sectional fMRI study in 
20 trans men and 20 trans women after long-term cross-sex hormone therapy compared to an 
age-matched control population. Data are currently being analysed. 
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ABSTRACT 
Gender nonconformity refers to the extent to which a person’s gender identity, gender role 
and/or gender expression differs from the cultural norms prescribed for people of a particular 
sex, within a certain society and time. Most data on the prevalence of gender nonconformity 
focus on the prevalence of gender dysphoria (which also includes a distress factor) or on the 
number of legal sex changes. However, not every gender nonconforming individual experiences 
distress or applies for treatment. Population-based research on the broad spectrum of gender 
nonconformity is scarce and more information on the variance outside the gender binary is 
needed. This study aimed to examine the prevalence of gender incongruence (stronger 
identification with the other sex than sex assigned at birth) and gender ambivalence (equal 
identification with the other sex as the sex assigned at birth)  in a population-based survey in 
1,832 Flemish persons and  in 2,472 lesbian, gay and bisexual (LGB) individuals in Flanders. In 
the general population, gender ambivalence was present in 2.2% of male and 1.9% of female 
participants whereas gender incongruence was found in 0.7% of men and 0.6% of women. In 
LBG individuals, the prevalence of gender ambivalence and gender incongruence were 1.8% and 
0.9% in males and 4.1% and 2.1% in females, respectively.  
This study was one of the first population-based surveys to assess gender nonconformity in a 
probability sample. Considering a current Flemish population of about 6 million, our results 
indicate the presence of gender incongruent men between 17,150 and 17,665 and between 14,473 
and 15,221 gender incongruent women in the Flemish population. Gender incongruence and 
gender ambivalence were generally more present in LGB women but not in LGB men. 
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INTRODUCTION 
Gender nonconformity refers to the extent to which a person’s gender identity, role or 
expression differs from the cultural norms prescribed for people of a particular sex, within a 
certain society and time. Gender dysphoria refers to the discomfort or distress that is caused by 
the incongruence between a person’s gender identity and that person’s sex assigned at birth (and 
the associated gender role and/or primary and secondary sex characteristics). The World 
Professional Association for Transgender Health stresses that only some gender nonconforming 
people experience gender dysphoria at some point in their lives[1]. Gender dysphoria however, is 
the most known, but also the most extreme form of a broad spectrum of gender nonconformity 
(DSM-5, 302.85; ICD-10, F64.0).  
Most data on the prevalence of gender nonconformity only focused on the prevalence of gender 
dypshoria. The prevalence in Belgium was 1: 12,900 for male-to-female and 1: 33,800 for female-
to-male transsexual persons, based on the number of sex reassignment operations done in 
Belgium[2]. The definition of gender dysphoria in current research has not been uniform: 
prevalence numbers were based on the number of legal sex change as noted in a national 
register[3], the start of cross-sex hormonal therapy[4-6], the number of applicants for sex 
reassignment surgeries (SRS)[7], attending a gender clinic[8], or the number of sex reassignment 
surgeries (SRS) performed by different surgeons[1]. This implies an important selection bias as 
only those who seek and/or have access to medical and/or surgical treatment will be counted. 
Indeed, a primary care study revealed that 40% of people defined as having a gender identity 
problem who consulted a general practitioner, had not received hormonal therapy or SRS[9]. This 
suggests that many gender incongruent persons are probably not attending a secondary care 
service or gender clinic. Some persons may be reluctant to seek health care and treatments due to 
financial restraints, shame,  or fear for potential for social exclusion, e.g., losing one’s family, job, 
friends or partner[1, 11-12]; whereas others may not desire hormonal treatment, SRS, or change of 
official documents. Our knowledge concerning this broader spectrum of gender nonconformity 
is currently scarce[11-12]. However, this information is needed to inform society on gender diversity 
and to address to potential needs of this group. 
Population-based research is required to address an estimation of this broader spectrum of 
gender nonconformity. The aims of this study were to investigate the prevalence of gender 
identity nonconformity in the general population in Flanders (Belgium). In particular, we 
measured gender incongruence (stronger identification with the other sex than sex assigned at 
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birth) and gender ambivalence (equal identification with the other sex as the sex assigned at 
birth).  
Although it is not evidence based, it is presumed, also by some health care professionals, that 
gender dysphoria is more frequent in LGB individuals. Therefore, the same questions on gender 
identity were included in a large study in LGB individuals as well.  
METHODS 
Participants 
This study used data from the survey “Sexual Health in Flanders”[13], a large-scale representative 
survey on sexuality, sexual health and relations in Flanders (the northern, Dutch speaking part of 
Belgium that has about 6 million inhabitants). The survey contained extensive information on 
sexual health characteristics and demographic, biomedical, psychological, and sociocultural 
correlates and aimed to investigate sexual health in Flanders and sought for possible explanations 
using bio-medical, psychological, demographic and socio-cultural correlates. 
Participants aged between 14 and 80 years were randomly drawn from the Belgian National 
Register. Data were collected between February 2011 and January 2012. The final database 
consisted of 1,832 participants (response rate: 40.0% of the eligible participants).  
In order to enhance statistical power in each of the three pre-defined age categories, we used a 
stratified sample implying that one-third of the sample consisted of adolescents (aged 14 to 25), 
one-third in the middle age group (aged 26 to 49), and one-third in the oldest group (50 to 80 
years old). After data collection, the data were weighted by gender, age, and schooling level in 
order to make them representative of the population of  Flanders aged 14–80. 
All data were gathered via face-to-face interviews, with a combination of computer-assisted 
personal interviewing (CAPI) and computer-assisted self-interviewing (CASI). In particular, all 
sensitive information, i.e., a wide range of sexual health characteristics, was gathered in a CASI 
set-up, so that participants never had to share private information about their sexual health with 
the interviewer. Detailed study design have been described elsewhere[13]. 
The second study used data from the internet based survey “Click Out of the Bed Room”, a 
large-scale survey on sexuality, sexual health, and relations in LGB individuals in Flanders. The 
questionnaire was identical to the first study but significantly shorter to avoid respondent drop 
out. Therefore, we only aimed to investigate the current sexual health in LGB individuals. Bio-
medical, psychological, extensive demographical and socio-cultural correlates were limited. 
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Participants between 13 and 86 years of age were included. Data were collected between 
September 2011 and March 2012. The final database consists of 3,702 participants. It was also 
important to recruit LBG individuals who do not identify themselves as gay, lesbian or bisexual. 
Therefore, we set up a neutral as well as a LGB-oriented campaign. The neutral campaign refers 
to 10,000 posters that were spread all over Flanders containing an image that did not refer to 
being lesbian, gay or bisexual in particular. The message on the poster presented the survey as 
related to sexual health in general. Banners, adds on the Internet, and press releases also 
contained this neutral image and message.  In addition, we also set up a specific recruitment 
strategy to target LGB individuals including the following channels to broadcast a request for 
participants: specific locations such as LGB discotheques, LGB parties, and LGB events; 
advertisements in the written press; LGB-specific and non-LGB-specific associations and 
organizations were invited to spread the invitation; electronic mailings were sent and the Internet 
was used (posting banners on LGB-specific websites). More details on the recruitment have been 
described elsewhere[14].  
Out of the total number of respondents, 35.4% found our site through a social network site 
(mainly Facebook), 18.5% through electronic mailing, 15.3% through television, radio, newspaper 
or magazine, 10.6% through clicking on a banner on a website, 6.7% through their school or 
work, 3.7% through a gadget or flyer, 2.2% through an association or activity, 1.7% through a 
poster and 5.8% through other means. 
Both studies were approved by a Medical Ethical Committee and all participants gave consent for 
participation to the study. The general characteristics both sampled are displayed in Table 1. 
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Table 1. General characteristics  of the study populations 
 Population 
survey 
(N= 1832) 
Sexual minority individual 
survey 
(N=2472) 
 
Gender 
    Women 
    Men 
Age (years) 
    ≤29  
     30- 49  
     50-80  
Education 
     School going 
     None / Primary School 
     Primary high School 
     Secondary high School 
     Bachelor/master 
 Partner 
     Yes 
      No      
  
49.8 
50.2 
 
27.0 
34.1 
39.1 
37.4 
62.6 
 
49.0 
37.5 
13.5 
 
11.6 
18.2 
20.4 
22.5 
27.0 
 
77.4 
22.6 
 
27.8 
1.4 
4.6 
17.8 
48.3 
 
36.7 
63.3 
Data are presented as (%) 
Measures 
Gender identity and role was assessed in both studies as described by Schoonacker, Dumon and 
Louckx[15] using 6 questions, each scored on a 5-point Likert-scale (1 = totally disagree, 5 = 
totally agree). Participants were asked to answer following items: “I feel like a woman” (Item 1), 
“I feel like a man” (Item 2), “I look feminine” (Item 3), “I look masculine” (Item 4), “I wish to 
be more feminine” (Item 5), “I wish to be more masculine” (Item 6). Based on the first two 
items, the presence of gender ambivalence (yes/no) and gender incongruence (yes/no) was 
assessed similarly to previous research[11,16]. Gender ambivalence was considered if the same 
answer was given on both Item 1 and 2 (scores 1–1; 2–2; 3–3; 4–4; and 5–5). Incongruent gender 
identity reflects a higher score on the scale measuring feeling like the opposite birth sex than on 
those of the sex assigned at birth (scores 1–2; 1–3; 1–4; 1–5; 2–3; 2–4; 2–5;  3–4; 3–5; 4–5). 
In the LGB survey, sexual orientation was conceptualized as a three dimensional construct 
measuring self-identification, sexual behavior, and sexual desire[17]. These dimensions were used 
to obtain a broader definition of LGB, as it is important to include persons who display 
homosexual behavior but do not identify as LGB[18-19]. The definition should not be too broad 
either, as we did not want to include people who scored on one or two dimensions completely 
heterosexual. Sexual self-identification was assessed with the question, “How would you identify 
yourself?”. Participants could answer on a 5-point Likert scale (i.e., straight, more straight then 
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gay/lesbian, bisexual, more gay/lesbian then straight, gay/lesbian). An open-end response 
category was added for participants who did not identify with any of these labels (referred to as 
“other”). To measure sexual behavior, we first asked participants “Throughout your life, with 
how many people did you have sex?” (open-ended numeric answer category). Then we asked 
“Were these people men, women or both?” Participants could answer on a 5-point Likert scale 
(from 1 = only women to 5 = only men). To measure sexual desire we asked participants “Do 
you sexually fantasize about men, women or both?” and “Do you feel sexually attracted to men, 
women or both?” Participants could answer on a 5-point Likert scale (from 1= only about or to 
women to 5= only about or to men). Participants could also answer these questions with “only 
about or to none” With the information from these four items, we created a dichotomous 
variable categorizing participants as non-heterosexual (i.e.,”0”) or heterosexual (i.e.,“1”). They 
were identified as non-heterosexual when they reported to identify as gay/lesbian, bisexual or 
more gay/lesbian than straight or when they reported to have at least as many same-sex sexual 
fantasies as opposite sex fantasies, or when they reported to feel at least as often attracted to the 
same-sex as to the opposite sex, or when they reported to have had at least as many same-sex 
sexual contacts as opposite sex sexual contacts[14]. This resulted in a final number of 2,472 non-
heterosexual persons included in our analyses; heterosexual defined persons were excluded. 
Statistical analysis  
Chi square analysis was used to evaluate differences in gender incongruence and gender 
ambivalence between men and women and to compare the prevalence of gender incongruence 
and ambivalence with previous research[11]. All data were analyzed using SPSS-software version 
21 (SPSS Inc., Chicago, IL). 
RESULTS 
Population   based  study 
In Flemish men, 1.4% reported feeling to be a woman and 2.3% did not feel being a man. Of all 
men, 2.4% desired to be more feminine and 47.6% did not want to be more masculine. When 
asked about their appearance, 1% of men reported to look feminine and 2.2% noted not to look 
masculine.  
In Flemish women, 1.7% felt being a man and 1.5% did not feel being a women. 1.7% reported 
to look masculine and 1.9% noted not to look feminine. 1.1% wished to be more masculine and 
58.7% disagreed on wishing to be more feminine.  
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Gender ambivalence was found in 2.2% of males and 1.9% of females. The prevalence of gender 
incongruence was 0.7% in men and 0.6% in women (Table 2). Prevalence rates of gender 
incongruence and ambivalence were not significantly different between men and women, χ²= 
1.28, p= .55. Not all gender incongruent or gender ambivalent persons wished to be more like the 
opposite sex and a variation in appearance was observed (Table 3).  
Table 2. Prevalence  of  gender  ambivalent and  incongruent  identity  in  the  population-survey  
 Men 
(N=894) 
Women 
(N=905) 
Total population 
(N=1799) 
Gendercongruent 97.1 (96.0-98.2) 97.5 (96.5-98.5) 97.4 (96.7-98.1) 
Genderambivalent 2.2 (1.5-3.4) 1.9 (1.0-2.8) 2.0 (1.4-2.7) 
Genderincongruent 0.7 (0.2-1.3) 0.6 (0.2-1.3) 0.6 (0.2-1.0) 
Data are presented as % (95% confidence interval) 
Table 3 .  self-perceived   appearance   
 Gender 
ambivalenT 
Gender 
Incongruent 
Gender 
congruent 
MEN 
I look masculine (disagree/totally disagree) 
I look feminine (agree/totally agree) 
I wish to be more masculine (disagree/totally disagree) 
I wish to be more feminine (agree/totally agree) 
 
WOMEN 
I look masculine (agree/totally agree) 
I look feminine (disagree/totally disagree) 
I wish to be more masculine (agree/totally agree) 
I wish to be more feminine (disagree/totally disagree) 
 
100 (N=20) 
36.9  
5.8  
79.2 
10.6 
 
100 (N=17) 
 11.9  
15.8  
11.9 
60.1 
100 (N=6) 
59.7  
0  
 75.5  
54.0 
 
100 (N=5) 
57.3 
86.4 
0 
60.4 
100 (N=868) 
1.3  
0.9  
48.6  
1.8  
 
100 (N=883) 
1.3  
0.9  
0.8 
60.3 
Data are presented as % within gender ambibalent, gender incongruent or gender congruent sample  
 
LGB Survey 
In the LGB survey, the prevalence of gender incongruence was 0.9% in men and 2.1% in women 
(Table 4). The prevalence of gender ambivalence was 1.8% in males and 4.1% in females. 
Prevalence rates of gender ambivalence and incongruence were significantly different between 
men and women (GA: χ²= 10.95, p<0.001; GI: χ²=5.39, P=0.02). A higher prevalence of gender 
incongruence and gender ambivalence was found in LGB women compared to women in the 
population based survey (GA: χ²= 6.84, p= .009; GI: χ²= 6.60, p= .01). No differences were 
observed in prevalence rates of gender incongruence and gender ambivalence in LGB men 
compared to men in the population based survey (GA: χ²= .29, p= .59; GI: χ²= .09, p= .76). 
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Table 4. Prevalence of gender  ambivalent and incongruent identity in  the  LGB  survey 
 
Men 
(N=1549) 
Women 
(N=923) 
Total population 
(N=2472) 
Gendercongruent 97.3 (95.5-98.1) 93.8 (92.3-95.4) 96.0 (95.2-96.8) 
Genderambivalent 1.8 (1.1-2.5) 4.1 (2.8-5.4) 2.7 (2.1-3.3) 
Genderincongruent 0.9 (0.4-1.4) 2.1 (1.2-3.0) 1.3 (0.9-1.8) 
Data are presented as % (95% confidence interval) 
 
Comparison   with   previous   research 
A comparison of the current results to Kuyper & Wijsen (2014)[11] is shown in Table 5. In this 
study in a neighbouring country, the Netherlands, Kuyper et al. asked participants if they felt 
psychologically as male and/or as female in an internet based population survey on two items, 
scored on a 5-point Likert-scale (1 = totally disagree, 5 = totally agree). The Dutch participants were 
recruited, by use of a random sample, from a large Internet panel for online surveys and 
members received so-called “clix” participating in online surveys, which they could use to buy 
products on the Internet. During data gathering, representativeness for the Dutch population was 
checked and recruitment was adapted to complete shortages or limit overrepresented population 
groups. 
The observed percentages of gender incongruence in Flanders were comparable to those of the 
Dutch survey. The prevalence of gender ambivalence in men was higher in the Dutch survey 
(Table 5). 
 
Table 5. Comparison with  Kuyper et al. 
 
Sexpert 
(N= 1799) 
Kuyper (2014) 
(N= 8064) 
χ² P* 
Genderambivalent men 
Genderambivalent women 
Genderincongruent men 
Genderincongruent women 
2.2 (1.5-3.4) 4.6 (4.0-5.2) 9.97 0.002 
1.9 (1.0-2.8)  3.2 (2.7-3.7)  3.90 0.05 
0.7 (0.2-1.3) 
0.6 (0.2-1.3) 
1.1 (0.8-1.4) 
0.8 (0.5-1.1) 
0.79 
0.17 
0.37 
0.68 
Data are presented as % (95% confidence interval); *Chi square test 
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DISCUSSION 
This is the first study investigating the prevalence of gender nonconformity in the Flemish 
population and one of the few studies assessing gender nonconformity in a population-based 
survey. We found a prevalence of gender incongruence of 0.7% and 0.6% and gender 
ambivalence of 2.2% and 1.9% in men and women, respectively. Extrapolated to the current 
number of Flemish inhabitants, gender ambivalence would concern between 54,256 and 55,162 
Flemish men (95% confidence interval) and between 47,020 and 47,865 women and gender 
incongruence between 17,150 and 17,665 men and between 14,743 and 15,221 women. These 
numbers are much higher than the prevalence of gender dysphoria in clinical settings. As 
mentioned before, a prevalence rate of transsexualism in Belgium was estimated at 1: 12,900 for 
male-to-female and 1: 33,800 for female-to-male transsexual persons[2]. Our findings may 
therefore suggest that prevalence rates based on the number of individuals seeking medical help 
might underestimate the prevalence of gender dysphoria in the general adult population. Indeed, 
two recent  population surveys reported similar findings[11-12]. In the latter[12], 28,662 residents of 
Massachusetts were explicitly asked if they would consider themselves to be transgender and 
0.5% of the participants identified themselves as transgender in a telephone health survey[12]. In 
the Netherlands, Kuyper et al.[11] asked participants if they felt psychologically male and/or 
female in an internet based population survey. Ambivalent gender identity was reported in 4.6% 
of  men and 3.2% of women and incongruent gender identity in 1.1% of males and 0.8% of 
females. This Dutch survey had a similar prevalence rate of gender incongruence but a higher 
prevalence of gender ambivalence compared with our results. Differences in methodology should 
be considered (a representative stratified sample randomly drawn from the National Register 
versus internet based stratified sample and differences in response rate (20.9% versus 40.0%) as 
well as different phrasing of the questions.  
In our LGB survey, we found a prevalence of gender incongruence of 0.9% and 2.1% and gender 
ambivalence of 1.8% and 4.1% in men and women, respectively. These findings were slightly 
lower compared to those from a United States LGB study, though the phrasing of the question 
was different. In the latter, 2.1% of the gay and bisexual men and 1.9% of the lesbian and 
bisexual women identified as transgender[21]. Of note, the observed prevalence of gender 
incongruence and gender ambivalence were generally more present in LGB women but not in 
LGB men. 
We also found that gender incongruent or gender ambivalent persons varied in their reported 
appearance and desire to be more masculine or feminine. Our results may thus support the fact 
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that only some gender-nonconforming people experience gender dysphoria at some point in their 
lives[1]. Therefore, the prevalence rates of gender non conformity was expected to be much higher 
than earlier figures based upon those who underwent SRS in Belgium[2]. Indeed, Kuyper and 
Wijsen, (2014)[11] observed that only a minority of gender incongruent or gender ambivalent 
persons were dissatisfied with their body and wished to undergo treatment. However, as we have 
not investigated the prevalence of dysphoria or desire for sex reassignment treatment in our 
current studies, we cannot confirm these findings.  
The strengths of our study are (1) the use of a large representative population survey and (2) the 
use of identical questionnaires in a large sample of LGB individuals. Our study is hampered by 
the differences in methodology between these two studies, which also resulted in a different 
socio-demographic population. However,  LGB individuals are considered as a hard-to-reach 
population. In addition,  in national surveys, the numbers of men and women identified as being 
non-heterosexual are often too small to allow for thorough statistical analysis. In order to acquire 
a sufficient number of LGB individuals, very large population-based samples are required. The 
latter, together with the costs and efforts that are typically associated with population-based 
representative surveys, especially in small communities like Flanders, makes it very hard to 
acquire adequate data[14]. Therefore we believe that we added valuable information on prevalence 
of gender ambivalence and gender incongruence in LGB individuals, despite these  
methodological shortcomings. Future studies should preferentially investigate these prevalence 
rates in very large population-based representative surveys to ensure sufficient power.  
Another limitation of this study can be found in the nature of our questions measuring gender 
ambivalence and gender incongruence. However, to our knowledge, no validated questionnaires 
are presently available. Finally, information on experience of gender dysphoric feelings and wish 
for treatment in gender ambivalent and gender incongruent persons were not included in our 
study. Future studies should add this. 
In conclusion, we found, in a large representative population survey on sexuality, 2.0% of gender 
ambivalent and 0.6% gender incongruent persons, together 2.6% of gender nonconformity. 
Evidence is growing that gender nonconformity is more prevalent, but it is of note that not all 
gender-nonconforming persons desire sex changes. To determine an appropriate approach, 
support, and potential need for intervention in these individuals, more detailed population-based 
research should be performed. 
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